gene_symbol,gene_symbol_official,gene_name,gene_description,gene_type,aliases,other_names,ensembl_gene_id,ensembl_transcript_ids,ensembl_protein_ids,uniprot_swissprot,uniprot_trembl,uniprot_entry_name,entrez_gene_id,refseq_mrna,refseq_protein,refseq_genomic,hgnc_id,omim_id,pharmgkb_id,string_id,pdb_ids,ec_number,interpro_domains,pfam_domains,prosite_domains,chromosome,start_position,end_position,strand,protein_length,subcellular_location,taxonomy_id,homologene_id,wikipedia_url,pathways,dgidb_found,dgidb_long_name,dgidb_num_interactions,dgidb_num_approved,dgidb_drugs,dgidb_approved_drugs,dgidb_top_5_drugs,dgidb_categories,dgidb_interaction_types,dgidb_sources,chembl_found,chembl_target_id,chembl_target_type,chembl_approved_drugs,chembl_clinical_compounds,chembl_bioactive_compounds,chembl_total_compounds,chembl_total_activities,opentargets_found,opentargets_total_drugs,opentargets_approved,opentargets_phase3,opentargets_phase2,opentargets_phase1,opentargets_drug_names,opentargets_drug_types,opentargets_mechanisms,has_approved_drugs,has_clinical_drugs,has_bioactive_compounds,druggability_evidence,uniprot_protein_name,uniprot_function,uniprot_keywords,uniprot_protein_families,pfam_domains.1,pfam_domain_count,interpro_domains.1,interpro_domain_count,interpro_families,interpro_entry_types,is_druggable_family,druggable_family_type,druggable_family_confidence,druggable_family_evidence,protein_class,has_pdb_structure,num_pdb_structures,pdb_ids.1,best_pdb_id,best_pdb_resolution,best_pdb_method,pdb_structure_file,has_alphafold_structure,alphafold_version,alphafold_avg_plddt,alphafold_quality,alphafold_structure_file,structure_source,structure_file,structure_quality_score,fpocket_run,pockets_found,best_pocket_id,best_pocket_volume,best_pocket_druggability,best_pocket_hydrophobicity,best_pocket_score,has_druggable_pocket,num_druggable_pockets,best_pocket_category,best_pocket_confidence,favorable_features,concerns,all_pockets_volumes,all_pockets_druggability,pocket_details
ADRB2,ADRB2,adrenoceptor beta 2,"This gene encodes beta-2-adrenergic receptor which is a member of the G protein-coupled receptor superfamily. This receptor is directly associated with one of its ultimate effectors, the class C L-type calcium channel Ca(V)1.2. This receptor-channel complex also contains a G protein, an adenylyl cyclase, cAMP-dependent kinase, and the counterbalancing phosphatase, PP2A. The assembly of the signaling complex provides a mechanism that ensures specific and rapid signaling by this G protein-coupled receptor. This receptor is also a transcription regulator of the alpha-synuclein gene, and together, both genes are believed to be associated with risk of Parkinson's Disease. This gene is intronless. Different polymorphic forms, point mutations, and/or downregulation of this gene are associated with nocturnal asthma, obesity, type 2 diabetes and cardiovascular disease. [provided by RefSeq, Oct 2019].",protein-coding,ADRB2R|ADRBR|ARB2|B2AR|BAR|BETA2AR,"adrenergic, beta-2-, receptor, surface|adrenoceptor beta 2 surface|beta-2 adrenergic receptor|beta-2 adrenoceptor|beta-2 adrenoreceptor",ENSG00000169252,ENST00000305988,ENSP00000305372,P07550,X5DQM5,ADRB2_HUMAN,154.0,NM_000024.6,NP_000015.2,NC_000005.10|NC_060929.1|NG_016421.2,286.0,109690.0,PA39,9606.ENSP00000305372,1GQ4|2R4R|2R4S|2RH1|3D4S|3KJ6|3NY8|3NY9|3NYA|3P0G|3PDS|3SN6|4GBR|4LDE|4LDL|4LDO|4QKX|5D5A|5D5B|5D6L,,IPR000276|IPR000332|IPR002233|IPR017452,PF00001,PS50262,5,148826611.0,148828623.0,1.0,413.0,Cell membrane|Early endosome|Golgi apparatus,9606.0,30948.0,Beta-2 adrenergic receptor,biocarta:barrestinpathway|biocarta:barrestinsrcpathway|biocarta:barrmapkpathway|biocarta:cftrpathway|biocarta:chrebppathway|kegg:hsa04020|kegg:hsa04022|kegg:hsa04024|kegg:hsa04080|kegg:hsa04261|pid:arf6_pathway|pid:arf6_traffickingpathway|reactome:R-HSA-162582|reactome:R-HSA-199991|reactome:R-HSA-372790|reactome:R-HSA-373076|reactome:R-HSA-375280|wikipathways:WP117|wikipathways:WP2877|wikipathways:WP3888|wikipathways:WP455|wikipathways:WP4962,True,adrenoceptor beta 2,129,85,CARVEDILOL|CHEMBL:CHEMBL1257092|SODIUM CHLORIDE|PENBUTOLOL SULFATE|DESIPRAMINE|METIPRANOLOL|CHEMBL:CHEMBL531322|NADOLOL|PIRBUTEROL|FENOTEROL|TIMOLOL|ABEDITEROL|PINDOLOL|BRONCHODILATOR|TULOBUTEROL|PHENYLEPHRINE HYDROCHLORIDE|GSK159802|PRILOCAINE HYDROCHLORIDE|CLENBUTEROL|PROPRANOLOL HYDROCHLORIDE,CARVEDILOL|SODIUM CHLORIDE|PENBUTOLOL SULFATE|DESIPRAMINE|METIPRANOLOL|NADOLOL|PIRBUTEROL|FENOTEROL|TIMOLOL|PINDOLOL,CLENBUTEROL|CARTEOLOL|PF-00610355|METAPROTERENOL SULFATE|BEDORADRINE SULFATE,DRUGGABLE GENOME|G PROTEIN COUPLED RECEPTOR|KINASE|EXTERNAL SIDE OF PLASMA MEMBRANE,agonist|inhibitor,"NCI Cancer Gene Index|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons|Therapeutic Target Database|The ChEMBL Bioactivity Database|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)",True,CHEMBL3373,SINGLE PROTEIN,0,0,69,69,183,True,976,25,0,0,0,PROPAFENONE HYDROCHLORIDE|NOREPINEPHRINE|EPHEDRINE|PROPRANOLOL|PROPRANOLOL|LABETALOL|ISOPROTERENOL|NEBIVOLOL|SALMETEROL XINAFOATE|SALMETEROL XINAFOATE,Small molecule,Adrenergic receptor agonist|Beta-2 adrenergic receptor partial agonist|Beta-2 adrenergic receptor antagonist|Adrenergic receptor antagonist|Adrenergic receptor beta antagonist|Adrenergic receptor beta agonist|Beta-2 adrenergic receptor agonist,True,False,True,HIGH - Approved drugs exist,Beta-2 adrenergic receptor,Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine,3D-structure|Cell membrane|Disulfide bond|Endosome|G-protein coupled receptor|Glycoprotein|Golgi apparatus|Hydroxylation|Lipoprotein|Membrane|Palmitate|Phosphoprotein|Proteomics identification|Receptor|Reference proteome|Transducer|Transmembrane|Transmembrane helix|Ubl conjugation,Belongs to the G-protein coupled receptor 1 family. Adrenergic receptor subfamily. ADRB2 sub-subfamily,PF00001:7tm_1,1,IPR002233:ADR_fam|IPR000332:ADRB2_rcpt|IPR000276:GPCR_Rhodpsn|IPR017452:GPCR_Rhodpsn_7TM,4,,domain|family,True,GPCR,HIGH,GPCR: Keyword: g-protein coupled receptor|GPCR: InterPro: IPR000276|GPCR: InterPro: IPR017452|GPCR: Pfam: PF00001,GPCR,True,138,1GQ4|2R4R|2R4S|2RH1|3D4S|3KJ6|3NY8|3NY9|3NYA|3P0G,1GQ4,1.9,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1GQ4.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1GQ4.pdb,Excellent (<2.0Å),True,7,5.0,389.616,0.095,11.545,0.049,True,6,Moderate,Low,Adequate volume (390A3),Low druggability (0.10),692|432|271|493|390|391|205,0.04|0.00|0.00|0.03|0.10|0.00,P1:Vol=692:Drug=0.04|P2:Vol=432:Drug=0.00|P3:Vol=271:Drug=0.00|P4:Vol=493:Drug=0.03|P5:Vol=390:Drug=0.10|P6:Vol=391:Drug=0.00|P7:Vol=205:Drug=0.00
ADRB1,ADRB1,adrenoceptor beta 1,"The adrenergic receptors (subtypes alpha 1, alpha 2, beta 1, and beta 2) are a prototypic family of guanine nucleotide binding regulatory protein-coupled receptors that mediate the physiological effects of the hormone epinephrine and the neurotransmitter norepinephrine. Beta-1 adrenoceptors are predominately located in the heart. Specific polymorphisms in this gene have been shown to affect the resting heart rate and can be involved in heart failure. [provided by RefSeq, Sep 2019].",protein-coding,ADRB1R|B1AR|BETA1AR|FNSS2|RHR,"adrenergic, beta-1-, receptor|beta-1 adrenergic receptor|beta-1 adrenoceptor|beta-1 adrenoreceptor",ENSG00000043591,ENST00000369295,ENSP00000358301,P08588,,ADRB1_HUMAN,153.0,NM_000684.3,NP_000675.1,NC_000010.11|NC_060934.1|NG_012187.1,285.0,109630.0,PA38,9606.ENSP00000358301,2LSQ|7BTS|7BU6|7BU7|7BVQ,,IPR000276|IPR000507|IPR002233|IPR017452,PF00001,PS50262,10,114043866.0,114046904.0,1.0,477.0,Cell membrane|Early endosome,9606.0,20171.0,Beta-1 adrenergic receptor,kegg:hsa04020|kegg:hsa04022|kegg:hsa04024|kegg:hsa04080|kegg:hsa04261|reactome:R-HSA-162582|reactome:R-HSA-372790|reactome:R-HSA-373076|reactome:R-HSA-375280|reactome:R-HSA-388396|smpdb:SMP00296|smpdb:SMP00297|smpdb:SMP00298|smpdb:SMP00299|smpdb:SMP00300|wikipathways:WP2197|wikipathways:WP3298|wikipathways:WP455|wikipathways:WP536|wikipathways:WP58,True,adrenoceptor beta 1,88,69,BRETYLIUM|PINDOLOL|BISOPROLOL|FLECAINIDE ACETATE|METIPRANOLOL|METOPROLOL|ATENOLOL|BUCINDOLOL HYDROCHLORIDE|METIPRANOLOL HYDROCHLORIDE|ALPRENOLOL|PRACTOLOL|XAMOTEROL|PENBUTOLOL|DOBUTAMINE|BETHANIDINE|BETAXOLOL|MURAGLITAZAR|ACEBUTOLOL|LABETALOL HYDROCHLORIDE|ACEBUTOLOL HYDROCHLORIDE,BRETYLIUM|PINDOLOL|BISOPROLOL|FLECAINIDE ACETATE|METIPRANOLOL|METOPROLOL|ATENOLOL|METIPRANOLOL HYDROCHLORIDE|PRACTOLOL|XAMOTEROL,PRACTOLOL|ARBUTAMINE|CARTEOLOL|ACEBUTOLOL|BUFURALOL,G PROTEIN COUPLED RECEPTOR|DRUGGABLE GENOME,agonist|inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons|Therapeutic Target Database|The ChEMBL Bioactivity Database|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)",True,CHEMBL5465184,SINGLE PROTEIN,0,0,1,1,1,True,824,25,0,0,0,PROPAFENONE HYDROCHLORIDE|PENBUTOLOL|NOREPINEPHRINE|PROPRANOLOL|CELIPROLOL|LABETALOL|NADOLOL|ACEBUTOLOL|BISOPROLOL|XAMOTEROL,Small molecule,Adrenergic receptor agonist|Beta-1 adrenergic receptor partial agonist|Beta-1 adrenergic receptor agonist|Adrenergic receptor beta antagonist|Adrenergic receptor antagonist|Beta-1 adrenergic receptor antagonist|Adrenergic receptor beta agonist,True,False,True,HIGH - Approved drugs exist,Beta-1 adrenergic receptor,Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling. Involved in the regulation of sleep/wake behaviors (PubMed:31473062),3D-structure|Cell membrane|Disulfide bond|Endosome|G-protein coupled receptor|Glycoprotein|Lipoprotein|Membrane|Palmitate|Phosphoprotein|Proteomics identification|Receptor|Reference proteome|Transducer|Transmembrane|Transmembrane helix,Belongs to the G-protein coupled receptor 1 family. Adrenergic receptor subfamily. ADRB1 sub-subfamily,PF00001:7tm_1,1,IPR002233:ADR_fam|IPR000507:ADRB1_rcpt|IPR000276:GPCR_Rhodpsn|IPR017452:GPCR_Rhodpsn_7TM,4,,domain|family,True,GPCR,HIGH,GPCR: Keyword: g-protein coupled receptor|GPCR: InterPro: IPR000276|GPCR: InterPro: IPR017452|GPCR: Pfam: PF00001,GPCR,True,6,2LSQ|7BTS|7BU6|7BU7|7BVQ|8S2T,2LSQ,,SOLUTION NMR,protein_structures/pdb_experimental/2LSQ.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/2LSQ.pdb,,True,1,1.0,388.968,0.157,11.857,0.352,True,1,Moderate,Low,Adequate volume (389A3),Low druggability (0.16),389,0.16,P1:Vol=389:Drug=0.16
ADRA1A,ADRA1D,adrenoceptor alpha 1D,"Alpha-1-adrenergic receptors (alpha-1-ARs) are members of the G protein-coupled receptor superfamily. They activate mitogenic responses and regulate growth and proliferation of many cells. There are 3 alpha-1-AR subtypes: alpha-1A, -1B and -1D, all of which signal through the Gq/11 family of G-proteins and different subtypes show different patterns of activation. This gene encodes alpha-1D-adrenergic receptor. Similar to alpha-1B-adrenergic receptor gene, this gene comprises 2 exons and a single intron that interrupts the coding region. [provided by RefSeq, Jul 2008].",protein-coding,ADRA1|ADRA1A|ADRA1R|ALPHA1|DAR|dJ779E11.2,"adrenergic, alpha -1D-, receptor|adrenergic, alpha-1A-, receptor|alpha-1A adrenergic receptor|alpha-1D adrenergic receptor|alpha-1D adrenoceptor",ENSG00000171873,ENST00000379453|ENST00000621688,ENSP00000368766,P25100,B0ZBE0,ADA1D_HUMAN,146.0,NM_000678.4,NP_000669.1,NC_000020.11|NC_060944.1,280.0,104219.0,PA24597,9606.ENSP00000368766,,,IPR000276|IPR000363|IPR002233|IPR017452,PF00001,PS50262,20,4220630.0,4249287.0,-1.0,572.0,Cell membrane,9606.0,551.0,Alpha-1D adrenergic receptor,kegg:hsa04020|kegg:hsa04022|kegg:hsa04080|kegg:hsa04261|kegg:hsa04270|reactome:R-HSA-162582|reactome:R-HSA-372790|reactome:R-HSA-373076|reactome:R-HSA-375280|reactome:R-HSA-388396|wikipathways:WP117|wikipathways:WP455|wikipathways:WP536|wikipathways:WP58,True,adrenoceptor alpha 1A,96,81,"PROPIOMAZINE|METHOTRIMEPRAZINE|METHOXAMINE|EPHEDRINE|ALFUZOSIN|TAMSULOSIN HYDROCHLORIDE|MIDODRINE|BUNAZOSIN|PHENTOLAMINE|PHENYLEPHRINE BITARTRATE|THIORIDAZINE|DISULFIRAM|DIPIVEFRIN HYDROCHLORIDE|ERGOLOID MESYLATES, USP|TRIMIPRAMINE MALEATE|R-SPONDIN-2|PHENDIMETRAZINE|HYDROXYAMPHETAMINE HYDROBROMIDE|LABETALOL HYDROCHLORIDE|PHENYLEPHRINE",PROPIOMAZINE|METHOTRIMEPRAZINE|METHOXAMINE|EPHEDRINE|ALFUZOSIN|TAMSULOSIN HYDROCHLORIDE|MIDODRINE|PHENTOLAMINE|PHENYLEPHRINE BITARTRATE|THIORIDAZINE,PHENYLPROPANOLAMINE|NICERGOLINE|MEPHENTERMINE|ALFUZOSIN HYDROCHLORIDE|DAPIPRAZOLE HYDROCHLORIDE,DRUGGABLE GENOME|G PROTEIN COUPLED RECEPTOR,agonist|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Guide to Pharmacology|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL2111447,SELECTIVITY GROUP,0,0,100,100,103,True,648,25,0,0,0,DOXAZOSIN MESYLATE|TAMSULOSIN HYDROCHLORIDE|TAMSULOSIN HYDROCHLORIDE|TAMSULOSIN HYDROCHLORIDE|ALFUZOSIN HYDROCHLORIDE|TERAZOSIN|ALFUZOSIN|TAMSULOSIN|TAMSULOSIN|TAMSULOSIN,Unknown|Small molecule,Adrenergic receptor agonist|Adrenergic receptor alpha-1 antagonist|Adrenergic receptor alpha antagonist|Adrenergic receptor alpha-1 agonist|Adrenergic receptor antagonist,True,False,True,HIGH - Approved drugs exist,Alpha-1D adrenergic receptor,This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium,Cell membrane|G-protein coupled receptor|Glycoprotein|Lipoprotein|Membrane|Palmitate|Receptor|Reference proteome|Transducer|Transmembrane|Transmembrane helix,Belongs to the G-protein coupled receptor 1 family. Adrenergic receptor subfamily. ADRA1D sub-subfamily,PF00001:7tm_1,1,IPR002233:ADR_fam|IPR000363:ADRA1D_rcpt|IPR000276:GPCR_Rhodpsn|IPR017452:GPCR_Rhodpsn_7TM,4,,domain|family,True,GPCR,HIGH,GPCR: Keyword: g-protein coupled receptor|GPCR: InterPro: IPR000276|GPCR: InterPro: IPR017452|GPCR: Pfam: PF00001,GPCR,False,0,,,,,,True,2025-08-01T00:00:00Z,,Unknown,,,,,False,0,,,,,,False,0,,,,,,,
DRD2,DRD2,dopamine receptor D2,"This gene encodes the D2 subtype of the dopamine receptor. This G-protein coupled receptor inhibits adenylyl cyclase activity. A missense mutation in this gene causes myoclonus dystonia; other mutations have been associated with schizophrenia. Alternative splicing of this gene results in two transcript variants encoding different isoforms. A third variant has been described, but it has not been determined whether this form is normal or due to aberrant splicing. [provided by RefSeq, Jul 2008].",protein-coding,D2DR|D2R,D(2) dopamine receptor|dopamine D2 receptor|seven transmembrane helix receptor,ENSG00000149295,ENST00000346454|ENST00000362072|ENST00000535984|ENST00000538967|ENST00000539420|ENST00000540600|ENST00000542616|ENST00000542968|ENST00000543292|ENST00000544518,ENSP00000278597|ENSP00000354859|ENSP00000438215|ENSP00000438419|ENSP00000441068|ENSP00000441474|ENSP00000442172|ENSP00000577544|ENSP00000577545|ENSP00000577546,P14416,F8VUV1|Q6LDH7|A0A1Y8EK52,DRD2_HUMAN,1813.0,NM_000795.4|NM_001440368.1|NM_016574.4|XM_017017296.3|XM_047426511.1|XM_054367935.1|XM_054367936.1,NP_000786.1|NP_001427297.1|NP_057658.2|XP_016872785.1|XP_047282467.1|XP_054223910.1|XP_054223911.1,NC_000011.10|NC_060935.1|NG_008841.1,3023.0,126450.0,PA27478,9606.ENSP00000354859,5AER|6CM4|6LUQ|6VMS|7DFP|7JVR|8IRS|8TZQ|8U02,,IPR000276|IPR000929|IPR001922|IPR017452,PF00001,PS50262,11,113409605.0,113476402.0,-1.0,443.0,Cell membrane|Golgi apparatus membrane,9606.0,22561.0,Dopamine receptor D2,kegg:hsa04015|kegg:hsa04024|kegg:hsa04080|kegg:hsa04540|kegg:hsa04728|reactome:R-HSA-162582|reactome:R-HSA-372790|reactome:R-HSA-373076|reactome:R-HSA-375280|reactome:R-HSA-390651|wikipathways:WP1602|wikipathways:WP2636|wikipathways:WP4222|wikipathways:WP455|wikipathways:WP4657,True,dopamine receptor D2,254,131,ASENAPINE|MEPHENTERMINE|HALOPERIDOL LACTATE|BREXPIPRAZOLE|ANALGESIC AGENT|AXITINIB|RG-1530|LOXAPINE SUCCINATE|QUETIAPINE FUMARATE|PROCHLORPERAZINE|APOMORPHINE|PRAMIPEXOLE|THIETHYLPERAZINE MALEATE|IBCASERTIB|FAMITINIB|SOXATALTINIB|SUMANIROLE|DOCARPAMINE|PALIPERIDONE|PRIDOPIDINE,ASENAPINE|MEPHENTERMINE|HALOPERIDOL LACTATE|BREXPIPRAZOLE|AXITINIB|LOXAPINE SUCCINATE|QUETIAPINE FUMARATE|PROCHLORPERAZINE|APOMORPHINE|PRAMIPEXOLE,NEMONAPRIDE|PRIDOPIDINE|JNJ-37822681|BROMPERIDOL|5-OH-DPAT,G PROTEIN COUPLED RECEPTOR|DRUGGABLE GENOME|TRANSPORTER|RNA DIRECTED DNA POLYMERASE|DRUG RESISTANCE|PROTEASE INHIBITOR|PROTEIN PHOSPHATASE|TRANSCRIPTION FACTOR COMPLEX|TRANSCRIPTION FACTOR BINDING|GROWTH FACTOR|DRUG METABOLISM|PROTEASE|ABC TRANSPORTER|NUCLEAR HORMONE RECEPTOR|HORMONE ACTIVITY|EXTERNAL SIDE OF PLASMA MEMBRANE|PHOSPHOLIPASE|HISTONE MODIFICATION|KINASE|DNA REPAIR|ION CHANNEL|TYROSINE KINASE|SERINE THREONINE KINASE|NEUTRAL ZINC METALLOPEPTIDASE|LIPID KINASE|TUMOR SUPPRESSOR|CELL SURFACE,antibody|inverse agonist|modulator|agonist|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|NCI Cancer Gene Index|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Guide to Pharmacology|Drug Target Commons|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL217,SINGLE PROTEIN,0,0,675,675,1000,True,1164,25,0,0,0,BROMOCRIPTINE MESYLATE|ERGOLOID MESYLATES|BROMOCRIPTINE MESYLATE|TRIFLUOPERAZINE HYDROCHLORIDE|HALOPERIDOL|CHLORPROMAZINE|FLUPHENAZINE HYDROCHLORIDE|ARIPIPRAZOLE|RISPERIDONE|ARIPIPRAZOLE,Unknown|Small molecule,D2-like dopamine receptor antagonist|D2-like dopamine receptor inverse agonist|Dopamine D2 receptor partial agonist|D2-like dopamine receptor agonist|Dopamine D2 receptor antagonist|Dopamine receptor agonist,True,False,True,HIGH - Approved drugs exist,D(2) dopamine receptor,"Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase (PubMed:21645528). Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)",3D-structure|Alternative splicing|Cell membrane|Disulfide bond|G-protein coupled receptor|Glycoprotein|Golgi apparatus|Lipoprotein|Membrane|Palmitate|Receptor|Reference proteome|Transducer|Transmembrane|Transmembrane helix,Belongs to the G-protein coupled receptor 1 family,PF00001:7tm_1,1,IPR001922:Dopamine_D2_rcpt|IPR000929:Dopamine_rcpt|IPR000276:GPCR_Rhodpsn|IPR017452:GPCR_Rhodpsn_7TM,4,,domain|family,True,GPCR,HIGH,GPCR: Keyword: g-protein coupled receptor|GPCR: InterPro: IPR000276|GPCR: InterPro: IPR017452|GPCR: Pfam: PF00001,GPCR,True,11,5AER|6CM4|6LUQ|6VMS|7DFP|7JVR|8IRS|8TZQ|8U02|9BS9,5AER,2.19,X-RAY DIFFRACTION,protein_structures/pdb_experimental/5AER.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/5AER.pdb,Good (2.0-2.5Å),True,12,1.0,640.15,0.325,21.5,0.366,True,8,Moderate,Low,Optimal volume (640A3),Low druggability (0.33),640|179|105|276|194|448|198|288|207|288|226|220,0.33|0.01|0.00|0.00|0.01,P1:Vol=640:Drug=0.33|P2:Vol=179:Drug=0.01|P3:Vol=105:Drug=0.00|P4:Vol=276:Drug=0.00|P5:Vol=194:Drug=0.00|P6:Vol=448:Drug=0.00|P7:Vol=198:Drug=0.00|P8:Vol=288:Drug=0.00|P9:Vol=207:Drug=0.01|P10:Vol=288:Drug=0.00
DRD3,DRD3,dopamine receptor D3,"This gene encodes the D3 subtype of the five (D1-D5) dopamine receptors. The activity of the D3 subtype receptor is mediated by G proteins which inhibit adenylyl cyclase. This receptor is localized to the limbic areas of the brain, which are associated with cognitive, emotional, and endocrine functions. Genetic variation in this gene may be associated with susceptibility to hereditary essential tremor 1. Alternative splicing of this gene results in transcript variants encoding different isoforms, although some variants may be subject to nonsense-mediated decay (NMD). [provided by RefSeq, Jul 2008].",protein-coding,D3DR|ETM1|FET1,D(3) dopamine receptor|essential tremor 1,ENSG00000151577,ENST00000295881|ENST00000383673|ENST00000460779|ENST00000467632|ENST00000698213,ENSP00000295881|ENSP00000373169|ENSP00000419402|ENSP00000420662|ENSP00000513607,P35462,A8K8E4|E9PCM4|A1A4V4|X5D2G4|A0A8V8TLH3,DRD3_HUMAN,1814.0,NM_000796.6|NM_001282563.2|NM_001290809.1|NM_033658.1|NM_033659.1|NM_033660.1|NM_033663.6,NP_000787.2|NP_001269492.1|NP_001277738.1|NP_387512.3,NC_000003.12|NC_060927.1|NG_008842.3,3024.0,126451.0,PA27479,9606.ENSP00000373169,3PBL|7CMU|7CMV|8IRT|9F33|9F34,,IPR000276|IPR000929|IPR001620|IPR017452,PF00001,PS50262,3,114127580.0,114199407.0,-1.0,400.0,Cell membrane,9606.0,623.0,Dopamine receptor D3,kegg:hsa04080|kegg:hsa04728|reactome:R-HSA-162582|reactome:R-HSA-372790|reactome:R-HSA-373076|reactome:R-HSA-375280|reactome:R-HSA-388396|wikipathways:WP117|wikipathways:WP1602|wikipathways:WP455|wikipathways:WP58,True,dopamine receptor D3,105,57,SUNITINIB|CHEMBL:CHEMBL1256698|MOTESANIB|CATEQUENTINIB|PRAMIPEXOLE|TIAPRIDE|OLANZAPINE|LEVODOPA|CHLORPROTHIXENE|TRIFLUOPERAZINE HYDROCHLORIDE|TAFETINIB|ATORVASTATIN CALCIUM TRIHYDRATE|ASENAPINE|CHLORPROMAZINE|DOVITINIB|TALIPEXOLE HYDROCHLORIDE|CEDIRANIB|SITRAVATINIB|PROMAZINE HYDROCHLORIDE|BROMOCRIPTINE MESYLATE,SUNITINIB|PRAMIPEXOLE|OLANZAPINE|LEVODOPA|CHLORPROTHIXENE|TRIFLUOPERAZINE HYDROCHLORIDE|ATORVASTATIN CALCIUM TRIHYDRATE|ASENAPINE|CHLORPROMAZINE|PROMAZINE HYDROCHLORIDE,CHEMBL:CHEMBL1256778|COMPOUND 38K [PMID: 34351741]|PRECLAMOL HYDROCHLORIDE|ABT-925|VEGFD,G PROTEIN COUPLED RECEPTOR|DRUGGABLE GENOME|TRANSPORTER|RNA DIRECTED DNA POLYMERASE|DRUG RESISTANCE|PROTEASE INHIBITOR|PROTEIN PHOSPHATASE|TRANSCRIPTION FACTOR COMPLEX|TRANSCRIPTION FACTOR BINDING|GROWTH FACTOR|DRUG METABOLISM|PROTEASE|ABC TRANSPORTER|NUCLEAR HORMONE RECEPTOR|HORMONE ACTIVITY|EXTERNAL SIDE OF PLASMA MEMBRANE|PHOSPHOLIPASE|HISTONE MODIFICATION|KINASE|DNA REPAIR|ION CHANNEL|TYROSINE KINASE|SERINE THREONINE KINASE|NEUTRAL ZINC METALLOPEPTIDASE|LIPID KINASE|TUMOR SUPPRESSOR|CELL SURFACE,inverse agonist|agonist|modulator|inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Guide to Pharmacology|Drug Target Commons|The ChEMBL Bioactivity Database|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)",True,CHEMBL234,SINGLE PROTEIN,0,0,864,864,1000,True,468,25,0,0,0,BROMOCRIPTINE MESYLATE|ERGOLOID MESYLATES|BROMOCRIPTINE MESYLATE|HALOPERIDOL|TRIFLUOPERAZINE HYDROCHLORIDE|CHLORPROMAZINE|APOMORPHINE|HALOPERIDOL|ROPINIROLE HYDROCHLORIDE|ROTIGOTINE,Unknown|Small molecule,D2-like dopamine receptor antagonist|D2-like dopamine receptor inverse agonist|Dopamine receptor antagonist|D2-like dopamine receptor agonist|Dopamine D3 receptor modulator|Dopamine receptor agonist,True,False,True,HIGH - Approved drugs exist,D(3) dopamine receptor,Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation,3D-structure|Alternative splicing|Cell membrane|Disulfide bond|G-protein coupled receptor|Glycoprotein|Lipoprotein|Membrane|Palmitate|Receptor|Reference proteome|Schizophrenia|Transducer|Transmembrane|Transmembrane helix,Belongs to the G-protein coupled receptor 1 family,PF00001:7tm_1,1,IPR001620:Dopamine_D3_rcpt|IPR000929:Dopamine_rcpt|IPR000276:GPCR_Rhodpsn|IPR017452:GPCR_Rhodpsn_7TM,4,,domain|family,True,GPCR,HIGH,GPCR: Keyword: g-protein coupled receptor|GPCR: InterPro: IPR000276|GPCR: InterPro: IPR017452|GPCR: Pfam: PF00001,GPCR,True,6,3PBL|7CMU|7CMV|8IRT|9F33|9F34,3PBL,2.89,X-RAY DIFFRACTION,protein_structures/pdb_experimental/3PBL.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/3PBL.pdb,Moderate (2.5-3.0Å),True,71,1.0,1129.334,0.962,41.233,0.577,True,57,Excellent,High,Optimal volume (1129A3)|High druggability (0.96),,1129|302|2855|379|134|363|291|203|135|123|97|1688|1164|283|384|199|400|83|233|188|166|296|272|261|173|314|230|272|274|202|199|225|184|282|200|230|234|125|307|499|132|351|286|476|252|268|214|365|251|267|237|263|266|262|306|480|232|321|383|166|346|312|234|274|233|318|462|647|631|502|1013,0.96|0.50|0.00|0.07|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.03|0.01|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.61|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.22|0.01|0.00|0.01|0.00|0.00|0.03|0.01|0.00,P1:Vol=1129:Drug=0.96|P2:Vol=302:Drug=0.50|P3:Vol=2855:Drug=0.00|P4:Vol=379:Drug=0.07|P5:Vol=134:Drug=0.00|P6:Vol=363:Drug=0.01|P7:Vol=291:Drug=0.00|P8:Vol=203:Drug=0.00|P9:Vol=135:Drug=0.00|P10:Vol=123:Drug=0.00
HTR1A,HTR1A,5-hydroxytryptamine receptor 1A,"This gene encodes a G protein-coupled receptor for 5-hydroxytryptamine (serotonin), and belongs to the 5-hydroxytryptamine receptor subfamily. Serotonin has been implicated in a number of physiologic processes and pathologic conditions. Inactivation of this gene in mice results in behavior consistent with an increased anxiety and stress response. Mutation in the promoter of this gene has been associated with menstrual cycle-dependent periodic fevers. [provided by RefSeq, Jun 2012].",protein-coding,5-HT-1A|5-HT1A|5HT1a|ADRB2RL1|ADRBRL1|G-21|PFMCD,"5-HT1a receptor|5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled|5-hydroxytryptamine receptor 1A|guanine nucleotide-binding regulatory protein-coupled receptor",ENSG00000178394,ENST00000323865|ENST00000506598,ENSP00000316244|ENSP00000423433,P08908,A8K5W4|Q5ZGX3|D6RA34,5HT1A_HUMAN,3350.0,NM_000524.4,NP_000515.2,NC_000005.10|NC_060929.1|NG_032816.1,5286.0,109760.0,PA192,9606.ENSP00000316244,7E2X|7E2Y|7E2Z|8FY8|8FYE|8FYL|8FYT|8FYX|8JSP|8JT6|8PJK|8PKM|8W8B,,IPR000610|IPR000276|IPR002231|IPR017452,PF00001,PS50262,5,63957874.0,63962507.0,-1.0,422.0,"Cell membrane|Cell projection, dendrite",9606.0,20148.0,5-HT1A receptor,kegg:hsa04024|kegg:hsa04080|kegg:hsa04726|kegg:hsa04742|reactome:R-HSA-162582|reactome:R-HSA-372790|reactome:R-HSA-373076|reactome:R-HSA-375280|reactome:R-HSA-390666|smpdb:SMP00392|smpdb:SMP00393|smpdb:SMP00394|smpdb:SMP00395|smpdb:SMP00396|wikipathways:WP3944|wikipathways:WP3947|wikipathways:WP455|wikipathways:WP58|wikipathways:WP706,True,5-hydroxytryptamine receptor 1A,74,41,SERTRALINE HYDROCHLORIDE|QUETIAPINE FUMARATE|FLIBANSERIN|SARIZOTAN HYDROCHLORIDE|LISURIDE|CLOZAPINE|BIFEPRUNOX|DU 125530|ILOPERIDONE|XALIPRODEN|BUSPIRONE HYDROCHLORIDE|ENSACULIN HYDROCHLORIDE|VORTIOXETINE HYDROBROMIDE|NORTRIPTYLINE|ELTOPRAZINE|ARIPIPRAZOLE LAUROXIL|METHYSERGIDE|TRAZODONE|PIROMELATINE|ULOTARONT,SERTRALINE HYDROCHLORIDE|QUETIAPINE FUMARATE|FLIBANSERIN|CLOZAPINE|ILOPERIDONE|BUSPIRONE HYDROCHLORIDE|VORTIOXETINE HYDROBROMIDE|NORTRIPTYLINE|ARIPIPRAZOLE LAUROXIL|METHYSERGIDE,XALIPRODEN|GEPIRONE|MN-305|NALUZOTAN|LECOZOTAN HYDROCHLORIDE,G PROTEIN COUPLED RECEPTOR|DRUGGABLE GENOME|CELL SURFACE,agonist|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL3638345,SINGLE PROTEIN,0,0,53,53,53,True,270,25,0,0,0,ERGOLOID MESYLATES|DEXFENFLURAMINE|ARIPIPRAZOLE|ARIPIPRAZOLE|AMISULPRIDE|BUSPIRONE|ARIPIPRAZOLE|ARIPIPRAZOLE|ARIPIPRAZOLE|BREXPIPRAZOLE,Unknown|Small molecule,Serotonin (5-HT) receptor antagonist|Serotonin (5-HT) receptor agonist|Serotonin 1a (5-HT1a) receptor partial agonist|Serotonin 1a (5-HT1a) receptor agonist,True,False,True,HIGH - Approved drugs exist,5-hydroxytryptamine receptor 1A,"G-protein coupled receptor for 5-hydroxytryptamine (serotonin) (PubMed:22957663, PubMed:3138543, PubMed:33762731, PubMed:37935376, PubMed:37935377, PubMed:8138923, PubMed:8393041). Also functions as a receptor for various drugs and psychoactive substances (PubMed:22957663, PubMed:3138543, PubMed:33762731, PubMed:38552625, PubMed:8138923, PubMed:8393041). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (PubMed:22957663, PubMed:3138543, PubMed:33762731, PubMed:8138923, PubMed:8393041). HTR1A is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission: signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores (PubMed:33762731, PubMed:35610220). Beta-arrestin family members regulate signaling by mediating both receptor desensitization and resensitization processes (PubMed:18476671, PubMed:20363322, PubMed:20945968). Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism (PubMed:18476671, PubMed:20363322, PubMed:20945968). Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior (PubMed:18476671, PubMed:20363322, PubMed:20945968). Plays a role in the response to anxiogenic stimuli (PubMed:18476671, PubMed:20363322, PubMed:20945968)",3D-structure|Behavior|Cell membrane|Cell projection|Disulfide bond|G-protein coupled receptor|Glycoprotein|Membrane|Proteomics identification|Receptor|Reference proteome|Transducer|Transmembrane|Transmembrane helix,Belongs to the G-protein coupled receptor 1 family. 5-hydroxytryptamine receptor subfamily. HTR1A sub-subfamily,PF00001:7tm_1,1,IPR000610:5HT1A_rcpt|IPR002231:5HT_rcpt|IPR000276:GPCR_Rhodpsn|IPR017452:GPCR_Rhodpsn_7TM,4,,domain|family,True,GPCR|Histone Acetyltransferase,HIGH,GPCR: Keyword: g-protein coupled receptor|GPCR: InterPro: IPR000276|GPCR: InterPro: IPR017452|GPCR: Pfam: PF00001|Histone Acetyltransferase: Keyword: hat,GPCR,True,25,7E2X|7E2Y|7E2Z|8FY8|8FYE|8FYL|8FYT|8FYX|8JSP|8JT6,7E2X,3.0,ELECTRON MICROSCOPY,protein_structures/pdb_experimental/7E2X.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/7E2X.pdb,Moderate (2.5-3.0Å),True,78,1.0,788.965,0.912,60.154,0.654,True,55,Excellent,High,Optimal volume (789A3)|High druggability (0.91),,789|936|349|447|210|272|174|239|113|112|543|58|444|304|121|864|470|93|270|165|139|1148|248|380|575|206|322|358|383|351|246|173|108|91|1213|401|567|200|107|214|508|255|120|282|229|288|161|244|94|149|119|179|292|363|326|388|132|252|382|194|313|298|362|326|410|187|381|323|440|203|371|421|486|238|345|525|675|716,0.91|0.61|0.03|0.01|0.00|0.03|0.00|0.02|0.01|0.00|0.00|0.00|0.00|0.12|0.00|0.01|0.01|0.01|0.01|0.01|0.00|0.11|0.00|0.01|0.00|0.01|0.00|0.04|0.00|0.00|0.00|0.00|0.83|0.00|0.00|0.01|0.01|0.01|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.03|0.06|0.05,P1:Vol=789:Drug=0.91|P2:Vol=936:Drug=0.61|P3:Vol=349:Drug=0.03|P4:Vol=447:Drug=0.01|P5:Vol=210:Drug=0.00|P6:Vol=272:Drug=0.03|P7:Vol=174:Drug=0.00|P8:Vol=239:Drug=0.02|P9:Vol=113:Drug=0.01|P10:Vol=112:Drug=0.00
HTR1B,HTR1B,5-hydroxytryptamine receptor 1B,"The protein encoded by this intronless gene is a G-protein coupled receptor for serotonin (5-hydroxytryptamine). Ligand binding activates second messengers that inhibit the activity of adenylate cyclase and manage the release of serotonin, dopamine, and acetylcholine in the brain. The encoded protein may be involved in several neuropsychiatric disorders and therefore is often a target of antidepressant and other psychotherapeutic drugs. [provided by RefSeq, Nov 2015].",protein-coding,5-HT-1B|5-HT-1D-beta|5-HT1B|5-HT1DB|HTR1D2|HTR1DB|S12,"5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled|5-hydroxytryptamine receptor 1B|serotonin 1D beta receptor|serotonin receptor 1B",ENSG00000135312,ENST00000369947,ENSP00000358963,P28222,A8K215|X5D7I5,5HT1B_HUMAN,3351.0,NM_000863.3,NP_000854.1,NC_000006.12|NC_060930.1,5287.0,182131.0,PA29549,9606.ENSP00000358963,4IAQ|4IAR|5V54|6G79|7C61,,IPR000276|IPR002147|IPR002231|IPR017452,PF00001,PS50262,6,77460924.0,77463491.0,-1.0,390.0,Cell membrane,9606.0,669.0,5-HT1B receptor,kegg:hsa04024|kegg:hsa04080|kegg:hsa04726|kegg:hsa04742|reactome:R-HSA-162582|reactome:R-HSA-372790|reactome:R-HSA-373076|reactome:R-HSA-375280|reactome:R-HSA-388396|wikipathways:WP455|wikipathways:WP58,True,5-hydroxytryptamine receptor 1B,34,27,FLUPHENAZINE HYDROCHLORIDE|ALMOTRIPTAN MALATE|TRELANSERIN|SUMATRIPTAN|RIZATRIPTAN BENZOATE|DONITRIPTAN|AMISULPRIDE|NXN-188|ELTOPRAZINE|FROVATRIPTAN|CITALOPRAM|NARATRIPTAN HYDROCHLORIDE|FROVATRIPTAN SUCCINATE|ALMOTRIPTAN|ZOLMITRIPTAN|ELETRIPTAN|ERGOTAMINE|GSK163090|NEFAZODONE|LITHIUM,FLUPHENAZINE HYDROCHLORIDE|ALMOTRIPTAN MALATE|SUMATRIPTAN|RIZATRIPTAN BENZOATE|AMISULPRIDE|FROVATRIPTAN|CITALOPRAM|NARATRIPTAN HYDROCHLORIDE|FROVATRIPTAN SUCCINATE|ALMOTRIPTAN,DRUGSATFDA.NDA:016727|TRELANSERIN|NXN-188|FROVATRIPTAN|NARATRIPTAN HYDROCHLORIDE,G PROTEIN COUPLED RECEPTOR|DRUGGABLE GENOME,agonist|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL3459,SINGLE PROTEIN,0,0,688,688,1000,True,102,25,0,0,0,ERGOLOID MESYLATES|DEXFENFLURAMINE|AMISULPRIDE|AMISULPRIDE|ZIMELDINE|AMISULPRIDE|ALMOTRIPTAN|ELETRIPTAN|FROVATRIPTAN SUCCINATE|RIZATRIPTAN,Unknown|Small molecule,Serotonin (5-HT) receptor antagonist|Serotonin (5-HT) receptor agonist|Serotonin 1b (5-HT1b) receptor agonist,True,False,True,HIGH - Approved drugs exist,5-hydroxytryptamine receptor 1B,"G-protein coupled receptor for 5-hydroxytryptamine (serotonin) (PubMed:10452531, PubMed:1315531, PubMed:1328844, PubMed:1348246, PubMed:1351684, PubMed:1559993, PubMed:1565658, PubMed:1610347, PubMed:23519210, PubMed:23519215, PubMed:29925951, PubMed:8218242). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD) (PubMed:23519210, PubMed:23519215, PubMed:29925951). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (PubMed:10452531, PubMed:1315531, PubMed:1328844, PubMed:1348246, PubMed:1351684, PubMed:1559993, PubMed:1565658, PubMed:1610347, PubMed:23519210, PubMed:23519215, PubMed:29925951, PubMed:8218242). HTR1B is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission by inhibiting adenylate cyclase activity (PubMed:29925951, PubMed:35610220). Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways (PubMed:29925951). Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior (PubMed:18476671, PubMed:20945968). Besides, plays a role in vasoconstriction of cerebral arteries (PubMed:15853772)",3D-structure|Behavior|Cell membrane|Disulfide bond|G-protein coupled receptor|Glycoprotein|Lipoprotein|Membrane|Palmitate|Phosphoprotein|Proteomics identification|Receptor|Reference proteome|Transducer|Transmembrane|Transmembrane helix,Belongs to the G-protein coupled receptor 1 family,PF00001:7tm_1,1,IPR002147:5HT1B_rcpt|IPR002231:5HT_rcpt|IPR000276:GPCR_Rhodpsn|IPR017452:GPCR_Rhodpsn_7TM,4,,domain|family,True,GPCR|Histone Acetyltransferase,HIGH,GPCR: Keyword: g-protein coupled receptor|GPCR: InterPro: IPR000276|GPCR: InterPro: IPR017452|GPCR: Pfam: PF00001|Histone Acetyltransferase: Keyword: hat,GPCR,True,5,4IAQ|4IAR|5V54|6G79|7C61,4IAQ,2.8,X-RAY DIFFRACTION,protein_structures/pdb_experimental/4IAQ.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/4IAQ.pdb,Moderate (2.5-3.0Å),True,32,1.0,1364.468,0.989,42.97,0.92,True,26,Excellent,High,Optimal volume (1364A3)|High druggability (0.99),,1364|195|397|336|120|525|74|301|72|71|302|93|141|209|415|200|304|222|562|271|413|135|370|473|330|260|293|884|386|966|209|417,0.99|0.01|0.03|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.08|0.00|0.01|0.00|0.12|0.06|0.00|0.00|0.55|0.00|0.00|0.00,P1:Vol=1364:Drug=0.99|P2:Vol=195:Drug=0.01|P3:Vol=397:Drug=0.03|P4:Vol=336:Drug=0.01|P5:Vol=120:Drug=0.00|P6:Vol=525:Drug=0.00|P7:Vol=74:Drug=0.00|P8:Vol=301:Drug=0.00|P9:Vol=72:Drug=0.00|P10:Vol=71:Drug=0.00
HTR2A,HTR2A,5-hydroxytryptamine receptor 2A,"This gene encodes one of the receptors for serotonin, a neurotransmitter with many roles. Mutations in this gene are associated with susceptibility to schizophrenia and obsessive-compulsive disorder, and are also associated with response to the antidepressant citalopram in patients with major depressive disorder (MDD). MDD patients who also have a mutation in intron 2 of this gene show a significantly reduced response to citalopram as this antidepressant downregulates expression of this gene. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2009].",protein-coding,5-HT2A|HTR2,"5-HT2 receptor|5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled|5-hydroxytryptamine receptor 2A|serotonin 5-HT-2A receptor",ENSG00000102468,ENST00000542664|ENST00000543956|ENST00000612998|ENST00000941626|ENST00000941627,ENSP00000437737|ENSP00000441861|ENSP00000482708|ENSP00000611685|ENSP00000611686,P28223,A0A087WZJ9|A0A7P0PKG8,5HT2A_HUMAN,3356.0,NM_000621.5|NM_001165947.5|NM_001378924.1,NP_000612.1|NP_001159419.2|NP_001365853.1,NC_000013.11|NC_060937.1|NG_013011.1,5293.0,182135.0,PA193,9606.ENSP00000437737,6A93|6A94|6WGT|6WH4|6WHA|7RAN|7VOD|7VOE|7WC4|7WC5|7WC6|7WC7|7WC8|7WC9|8JT8|8UWL|8V6U|8ZMG,,IPR000276|IPR000455|IPR002231|IPR017452,PF00001,PS50262,13,46831546.0,46897076.0,-1.0,471.0,"Cell membrane|Cell projection, dendrite|Cell projection, axon",9606.0,68073.0,5-HT2A receptor,kegg:hsa04020|kegg:hsa04080|kegg:hsa04540|kegg:hsa04726|kegg:hsa04750|wikipathways:WP117|wikipathways:WP3944|wikipathways:WP3947|wikipathways:WP455|wikipathways:WP58,True,5-hydroxytryptamine receptor 2A,104,69,RISPERIDONE|THIORIDAZINE|BREXPIPRAZOLE|CHLORPROMAZINE HYDROCHLORIDE|PRUVANSERIN|OCAPERIDONE|IFERANSERIN|SARPOGRELATE|KETANSERIN|LOXAPINE|CHLORPROTHIXENE|CHLORPROMAZINE|VABICASERIN HYDROCHLORIDE|ARIPIPRAZOLE LAUROXIL|HALOPERIDOL DECANOATE|METHYSERGIDE|TRELANSERIN|MINAPRINE HYDROCHLORIDE|ZIPRASIDONE|QUETIAPINE FUMARATE,RISPERIDONE|THIORIDAZINE|BREXPIPRAZOLE|CHLORPROMAZINE HYDROCHLORIDE|LOXAPINE|CHLORPROTHIXENE|CHLORPROMAZINE|ARIPIPRAZOLE LAUROXIL|HALOPERIDOL DECANOATE|METHYSERGIDE,NELOTANSERIN|PRUVANSERIN|IFERANSERIN|TEMANOGREL|PIMAVANSERIN,G PROTEIN COUPLED RECEPTOR|DRUGGABLE GENOME|KINASE,inverse agonist|agonist|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|NCI Cancer Gene Index|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL5781,SINGLE PROTEIN,0,0,19,19,30,True,991,25,0,0,0,HALOPERIDOL|TRIFLUOPERAZINE HYDROCHLORIDE|CHLORPROMAZINE|ARIPIPRAZOLE|ARIPIPRAZOLE|DEXFENFLURAMINE|CHLORPROMAZINE|ZIPRASIDONE HYDROCHLORIDE|RISPERIDONE|RISPERIDONE,Small molecule,Serotonin (5-HT) receptor antagonist|Serotonin 2 receptors; 5-HT2a & 5-HT2c antagonist|Serotonin 2a (5-HT2a) receptor antagonist|Serotonin (5-HT) receptor agonist,True,False,True,HIGH - Approved drugs exist,5-hydroxytryptamine receptor 2A,(Microbial infection) Acts as a receptor for human JC polyomavirus/JCPyV,3D-structure|Alternative splicing|Behavior|Cell membrane|Cell projection|Cytoplasmic vesicle|Disulfide bond|G-protein coupled receptor|Glycoprotein|Host cell receptor for virus entry|Host-virus interaction|Membrane|Phosphoprotein|Proteomics identification|Receptor|Reference proteome|Synapse|Transducer|Transmembrane|Transmembrane helix,Belongs to the G-protein coupled receptor 1 family,PF00001:7tm_1,1,IPR000455:5HT2A_rcpt|IPR002231:5HT_rcpt|IPR000276:GPCR_Rhodpsn|IPR017452:GPCR_Rhodpsn_7TM,4,,domain|family,True,GPCR,HIGH,GPCR: Keyword: g-protein coupled receptor|GPCR: InterPro: IPR000276|GPCR: InterPro: IPR017452|GPCR: Pfam: PF00001,GPCR,True,32,6A93|6A94|6WGT|6WH4|6WHA|7RAN|7VOD|7VOE|7WC4|7WC5,6A93,3.0,X-RAY DIFFRACTION,protein_structures/pdb_experimental/6A93.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/6A93.pdb,Moderate (2.5-3.0Å),True,56,1.0,1717.391,0.999,50.667,0.723,True,44,Excellent,High,Optimal volume (1717A3)|High druggability (1.00),,1717|2118|847|421|284|182|118|351|213|344|566|302|346|72|355|288|553|220|230|202|256|209|246|225|67|214|235|289|185|178|123|211|403|231|150|153|239|130|296|556|437|289|336|444|177|330|251|466|348|624|375|489|455|481|300|781,1.00|1.00|0.46|0.00|0.01|0.01|0.00|0.01|0.00|0.00|0.38|0.00|0.00|0.08|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.04|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.01|0.00|0.01|0.01|0.00|0.00|0.01|0.01|0.08|0.00,P1:Vol=1717:Drug=1.00|P2:Vol=2118:Drug=1.00|P3:Vol=847:Drug=0.46|P4:Vol=421:Drug=0.00|P5:Vol=284:Drug=0.01|P6:Vol=182:Drug=0.01|P7:Vol=118:Drug=0.00|P8:Vol=351:Drug=0.01|P9:Vol=213:Drug=0.00|P10:Vol=344:Drug=0.00
HTR2C,HTR2C,5-hydroxytryptamine receptor 2C,"This gene encodes a seven-transmembrane G-protein-coupled receptor. The encoded protein responds to signaling through the neurotransmitter serotonin. The mRNA of this gene is subject to multiple RNA editing events, where adenosine residues encoded by the genome are converted to inosines. RNA editing is predicted to alter the structure of the second intracellular loop, thereby generating alternate protein forms with decreased ability to interact with G proteins. Abnormalities in RNA editing of this gene have been detected in victims of suicide that suffer from depression. In addition, naturally-occuring variation in the promoter and 5' non-coding and coding regions of this gene may show statistically-significant association with mental illness and behavioral disorders. Alternative splicing results in multiple different transcript variants. [provided by RefSeq, Jan 2015].",protein-coding,5-HT1C|5-HT2C|5-HTR2C|5HTR2C|HTR1C,"5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled|5-hydroxytryptamine receptor 1C|5-hydroxytryptamine receptor 2C|serotonin 5-HT-1C receptor|serotonin 5-HT-2C receptor",ENSG00000147246,ENST00000276198|ENST00000371950|ENST00000371951|ENST00000894573,ENSP00000276198|ENSP00000361018|ENSP00000361019|ENSP00000564632,P28335,K9J958,5HT2C_HUMAN,3358.0,NM_000868.4|NM_001256760.3|NM_001256761.3,NP_000859.2|NP_001243689.2|NP_001243690.2,NC_000023.11|NC_060947.1|NG_012082.3,5295.0,312861.0,PA194,9606.ENSP00000276198,6BQG|6BQH|8DPF|8DPG|8DPH|8DPI|8ZMF,,IPR000276|IPR000377|IPR002231|IPR017452,PF00001,PS50262,X,114584078.0,114910061.0,1.0,458.0,Cell membrane,9606.0,20242.0,5-HT2C receptor,biocarta:barrestinpathway|biocarta:barrestinsrcpathway|biocarta:barrmapkpathway|biocarta:chrebppathway|biocarta:cskpathway|kegg:hsa04020|kegg:hsa04080|kegg:hsa04540|kegg:hsa04726|kegg:hsa04750|reactome:R-HSA-162582|reactome:R-HSA-372790|reactome:R-HSA-373076|reactome:R-HSA-375280|reactome:R-HSA-388396|wikipathways:WP3944|wikipathways:WP3947|wikipathways:WP3998|wikipathways:WP455|wikipathways:WP58,True,5-hydroxytryptamine receptor 2C,136,53,SB 204741|QUINPIROLE|SB 221284|SERTINDOLE|METHIXENE HYDROCHLORIDE|TRAMADOL|5-MEO-DMT|AGOMELATINE|LISURIDE|CHLORPROTHIXENE|METHYLERGONOVINE|MESORIDAZINE|RS-102221|IDALOPIRDINE|S 16924|DOXEPIN HYDROCHLORIDE|LY344864|SB 243213|PROPIOMAZINE|TEDATIOXETINE,SERTINDOLE|METHIXENE HYDROCHLORIDE|TRAMADOL|AGOMELATINE|CHLORPROTHIXENE|METHYLERGONOVINE|MESORIDAZINE|DOXEPIN HYDROCHLORIDE|PROPIOMAZINE|LOXAPINE HYDROCHLORIDE,LORCASERIN HYDROCHLORIDE|LY334362|FR260010|LORCASERIN|YM348,G PROTEIN COUPLED RECEPTOR|DRUGGABLE GENOME|KINASE,agonist|inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Guide to Pharmacology|Therapeutic Target Database|The ChEMBL Bioactivity Database|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)",True,CHEMBL1770041,SINGLE PROTEIN,0,0,2,2,4,True,558,25,0,0,0,FENFLURAMINE|TRIFLUOPERAZINE HYDROCHLORIDE|DEXFENFLURAMINE|RISPERIDONE|RISPERIDONE|LORCASERIN|LORCASERIN|FENFLURAMINE|RISPERIDONE|AMISULPRIDE,Small molecule,Serotonin 2c (5-HT2c) receptor agonist|Serotonin 2c (5-HT2c) receptor antagonist|Serotonin (5-HT) receptor agonist|Serotonin (5-HT) receptor antagonist|Serotonin 2 receptors; 5-HT2a & 5-HT2c antagonist,True,False,True,HIGH - Approved drugs exist,5-hydroxytryptamine receptor 2C,"G-protein coupled receptor for 5-hydroxytryptamine (serotonin) (PubMed:12970106, PubMed:18703043, PubMed:19057895, PubMed:29398112, PubMed:7895773). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD) (PubMed:19057895, PubMed:29398112). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors (PubMed:18703043, PubMed:29398112). HTR2C is coupled to G(q)/G(11) G alpha proteins and activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca(2+) ions from intracellular stores, respectively (PubMed:18703043, PubMed:29398112). Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways (PubMed:29398112). Regulates neuronal activity via the activation of short transient receptor potential calcium channels in the brain, and thereby modulates the activation of pro-opiomelanocortin neurons and the release of CRH that then regulates the release of corticosterone (By similarity). Plays a role in the regulation of appetite and eating behavior, responses to anxiogenic stimuli and stress (By similarity). Plays a role in insulin sensitivity and glucose homeostasis (By similarity)",3D-structure|Alternative splicing|Behavior|Cell membrane|Disulfide bond|G-protein coupled receptor|Glycoprotein|Membrane|Receptor|Reference proteome|RNA editing|Signal|Transducer|Transmembrane|Transmembrane helix,Belongs to the G-protein coupled receptor 1 family,PF00001:7tm_1,1,IPR000377:5HT2C_rcpt|IPR002231:5HT_rcpt|IPR000276:GPCR_Rhodpsn|IPR017452:GPCR_Rhodpsn_7TM,4,,domain|family,True,Kinase|GPCR|Lipid Kinase|Ion Channel|Histone Acetyltransferase|Hydrolase,HIGH,GPCR: Keyword: g-protein coupled receptor|GPCR: InterPro: IPR000276|GPCR: InterPro: IPR017452|GPCR: Pfam: PF00001|Kinase: Keyword: kinase|Ion Channel: Keyword: calcium channel|Ion Channel: Keyword: transient receptor potential|Histone Acetyltransferase: Keyword: hat|Lipid Kinase: Keyword: phosphatidylinositol 3-kinase|Hydrolase: Keyword: lipase,Kinase,True,7,6BQG|6BQH|8DPF|8DPG|8DPH|8DPI|8ZMF,6BQG,3.0,X-RAY DIFFRACTION,protein_structures/pdb_experimental/6BQG.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/6BQG.pdb,Moderate (2.5-3.0Å),True,31,1.0,446.633,0.832,53.684,0.599,True,25,Excellent,High,Adequate volume (447A3)|High druggability (0.83),,447|1219|361|213|628|119|353|362|120|326|133|260|194|60|218|232|161|132|1553|292|273|206|222|348|423|245|314|212|174|338|311,0.83|0.68|0.06|0.13|0.50|0.01|0.00|0.08|0.00|0.03|0.00|0.00|0.00|0.00|0.00|0.11|0.00|0.00|0.01|0.01,P1:Vol=447:Drug=0.83|P2:Vol=1219:Drug=0.68|P3:Vol=361:Drug=0.06|P4:Vol=213:Drug=0.13|P5:Vol=628:Drug=0.50|P6:Vol=119:Drug=0.01|P7:Vol=353:Drug=0.00|P8:Vol=362:Drug=0.08|P9:Vol=120:Drug=0.00|P10:Vol=326:Drug=0.03
CHRM1,CHRM1,cholinergic receptor muscarinic 1,"The muscarinic cholinergic receptors belong to a larger family of G protein-coupled receptors. The functional diversity of these receptors is defined by the binding of acetylcholine and includes cellular responses such as adenylate cyclase inhibition, phosphoinositide degeneration, and potassium channel mediation. Muscarinic receptors influence many effects of acetylcholine in the central and peripheral nervous system. The muscarinic cholinergic receptor 1 is involved in mediation of vagally-induced bronchoconstriction and in the acid secretion of the gastrointestinal tract. The gene encoding this receptor is localized to 11q13. [provided by RefSeq, Jul 2008].",protein-coding,HM1|M1|M1R,"acetylcholine receptor, muscarinic 1|muscarinic acetylcholine receptor M1",ENSG00000168539,ENST00000306960|ENST00000536524|ENST00000543973|ENST00000856787|ENST00000856788,ENSP00000306490|ENSP00000441188|ENSP00000444482|ENSP00000526846|ENSP00000526847,P11229,F5GZF8|Q53XZ3,ACM1_HUMAN,1128.0,NM_000738.3|XM_011544742.3|XM_054367566.1,NP_000729.2|XP_011543044.1|XP_054223541.1,NC_000011.10|NC_060935.1,1950.0,118510.0,PA26484,9606.ENSP00000306490,5CXV|6OIJ|6WJC|6ZFZ|6ZG4|6ZG9,,IPR000276|IPR000995|IPR002228|IPR017452,PF00001,PS50262,11,62908679.0,62921877.0,-1.0,460.0,Cell membrane|Postsynaptic cell membrane,9606.0,20189.0,Muscarinic acetylcholine receptor M1,biocarta:agrpathway|biocarta:barrestinpathway|biocarta:barrestinsrcpathway|biocarta:barrmapkpathway|biocarta:chrebppathway|kegg:hsa04020|kegg:hsa04024|kegg:hsa04080|kegg:hsa04151|kegg:hsa04725|reactome:R-HSA-162582|reactome:R-HSA-372790|reactome:R-HSA-373076|reactome:R-HSA-375280|reactome:R-HSA-388396|wikipathways:WP2597|wikipathways:WP3932|wikipathways:WP4172|wikipathways:WP455|wikipathways:WP4698,True,cholinergic receptor muscarinic 1,95,78,DICYCLOMINE HYDROCHLORIDE|GLYCOPYRRONIUM|PROCYCLIDINE HYDROCHLORIDE|ATROPINE|ARECOLINE|GLYCOPYRRONIUM TOSYLATE|METHOTRIMEPRAZINE|BENZQUINAMIDE|BIPERIDEN HYDROCHLORIDE|BIPERIDEN|ISOPROPAMIDE IODIDE|CYCLOPENTOLATE|MINAPRINE|SCOPOLAMINE|OXYBUTYNIN|PILOCARPINE HYDROCHLORIDE|CLIDINIUM|DIPHENIDOL|PIPERTRAMINE|TRIHEXYPHENIDYL HYDROCHLORIDE,DICYCLOMINE HYDROCHLORIDE|GLYCOPYRRONIUM|PROCYCLIDINE HYDROCHLORIDE|ATROPINE|GLYCOPYRRONIUM TOSYLATE|METHOTRIMEPRAZINE|BENZQUINAMIDE|BIPERIDEN HYDROCHLORIDE|BIPERIDEN|ISOPROPAMIDE IODIDE,CYCRIMINE|TAK-071|AZD-6088|OXYPHENONIUM|PROCYCLIDINE HYDROCHLORIDE,G PROTEIN COUPLED RECEPTOR|DRUGGABLE GENOME,positive modulator|agonist|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL4295543,SINGLE PROTEIN,0,0,1,1,1,True,247,25,0,0,0,GLYCOPYRROLATE|GLYCOPYRROLATE|GLYCOPYRROLATE|GLYCOPYRROLATE|GLYCOPYRRONIUM TOSYLATE|DICYCLOMINE HYDROCHLORIDE|PILOCARPINE|ATROPINE SULFATE|SCOPOLAMINE|ATROPINE,Small molecule,Muscarinic acetylcholine receptor inhibitor|Muscarinic acetylcholine receptor M1 agonist|Muscarinic acetylcholine receptor M1 antagonist,True,False,True,HIGH - Approved drugs exist,Muscarinic acetylcholine receptor M1,"The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover",3D-structure|Alternative splicing|Cell membrane|Disulfide bond|G-protein coupled receptor|Glycoprotein|Membrane|Phosphoprotein|Postsynaptic cell membrane|Proteomics identification|Receptor|Reference proteome|Synapse|Transducer|Transmembrane|Transmembrane helix,Belongs to the G-protein coupled receptor 1 family. Muscarinic acetylcholine receptor subfamily. CHRM1 sub-subfamily,PF00001:7tm_1,1,IPR000276:GPCR_Rhodpsn|IPR017452:GPCR_Rhodpsn_7TM|IPR002228:Musac_Ach_M1_rcpt|IPR000995:Musac_Ach_rcpt,4,,domain|family,True,Ion Channel|GPCR,HIGH,GPCR: Keyword: g-protein coupled receptor|GPCR: InterPro: IPR000276|GPCR: InterPro: IPR017452|GPCR: Pfam: PF00001|Ion Channel: Keyword: potassium channel,Ion Channel,True,7,5CXV|6OIJ|6WJC|6ZFZ|6ZG4|6ZG9|9JEA,5CXV,2.7,X-RAY DIFFRACTION,protein_structures/pdb_experimental/5CXV.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/5CXV.pdb,Moderate (2.5-3.0Å),True,35,1.0,578.701,0.909,47.65,0.586,True,31,Excellent,High,Optimal volume (579A3)|High druggability (0.91),,579|517|2238|382|637|441|241|197|76|301|348|235|416|208|219|243|208|237|169|325|237|650|461|293|134|146|285|277|330|227|354|257|424|591|217,0.91|0.55|0.01|0.00|0.00|0.74|0.02|0.00|0.00|0.01|0.00|0.00|0.00|0.01|0.07|0.00|0.02|0.14|0.01|0.00|0.00|0.00|0.00|0.01|0.20,P1:Vol=579:Drug=0.91|P2:Vol=517:Drug=0.55|P3:Vol=2238:Drug=0.01|P4:Vol=382:Drug=0.00|P5:Vol=637:Drug=0.00|P6:Vol=441:Drug=0.74|P7:Vol=241:Drug=0.02|P8:Vol=197:Drug=0.00|P9:Vol=76:Drug=0.00|P10:Vol=301:Drug=0.01
CHRM3,CHRM3,cholinergic receptor muscarinic 3,"The muscarinic cholinergic receptors belong to a larger family of G protein-coupled receptors. The functional diversity of these receptors is defined by the binding of acetylcholine and includes cellular responses such as adenylate cyclase inhibition, phosphoinositide degeneration, and potassium channel mediation. Muscarinic receptors influence many effects of acetylcholine in the central and peripheral nervous system. The muscarinic cholinergic receptor 3 controls smooth muscle contraction and its stimulation causes secretion of glandular tissue. Alternative promoter use and alternative splicing results in multiple transcript variants that have different tissue specificities. [provided by RefSeq, Dec 2016].",protein-coding,EGBRS|HM3|PBS|m3AChR,"acetylcholine receptor, muscarinic 3|m3 muscarinic receptor|muscarinic acetylcholine receptor M3",ENSG00000133019,ENST00000255380|ENST00000448020|ENST00000468573|ENST00000481779|ENST00000487470|ENST00000492335|ENST00000615928|ENST00000674678|ENST00000675184|ENST00000675709,ENSP00000255380|ENSP00000404764|ENSP00000482377|ENSP00000502013|ENSP00000502129|ENSP00000502349|ENSP00000502667|ENSP00000545896|ENSP00000545897|ENSP00000545898,P20309,A0A6Q8PG67|B1AN12,ACM3_HUMAN,1131.0,NM_000740.4|NM_001347716.2|NM_001375978.1|NM_001375979.1|NM_001375980.1|NM_001375981.1|NM_001375982.1|NM_001375983.1|NM_001375984.1|NM_001375985.1,NP_000731.1|NP_001334645.1|NP_001362907.1|NP_001362908.1|NP_001362909.1|NP_001362910.1|NP_001362911.1|NP_001362912.1|NP_001362913.1|NP_001362914.1,NC_000001.11|NC_060925.1|NG_032046.2,1952.0,118494.0,PA112,9606.ENSP00000255380,2CSA|8E9W|8E9Y|8E9Z|8EA0,,IPR000276|IPR000995|IPR001183|IPR017452,PF00001,PS50262,1,239386513.0,239915452.0,1.0,590.0,Cell membrane|Postsynaptic cell membrane|Basolateral cell membrane,9606.0,20191.0,Muscarinic acetylcholine receptor M3,kegg:hsa04020|kegg:hsa04080|kegg:hsa04725|kegg:hsa04742|kegg:hsa04810|reactome:R-HSA-1430728|reactome:R-HSA-162582|reactome:R-HSA-163685|reactome:R-HSA-372790|reactome:R-HSA-373076|smpdb:SMP00225|smpdb:SMP00226|smpdb:SMP00227|smpdb:SMP00228|smpdb:SMP00229|wikipathways:WP117|wikipathways:WP455|wikipathways:WP4874|wikipathways:WP51|wikipathways:WP536,True,cholinergic receptor muscarinic 3,76,57,TARAFENACIN|METHIXENE|OXYBUTYNIN|CEVIMELINE HYDROCHLORIDE|ZAMIFENACIN|IMIDAFENACIN|TIOTROPIUM|BENZQUINAMIDE|TOLTERODINE|OCTOTROPINE METHYLBROMIDE|SOLIFENACIN|DOXEPIN HYDROCHLORIDE|CHEMBL:CHEMBL1084941|IPRATROPIUM CATION|PROMAZINE|CLIDINIUM|BATEFENTEROL|BETHANECHOL CHLORIDE|OLANZAPINE|OXYPHENCYCLIMINE,METHIXENE|OXYBUTYNIN|CEVIMELINE HYDROCHLORIDE|TIOTROPIUM|BENZQUINAMIDE|TOLTERODINE|OCTOTROPINE METHYLBROMIDE|SOLIFENACIN|DOXEPIN HYDROCHLORIDE|IPRATROPIUM CATION,TARAFENACIN|DIPHEMANIL METHYLSULFATE|TARAFENACIN|IMIDAFENACIN|CHEMBL:CHEMBL1084941,G PROTEIN COUPLED RECEPTOR|DRUGGABLE GENOME,agonist|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL245,SINGLE PROTEIN,0,0,674,674,1000,True,519,25,0,0,0,IPRATROPIUM BROMIDE|GLYCOPYRROLATE|GLYCOPYRROLATE|IPRATROPIUM BROMIDE|IPRATROPIUM BROMIDE|TIOTROPIUM BROMIDE|TIOTROPIUM BROMIDE|GLYCOPYRRONIUM TOSYLATE|REVEFENACIN|REVEFENACIN,Small molecule,Muscarinic acetylcholine receptor inhibitor|Muscarinic acetylcholine receptor M3 antagonist,True,False,True,HIGH - Approved drugs exist,Muscarinic acetylcholine receptor M3,"The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover",3D-structure|Cell membrane|Disulfide bond|Endoplasmic reticulum|G-protein coupled receptor|Glycoprotein|Membrane|Phosphoprotein|Postsynaptic cell membrane|Proteomics identification|Receptor|Reference proteome|Synapse|Transducer|Transmembrane|Transmembrane helix,Belongs to the G-protein coupled receptor 1 family. Muscarinic acetylcholine receptor subfamily. CHRM3 sub-subfamily,PF00001:7tm_1,1,IPR000276:GPCR_Rhodpsn|IPR017452:GPCR_Rhodpsn_7TM|IPR001183:Musac_Ach_M3_rcpt|IPR000995:Musac_Ach_rcpt,4,,domain|family,True,Ion Channel|GPCR,HIGH,GPCR: Keyword: g-protein coupled receptor|GPCR: InterPro: IPR000276|GPCR: InterPro: IPR017452|GPCR: Pfam: PF00001|Ion Channel: Keyword: potassium channel,Ion Channel,True,5,2CSA|8E9W|8E9Y|8E9Z|8EA0,2CSA,,SOLUTION NMR,protein_structures/pdb_experimental/2CSA.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/2CSA.pdb,,True,1,1.0,442.056,0.038,,0.277,False,0,Poor,Low,Adequate volume (442A3),Low druggability (0.04),442,0.04,P1:Vol=442:Drug=0.04
OPRM1,OPRM1,opioid receptor mu 1,"This gene encodes one of at least three opioid receptors in humans; the mu opioid receptor (MOR). The MOR is the principal target of endogenous opioid peptides and opioid analgesic agents such as beta-endorphin and enkephalins. The MOR also has an important role in dependence to other drugs of abuse, such as nicotine, cocaine, and alcohol via its modulation of the dopamine system. The NM_001008503.2:c.118A>G allele has been associated with opioid and alcohol addiction and variations in pain sensitivity but evidence for it having a causal role is conflicting. Multiple transcript variants encoding different isoforms have been found for this gene. Though the canonical MOR belongs to the superfamily of 7-transmembrane-spanning G-protein-coupled receptors some isoforms of this gene have only 6 transmembrane domains. [provided by RefSeq, Oct 2013].",protein-coding,LMOR|M-OR-1|MOP|MOR|MOR1|OPRM,mu opiate receptor|mu opioid receptor hMOR-1a|mu-type opioid receptor,ENSG00000112038,ENST00000229768|ENST00000330432|ENST00000337049|ENST00000360422|ENST00000414028|ENST00000419506|ENST00000428397|ENST00000434900|ENST00000435918|ENST00000452687,ENSP00000229768|ENSP00000328264|ENSP00000338381|ENSP00000353598|ENSP00000394624|ENSP00000399359|ENSP00000403549|ENSP00000410497|ENSP00000411903|ENSP00000413752,P35372,G8XRH4|L0E130|G8XRH5|A0A6H0WF09|B8K2Q5,OPRM_HUMAN,4988.0,NM_000914.5|NM_001008503.3|NM_001008504.4|NM_001008505.2|NM_001145279.4|NM_001145280.4|NM_001145281.3|NM_001145282.2|NM_001145283.2|NM_001145284.3,NP_000905.3|NP_001008503.2|NP_001008504.2|NP_001008505.2|NP_001138751.1|NP_001138752.1|NP_001138753.1|NP_001138754.1|NP_001138755.1|NP_001138756.1,NC_000006.12|NC_060930.1|NG_021208.2,8156.0,600018.0,PA31945,9606.ENSP00000394624,8EF5|8EF6|8EFB|8EFL|8EFO|8EFQ|8F7Q|8F7R|8K9K|8K9L|9MQH|9MQI|9MQJ,,IPR000105|IPR000276|IPR001418|IPR017452,PF00001,PS50262,6,154010496.0,154246867.0,1.0,400.0,"Cell membrane|Cell projection, axon|Perikaryon",9606.0,37368.0,?-opioid receptor,kegg:hsa04080|kegg:hsa04915|kegg:hsa05032|smpdb:SMP00392|smpdb:SMP00393|smpdb:SMP00394|smpdb:SMP00395|smpdb:SMP00396|wikipathways:WP24|wikipathways:WP455|wikipathways:WP69,True,opioid receptor mu 1,110,76,DIFENOXIN HYDROCHLORIDE|SUMATRIPTAN|DIACETYLMORPHINE|NALTALIMIDE|CLOCINNAMOX|METHADONE HYDROCHLORIDE|NALTREXONE HYDROCHLORIDE|CP-866087|PENTAZOCINE|MONOAMINE OXIDASE INHIBITOR|PAREGORIC|NALOXONE HYDROCHLORIDE|BUPRENORPHINE|CEBRANOPADOL|OXYCODONE|CODEINE PHOSPHATE|AXELOPRAN|SAMIDORPHAN L-MALATE|ALFENTANIL HYDROCHLORIDE|TIANEPTINE,DIFENOXIN HYDROCHLORIDE|SUMATRIPTAN|DIACETYLMORPHINE|METHADONE HYDROCHLORIDE|NALTREXONE HYDROCHLORIDE|PENTAZOCINE|PAREGORIC|NALOXONE HYDROCHLORIDE|BUPRENORPHINE|OXYCODONE,CLOCINNAMOX|CHEMBL:CHEMBL255300|DEZOCINE|DAMGO|NABIXIMOLS,G PROTEIN COUPLED RECEPTOR|DRUGGABLE GENOME|KINASE,agonist|inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons|The ChEMBL Bioactivity Database|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)",True,CHEMBL5430,SINGLE PROTEIN,0,0,26,26,26,True,1273,25,0,0,0,ELUXADOLINE|ELUXADOLINE|FENTANYL|FENTANYL|FENTANYL|MEPERIDINE|METHADONE|METHADONE|METHADONE|METHADONE,Small molecule,Opioid receptors; mu/kappa/delta agonist|Mu opioid receptor agonist,True,False,True,HIGH - Approved drugs exist,Mu-type opioid receptor,Does not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity,3D-structure|Alternative splicing|Cell membrane|Cell projection|Cytoplasm|Disulfide bond|Endosome|G-protein coupled receptor|Glycoprotein|Lipoprotein|Membrane|Palmitate|Phosphoprotein|Proteomics identification|Receptor|Reference proteome|Transducer|Transmembrane|Transmembrane helix|Ubl conjugation,Belongs to the G-protein coupled receptor 1 family,PF00001:7tm_1,1,IPR000276:GPCR_Rhodpsn|IPR017452:GPCR_Rhodpsn_7TM|IPR000105:Mu_opioid_rcpt|IPR001418:Opioid_rcpt,4,,domain|family,True,GPCR,HIGH,GPCR: Keyword: g-protein coupled receptor|GPCR: InterPro: IPR000276|GPCR: InterPro: IPR017452|GPCR: Pfam: PF00001,GPCR,True,23,8EF5|8EF6|8EFB|8EFL|8EFO|8EFQ|8F7Q|8F7R|8K9K|8K9L,8EF5,3.3,ELECTRON MICROSCOPY,protein_structures/pdb_experimental/8EF5.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/8EF5.pdb,Low (>3.3Å),True,129,10.0,704.029,0.882,55.067,0.287,True,103,Good,Medium,Optimal volume (704A3)|High druggability (0.88),,649|1285|620|518|489|353|327|689|442|704|387|296|204|393|536|346|258|215|562|77|268|102|78|141|76|140|270|377|227|110|84|310|214|447|723|211|274|339|459|246|498|554|151|236|239|205|271|297|188|181|312|576|284|411|395|163|95|187|507|222|166|192|334|176|227|202|680|317|973|400|294|224|231|235|192|311|124|215|201|530|308|186|169|147|640|464|195|175|315|228|259|431|123|195|270|666|144|467|258|277|254|645|202|165|258|387|428|188|265|223|214|310|234|185|578|370|798|244|244|347|517|372|580|400|332|636|286|306|1527,0.56|0.79|0.64|0.79|0.10|0.02|0.65|0.09|0.15|0.88|0.09|0.01|0.00|0.25|0.00|0.00|0.00|0.01|0.00|0.01|0.00|0.00|0.02|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.03|0.07|0.00|0.00|0.00|0.02|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.02|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.02|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.01|0.03|0.00|0.02|0.00|0.00|0.00|0.00|0.01|0.00,P1:Vol=649:Drug=0.56|P2:Vol=1285:Drug=0.79|P3:Vol=620:Drug=0.64|P4:Vol=518:Drug=0.79|P5:Vol=489:Drug=0.10|P6:Vol=353:Drug=0.02|P7:Vol=327:Drug=0.65|P8:Vol=689:Drug=0.09|P9:Vol=442:Drug=0.15|P10:Vol=704:Drug=0.88
OPRD1,OPRD1,opioid receptor delta 1,"Enables G protein-coupled enkephalin receptor activity. Involved in several processes, including G protein-coupled opioid receptor signaling pathway; cellular response to hypoxia; and positive regulation of peptidyl-serine phosphorylation. Is intrinsic component of plasma membrane. [provided by Alliance of Genome Resources, Apr 2022]",protein-coding,DOP|DOR|DOR1|OPRD,D-OR-1|DOR-1|delta opioid receptor 1|delta-type opioid receptor,ENSG00000116329,ENST00000234961,ENSP00000234961,P41143,,OPRD_HUMAN,4985.0,NM_000911.4,NP_000902.3,NC_000001.11|NC_060925.1,8153.0,165195.0,PA31942,9606.ENSP00000234961,4N6H|4RWA|4RWD|6PT2|6PT3|8F7S|8Y45,,IPR000276|IPR000321|IPR001418|IPR017452,PF00001,PS50262,1,28812170.0,28871267.0,1.0,372.0,Cell membrane,9606.0,20252.0,?-opioid receptor,kegg:hsa04022|kegg:hsa04071|kegg:hsa04080|reactome:R-HSA-1280215|reactome:R-HSA-162582|reactome:R-HSA-168256|reactome:R-HSA-372790|reactome:R-HSA-373076|wikipathways:WP24|wikipathways:WP455,True,opioid receptor delta 1,46,32,HYDROCODONE BITARTRATE|OXYCODONE|AXOMADOL|DISULFIRAM|FENTANYL CITRATE|ADL-5747|NALOXONE HYDROCHLORIDE|DEXTROMORAMIDE|NALBUPHINE HYDROCHLORIDE|HYDROCODONE|METENKEFALIN|LOPERAMIDE|BUTORPHANOL|PAREGORIC|CARFENTANIL|CHEMBL:CHEMBL409225|TRAMADOL|NALOXONE HYDROCHLORIDE DIHYDRATE|NALMEFENE HYDROCHLORIDE DIHYDRATE|PROPOXYPHENE,HYDROCODONE BITARTRATE|OXYCODONE|DISULFIRAM|FENTANYL CITRATE|NALOXONE HYDROCHLORIDE|DEXTROMORAMIDE|NALBUPHINE HYDROCHLORIDE|HYDROCODONE|LOPERAMIDE|BUTORPHANOL,ADL-5747|CHEMBL:CHEMBL409225|ADL5859|ELUXADOLINE|PROPOXYPHENE,DRUGGABLE GENOME|G PROTEIN COUPLED RECEPTOR,agonist|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL2169734,SINGLE PROTEIN,0,0,1,1,1,True,368,25,0,0,0,NALBUPHINE|NALBUPHINE|NALBUPHINE|NALBUPHINE|OXYMORPHONE|CODEINE PHOSPHATE|NALBUPHINE HYDROCHLORIDE|NALOXONE HYDROCHLORIDE|BENZHYDROCODONE HYDROCHLORIDE|DEXTROMORAMIDE,Small molecule,Opioid receptors; mu/kappa/delta agonist|Opioid receptors; mu/kappa/delta antagonist,True,False,True,HIGH - Approved drugs exist,Delta-type opioid receptor,"G-protein coupled receptor that functions as a receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine",3D-structure|Cell membrane|Disulfide bond|G-protein coupled receptor|Glycoprotein|Lipoprotein|Membrane|Palmitate|Proteomics identification|Receptor|Reference proteome|Transducer|Transmembrane|Transmembrane helix|Ubl conjugation,Belongs to the G-protein coupled receptor 1 family,PF00001:7tm_1,1,IPR000321:Delta_opi_rcpt|IPR000276:GPCR_Rhodpsn|IPR017452:GPCR_Rhodpsn_7TM|IPR001418:Opioid_rcpt,4,,domain|family,True,GPCR|Histone Acetyltransferase,HIGH,GPCR: Keyword: g-protein coupled receptor|GPCR: InterPro: IPR000276|GPCR: InterPro: IPR017452|GPCR: Pfam: PF00001|Histone Acetyltransferase: Keyword: hat,GPCR,True,9,4N6H|4RWA|4RWD|6PT2|6PT3|8F7S|8Y45|9CGJ|9CGK,4N6H,1.8,X-RAY DIFFRACTION,protein_structures/pdb_experimental/4N6H.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/4N6H.pdb,Excellent (<2.0Å),True,30,1.0,1015.005,0.976,51.481,0.954,True,25,Excellent,High,Optimal volume (1015A3)|High druggability (0.98),,1015|711|674|292|335|241|292|251|349|229|321|222|209|115|322|289|180|356|503|260|386|317|96|224|240|379|381|261|229|372,0.98|0.95|0.79|0.00|0.02|0.01|0.00|0.01|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.07|0.00|0.00|0.01|0.11|0.15|0.00|0.00,P1:Vol=1015:Drug=0.98|P2:Vol=711:Drug=0.95|P3:Vol=674:Drug=0.79|P4:Vol=292:Drug=0.00|P5:Vol=335:Drug=0.02|P6:Vol=241:Drug=0.01|P7:Vol=292:Drug=0.00|P8:Vol=251:Drug=0.01|P9:Vol=349:Drug=0.00|P10:Vol=229:Drug=0.00
CNR1,PCDHA4,protocadherin alpha 4,"This gene is a member of the protocadherin alpha gene cluster, one of three related gene clusters tandemly linked on chromosome five that demonstrate an unusual genomic organization similar to that of B-cell and T-cell receptor gene clusters. The alpha gene cluster is composed of 15 cadherin superfamily genes related to the mouse CNR genes and consists of 13 highly similar and 2 more distantly related coding sequences. The tandem array of 15 N-terminal exons, or variable exons, are followed by downstream C-terminal exons, or constant exons, which are shared by all genes in the cluster. The large, uninterrupted N-terminal exons each encode six cadherin ectodomains while the C-terminal exons encode the cytoplasmic domain. These neural cadherin-like cell adhesion proteins are integral plasma membrane proteins that most likely play a critical role in the establishment and function of specific cell-cell connections in the brain. Alternative splicing has been observed and additional variants have been suggested but their full-length nature has yet to be determined. [provided by RefSeq, Jul 2008].",protein-coding,CNR1|CNRN1|CRNR1|PCDH-ALPHA4,"KIAA0345-like 10|PCDH-alpha-4|ortholog of mouse CNR1|ortholog of mouse CNR1, KIAA0345-like 10|protocadherin alpha-4",ENSG00000291652,ENST00000708293|ENST00000708294|ENST00000708295|ENST00000708296|ENST00000708297,ENSP00000517144|ENSP00000517145|ENSP00000517146|ENSP00000517147|ENSP00000517148,Q9UN74,A0A5F9ZHY0|Q59H34|D6RA20|A0AAG2UV88,CNR1_HUMAN,56144.0,NM_018907.4|NM_031500.3,NP_061730.1|NP_113688.1,NC_000005.10|NC_060929.1|NG_000016.2|NG_050675.1|NG_050677.1,8670.0,606310.0,PA33016,9606.ENSP00000358513,1LVQ|1LVR|2B0Y|2KOE|2MZ2|2MZ3|2MZA|5TGZ|5U09|5XR8|5XRA|6KPG|6KQI|6N4B|7FEE|7V3Z|7WV9|8GAG|8GHV|8IKG,,IPR002126|IPR013164|IPR015919|IPR020894|IPR050174|IPR031904,PF00028|PF08266|PF15974,PS50268,5,140807037.0,141012347.0,1.0,472.0,Cell membrane|Membrane raft|Mitochondrion outer membrane,9606.0,130626.0,PCDHA4,,True,cannabinoid receptor 1,30,6,AMAUROMINE|TM38837|AVE-1625|RIMONABANT|ANISINDIONE|NABILONE|ORLISTAT|OTENABANT|TARANABANT|HEMOPRESSIN|SAD448|NIMACIMAB|V24343|IBIPINABANT|2-ARACHIDONYL GLYCERYL ETHER|WIN55212-2|CONATUMUMAB|CANNABIDIOL|AZD2207|CHEMBL:CHEMBL498746,RIMONABANT|ANISINDIONE|NABILONE|ORLISTAT|CANNABIDIOL|DRONABINOL,NABILONE|HEMOPRESSIN|CHEMBL:CHEMBL498746|TARANABANT|AMAUROMINE,G PROTEIN COUPLED RECEPTOR|DRUGGABLE GENOME|KINASE|ENZYME,inverse agonist|negative modulator|agonist|inhibitor,"NCI Cancer Gene Index|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|Guide to Pharmacology|Drug Target Commons|Therapeutic Target Database|The ChEMBL Bioactivity Database|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)",True,CHEMBL218,SINGLE PROTEIN,0,0,658,658,1000,False,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Protocadherin alpha-4,"Calcium-dependent cell-adhesion protein involved in cells self-recognition and non-self discrimination. Thereby, it is involved in the establishment and maintenance of specific neuronal connections in the brain",Alternative splicing|Calcium|Cell adhesion|Cell membrane|Disulfide bond|Glycoprotein|Membrane|Metal-binding|Proteomics identification|Reference proteome|Repeat|Signal|Transmembrane|Transmembrane helix,,PF00028:Cadherin|PF08266:Cadherin_2|PF15974:Cadherin_tail,3,IPR002126:Cadherin-like_dom|IPR015919:Cadherin-like_sf|IPR031904:Cadherin_CBD|IPR020894:Cadherin_CS|IPR013164:Cadherin_N|IPR050174:Protocadherin/Cadherin-CA,6,,domain|family|conserved_site|homologous_superfamily,True,Integrin,LOW,Integrin: Keyword: cell adhesion,Integrin,False,0,,,,,,True,2025-08-01T00:00:00Z,,Unknown,,,,,False,0,,,,,,False,0,,,,,,,
HRH1,DHX8,DEAH-box helicase 8,"This gene is a member of the DEAH box polypeptide family. The encoded protein contains the DEAH (Asp-Glu-Ala-His) motif which is characteristic of all DEAH box proteins, and is thought to function as an ATP-dependent RNA helicase that regulates the release of spliced mRNAs from spliceosomes prior to their export from the nucleus. This protein may be required for the replication of human immunodeficiency virus type 1 (HIV-1). Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2014].",protein-coding,DDX8|Dhr2|HRH1|PRP22|PRPF22,ATP-dependent RNA helicase DHX8|DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 8 (RNA helicase)|DEAH (Asp-Glu-Ala-His) box polypeptide 8|DEAH box protein 8|RNA helicase HRH1,ENSG00000067596,ENST00000262415|ENST00000540306|ENST00000587044|ENST00000587574|ENST00000588996|ENST00000589898|ENST00000592258|ENST00000605777|ENST00000650571|ENST00000872044,ENSP00000262415|ENSP00000437886|ENSP00000465178|ENSP00000466900|ENSP00000467834|ENSP00000496923|ENSP00000542103|ENSP00000542104|ENSP00000628263|ENSP00000628264,Q14562,Q86YB2|K7END7|F5H658|B7Z8F4|Q05CV4,HRH1_HUMAN,1659.0,NM_001302623.3|NM_001322216.2|NM_001322217.2|NM_001322218.3|NM_001322219.2|NM_001322220.3|NM_001322221.2|NM_004941.3|NR_136225.2|NR_136226.2,NP_001289552.1|NP_001309145.1|NP_001309146.1|NP_001309147.1|NP_001309148.1|NP_001309149.1|NP_001309150.1|NP_004932.1,NC_000017.11|NC_060941.1,2749.0,600396.0,PA27231,9606.ENSP00000380247,2EQS|3I4U|5MQF|5XJC|6HYS|6HYT|6HYU|6ICZ|6QDV|7W59|7W5A|7W5B|8C6J|9FMD,3.6.4.13,IPR001650|IPR002464|IPR003029|IPR007502|IPR011545|IPR011709|IPR012340|IPR014001|IPR027417|IPR042035,PF00270|PF00271|PF00575|PF04408|PF07717|PF21010,PS50126|PS51192|PS51194,17,43483865.0,43610338.0,1.0,487.0,Cell membrane,9606.0,3628.0,,reactome:R-HSA-72163|reactome:R-HSA-72172|reactome:R-HSA-72203|reactome:R-HSA-8953854,True,histamine receptor H1,124,110,BILASTINE|HYDROXYZINE|CARBINOXAMINE|METHDILAZINE|PROMETHAZINE HYDROCHLORIDE|LORATADINE|FEXOFENADINE HYDROCHLORIDE|ILOPERIDONE|MEQUITAZINE|ACRIVASTINE|THIETHYLPERAZINE|CETIRIZINE HYDROCHLORIDE|ANTAZOLINE|TRIMEPRAZINE|BROMPHENIRAMINE MALEATE|DIPHENHYDRAMINE CITRATE|DIPHENYLPYRALINE HYDROCHLORIDE|DIPHENHYDRAMINE|PROPIOMAZINE HYDROCHLORIDE|BEPOTASTINE BESILATE,BILASTINE|HYDROXYZINE|CARBINOXAMINE|METHDILAZINE|PROMETHAZINE HYDROCHLORIDE|LORATADINE|FEXOFENADINE HYDROCHLORIDE|ILOPERIDONE|MEQUITAZINE|ACRIVASTINE,METHDILAZINE|MEQUITAZINE|BEPOTASTINE BESILATE|ALCAFTADINE|OLOPATADINE,G PROTEIN COUPLED RECEPTOR|DRUGGABLE GENOME,inverse agonist|agonist|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|Drug Target Commons|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL231,SINGLE PROTEIN,0,0,825,825,1000,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,ATP-dependent RNA helicase DHX8,"Involved in pre-mRNA splicing as component of the spliceosome (PubMed:11991638, PubMed:28076346, PubMed:28502770). Facilitates nuclear export of spliced mRNA by releasing the RNA from the spliceosome (PubMed:8608946)",3D-structure|ATP-binding|Helicase|Hydrolase|Isopeptide bond|mRNA processing|mRNA splicing|Nucleotide-binding|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|Spliceosome|Ubl conjugation,Belongs to the DEAD box helicase family. DEAH subfamily. DDX8/PRP22 sub-subfamily,PF00270:DEAD|PF21010:HA2_C|PF04408:HA2_N|PF00271:Helicase_C|PF07717:OB_NTP_bind|PF00575:S1,6,IPR011709:DEAD-box_helicase_OB_fold|IPR011545:DEAD/DEAH_box_helicase_dom|IPR044762:DHX8/Prp22_DEXHc|IPR049588:DHX8_GH2-like|IPR002464:DNA/RNA_helicase_DEAH_CS|IPR048333:HA2_WH|IPR007502:Helicase-assoc_dom|IPR014001:Helicase_ATP-bd|IPR001650:Helicase_C-like|IPR012340:NA-bd_OB-fold|IPR027417:P-loop_NTPase|IPR049621:S1_DHX8_helicase|IPR003029:S1_domain,13,,domain|homologous_superfamily|conserved_site,True,GTPase|Motor Protein|Hydrolase,HIGH,Motor Protein: InterPro: IPR027417|GTPase: InterPro: IPR027417|Hydrolase: Keyword: hydrolase,GTPase,True,14,2EQS|3I4U|5MQF|5XJC|6HYS|6HYT|6HYU|6ICZ|6QDV|7W59,2EQS,,SOLUTION NMR,protein_structures/pdb_experimental/2EQS.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/2EQS.pdb,,True,6,2.0,515.833,0.094,8.222,0.246,True,5,Moderate,Low,Optimal volume (516A3),Low druggability (0.09),634|516|373|510|160|381,0.02|0.09|0.03|0.00|0.01,P1:Vol=634:Drug=0.02|P2:Vol=516:Drug=0.09|P3:Vol=373:Drug=0.03|P4:Vol=510:Drug=0.00|P5:Vol=160:Drug=0.01|P6:Vol=381:Drug=0.00
ABL1,ABL1,"ABL proto-oncogene 1, non-receptor tyrosine kinase","This gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and response to stress. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons. [provided by RefSeq, Aug 2014].",protein-coding,ABL|BCR-ABL|CHDSKM|JTK7|bcr/abl|c-ABL|c-ABL1|p150|v-abl,ABL protooncogene 1 nonreceptor tyrosine kinase|Abelson tyrosine-protein kinase 1|BCR-ABL1 p190|BCR/ABL e8a2 fusion|BCR/ABL1 e1a2 fusion protein,ENSG00000097007,ENST00000318560|ENST00000372348|ENST00000393293|ENST00000929253|ENST00000929254|ENST00000929255,ENSP00000323315|ENSP00000361423|ENSP00000376971|ENSP00000599312|ENSP00000599313|ENSP00000599314,P00519,R4GRW0|Q59FK4,ABL1_HUMAN,25.0,NM_005157.6|NM_007313.3,NP_005148.2|NP_009297.2,NC_000009.12|NC_060933.1|NG_012034.1,76.0,189980.0,PA24413,9606.ENSP00000361423,1AB2|1AWO|1BBZ|1JU5|1OPL|1ZZP|2ABL|2E2B|2F4J|2FO0|2G1T|2G2F|2G2H|2G2I|2GQG|2HIW|2HYY|2HZ0|2HZ4|2HZI,2.7.10.2,IPR000719|IPR000980|IPR001245|IPR001452|IPR011009|IPR015015|IPR017441|IPR035837|IPR036028|IPR036860,PF00017|PF00018|PF07714|PF08919,PS50001|PS50002|PS50011,9,130713043.0,130887675.0,1.0,1130.0,"Cytoplasm, cytoskeleton|Nucleus|Mitochondrion",9606.0,3783.0,ABL (gene),biocarta:arfpathway|biocarta:atmpathway|biocarta:g1pathway|biocarta:lis1pathway|kegg:hsa04012|kegg:hsa04014|kegg:hsa04110|kegg:hsa04360|kegg:hsa04722|netpath:Pathway_Alpha6Beta4Integrin|netpath:Pathway_EGFR1|netpath:Pathway_KitReceptor|netpath:Pathway_TCR|pid:ajdiss_2pathway|pid:atm_pathway|pid:lis1pathway|pid:p53regulationpathway|pid:p73pathway|wikipathways:WP1530|wikipathways:WP1545|wikipathways:WP1742|wikipathways:WP179|wikipathways:WP1984,True,"ABL proto-oncogene 1, non-receptor tyrosine kinase",143,66,RUSERONTINIB|MK-912|AZACITIDINE|MLN-8054|1-AZAKENPAULLONE|BOSUTINIB|AZM-475271|TIZANIDINE HYDROCHLORIDE|TRAMETINIB DIMETHYL SULFOXIDE|RS79948|RADOTINIB|COMPOUND 33A [PMID: 35944901]|EPINEPHRINE|GUANABENZ|IMATINIB|MELPHALAN|BRIMONIDINE|BAFETINIB|REBASTINIB|VINCRISTINE,AZACITIDINE|BOSUTINIB|TIZANIDINE HYDROCHLORIDE|TRAMETINIB DIMETHYL SULFOXIDE|EPINEPHRINE|GUANABENZ|IMATINIB|MELPHALAN|BRIMONIDINE|VINCRISTINE,ASCIMINIB|PONATINIB|NILOTINIB|BOSUTINIB|OMACETAXINE,KINASE|TYROSINE KINASE|DRUGGABLE GENOME|ENZYME|DRUG RESISTANCE|CLINICALLY ACTIONABLE|TUMOR SUPPRESSOR,modulator|agonist|inhibitor,"Catalogue Of Somatic Mutations In Cancer|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|NCI Cancer Gene Index|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|FDA Pharmacogenomic Biomarkers|OncoKB: A Precision Oncology Knowledge Base|PharmGKB - The Pharmacogenomics Knowledgebase|Targeted Agents in Lung Cancer (Commentary, 2014)|The Clinical Knowledgebase",True,CHEMBL1862,SINGLE PROTEIN,0,0,690,690,1000,True,1024,24,1,0,0,DASATINIB|PONATINIB HYDROCHLORIDE|DASATINIB|DASATINIB|DASATINIB|IMATINIB MESYLATE|PONATINIB HYDROCHLORIDE|NILOTINIB HYDROCHLORIDE MONOHYDRATE|DASATINIB|DASATINIB,Small molecule,Bcr/Abl fusion protein|Bcr/Abl fusion protein inhibitor|Tyrosine-protein kinase ABL inhibitor,True,True,True,HIGH - Approved drugs exist,Tyrosine-protein kinase ABL1,"Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9 (PubMed:22810897). Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. In response to oxidative stress, phosphorylates serine/threonine kinase PRKD2 at 'Tyr-717' (PubMed:28428613). ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 also acts as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E.coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H.pylori, or AnkA (ankyrin repeat-containing protein A) of A.phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Regulates T-cell differentiation in a TBX21-dependent manner (By similarity). Positively regulates chemokine-mediated T-cell migration, polarization, and homing to lymph nodes and immune-challenged tissues, potentially via activation of NEDD9/HEF1 and RAP1 (By similarity). Phosphorylates TBX21 on tyrosine residues leading to an enhancement of its transcriptional activator activity (By similarity)",3D-structure|Acetylation|Alternative splicing|Apoptosis|ATP-binding|Autophagy|Cell adhesion|Chromosomal rearrangement|Cytoplasm|Cytoskeleton|Disease variant|DNA damage|DNA repair|DNA-binding|Endocytosis|Kinase|Lipoprotein|Magnesium|Manganese|Membrane,Belongs to the protein kinase superfamily. Tyr protein kinase family. ABL subfamily,PF08919:F_actin_bind|PF07714:PK_Tyr_Ser-Thr|PF00017:SH2|PF00018:SH3_1,4,IPR035837:ABL_SH2|IPR015015:F-actin-binding|IPR011009:Kinase-like_dom_sf|IPR050198:Non-receptor_tyrosine_kinases|IPR000719:Prot_kinase_dom|IPR017441:Protein_kinase_ATP_BS|IPR001245:Ser-Thr/Tyr_kinase_cat_dom|IPR000980:SH2|IPR036860:SH2_dom_sf|IPR036028:SH3-like_dom_sf|IPR001452:SH3_domain|IPR008266:Tyr_kinase_AS|IPR020635:Tyr_kinase_cat_dom,13,,active_site|domain|homologous_superfamily|family|binding_site,True,Kinase|Actin|Tubulin|E3 Ubiquitin Ligase|Protease|Transferase|Integrin|Ligase|Histone Acetyltransferase|Transcription Factor,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: Keyword: tyrosine kinase|Kinase: Keyword: serine/threonine kinase|Kinase: Keyword: receptor tyrosine kinase|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR017441|Kinase: InterPro: IPR020635|Kinase: Pfam: PF07714,Kinase,True,84,1AB2|1AWO|1BBZ|1JU5|1OPL|1ZZP|2ABL|2E2B|2F4J|2FO0,1AB2,,SOLUTION NMR,protein_structures/pdb_experimental/1AB2.pdb,False,,,,,PDB,protein_structures/pdb_experimental/1AB2.pdb,,True,9,1.0,822.678,0.9,29.909,0.211,True,9,Good,Medium,Optimal volume (823A3)|High druggability (0.90),,823|270|290|156|247|301|358|269|234,0.90|0.10|0.00|0.00|0.01,P1:Vol=823:Drug=0.90|P2:Vol=270:Drug=0.10|P3:Vol=290:Drug=0.00|P4:Vol=156:Drug=0.00|P5:Vol=247:Drug=0.00|P6:Vol=301:Drug=0.00|P7:Vol=358:Drug=0.00|P8:Vol=269:Drug=0.00|P9:Vol=234:Drug=0.01
EGFR,EGFR,epidermal growth factor receptor,"The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor, thus inducing receptor dimerization and tyrosine autophosphorylation leading to cell proliferation. Mutations in this gene are associated with lung cancer. EGFR is a component of the cytokine storm which contributes to a severe form of Coronavirus Disease 2019 (COVID-19) resulting from infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). [provided by RefSeq, Jul 2020].",protein-coding,ERBB|ERBB1|ERRP|HER1|NISBD2|NNCIS|PIG61|mENA,EGFR vIII|avian erythroblastic leukemia viral (v-erb-b) oncogene homolog|cell growth inhibiting protein 40|cell proliferation-inducing protein 61|epidermal growth factor receptor,ENSG00000146648,ENST00000275493|ENST00000342916|ENST00000344576|ENST00000420316|ENST00000450046|ENST00000455089|ENST00000459688|ENST00000463948|ENST00000485503|ENST00000700144,ENSP00000275493|ENSP00000342376|ENSP00000345973|ENSP00000413354|ENSP00000413843|ENSP00000415559|ENSP00000514824|ENSP00000568258|ENSP00000568259|ENSP00000568260,P00533,C9JYS6|Q504U8|B7Z2I3|E7BSV0|F2YGG7,EGFR_HUMAN,1956.0,NM_001346897.2|NM_001346898.2|NM_001346899.2|NM_001346900.2|NM_001346941.2|NM_005228.5|NM_201282.2|NM_201283.2|NM_201284.2|XM_047419952.1,NP_001333826.1|NP_001333827.1|NP_001333828.1|NP_001333829.1|NP_001333870.1|NP_005219.2|NP_958439.1|NP_958440.1|NP_958441.1|XP_047275908.1,NC_000007.14|NC_060931.1|NG_007726.3,3236.0,131550.0,PA7360,9606.ENSP00000275493,1IVO|1M14|1M17|1MOX|1NQL|1XKK|1YY9|1Z9I|2EB2|2EB3|2GS2|2GS6|2GS7|2ITN|2ITO|2ITP|2ITQ|2ITT|2ITU|2ITV,2.7.10.1,IPR000494|IPR000719|IPR001245|IPR006211|IPR006212|IPR008266|IPR009030|IPR011009|IPR016245|IPR017441,PF00757|PF01030|PF07714|PF14843|PF21314,PS50011,7,55018820.0,55211628.0,1.0,1210.0,Cell membrane|Endoplasmic reticulum membrane|Golgi apparatus membrane,9606.0,74545.0,Epidermal growth factor receptor,biocarta:agrpathway|biocarta:at1rpathway|biocarta:cardiacegfpathway|biocarta:cblpathway|biocarta:egfpathway|kegg:hsa04010|kegg:hsa04012|kegg:hsa04014|kegg:hsa04015|kegg:hsa04020|netpath:Pathway_Alpha6Beta4Integrin|netpath:Pathway_AndrogenReceptor|netpath:Pathway_EGFR1|netpath:Pathway_Gastrin|netpath:Pathway_Leptin|pid:a6b1_a6b4_integrin_pathway|pid:ajdiss_2pathway|pid:arf6_pathway|pid:ecadherin_keratinocyte_pathway|pid:ecadherin_stabilization_pathway|smpdb:SMP00463|smpdb:SMP00472|smpdb:SMP00473|smpdb:SMP00474|smpdb:SMP00475|wikipathways:WP138|wikipathways:WP2261|wikipathways:WP2324|wikipathways:WP2363|wikipathways:WP2431,True,epidermal growth factor receptor,192,60,ILORASERTIB|ERLOTINIB|MDX-447|ZALUTUMUMAB|RUSERONTINIB|LAPATINIB|DACOMITINIB ANHYDROUS|AFATINIB|RAMUCIRUMAB|SIROLIMUS|DULIGOTUZUMAB|REGORAFENIB|OSIMERTINIB|CETUXIMAB|ROCILETINIB|MOMELOTINIB|DIMETHYLCURCUMIN|GW843682X|FALNIDAMOL|BRIGATINIB,ERLOTINIB|LAPATINIB|DACOMITINIB ANHYDROUS|AFATINIB|RAMUCIRUMAB|SIROLIMUS|REGORAFENIB|OSIMERTINIB|CETUXIMAB|MOMELOTINIB,RINDOPEPIMUT|AFATINIB|MOBOCERTINIB|ZALUTUMUMAB|DEPATUXIZUMAB,CLINICALLY ACTIONABLE|KINASE|TYROSINE KINASE|DRUGGABLE GENOME|DRUG RESISTANCE|CELL SURFACE,vaccine|antibody|modulator|binder|negative modulator|inhibitor,"Clearity Foundation Biomarkers|CIViC: Clinical Interpretation of Variants in Cancer|Guide to Pharmacology|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|Catalogue Of Somatic Mutations In Cancer|FDA Pharmacogenomic Biomarkers|PharmGKB - The Pharmacogenomics Knowledgebase|Targeted Agents in Lung Cancer (Commentary, 2014)|Clearity Foundation Clinical Trial|Cancer Commons",True,CHEMBL3608,SINGLE PROTEIN,0,0,125,125,160,True,1874,25,0,0,0,LAPATINIB DITOSYLATE|NERATINIB MALEATE|CETUXIMAB|PANITUMUMAB|VANDETANIB|CETUXIMAB|PANITUMUMAB|NECITUMUMAB|AMIVANTAMAB|CETUXIMAB,Antibody|Small molecule,Epidermal growth factor receptor erbB1 inhibitor|Epidermal growth factor receptor inhibitor,True,False,True,HIGH - Approved drugs exist,Epidermal growth factor receptor,(Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins,3D-structure|Alternative splicing|ATP-binding|Cell membrane|Developmental protein|Direct protein sequencing|Disease variant|Disulfide bond|Endoplasmic reticulum|Endosome|Glycoprotein|Golgi apparatus|Host cell receptor for virus entry|Host-virus interaction|Hydroxylation|Isopeptide bond|Kinase|Lipoprotein|Membrane|Methylation,Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily,PF00757:Furin-like|PF14843:GF_recep_IV|PF07714:PK_Tyr_Ser-Thr|PF01030:Recep_L_domain|PF21314:TM_ErbB1,5,IPR006211:Furin-like_Cys-rich_dom|IPR006212:Furin_repeat|IPR032778:GF_recep_IV|IPR009030:Growth_fac_rcpt_cys_sf|IPR011009:Kinase-like_dom_sf|IPR000719:Prot_kinase_dom|IPR017441:Protein_kinase_ATP_BS|IPR000494:Rcpt_L-dom|IPR036941:Rcpt_L-dom_sf|IPR050122:RTK|IPR001245:Ser-Thr/Tyr_kinase_cat_dom|IPR049328:TM_ErbB1|IPR008266:Tyr_kinase_AS|IPR020635:Tyr_kinase_cat_dom|IPR016245:Tyr_kinase_EGF/ERB/XmrK_rcpt,15,,active_site|domain|homologous_superfamily|family|binding_site|repeat,True,Kinase|T-cell Receptor|Transferase|Cytokine Receptor|Histone Acetyltransferase,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR017441|Kinase: InterPro: IPR020635|Kinase: Pfam: PF07714|Histone Acetyltransferase: Keyword: hat|Cytokine Receptor: Pfam: PF01030|T-cell Receptor: Keyword: cd8,Kinase,True,369,1IVO|1M14|1M17|1MOX|1NQL|1XKK|1YY9|1Z9I|2EB2|2EB3,1IVO,3.3,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1IVO.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1IVO.pdb,Low (>3.3Å),True,81,24.0,751.771,0.566,17.217,0.042,True,70,Good,Medium,Optimal volume (752A3),,653|516|400|655|367|141|236|316|427|327|276|415|294|405|61|757|282|336|238|351|105|270|332|752|287|335|824|264|202|505|407|516|554|248|229|318|514|270|213|175|217|348|232|118|163|248|236|316|597|224|163|414|247|185|408|239|142|351|199|539|425|170|417|222|474|235|143|1193|1459|367|305|372|341|615|463|221|548|734|410|1365|1053,0.09|0.02|0.28|0.00|0.10|0.00|0.00|0.00|0.00|0.00|0.00|0.07|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.57|0.52|0.00|0.27|0.04|0.00|0.12|0.00|0.01|0.00|0.00|0.08|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00,P1:Vol=653:Drug=0.09|P2:Vol=516:Drug=0.02|P3:Vol=400:Drug=0.28|P4:Vol=655:Drug=0.00|P5:Vol=367:Drug=0.10|P6:Vol=141:Drug=0.00|P7:Vol=236:Drug=0.00|P8:Vol=316:Drug=0.00|P9:Vol=427:Drug=0.00|P10:Vol=327:Drug=0.00
BRAF,BRAF,"B-Raf proto-oncogene, serine/threonine kinase","This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this gene has been identified on the X chromosome. [provided by RefSeq, Aug 2017].",protein-coding,B-RAF1|B-raf|BRAF-1|BRAF1|NS7|RAFB1,94 kDa B-raf protein|B-Raf proto-oncogene serine/threonine-protein kinase (p94)|B-Raf serine/threonine-protein|murine sarcoma viral (v-raf) oncogene homolog B1|proto-oncogene B-Raf,ENSG00000157764,ENST00000288602|ENST00000469930|ENST00000479537|ENST00000496384|ENST00000497784|ENST00000642228|ENST00000642272|ENST00000642808|ENST00000642875|ENST00000643356,ENSP00000288602|ENSP00000418033|ENSP00000419060|ENSP00000420119|ENSP00000493543|ENSP00000493678|ENSP00000493783|ENSP00000494784|ENSP00000495132|ENSP00000495858,P15056,H7C560|A0A2U3TZI2|A0A2R8Y8E0|A0A2R8Y679|A0A2R8Y492,BRAF_HUMAN,673.0,NM_001354609.2|NM_001374244.1|NM_001374258.1|NM_001378467.1|NM_001378468.1|NM_001378469.1|NM_001378470.1|NM_001378471.1|NM_001378472.1|NM_001378473.1,NP_001341538.1|NP_001361173.1|NP_001361187.1|NP_001365396.1|NP_001365397.1|NP_001365398.1|NP_001365399.1|NP_001365400.1|NP_001365401.1|NP_001365402.1,NC_000007.14|NC_060931.1|NG_007873.3,1097.0,164757.0,PA25408,9606.ENSP00000419060,1UWH|1UWJ|2FB8|2L05|3C4C|3D4Q|3IDP|3II5|3NY5|3OG7|3PPJ|3PPK|3PRF|3PRI|3PSB|3PSD|3Q4C|3Q96|3SKC|3TV4,2.7.11.1,IPR000719|IPR001245|IPR002219|IPR003116|IPR008271|IPR011009|IPR017441|IPR020454|IPR029071|IPR046349,PF00130|PF02196|PF07714,PS50011|PS50081|PS50898,7,140719327.0,140924976.0,-1.0,766.0,Nucleus|Cytoplasm|Cell membrane,9606.0,3197.0,BRAF (gene),kegg:hsa04010|kegg:hsa04012|kegg:hsa04015|kegg:hsa04024|kegg:hsa04062|pid:cd8tcrdownstreampathway|pid:cdc42_pathway|pid:erbb1_downstream_pathway|pid:fak_pathway|pid:mapktrkpathway|reactome:R-HSA-1295596|reactome:R-HSA-162582|reactome:R-HSA-162582|reactome:R-HSA-1643685|reactome:R-HSA-166520|smpdb:SMP00320|smpdb:SMP00321|wikipathways:WP185|wikipathways:WP2032|wikipathways:WP2253|wikipathways:WP2261|wikipathways:WP23,True,"B-Raf proto-oncogene, serine/threonine kinase",200,71,"TGX-221|SORAFENIB|BINIMETINIB|HSP90 INHIBITOR XL888|UPROSERTIB|TOVORAFENIB|EXARAFENIB|PLX-4720|DABRAFENIB|KO-947|VEMURAFENIB|DASATINIB ANHYDROUS|OXALIPLATIN|BEVACIZUMAB|FUTIBATINIB|LGX-806|TRAMETINIB DIMETHYL SULFOXIDE|RABEPRAZOLE|(10R)-10-METHYL-3-(6-METHYLPYRIDIN-3-YL)-9,10,11,12-TETRAHYDRO-8H-[1,4]DIAZEPINO[5',6':4,5]THIENO[3,2-F]QUINOLIN-8-ONE|RAVOXERTINIB",SORAFENIB|BINIMETINIB|TOVORAFENIB|DABRAFENIB|VEMURAFENIB|DASATINIB ANHYDROUS|OXALIPLATIN|BEVACIZUMAB|FUTIBATINIB|TRAMETINIB DIMETHYL SULFOXIDE,DABRAFENIB|VEMURAFENIB|ENCORAFENIB|TRAMETINIB DIMETHYL SULFOXIDE|PANITUMUMAB,DRUGGABLE GENOME|KINASE|ENZYME|DRUG RESISTANCE|CLINICALLY ACTIONABLE|SERINE THREONINE KINASE,activator|inhibitor,"Clearity Foundation Biomarkers|CIViC: Clinical Interpretation of Variants in Cancer|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|Catalogue Of Somatic Mutations In Cancer|FDA Pharmacogenomic Biomarkers|The Clinical Knowledgebase|PharmGKB - The Pharmacogenomics Knowledgebase|Targeted Agents in Lung Cancer (Commentary, 2014)|Clearity Foundation Clinical Trial|Cancer Commons",True,CHEMBL2331061,SINGLE PROTEIN,0,0,84,84,85,True,821,19,6,0,0,DABRAFENIB|VEMURAFENIB|ENCORAFENIB|ENCORAFENIB|VEMURAFENIB|REGORAFENIB|SORAFENIB TOSYLATE|VEMURAFENIB|VEMURAFENIB|DABRAFENIB MESYLATE,Small molecule,Serine/threonine-protein kinase B-raf inhibitor,True,True,True,HIGH - Approved drugs exist,Serine/threonine-protein kinase B-raf,"Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)",3D-structure|Acetylation|Allosteric enzyme|ATP-binding|Cardiomyopathy|Cell membrane|Chromosomal rearrangement|Cytoplasm|Deafness|Direct protein sequencing|Disease variant|Ectodermal dysplasia|Intellectual disability|Isopeptide bond|Kinase|Membrane|Metal-binding|Methylation|Nucleotide-binding|Nucleus,Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. RAF subfamily,PF00130:C1_1|PF07714:PK_Tyr_Ser-Thr|PF02196:RBD,3,IPR046349:C1-like_sf|IPR020454:DAG/PE-bd|IPR011009:Kinase-like_dom_sf|IPR002219:PE/DAG-bd|IPR000719:Prot_kinase_dom|IPR017441:Protein_kinase_ATP_BS|IPR003116:RBD_dom|IPR001245:Ser-Thr/Tyr_kinase_cat_dom|IPR008271:Ser/Thr_kinase_AS|IPR051681:Ser/Thr_Kinases-Pseudokinases|IPR029071:Ubiquitin-like_domsf,11,,active_site|domain|homologous_superfamily|family|binding_site,True,Kinase|Transferase,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR017441|Kinase: InterPro: IPR008271|Kinase: Pfam: PF07714|Transferase: Keyword: transferase,Kinase,True,130,1UWH|1UWJ|2FB8|2L05|3C4C|3D4Q|3IDP|3II5|3NY5|3OG7,1UWH,2.95,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1UWH.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1UWH.pdb,Moderate (2.5-3.0Å),True,39,1.0,1454.837,0.993,49.846,0.95,True,34,Excellent,High,Optimal volume (1455A3)|High druggability (0.99),,1455|1438|466|153|407|467|455|143|474|285|400|146|212|766|358|144|253|278|475|274|445|365|274|273|630|623|223|222|394|230|555|242|282|239|310|148|301|550|955,0.99|0.98|0.01|0.00|0.01|0.01|0.01|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.02|0.01|0.00|0.00|0.01|0.00|0.00|0.00|0.02,P1:Vol=1455:Drug=0.99|P2:Vol=1438:Drug=0.98|P3:Vol=466:Drug=0.01|P4:Vol=153:Drug=0.00|P5:Vol=407:Drug=0.01|P6:Vol=467:Drug=0.01|P7:Vol=455:Drug=0.01|P8:Vol=143:Drug=0.00|P9:Vol=474:Drug=0.00|P10:Vol=285:Drug=0.00
ERBB2,ERBB2,erb-b2 receptor tyrosine kinase 2,"This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008].",protein-coding,CD340|HER-2|HER-2/neu|HER2|MLN 19|MLN-19|NEU|NGL|TKR1|VSCN2|c-ERB-2|c-ERB2|p185(erbB2),c-erb B2/neu protein|herstatin|human epidermal growth factor receptor 2|metastatic lymph node gene 19 protein|neuro/glioblastoma derived oncogene homolog,ENSG00000141736,ENST00000269571|ENST00000445658|ENST00000578199|ENST00000578373|ENST00000578502|ENST00000578630|ENST00000578709|ENST00000580074|ENST00000582648|ENST00000582788,ENSP00000269571|ENSP00000404047|ENSP00000462024|ENSP00000462438|ENSP00000462808|ENSP00000463002|ENSP00000463427|ENSP00000463714|ENSP00000463719|ENSP00000464252,P04626,F5H1T4|B4DTR1|X5DNK3|J3QLU9|J3KTI5,ERBB2_HUMAN,2064.0,NM_001005862.3|NM_001289936.2|NM_001289937.2|NM_001289938.2|NM_001382782.1|NM_001382783.1|NM_001382784.1|NM_001382785.1|NM_001382786.1|NM_001382787.1,NP_001005862.1|NP_001276865.1|NP_001276866.1|NP_001276867.1|NP_001369711.1|NP_001369712.1|NP_001369713.1|NP_001369714.1|NP_001369715.1|NP_001369716.1,NC_000017.11|NC_060941.1|NG_007503.1,3430.0,164870.0,PA27844,9606.ENSP00000269571,1MFG|1MFL|1MW4|1N8Z|1QR1|1S78|2A91|2JWA|2KS1|2L4K|2N2A|3BE1|3H3B|3MZW|3N85|3PP0|3RCD|3WLW|3WSQ|4GFU,2.7.10.1,IPR000494|IPR000719|IPR001245|IPR006211|IPR006212|IPR008266|IPR009030|IPR011009|IPR016245|IPR017441,PF00757|PF01030|PF07714|PF14843|PF21314,PS50011,17,39687914.0,39730426.0,1.0,1255.0,"Cell membrane|Cell projection, ruffle membrane",9606.0,3273.0,HER2/neu,biocarta:her2pathway|biocarta:tffpathway|kegg:hsa04010|kegg:hsa04012|kegg:hsa04020|kegg:hsa04066|kegg:hsa04151|netpath:Pathway_Alpha6Beta4Integrin|netpath:Pathway_EGFR1|netpath:Pathway_IL6|netpath:Pathway_Leptin|netpath:Pathway_Oncostatin_M|pid:a6b1_a6b4_integrin_pathway|pid:erbb2erbb3pathway|pid:erbb4_pathway|pid:erbb_network_pathway|pid:myc_represspathway|reactome:R-HSA-1227986|reactome:R-HSA-1227986|reactome:R-HSA-1227990|reactome:R-HSA-1250196|reactome:R-HSA-1250196|smpdb:SMP00463|smpdb:SMP00582|wikipathways:WP2034|wikipathways:WP2037|wikipathways:WP2261|wikipathways:WP2814|wikipathways:WP2817,True,erb-b2 receptor tyrosine kinase 2,153,64,MM-111|TRASTUZUMAB|PERTUZUMAB|FULVESTRANT|IL-12|ADO-TRASTUZUMAB EMTANSINE|MARGETUXIMAB|POZIOTINIB|BMS-599626|CETUXIMAB|LAPATINIB|LETROZOLE|ABEMACICLIB|ALLITINIB|TIPIRACIL / TRIFLURIDINE|PLATINUM COMPOUND|T-DM1|TESEVATINIB|ANTINEOPLASTIC AGENT|AFATINIB,TRASTUZUMAB|PERTUZUMAB|FULVESTRANT|ADO-TRASTUZUMAB EMTANSINE|MARGETUXIMAB|CETUXIMAB|LAPATINIB|LETROZOLE|ABEMACICLIB|AFATINIB,MM-111|CP-724714|NAKIJIQUINONES H|NAKIJIQUINONE I|NAKIJIQUINONES G,KINASE|TYROSINE KINASE|DRUGGABLE GENOME|CLINICALLY ACTIONABLE|DRUG RESISTANCE,vaccine|antibody|modulator|binder|negative modulator|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|Drug Target Commons|Clearity Foundation Biomarkers|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|FDA Pharmacogenomic Biomarkers|OncoKB: A Precision Oncology Knowledge Base|Targeted Agents in Lung Cancer (Commentary, 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Clearity Foundation Clinical Trial",True,CHEMBL2311234,SINGLE PROTEIN,0,0,8,8,10,True,1054,25,0,0,0,LAPATINIB DITOSYLATE|TRASTUZUMAB EMTANSINE|NERATINIB MALEATE|TRASTUZUMAB|PERTUZUMAB|PERTUZUMAB|DACOMITINIB|VANDETANIB|TRASTUZUMAB|MASOPROCOL,Antibody|Small molecule|Antibody drug conjugate,Receptor protein-tyrosine kinase erbB-2 inhibitor|Epidermal growth factor receptor inhibitor|Receptor protein-tyrosine kinase erbB-2 binding agent,True,False,True,HIGH - Approved drugs exist,Receptor tyrosine-protein kinase erbB-2,In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth,3D-structure|Activator|Alternative initiation|Alternative splicing|ATP-binding|Cell membrane|Cell projection|Chromosomal rearrangement|Cytoplasm|Disease variant|Disulfide bond|Endosome|Glycoprotein|Kinase|Membrane|Nucleotide-binding|Nucleus|Phosphoprotein|Proteomics identification|Receptor,Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily,PF00757:Furin-like|PF14843:GF_recep_IV|PF07714:PK_Tyr_Ser-Thr|PF01030:Recep_L_domain|PF21314:TM_ErbB1,5,IPR006211:Furin-like_Cys-rich_dom|IPR006212:Furin_repeat|IPR032778:GF_recep_IV|IPR009030:Growth_fac_rcpt_cys_sf|IPR011009:Kinase-like_dom_sf|IPR000719:Prot_kinase_dom|IPR017441:Protein_kinase_ATP_BS|IPR000494:Rcpt_L-dom|IPR036941:Rcpt_L-dom_sf|IPR050122:RTK|IPR001245:Ser-Thr/Tyr_kinase_cat_dom|IPR049328:TM_ErbB1|IPR008266:Tyr_kinase_AS|IPR020635:Tyr_kinase_cat_dom|IPR016245:Tyr_kinase_EGF/ERB/XmrK_rcpt,15,,active_site|domain|homologous_superfamily|family|binding_site|repeat,True,Kinase|Cyclooxygenase|Cytokine Receptor|Transferase,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: Keyword: cdk|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR017441|Kinase: InterPro: IPR020635|Kinase: Pfam: PF07714|Cytokine Receptor: Pfam: PF01030|Cyclooxygenase: Keyword: cox-2,Kinase,True,61,1MFG|1MFL|1MW4|1N8Z|1QR1|1S78|2A91|2JWA|2KS1|2L4K,1MFG,1.25,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1MFG.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1MFG.pdb,Excellent (<2.0Å),True,6,1.0,355.99,0.772,42.571,0.346,True,3,Good,Medium,Adequate volume (356A3)|High druggability (0.77),,356|420|287|182|200|180,0.77|0.01|0.00,P1:Vol=356:Drug=0.77|P2:Vol=420:Drug=0.00|P3:Vol=287:Drug=0.01|P4:Vol=182:Drug=0.00|P5:Vol=200:Drug=0.00|P6:Vol=180:Drug=0.00
ALK,ALK,ALK receptor tyrosine kinase,"This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQSTM1 (chromosome 5), ALK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).[provided by RefSeq, Jan 2011].",protein-coding,ALK1|CD246|NBLST3,ALK tyrosine kinase receptor|CD246 antigen|anaplastic lymphoma receptor tyrosine kinase|mutant anaplastic lymphoma kinase,ENSG00000171094,ENST00000389048|ENST00000431873|ENST00000453137|ENST00000498037|ENST00000618119|ENST00000638605|ENST00000642122,ENSP00000373700|ENSP00000387488|ENSP00000414027|ENSP00000482733|ENSP00000493203,Q9UM73,B6D4Y2|A0A0K2YUJ3|E7EPW7|H7BZ33|A0A087WZL3,ALK_HUMAN,238.0,NM_001353765.2|NM_004304.5|XM_054341245.1|XR_001738688.3|XR_008486309.1,NP_001340694.1|NP_004295.2|XP_054197220.1,NC_000002.12|NC_060926.1|NG_009445.1,427.0,105590.0,PA24719,9606.ENSP00000373700,2KUP|2KUQ|2XB7|2XBA|2XP2|2YFX|2YHV|2YJR|2YJS|2YS5|2YT2|3AOX|3L9P|3LCS|3LCT|4ANL|4ANQ|4ANS|4CCB|4CCU,2.7.10.1,IPR000719|IPR000998|IPR001245|IPR002011|IPR002172|IPR008266|IPR011009|IPR013320|IPR017441|IPR020635,PF00629|PF07714|PF12810,PS50011|PS50060,2,29192774.0,29921586.0,-1.0,1620.0,Cell membrane,9606.0,68387.0,Anaplastic lymphoma kinase,kegg:hsa05200|kegg:hsa05223|kegg:hsa05235|reactome:R-HSA-162582|reactome:R-HSA-162582|reactome:R-HSA-1643685|reactome:R-HSA-201556|reactome:R-HSA-201556|wikipathways:WP2848|wikipathways:WP4255,True,ALK receptor tyrosine kinase,111,53,CEP-37440|ENTRECTINIB|VENETOCLAX|CONTELTINIB|ALECTINIB|ENSARTINIB|VANDETANIB|VINCRISTINE SULFATE|LORLATINIB|TOZASERTIB|TEMOZOLOMIDE|TALETRECTINIB|BEVACIZUMAB|BRENTUXIMAB VEDOTIN|ETOPOSIDE|ALK/C-MET INHIBITOR TQ-B3139|CEMIPLIMAB|ALK/TRK INHIBITOR TSR-011|LUMINESPIB|ATEZOLIZUMAB,ENTRECTINIB|VENETOCLAX|ALECTINIB|VANDETANIB|VINCRISTINE SULFATE|LORLATINIB|TEMOZOLOMIDE|BEVACIZUMAB|BRENTUXIMAB VEDOTIN|ETOPOSIDE,ALECTINIB|ENSARTINIB|LORLATINIB|BRIGATINIB|CRIZOTINIB,DRUGGABLE GENOME|KINASE|CLINICALLY ACTIONABLE|DRUG RESISTANCE|TYROSINE KINASE,inhibitor,"Catalogue Of Somatic Mutations In Cancer|NCI Cancer Gene Index|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|FDA Pharmacogenomic Biomarkers|OncoKB: A Precision Oncology Knowledge Base|The Clinical Knowledgebase|PharmGKB - The Pharmacogenomics Knowledgebase|Cancer Commons|Targeted Agents in Lung Cancer (Commentary, 2014)",True,CHEMBL4247,SINGLE PROTEIN,0,0,658,658,1000,True,208,20,5,0,0,CRIZOTINIB|BRIGATINIB|LORLATINIB|ALECTINIB|CRIZOTINIB|ENTRECTINIB|CERITINIB|LORLATINIB|CRIZOTINIB|CRIZOTINIB,Small molecule,NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor)|ALK tyrosine kinase receptor inhibitor|EML4-ALK|EML4-ALK  inhibitor,True,True,True,HIGH - Approved drugs exist,ALK tyrosine kinase receptor,"Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system (PubMed:11121404, PubMed:11387242, PubMed:16317043, PubMed:17274988, PubMed:30061385, PubMed:34646012, PubMed:34819673). Also acts as a key thinness protein involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue lipolysis and sympathetic tone to fine-tune energy homeostasis (By similarity). Following activation by ALKAL2 ligand at the cell surface, transduces an extracellular signal into an intracellular response (PubMed:30061385, PubMed:33411331, PubMed:34646012, PubMed:34819673). In contrast, ALKAL1 is not a potent physiological ligand for ALK (PubMed:34646012). Ligand-binding to the extracellular domain induces tyrosine kinase activation, leading to activation of the mitogen-activated protein kinase (MAPK) pathway (PubMed:34819673). Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif (PubMed:15226403, PubMed:16878150). Induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1 (PubMed:15226403, PubMed:16878150). ALK activation may also be regulated by pleiotrophin (PTN) and midkine (MDK) (PubMed:11278720, PubMed:11809760, PubMed:12107166, PubMed:12122009). PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation (PubMed:11278720, PubMed:11809760, PubMed:12107166). MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction (PubMed:12122009). Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase (PubMed:15226403, PubMed:16878150). Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK (PubMed:15226403, PubMed:16878150)",3D-structure|ATP-binding|Cell membrane|Chromosomal rearrangement|Disease variant|Disulfide bond|Glycoprotein|Kinase|Membrane|Nucleotide-binding|Phosphoprotein|Proteomics identification|Proto-oncogene|Receptor|Reference proteome|Repeat|Signal|Transferase|Transmembrane|Transmembrane helix,Belongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily,PF12810:ALK_LTK_GRD|PF00629:MAM|PF07714:PK_Tyr_Ser-Thr,3,IPR055163:ALK/LTK-like_GRD|IPR013320:ConA-like_dom_sf|IPR011009:Kinase-like_dom_sf|IPR036055:LDL_receptor-like_sf|IPR002172:LDrepeatLR_classA_rpt|IPR000998:MAM_dom|IPR000719:Prot_kinase_dom|IPR017441:Protein_kinase_ATP_BS|IPR050122:RTK|IPR001245:Ser-Thr/Tyr_kinase_cat_dom|IPR008266:Tyr_kinase_AS|IPR020635:Tyr_kinase_cat_dom|IPR002011:Tyr_kinase_rcpt_2_CS,13,,active_site|domain|homologous_superfamily|conserved_site|family|binding_site|repeat,True,Kinase|Actin|Transferase|Lipid Kinase|Histone Acetyltransferase,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: Keyword: tyrosine kinase|Kinase: Keyword: serine/threonine kinase|Kinase: Keyword: receptor tyrosine kinase|Kinase: Keyword: mapk|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR017441|Kinase: InterPro: IPR020635,Kinase,True,79,2KUP|2KUQ|2XB7|2XBA|2XP2|2YFX|2YHV|2YJR|2YJS|2YS5,2KUP,,SOLUTION NMR,protein_structures/pdb_experimental/2KUP.pdb,False,,,,,PDB,protein_structures/pdb_experimental/2KUP.pdb,,True,17,1.0,270.563,0.415,49.0,0.392,True,14,Moderate,Low,Adequate volume (271A3),Low druggability (0.41),271|600|373|304|441|422|474|602|324|402|340|379|526|247|219|184|317,0.41|0.00|0.00|0.00|0.12|0.02|0.00|0.00|0.00|0.01|0.00,P1:Vol=271:Drug=0.41|P2:Vol=600:Drug=0.00|P3:Vol=373:Drug=0.00|P4:Vol=304:Drug=0.00|P5:Vol=441:Drug=0.00|P6:Vol=422:Drug=0.00|P7:Vol=474:Drug=0.00|P8:Vol=602:Drug=0.00|P9:Vol=324:Drug=0.12|P10:Vol=402:Drug=0.02
JAK2,JAK2,Janus kinase 2,"This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020].",protein-coding,JTK10,JAK-2|Janus kinase 2 (a protein tyrosine kinase)|tyrosine-protein kinase JAK2,ENSG00000096968,ENST00000381652|ENST00000476574|ENST00000487310|ENST00000636127|ENST00000870320|ENST00000870321|ENST00000870322|ENST00000870323|ENST00000870324|ENST00000870325,ENSP00000371067|ENSP00000489812|ENSP00000490624|ENSP00000540379|ENSP00000540380|ENSP00000540381|ENSP00000540382|ENSP00000540383|ENSP00000540384|ENSP00000633996,O60674,B4DYV1|A8K910|A0A1B0GVR5|A0A1B0GTR9,JAK2_HUMAN,3717.0,NM_001322194.2|NM_001322195.2|NM_001322196.2|NM_001322198.2|NM_001322199.2|NM_001322204.2|NM_004972.4|NR_169763.1|NR_169764.1,NP_001309123.1|NP_001309124.1|NP_001309125.1|NP_001309127.1|NP_001309128.1|NP_001309133.1|NP_004963.1,NC_000009.12|NC_060933.1|NG_009904.1,6192.0,147796.0,PA29989,9606.ENSP00000371067,2B7A|2W1I|2XA4|3E62|3E63|3E64|3FUP|3IO7|3IOK|3JY9|3KCK|3KRR|3LPB|3Q32|3RVG|3TJC|3TJD|3UGC|3ZMM|4AQC,2.7.10.2,IPR000299|IPR000719|IPR000980|IPR001245|IPR008266|IPR011009|IPR011993|IPR016251|IPR017441|IPR019748,PF07714|PF17887|PF18377|PF18379|PF21990,PS50001|PS50011|PS50057,9,4984390.0,5129948.0,1.0,1132.0,Endomembrane system|Cytoplasm|Nucleus,9606.0,21033.0,Janus kinase 2,biocarta:biopeptidespathway|biocarta:eponfkbpathway|biocarta:epopathway|biocarta:ghpathway|biocarta:gleevecpathway|kegg:hsa04062|kegg:hsa04151|kegg:hsa04217|kegg:hsa04550|kegg:hsa04630|netpath:Pathway_EGFR1|netpath:Pathway_Gastrin|netpath:Pathway_IL11|netpath:Pathway_IL3|netpath:Pathway_IL4|pid:cxcr4_pathway|pid:endothelinpathway|pid:epopathway|pid:erbb2erbb3pathway|pid:erbb4_pathway|reactome:R-HSA-1059683|reactome:R-HSA-1059683|reactome:R-HSA-109582|reactome:R-HSA-110056|reactome:R-HSA-112409|wikipathways:WP127|wikipathways:WP2032|wikipathways:WP2034|wikipathways:WP2037|wikipathways:WP2112,True,Janus kinase 2,98,32,TYRPHOSTIN 23|AZD1480|PF-562271|JAK2V617F INHIBITOR INCB160058|PEMBROLIZUMAB|TOFACITINIB|RUXOLITINIB|FEDRATINIB|TENALISIB|FILGOTINIB|PACRITINIB|BARICITINIB|NS-018|TANESPIMYCIN|AZD1208|PICTILISIB|DOVITINIB|AZ960|GANDOTINIB|PEGINTERFERON ALFA-2B,PEMBROLIZUMAB|TOFACITINIB|RUXOLITINIB|FEDRATINIB|FILGOTINIB|PACRITINIB|BARICITINIB|PEGINTERFERON ALFA-2B|ROPEGINTERFERON ALFA-2B|MOMELOTINIB,RUXOLITINIB|BMS-911543|A-1155463|AZ960|GANDOTINIB,DRUGGABLE GENOME|KINASE|ENZYME|TYROSINE KINASE|CLINICALLY ACTIONABLE|DRUG RESISTANCE,inhibitor,"Catalogue Of Somatic Mutations In Cancer|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|OncoKB: A Precision Oncology Knowledge Base|Targeted Agents in Lung Cancer (Commentary, 2014)|The Clinical Knowledgebase|PharmGKB - The Pharmacogenomics Knowledgebase|Cancer Genome Interpreter|MyCancerGenome Clinical Trial|Database of Curated Mutations",True,CHEMBL2971,SINGLE PROTEIN,0,0,772,772,1000,True,551,25,0,0,0,BARICITINIB|FILGOTINIB|PACRITINIB|RUXOLITINIB|FEDRATINIB|TOFACITINIB CITRATE|TOFACITINIB CITRATE|BARICITINIB|BARICITINIB|FILGOTINIB MALEATE,Small molecule,Tyrosine-protein kinase JAK2 inhibitor|Janus Kinase (JAK) inhibitor,True,False,True,HIGH - Approved drugs exist,Tyrosine-protein kinase JAK2,"Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin receptor (MPL/TPOR); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins (PubMed:15690087, PubMed:7615558, PubMed:9657743, PubMed:15899890). Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins (PubMed:15690087, PubMed:9618263). Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain (PubMed:9657743). Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. Part of a signaling cascade that is activated by increased cellular retinol and that leads to the activation of STAT5 (STAT5A or STAT5B) (PubMed:21368206). In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation (PubMed:20098430). Plays a role in cell cycle by phosphorylating CDKN1B (PubMed:21423214). Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin (PubMed:19783980). Up-regulates the potassium voltage-gated channel activity of KCNA3 (PubMed:25644777)",3D-structure|Adaptive immunity|ATP-binding|Chromatin regulator|Chromosomal rearrangement|Cytoplasm|Disease variant|Immunity|Innate immunity|Kinase|Magnesium|Membrane|Metal-binding|Nucleotide-binding|Nucleus|Phosphoprotein|Proteomics identification|Proto-oncogene|Reference proteome|Repeat,Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily,PF18379:FERM_F1|PF18377:FERM_F2|PF17887:Jak1_Phl|PF07714:PK_Tyr_Ser-Thr|PF21990:SH2_1,5,IPR019749:Band_41_domain|IPR035963:FERM_2|IPR019748:FERM_central|IPR000299:FERM_domain|IPR041155:FERM_F1|IPR041046:FERM_F2|IPR051286:JAK|IPR041381:JAK1-3/TYK2_PHL_dom|IPR037838:JAK2_FERM_C-lobe|IPR035860:JAK2_SH2|IPR011009:Kinase-like_dom_sf|IPR011993:PH-like_dom_sf|IPR000719:Prot_kinase_dom|IPR017441:Protein_kinase_ATP_BS|IPR035588:PTK_Jak2_rpt1,23,,active_site|domain|homologous_superfamily|family|binding_site,True,Kinase|Actin|Chromodomain Protein|Transferase|Ion Channel|Histone Acetyltransferase,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: Keyword: tyrosine kinase|Kinase: Keyword: receptor tyrosine kinase|Kinase: Keyword: cdk|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR017441|Kinase: InterPro: IPR020635|Kinase: Pfam: PF07714,Kinase,True,164,2B7A|2W1I|2XA4|3E62|3E63|3E64|3FUP|3IO7|3IOK|3JY9,2B7A,2.0,X-RAY DIFFRACTION,protein_structures/pdb_experimental/2B7A.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/2B7A.pdb,Excellent (<2.0Å),True,39,2.0,841.729,0.412,15.833,0.278,True,31,Moderate,Low,Optimal volume (842A3),Low druggability (0.41),1923|842|373|188|278|72|447|348|521|510|334|388|324|563|265|364|210|476|187|359|496|96|358|249|243|286|383|207|460|393|776|382|204|533|504|211|223|562|999,0.25|0.41|0.01|0.00|0.00|0.00|0.06|0.03|0.08|0.00|0.01|0.01|0.08|0.00|0.00|0.01|0.00|0.04|0.00|0.00|0.00|0.01,P1:Vol=1923:Drug=0.25|P2:Vol=842:Drug=0.41|P3:Vol=373:Drug=0.01|P4:Vol=188:Drug=0.00|P5:Vol=278:Drug=0.00|P6:Vol=72:Drug=0.00|P7:Vol=447:Drug=0.00|P8:Vol=348:Drug=0.00|P9:Vol=521:Drug=0.00|P10:Vol=510:Drug=0.06
JAK1,JAK1,Janus kinase 1,"This gene encodes a membrane protein that is a member of a class of protein-tyrosine kinases (PTK) characterized by the presence of a second phosphotransferase-related domain immediately N-terminal to the PTK domain. The encoded kinase phosphorylates STAT proteins (signal transducers and activators of transcription) and plays a key role in interferon-alpha/beta, interferon-gamma, and cytokine signal transduction. This gene plays a crucial role in effecting the expression of genes that mediate inflammation, epithelial remodeling, and metastatic cancer progression. This gene is a key component of the interleukin-6 (IL-6)/JAK1/STAT3 immune and inflammation response and is a therapeutic target for alleviating cytokine storms. The kinase activity of this gene is directly inhibited by the suppressor of cytokine signalling 1 (SOCS1) protein. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2020].",protein-coding,AIIDE|JAK1A|JAK1B|JTK3,tyrosine-protein kinase JAK1,ENSG00000162434,ENST00000342505|ENST00000465376|ENST00000471473|ENST00000481702|ENST00000494904|ENST00000671746|ENST00000671929|ENST00000671954|ENST00000672099|ENST00000672179,ENSP00000343204|ENSP00000499884|ENSP00000499900|ENSP00000499942|ENSP00000500065|ENSP00000500296|ENSP00000500328|ENSP00000500422|ENSP00000500476|ENSP00000500485,P23458,Q6P669|A0A8V8TPQ9|A0A0A0N0M2|A0A8V8TN56|A0A5F9ZI39,JAK1_HUMAN,3716.0,NM_001320923.2|NM_001321852.2|NM_001321853.2|NM_001321854.2|NM_001321855.2|NM_001321856.2|NM_001321857.2|NM_002227.4|XM_047419674.1|XM_047419675.1,NP_001307852.1|NP_001308781.1|NP_001308782.1|NP_001308783.1|NP_001308784.1|NP_001308785.1|NP_001308786.1|NP_002218.2|XP_047275630.1|XP_047275631.1,NC_000001.11|NC_060925.1|NG_023402.2,6190.0,147795.0,PA29988,9606.ENSP00000499900,3EYG|3EYH|4E4L|4E4N|4E5W|4EHZ|4EI4|4FK6|4GS0|4I5C|4IVB|4IVC|4IVD|4K6Z|4K77|4L00|4L01|5E1E|5HX8|5IXD,2.7.10.2,IPR000299|IPR000719|IPR000980|IPR001245|IPR008266|IPR011009|IPR016251|IPR017441|IPR019748|IPR019749,PF07714|PF17887|PF18377|PF18379|PF21990,PS50001|PS50011|PS50057,1,64833223.0,65067754.0,-1.0,1154.0,Endomembrane system,9606.0,1678.0,Janus kinase 1,biocarta:egfpathway|biocarta:her2pathway|biocarta:ifnapathway|biocarta:ifngpathway|biocarta:il10pathway|kegg:hsa04151|kegg:hsa04217|kegg:hsa04380|kegg:hsa04550|kegg:hsa04621|netpath:Pathway_EGFR1|netpath:Pathway_IL-7|netpath:Pathway_IL11|netpath:Pathway_IL2|netpath:Pathway_IL4|pid:ifngpathway|pid:il27pathway|pid:il2_1pathway|pid:il2_pi3kpathway|pid:il2_stat5pathway|reactome:R-HSA-1059683|reactome:R-HSA-1059683|reactome:R-HSA-110056|reactome:R-HSA-112409|reactome:R-HSA-112411|wikipathways:WP127|wikipathways:WP2032|wikipathways:WP2034|wikipathways:WP2037|wikipathways:WP205,True,Janus kinase 1,26,12,RUXOLITINIB|IZENCITINIB|PEMBROLIZUMAB|RUXOLITINIB PHOSPHATE|GOLIDOCITINIB|FILGOTINIB MALEATE|MOMELOTINIB|AZD1480|DELGOCITINIB|TRICETAMIDE|TOFACITINIB|PEFICITINIB|BREPOCITINIB|UPADACITINIB HEMIHYDRATE|CYCLOSPORINE|INCB-047986|ABROCITINIB|ENZASTAURIN|CERDULATINIB|NEZULCITINIB,RUXOLITINIB|PEMBROLIZUMAB|RUXOLITINIB PHOSPHATE|FILGOTINIB MALEATE|MOMELOTINIB|TOFACITINIB|PEFICITINIB|UPADACITINIB HEMIHYDRATE|CYCLOSPORINE|ABROCITINIB,GOLIDOCITINIB|INCB-047986|GLPG-0555|RUXOLITINIB PHOSPHATE|TRICETAMIDE,DRUGGABLE GENOME|KINASE|DRUG RESISTANCE|TYROSINE KINASE|CLINICALLY ACTIONABLE|ENZYME,inhibitor,"Catalogue Of Somatic Mutations In Cancer|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|Cancer Genome Interpreter|Database of Curated Mutations|Drug Target Commons|The ChEMBL Bioactivity Database|My Cancer Genome",True,CHEMBL2835,SINGLE PROTEIN,0,0,549,549,1000,True,556,22,3,0,0,ABROCITINIB|ABROCITINIB|FILGOTINIB|BARICITINIB|RUXOLITINIB|TOFACITINIB CITRATE|FILGOTINIB MALEATE|TOFACITINIB CITRATE|BARICITINIB|BARICITINIB,Small molecule,Janus Kinase (JAK) inhibitor|Tyrosine-protein kinase JAK1 inhibitor,True,True,True,HIGH - Approved drugs exist,Tyrosine-protein kinase JAK1,"Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway (PubMed:16239216, PubMed:28111307, PubMed:32750333, PubMed:7615558, PubMed:8232552). Kinase partner for the interleukin (IL)-2 receptor (PubMed:11909529) as well as interleukin (IL)-10 receptor (PubMed:12133952). Kinase partner for the type I interferon receptor IFNAR2 (PubMed:16239216, PubMed:28111307, PubMed:32750333, PubMed:7615558, PubMed:8232552). In response to interferon-binding to IFNAR1-IFNAR2 heterodimer, phosphorylates and activates its binding partner IFNAR2, creating docking sites for STAT proteins (PubMed:7759950). Directly phosphorylates STAT proteins but also activates STAT signaling through the transactivation of other JAK kinases associated with signaling receptors (PubMed:16239216, PubMed:32750333, PubMed:8232552)",3D-structure|Acetylation|ATP-binding|Disease variant|Kinase|Magnesium|Membrane|Metal-binding|Nucleotide-binding|Phosphoprotein|Proteomics identification|Reference proteome|Repeat|SH2 domain|Transferase|Tyrosine-protein kinase|Ubl conjugation,Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily,PF18379:FERM_F1|PF18377:FERM_F2|PF17887:Jak1_Phl|PF07714:PK_Tyr_Ser-Thr|PF21990:SH2_1,5,IPR019749:Band_41_domain|IPR035963:FERM_2|IPR019748:FERM_central|IPR000299:FERM_domain|IPR041155:FERM_F1|IPR041046:FERM_F2|IPR051286:JAK|IPR041381:JAK1-3/TYK2_PHL_dom|IPR011009:Kinase-like_dom_sf|IPR000719:Prot_kinase_dom|IPR017441:Protein_kinase_ATP_BS|IPR001245:Ser-Thr/Tyr_kinase_cat_dom|IPR000980:SH2|IPR036860:SH2_dom_sf|IPR008266:Tyr_kinase_AS,18,,active_site|domain|homologous_superfamily|family|binding_site,True,Kinase|Cytokine Receptor|Transferase,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: Keyword: tyrosine kinase|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR017441|Kinase: InterPro: IPR020635|Kinase: Pfam: PF07714|Cytokine Receptor: Keyword: interferon receptor|Transferase: Keyword: transferase,Kinase,True,51,3EYG|3EYH|4E4L|4E4N|4E5W|4EHZ|4EI4|4FK6|4GS0|4I5C,3EYG,1.9,X-RAY DIFFRACTION,protein_structures/pdb_experimental/3EYG.pdb,False,,,,,PDB,protein_structures/pdb_experimental/3EYG.pdb,Excellent (<2.0Å),True,21,1.0,912.525,0.563,13.875,0.43,True,17,Good,Medium,Optimal volume (913A3),,913|345|731|315|828|269|242|235|326|553|162|276|351|276|190|157|484|301|212|278|212,0.56|0.00|0.04|0.00|0.06|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00,P1:Vol=913:Drug=0.56|P2:Vol=345:Drug=0.00|P3:Vol=731:Drug=0.04|P4:Vol=315:Drug=0.00|P5:Vol=828:Drug=0.06|P6:Vol=269:Drug=0.00|P7:Vol=242:Drug=0.00|P8:Vol=235:Drug=0.00|P9:Vol=326:Drug=0.00|P10:Vol=553:Drug=0.00
BTK,BTK,Bruton tyrosine kinase,"The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Dec 2013].",protein-coding,AGMX1|AT|ATK|BPK|IGHD3|IMD1|PSCTK1|XLA,B-cell progenitor kinase|Bruton agammaglobulinemia tyrosine kinase|Bruton's tyrosine kinase|agammaglobulinaemia tyrosine kinase|dominant-negative kinase-deficient Brutons tyrosine kinase,ENSG00000010671,ENST00000308731|ENST00000464006|ENST00000464567|ENST00000470069|ENST00000470329|ENST00000478995|ENST00000488970|ENST00000621635|ENST00000695614|ENST00000695615,ENSP00000308176|ENSP00000483570|ENSP00000512053|ENSP00000512054|ENSP00000512055|ENSP00000512056|ENSP00000512057|ENSP00000512058|ENSP00000512059|ENSP00000512060,Q06187,Q3MS88|Q5JY90|Q3MS97|Q3MS94|Q3MS90,BTK_HUMAN,695.0,NM_000061.3|NM_001287344.2|NM_001287345.2,NP_000052.1|NP_001274273.1|NP_001274274.1,NC_000023.11|NC_060947.1|NG_009616.1,1133.0,300300.0,PA25454,9606.ENSP00000483570,1AWW|1AWX|1B55|1BTK|1BWN|1K2P|1QLY|2GE9|2Z0P|3GEN|3K54|3OCS|3OCT|3P08|3PIX|3PIY|3PIZ|3PJ1|3PJ2|3PJ3,2.7.10.2,IPR000719|IPR000980|IPR001245|IPR001452|IPR001562|IPR001849|IPR008266|IPR011009|IPR011993|IPR017441,PF00017|PF00018|PF00169|PF00779|PF07714,PS50001|PS50002|PS50003|PS50011|PS51113,X,101349338.0,101390796.0,-1.0,659.0,Cytoplasm|Cell membrane|Nucleus,9606.0,30953.0,Bruton's tyrosine kinase,biocarta:bcrpathway|biocarta:fcer1pathway|biocarta:ptdinspathway|kegg:hsa04064|kegg:hsa04380|kegg:hsa04611|kegg:hsa04662|kegg:hsa04664|netpath:Pathway_BCR|netpath:Pathway_IL6|pid:bcr_5pathway|pid:epopathway|pid:faspathway|pid:fcer1pathway|pid:pi3kcipathway|reactome:R-HSA-1236974|reactome:R-HSA-1236975|reactome:R-HSA-1280218|reactome:R-HSA-1280218|reactome:R-HSA-162582|wikipathways:WP127|wikipathways:WP1449|wikipathways:WP2203|wikipathways:WP23|wikipathways:WP304,True,Bruton tyrosine kinase,52,11,NEMTABRUTINIB|TIRABRUTINIB|BMS-986142|ZM447439|CENISERTIB|RILZABRUTINIB|ABIVERTINIB MALEATE|MSC-2364447|TAK-020|BIIB068|ACALABRUTINIB|SPEBRUTINIB|BTK INHIBITOR TL-895|PP2|TAMATINIB|DASATINIB ANHYDROUS|ALISERTIB|ILORASERTIB|ZANUBRUTINIB|BTK INHIBITOR DTRMWXHS-12,TIRABRUTINIB|ACALABRUTINIB|DASATINIB ANHYDROUS|ZANUBRUTINIB|PIRTOBRUTINIB|RITLECITINIB TOSYLATE|ENTRECTINIB|VANDETANIB|ACALABRUTINIB MALEATE|RITLECITINIB,BMS-986142|RILZABRUTINIB|TIRABRUTINIB|MSC-2364447|BTK INHIBITOR TL-895,KINASE|TYROSINE KINASE|DRUGGABLE GENOME|DRUG RESISTANCE|TRANSCRIPTION FACTOR|CLINICALLY ACTIONABLE|ENZYME,inhibitor,"Catalogue Of Somatic Mutations In Cancer|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|Targeted Agents in Lung Cancer (Commentary, 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Guide to Pharmacology|Cancer Genome Interpreter|Database of Curated Mutations|Drug Target Commons|The ChEMBL Bioactivity Database",True,CHEMBL4879468,SINGLE PROTEIN,0,0,4,4,18,True,447,16,9,0,0,IBRUTINIB|ACALABRUTINIB|ACALABRUTINIB MALEATE|ACALABRUTINIB|IBRUTINIB|ZANUBRUTINIB|RITLECITINIB TOSYLATE|IBRUTINIB|IBRUTINIB|IBRUTINIB,Small molecule,Tyrosine-protein kinase BTK inhibitor|TEC family kinase inhibitor,True,True,True,HIGH - Approved drugs exist,Tyrosine-protein kinase BTK,"Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling (PubMed:19290921). Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation (PubMed:19290921). After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members (PubMed:11606584). PLCG2 phosphorylation is performed in close cooperation with the adapter protein B-cell linker protein BLNK (PubMed:11606584). BTK acts as a platform to bring together a diverse array of signaling proteins and is implicated in cytokine receptor signaling pathways (PubMed:16517732, PubMed:17932028). Plays an important role in the function of immune cells of innate as well as adaptive immunity, as a component of the Toll-like receptors (TLR) pathway (PubMed:16517732). The TLR pathway acts as a primary surveillance system for the detection of pathogens and are crucial to the activation of host defense (PubMed:16517732). Especially, is a critical molecule in regulating TLR9 activation in splenic B-cells (PubMed:16517732, PubMed:17932028). Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which leads to TIRAP degradation (PubMed:16415872). BTK also plays a critical role in transcription regulation (PubMed:19290921). Induces the activity of NF-kappa-B, which is involved in regulating the expression of hundreds of genes (PubMed:19290921). BTK is involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B (PubMed:19290921). Acts as an activator of NLRP3 inflammasome assembly by mediating phosphorylation of NLRP3 (PubMed:34554188). Transiently phosphorylates transcription factor GTF2I on tyrosine residues in response to BCR (PubMed:9012831). GTF2I then translocates to the nucleus to bind regulatory enhancer elements to modulate gene expression (PubMed:9012831). ARID3A and NFAT are other transcriptional target of BTK (PubMed:16738337). BTK is required for the formation of functional ARID3A DNA-binding complexes (PubMed:16738337). There is however no evidence that BTK itself binds directly to DNA (PubMed:16738337). BTK has a dual role in the regulation of apoptosis (PubMed:9751072). Plays a role in STING1-mediated induction of type I interferon (IFN) response by phosphorylating DDX41 (PubMed:25704810)",3D-structure|Acetylation|Adaptive immunity|Alternative promoter usage|Apoptosis|ATP-binding|Cell membrane|Cytoplasm|Direct protein sequencing|Disease variant|Dwarfism|Immunity|Innate immunity|Kinase|Lipid-binding|Membrane|Metal-binding|Nucleotide-binding|Nucleus|Phosphoprotein,Belongs to the protein kinase superfamily. Tyr protein kinase family. TEC subfamily,PF00779:BTK|PF00169:PH|PF07714:PK_Tyr_Ser-Thr|PF00017:SH2|PF00018:SH3_1,5,IPR035574:BTK_SH3|IPR011009:Kinase-like_dom_sf|IPR050198:Non-receptor_tyrosine_kinases|IPR011993:PH-like_dom_sf|IPR001849:PH_domain|IPR000719:Prot_kinase_dom|IPR017441:Protein_kinase_ATP_BS|IPR001245:Ser-Thr/Tyr_kinase_cat_dom|IPR000980:SH2|IPR036860:SH2_dom_sf|IPR036028:SH3-like_dom_sf|IPR001452:SH3_domain|IPR008266:Tyr_kinase_AS|IPR020635:Tyr_kinase_cat_dom|IPR001562:Znf_Btk_motif,15,,active_site|domain|homologous_superfamily|conserved_site|family|binding_site,True,Kinase|Transferase|Cytokine Receptor|Histone Acetyltransferase|Transcription Factor,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: Keyword: tyrosine kinase|Kinase: Keyword: receptor tyrosine kinase|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR017441|Kinase: InterPro: IPR020635|Kinase: Pfam: PF07714|Histone Acetyltransferase: Keyword: hat,Kinase,True,133,1AWW|1AWX|1B55|1BTK|1BWN|1K2P|1QLY|2GE9|2Z0P|3GEN,1AWW,,SOLUTION NMR,protein_structures/pdb_experimental/1AWW.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1AWW.pdb,,True,7,4.0,470.723,0.606,2.7,0.2,True,4,Moderate,Low,Adequate volume (471A3),,480|356|198|471|332|220|173,0.31|0.00|0.00|0.61|0.01|0.00|0.00,P1:Vol=480:Drug=0.31|P2:Vol=356:Drug=0.00|P3:Vol=198:Drug=0.00|P4:Vol=471:Drug=0.61|P5:Vol=332:Drug=0.01|P6:Vol=220:Drug=0.00|P7:Vol=173:Drug=0.00
SRC,SRC,"SRC proto-oncogene, non-receptor tyrosine kinase","This gene is highly similar to the v-src gene of Rous sarcoma virus. This proto-oncogene may play a role in the regulation of embryonic development and cell growth. The protein encoded by this gene is a tyrosine-protein kinase whose activity can be inhibited by phosphorylation by c-SRC kinase. Mutations in this gene could be involved in the malignant progression of colon cancer. Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008].",protein-coding,ASV|SRC1|THC6|c-SRC|p60-Src,"proto-oncogene c-Src|proto-oncogene tyrosine-protein kinase Src|protooncogene SRC, Rous sarcoma|tyrosine kinase pp60c-src|tyrosine-protein kinase SRC-1",ENSG00000291971,ENST00000709391|ENST00000709392|ENST00000709393|ENST00000709394|ENST00000709395|ENST00000709396|ENST00000709397|ENST00000709398|ENST00000709399|ENST00000709400,ENSP00000517666|ENSP00000517667|ENSP00000517668|ENSP00000517669|ENSP00000517670|ENSP00000517671|ENSP00000517672,P12931,A0A8I5KYU4,SRC_HUMAN,6714.0,NM_005417.5|NM_198291.3|XM_017028026.2|XM_047440396.1|XM_047440397.1|XM_047440398.1|XM_047440399.1|XM_047440400.1|XM_047440401.1|XM_047440402.1,NP_005408.1|NP_938033.1|XP_016883515.1|XP_047296352.1|XP_047296353.1|XP_047296354.1|XP_047296355.1|XP_047296356.1|XP_047296357.1|XP_047296358.1,NC_000020.11|NC_060944.1|NG_023033.1|NW_025791812.1,11283.0,190090.0,PA36111,9606.ENSP00000362680,1A07|1A08|1A09|1A1A|1A1B|1A1C|1A1E|1FMK|1HCS|1HCT|1KSW|1O41|1O42|1O43|1O44|1O45|1O46|1O47|1O48|1O49,2.7.10.2,IPR000719|IPR000980|IPR001245|IPR001452|IPR008266|IPR011009|IPR017441|IPR020635|IPR036028|IPR036860,PF00017|PF00018|PF07714|PF14604,PS50001|PS50002|PS50011,20,37344673.0,37406050.0,1.0,536.0,Cell membrane|Mitochondrion inner membrane|Nucleus,9606.0,21120.0,Src (gene),biocarta:achpathway|biocarta:agrpathway|biocarta:at1rpathway|biocarta:barrestinsrcpathway|biocarta:cblpathway|kegg:hsa04012|kegg:hsa04015|kegg:hsa04062|kegg:hsa04137|kegg:hsa04144|netpath:Pathway_Alpha6Beta4Integrin|netpath:Pathway_AndrogenReceptor|netpath:Pathway_EGFR1|netpath:Pathway_Fibroblast__growth__factor-1|netpath:Pathway_Ghrelin|pid:ajdiss_2pathway|pid:alphasynuclein_pathway|pid:ar_nongenomic_pathway|pid:ar_tf_pathway|pid:arf6_pathway|reactome:R-HSA-157858|reactome:R-HSA-191650|reactome:R-HSA-199991|reactome:R-HSA-5653656|wikipathways:WP138|wikipathways:WP1539|wikipathways:WP185|wikipathways:WP2018|wikipathways:WP2032,True,"SRC proto-oncogene, non-receptor tyrosine kinase",54,10,XL-228|ILORASERTIB|GW843682X|CEDIRANIB|MASITINIB|DASATINIB ANHYDROUS|TYRPHOSTIN A9|GW459057A|TG100-801|XL228|CATEQUENTINIB|LAVENDUSTIN A|CENISERTIB|AZM-475271|DOXORUBICIN HYDROCHLORIDE|ENTRECTINIB|ALISERTIB|MLN-8054|CINNAMTANNIN B1|XL999,MASITINIB|DASATINIB ANHYDROUS|DOXORUBICIN HYDROCHLORIDE|ENTRECTINIB|INTERLEUKIN-11|VANDETANIB|PONATINIB|CLOZAPINE|TIRBANIBULIN|BOSUTINIB,CINNAMTANNIN B1|CHEMBL:CHEMBL230686|GW459057A|TIRBANIBULIN|AZM-475271,KINASE|TYROSINE KINASE|DRUGGABLE GENOME|TRANSCRIPTION FACTOR|CLINICALLY ACTIONABLE|ENZYME,inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|NCI Cancer Gene Index|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|Cancer Commons|Targeted Agents in Lung Cancer (Commentary, 2014)|Drug Target Commons|The ChEMBL Bioactivity Database|Therapeutic Target Database|My Cancer Genome",True,CHEMBL267,SINGLE PROTEIN,0,0,891,891,1000,False,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Proto-oncogene tyrosine-protein kinase Src,"Non-receptor protein tyrosine kinase which shows higher basal kinase activity than isoform 1, possibly due to weakened intramolecular interactions which enhance autophosphorylation of Tyr-419 and subsequent activation (By similarity). The SH3 domain shows reduced affinity with the linker sequence between the SH2 and kinase domains which may account for the increased basal activity (By similarity). Displays altered substrate specificity compared to isoform 1, showing weak affinity for synaptophysin and for peptide substrates containing class I or class II SH3 domain-binding motifs (By similarity). Plays a role in neurite elongation (By similarity)",3D-structure|Alternative splicing|ATP-binding|Cell adhesion|Cell cycle|Cell junction|Cell membrane|Cytoplasm|Cytoskeleton|Disease variant|Host-virus interaction|Immunity|Kinase|Lipoprotein|Membrane|Mitochondrion|Mitochondrion inner membrane|Myristate|Nucleotide-binding|Nucleus,Belongs to the protein kinase superfamily. Tyr protein kinase family. SRC subfamily,PF07714:PK_Tyr_Ser-Thr|PF00017:SH2|PF00018:SH3_1,3,IPR011009:Kinase-like_dom_sf|IPR050198:Non-receptor_tyrosine_kinases|IPR000719:Prot_kinase_dom|IPR017441:Protein_kinase_ATP_BS|IPR001245:Ser-Thr/Tyr_kinase_cat_dom|IPR000980:SH2|IPR036860:SH2_dom_sf|IPR036028:SH3-like_dom_sf|IPR001452:SH3_domain|IPR008266:Tyr_kinase_AS|IPR020635:Tyr_kinase_cat_dom,11,,active_site|domain|homologous_superfamily|family|binding_site,True,Kinase|Transferase|Integrin,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: Keyword: tyrosine kinase|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR017441|Kinase: InterPro: IPR020635|Kinase: Pfam: PF07714|Integrin: Keyword: cell adhesion|Transferase: Keyword: transferase,Kinase,True,76,1A07|1A08|1A09|1A1A|1A1B|1A1C|1A1E|1FMK|1HCS|1HCT,1A07,2.2,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1A07.pdb,False,,,,,PDB,protein_structures/pdb_experimental/1A07.pdb,Good (2.0-2.5Å),True,10,4.0,207.065,0.415,39.875,0.138,True,8,Moderate,Low,Adequate volume (207A3),Low druggability (0.41),209|360|205|207|196|234|289|314|196|196,0.36|0.02|0.41|0.00|0.00|0.00,P1:Vol=209:Drug=0.36|P2:Vol=360:Drug=0.02|P3:Vol=205:Drug=0.00|P4:Vol=207:Drug=0.41|P5:Vol=196:Drug=0.00|P6:Vol=234:Drug=0.00|P7:Vol=289:Drug=0.00|P8:Vol=314:Drug=0.00|P9:Vol=196:Drug=0.00|P10:Vol=196:Drug=0.00
KIT,KIT,"KIT proto-oncogene, receptor tyrosine kinase","This gene encodes a receptor tyrosine kinase. This gene was initially identified as a homolog of the feline sarcoma viral oncogene v-kit and is often referred to as proto-oncogene c-Kit. The canonical form of this glycosylated transmembrane protein has an N-terminal extracellular region with five immunoglobulin-like domains, a transmembrane region, and an intracellular tyrosine kinase domain at the C-terminus. Upon activation by its cytokine ligand, stem cell factor (SCF), this protein phosphorylates multiple intracellular proteins that play a role in in the proliferation, differentiation, migration and apoptosis of many cell types and thereby plays an important role in hematopoiesis, stem cell maintenance, gametogenesis, melanogenesis, and in mast cell development, migration and function. This protein can be a membrane-bound or soluble protein. Mutations in this gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous leukemia, and piebaldism. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2020].",protein-coding,C-Kit|CD117|MASTC|PBT|SCFR,c-Kit protooncogene|mast/stem cell growth factor receptor Kit|p145 c-kit|piebald trait protein|proto-oncogene c-Kit,ENSG00000157404,ENST00000288135|ENST00000412167|ENST00000512959|ENST00000514582|ENST00000684818|ENST00000685269|ENST00000685816|ENST00000686011|ENST00000687109|ENST00000687208,ENSP00000288135|ENSP00000390987|ENSP00000508733|ENSP00000508749|ENSP00000508831|ENSP00000508845|ENSP00000509084|ENSP00000509114|ENSP00000509156|ENSP00000509371,P10721,A0A8I5QKL5|A0A0U2N547|A0A8I5KQZ6|A0A8I5QKP7|A0A8I5KS03,KIT_HUMAN,3815.0,NM_000222.3|NM_001093772.2|NM_001385284.1|NM_001385285.1|NM_001385286.1|NM_001385288.1|NM_001385290.1|NM_001385292.1,NP_000213.1|NP_001087241.1|NP_001372213.1|NP_001372214.1|NP_001372215.1|NP_001372217.1|NP_001372219.1|NP_001372221.1,NC_000004.12|NC_060928.1|NG_007456.1,6342.0,164920.0,PA30128,9606.ENSP00000288135,1PKG|1T45|1T46|2E9W|2EC8|2IUH|2VIF|3G0E|3G0F|4HVS|4K94|4K9E|4PGZ|4U0I|6GQJ|6GQK|6GQL|6GQM|6HH1|6ITT,2.7.10.1,IPR000719|IPR001245|IPR003598|IPR003599|IPR007110|IPR008266|IPR011009|IPR013151|IPR013783|IPR020635,PF00047|PF07714|PF00069,PS50011|PS50835,4,54657267.0,54740783.0,1.0,976.0,Cell membrane,9606.0,187.0,CD117,biocarta:badpathway|biocarta:melanocytepathway|kegg:hsa04010|kegg:hsa04014|kegg:hsa04015|kegg:hsa04072|kegg:hsa04151|netpath:Pathway_EGFR1|netpath:Pathway_Gastrin|netpath:Pathway_KitReceptor|pid:cmyb_pathway|pid:kitpathway|reactome:R-HSA-1257604|reactome:R-HSA-1266738|reactome:R-HSA-1433557|reactome:R-HSA-1433557|reactome:R-HSA-1433559|wikipathways:WP2406|wikipathways:WP2848|wikipathways:WP304|wikipathways:WP3640|wikipathways:WP3932,True,"KIT proto-oncogene, receptor tyrosine kinase",85,35,BINIMETINIB|BEVACIZUMAB|DOVITINIB|AMUVATINIB|AKT INHIBITOR MK2206|SP-600125|SORAFENIB|CABOZANTINIB S-MALATE|MOTESANIB|SUNITINIB|XL-999|PEXIDARTINIB|PAZOPANIB HYDROCHLORIDE|RIPRETINIB|MIDOSTAURIN|MASITINIB|NINTEDANIB ESYLATE|JNJ-7706621|TANDUTINIB|NILOTINIB,BINIMETINIB|BEVACIZUMAB|SORAFENIB|CABOZANTINIB S-MALATE|SUNITINIB|PEXIDARTINIB|RIPRETINIB|MIDOSTAURIN|MASITINIB|NINTEDANIB ESYLATE,AVAPRITINIB|BEZUCLASTINIB|RIPRETINIB|AMG-191|AZD3229,DRUGGABLE GENOME|KINASE|EXTERNAL SIDE OF PLASMA MEMBRANE|TYROSINE KINASE|CLINICALLY ACTIONABLE|DRUG RESISTANCE|TRANSCRIPTION FACTOR,inhibitor,"Catalogue Of Somatic Mutations In Cancer|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|Cancer Commons|OncoKB: A Precision Oncology Knowledge Base|The Clinical Knowledgebase|Targeted Agents in Lung Cancer (Commentary, 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|FDA Pharmacogenomic Biomarkers",True,CHEMBL2034798,SINGLE PROTEIN,0,0,47,47,47,True,2347,25,0,0,0,DASATINIB|DASATINIB|MIDOSTAURIN|DASATINIB|DASATINIB|IMATINIB MESYLATE|DASATINIB|DASATINIB|IMATINIB MESYLATE|PEXIDARTINIB,Small molecule,Stem cell growth factor receptor inhibitor,True,False,True,HIGH - Approved drugs exist,Mast/stem cell growth factor receptor Kit,"Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT also transmits signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT signaling is modulated by protein phosphatases, and by rapid internalization and degradation of the receptor. Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform Crk-II), LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1",3D-structure|Alternative splicing|ATP-binding|Cell membrane|Cytoplasm|Direct protein sequencing|Disease variant|Disulfide bond|Glycoprotein|Immunoglobulin domain|Kinase|Magnesium|Membrane|Metal-binding|Nucleotide-binding|Phosphoprotein|Proteomics identification|Proto-oncogene|Receptor|Reference proteome,Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily,PF00047:ig|PF07714:PK_Tyr_Ser-Thr,2,IPR007110:Ig-like_dom|IPR036179:Ig-like_dom_sf|IPR013783:Ig-like_fold|IPR003599:Ig_sub|IPR003598:Ig_sub2|IPR013151:Immunoglobulin_dom|IPR011009:Kinase-like_dom_sf|IPR000719:Prot_kinase_dom|IPR017441:Protein_kinase_ATP_BS|IPR050122:RTK|IPR027263:SCGF_receptor|IPR001245:Ser-Thr/Tyr_kinase_cat_dom|IPR008266:Tyr_kinase_AS|IPR020635:Tyr_kinase_cat_dom|IPR001824:Tyr_kinase_rcpt_3_CS,15,,active_site|domain|homologous_superfamily|conserved_site|family|binding_site,True,Kinase|T-cell Receptor|Transferase|Lipid Kinase|Immune Checkpoint|Histone Acetyltransferase|Phosphatase|Transcription Factor,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: Keyword: mapk|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR017441|Kinase: InterPro: IPR020635|Kinase: Pfam: PF07714|Phosphatase: Keyword: phosphatase|Phosphatase: Keyword: protein phosphatase,Kinase,True,51,1PKG|1T45|1T46|2E9W|2EC8|2IUH|2VIF|3G0E|3G0F|4HVS,1PKG,2.9,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1PKG.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1PKG.pdb,Moderate (2.5-3.0Å),True,46,1.0,669.092,0.881,20.458,0.692,True,39,Excellent,High,Optimal volume (669A3)|High druggability (0.88),,669|1023|419|499|517|327|333|343|307|212|100|194|270|909|255|272|378|493|234|238|179|185|613|286|107|211|408|189|317|286|439|262|185|267|299|256|266|250|540|320|398|509|204|205|360|1101,0.88|0.41|0.04|0.03|0.16|0.04|0.02|0.00|0.00|0.00|0.01|0.02|0.54|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.02|0.00|0.00|0.01|0.00|0.01,P1:Vol=669:Drug=0.88|P2:Vol=1023:Drug=0.41|P3:Vol=419:Drug=0.04|P4:Vol=499:Drug=0.03|P5:Vol=517:Drug=0.16|P6:Vol=327:Drug=0.04|P7:Vol=333:Drug=0.02|P8:Vol=343:Drug=0.00|P9:Vol=307:Drug=0.00|P10:Vol=212:Drug=0.00
MET,SLTM,SAFB like transcription modulator,"Enables RNA binding activity. Predicted to be involved in regulation of mRNA processing and regulation of transcription by RNA polymerase II. Located in nuclear body. [provided by Alliance of Genome Resources, Apr 2022]",protein-coding,Met,SAFB-like transcription modulator|modulator of estrogen-induced transcription,ENSG00000137776,ENST00000249736|ENST00000380516|ENST00000432750|ENST00000473359|ENST00000474342|ENST00000480144|ENST00000484498|ENST00000492526|ENST00000493062|ENST00000497088,ENSP00000249736|ENSP00000369887|ENSP00000411534|ENSP00000452805|ENSP00000452945|ENSP00000453065|ENSP00000453179|ENSP00000453371|ENSP00000453662|ENSP00000453711,Q9NWH9,H0YLE6|H0YLW7|H0YL55|H0YMR6|H0YNF3,MET_HUMAN,79811.0,NM_001013843.3|NM_017968.2|NM_024755.4|NR_135042.2|NR_135043.2|XM_006720686.4|XM_011522022.2|XM_011522023.2|XM_011522024.2|XM_011522027.2,NP_001013865.1|NP_079031.2|XP_006720749.4|XP_011520324.2|XP_011520325.2|XP_011520326.2|XP_011520329.2|XP_011520330.2|XP_011520331.1|XP_011520332.2,NC_000015.10|NC_060939.1,20709.0,620992.0,PA142670898,9606.ENSP00000317272,1FYR|1R0P|1R1W|1SHY|1SSL|2G15|2RFN|2RFS|2UZX|2UZY|2WD1|2WGJ|2WKM|3A4P|3BUX|3C1X|3CCN|3CD8|3CE3|3CTH,,IPR000504|IPR003034|IPR012677|IPR035979|IPR036361|IPR051738,PF00076|PF02037,PS50102|PS50800,15,58879049.0,58933991.0,-1.0,1390.0,Membrane,9606.0,11696.0,,,True,"MET proto-oncogene, receptor tyrosine kinase",104,21,MK-2461|PF-04217903|CABOZANTINIB S-MALATE|CAPMATINIB|GLESATINIB|CRIZOTINIB|TEPOTINIB|AMUVATINIB|ANTI-C-MET MONOCLONAL ANTIBODY SAIT301|BMS-777607|CMX-2043|AMG-337|DACTOLISIB|MET TYROSINE KINASE INHIBITOR SGX523|ERLOTINIB|FORETINIB|AMG-208|ONARTUZUMAB|TIVANTINIB|BMS-698769,CABOZANTINIB S-MALATE|CAPMATINIB|CRIZOTINIB|TEPOTINIB|ERLOTINIB|CETUXIMAB|GEFITINIB|PAZOPANIB|OSIMERTINIB|ENTRECTINIB,TIVANTINIB|ONARTUZUMAB|EMIBETUZUMAB|CAPMATINIB|MET TYROSINE KINASE INHIBITOR SGX523,DRUGGABLE GENOME|KINASE|CLINICALLY ACTIONABLE|DRUG RESISTANCE|TYROSINE KINASE|CELL SURFACE,binder|agonist|antibody|inhibitor,"Catalogue Of Somatic Mutations In Cancer|Clearity Foundation Biomarkers|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|Cancer Commons|OncoKB: A Precision Oncology Knowledge Base|Targeted Agents in Lung Cancer (Commentary, 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Clearity Foundation Clinical Trial|Cancer Genome Interpreter",True,CHEMBL1938227,SINGLE PROTEIN,0,0,22,22,40,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,SAFB-like transcription modulator,"When overexpressed, acts as a general inhibitor of transcription that eventually leads to apoptosis",Acetylation|Alternative splicing|Apoptosis|Coiled coil|Direct protein sequencing|Isopeptide bond|Methylation|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|Repressor|RNA-binding|Transcription|Transcription regulation|Ubl conjugation,,PF00076:RRM_1|PF02037:SAP,2,IPR012677:Nucleotide-bd_a/b_plait_sf|IPR035979:RBD_domain_sf|IPR000504:RRM_dom|IPR051738:SAF_Modulators|IPR003034:SAP_dom|IPR036361:SAP_dom_sf,6,,domain|family|homologous_superfamily,True,Histone Acetyltransferase,LOW,Histone Acetyltransferase: Keyword: hat,Histone Acetyltransferase,False,0,,,,,,True,2025-08-01T00:00:00Z,,Unknown,,,,,False,0,,,,,,False,0,,,,,,,
RET,RET,ret proto-oncogene,"This gene encodes a transmembrane receptor and member of the tyrosine protein kinase family of proteins. Binding of ligands such as GDNF (glial cell-line derived neurotrophic factor) and other related proteins to the encoded receptor stimulates receptor dimerization and activation of downstream signaling pathways that play a role in cell differentiation, growth, migration and survival. The encoded receptor is important in development of the nervous system, and the development of organs and tissues derived from the neural crest. This proto-oncogene can undergo oncogenic activation through both cytogenetic rearrangement and activating point mutations. Mutations in this gene are associated with Hirschsprung disease and central hypoventilation syndrome and have been identified in patients with renal agenesis. [provided by RefSeq, Sep 2017].",protein-coding,CDHF12|CDHR16|HSCR1|MEN2A|MEN2B|MTC1|PTC|RET-ELE1,RET receptor tyrosine kinase|cadherin family member 12|cadherin-related family member 16|proto-oncogene c-Ret|proto-oncogene tyrosine-protein kinase receptor Ret,ENSG00000165731,ENST00000340058|ENST00000355710|ENST00000498820|ENST00000615310|ENST00000638465|ENST00000640619|ENST00000671844|ENST00000672389|ENST00000683007|ENST00000683278,ENSP00000344798|ENSP00000347942|ENSP00000419080|ENSP00000480088|ENSP00000491505|ENSP00000492728|ENSP00000500252|ENSP00000500541|ENSP00000507117|ENSP00000508223,P07949,A0A087WWB1|B4DGX8|A0AAQ5BH28|A0A804HIK7|A0A5F9ZHB7,RET_HUMAN,5979.0,NM_001355216.2|NM_001406743.1|NM_001406744.1|NM_001406759.1|NM_001406760.1|NM_001406761.1|NM_001406762.1|NM_001406763.1|NM_001406764.1|NM_001406765.1,NP_001342145.1|NP_001393672.1|NP_001393673.1|NP_001393688.1|NP_001393689.1|NP_001393690.1|NP_001393691.1|NP_001393692.1|NP_001393693.1|NP_001393694.1,NC_000010.11|NC_060934.1|NG_007489.1,9967.0,164761.0,PA34335,9606.ENSP00000347942,2IVS|2IVT|2IVU|2IVV|2X2K|2X2L|2X2M|2X2U|4CKI|4CKJ|4UX8|5AMN|5FM2|5FM3|6FEK|6GL7|6I82|6I83|6NE7|6NEC,2.7.10.1,IPR000719|IPR001245|IPR008266|IPR011009|IPR017441|IPR020635|IPR041163|IPR050122|IPR055162|IPR002126,PF07714|PF17756|PF22540|PF00028|PF17813|PF17812,PS50011|PS50268,10,43077026.0,43130351.0,1.0,1114.0,Cell membrane|Endosome membrane,9606.0,7517.0,RET proto-oncogene,kegg:hsa04020|kegg:hsa05200|kegg:hsa05216|kegg:hsa05223|kegg:hsa05230|pid:ajdiss_2pathway|pid:ret_pathway|wikipathways:WP2586|wikipathways:WP2855|wikipathways:WP4823|wikipathways:WP4830|wikipathways:WP5053,True,ret proto-oncogene,82,26,SUNITINIB|CYC-116|HISTONE DEACETYLASE INHIBITOR|RET INHIBITOR APS03118|SELPERCATINIB|GW441756X|PONATINIB|TOZASERTIB|TYROSINE KINASE INHIBITOR|VANDETANIB|VOLASERTIB|CEP-2563 DIHYDROCHLORIDE|BARASERTIB-HQPA|ENBEZOTINIB|PD-0166285|ENMD-2076|DEXAMETHASONE|AT9283|RECOMBINANT CHEMOKINE|BARASERTIB,SUNITINIB|SELPERCATINIB|PONATINIB|VANDETANIB|DEXAMETHASONE|NINTEDANIB ESYLATE|LAPATINIB|PRALSETINIB|REGORAFENIB|ALECTINIB HYDROCHLORIDE,SELPERCATINIB|PRALSETINIB|MITOQUINONE MESYLATE|RET INHIBITOR SY-5007|VEPAFESTINIB,DRUGGABLE GENOME|KINASE|DRUG RESISTANCE|CLINICALLY ACTIONABLE|TYROSINE KINASE,inhibitor,"Drug Target Commons|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|FDA Pharmacogenomic Biomarkers|OncoKB: A Precision Oncology Knowledge Base|Targeted Agents in Lung Cancer (Commentary, 2014)|The Clinical Knowledgebase|PharmGKB - The Pharmacogenomics Knowledgebase|Cancer Genome Interpreter|Clearity Foundation Clinical Trial",True,CHEMBL2034799,SINGLE PROTEIN,0,0,11,11,28,True,1123,25,0,0,0,REGORAFENIB|SUNITINIB|SELPERCATINIB|PRALSETINIB|ALECTINIB|VANDETANIB|SUNITINIB MALATE|SUNITINIB|SUNITINIB|SUNITINIB,Small molecule,Tyrosine-protein kinase receptor RET inhibitor,True,False,True,HIGH - Approved drugs exist,Proto-oncogene tyrosine-protein kinase receptor Ret,Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL,3D-structure|Alternative splicing|ATP-binding|Cell adhesion|Cell membrane|Chromosomal rearrangement|Disease variant|Disulfide bond|Endosome|Glycoprotein|Hirschsprung disease|Kinase|Membrane|Nucleotide-binding|Phosphoprotein|Proteomics identification|Proto-oncogene|Receptor|Reference proteome|Signal,Belongs to the protein kinase superfamily. Tyr protein kinase family,PF00028:Cadherin|PF07714:PK_Tyr_Ser-Thr|PF17756:RET_CLD1|PF17812:RET_CLD3|PF17813:RET_CLD4|PF22540:RET_CRD,6,IPR002126:Cadherin-like_dom|IPR015919:Cadherin-like_sf|IPR011009:Kinase-like_dom_sf|IPR000719:Prot_kinase_dom|IPR017441:Protein_kinase_ATP_BS|IPR041163:Ret_CLD1|IPR040667:Ret_CLD3|IPR041317:RET_CLD4|IPR055162:RET_CRD|IPR050122:RTK|IPR001245:Ser-Thr/Tyr_kinase_cat_dom|IPR008266:Tyr_kinase_AS|IPR020635:Tyr_kinase_cat_dom|IPR016249:Tyr_kinase_Ret_rcpt,14,,active_site|domain|homologous_superfamily|family|binding_site,True,Kinase|Transferase|Integrin,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: Keyword: mapk|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR017441|Kinase: InterPro: IPR020635|Kinase: Pfam: PF07714|Integrin: Keyword: cell adhesion|Transferase: Keyword: transferase,Kinase,True,34,2IVS|2IVT|2IVU|2IVV|2X2K|2X2L|2X2M|2X2U|4CKI|4CKJ,2IVS,2.0,X-RAY DIFFRACTION,protein_structures/pdb_experimental/2IVS.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/2IVS.pdb,Excellent (<2.0Å),True,35,2.0,680.079,0.453,17.2,0.473,True,31,Moderate,Low,Optimal volume (680A3),Low druggability (0.45),1411|680|62|497|63|72|69|171|284|365|290|278|432|497|300|232|377|268|246|249|540|324|216|200|222|265|352|303|211|140|314|286|393|347|606,0.12|0.45|0.00|0.06|0.00|0.02|0.00|0.12|0.00|0.01|0.04|0.34|0.00|0.00|0.01|0.01|0.01|0.00|0.01|0.02|0.01|0.00|0.00|0.01|0.41,P1:Vol=1411:Drug=0.12|P2:Vol=680:Drug=0.45|P3:Vol=62:Drug=0.00|P4:Vol=497:Drug=0.06|P5:Vol=63:Drug=0.00|P6:Vol=72:Drug=0.00|P7:Vol=69:Drug=0.00|P8:Vol=171:Drug=0.02|P9:Vol=284:Drug=0.00|P10:Vol=365:Drug=0.12
FLT3,FLT3,fms related receptor tyrosine kinase 3,"This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. This receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia. [provided by RefSeq, Jan 2015].",protein-coding,CD135|FLK-2|FLK2|STK1,CD135 antigen|FL cytokine receptor|fetal liver kinase 2|fms related tyrosine kinase 3|fms-like tyrosine kinase 3,ENSG00000122025,ENST00000241453|ENST00000380987|ENST00000469894|ENST00000864668,ENSP00000241453|ENSP00000370374|ENSP00000534727,P36888,E7ER61,FLT3_HUMAN,2322.0,NM_004119.3|NR_130706.2|XM_011535015.3|XM_011535018.3|XM_017020486.2|XM_017020488.2|XM_047430216.1|XM_054374312.1|XM_054374313.1|XM_054374314.1,NP_004110.2|XP_011533317.1|XP_011533320.1|XP_016875975.1|XP_016875977.1|XP_047286172.1|XP_054230287.1|XP_054230288.1|XP_054230289.1|XP_054230290.1,NC_000013.11|NC_060937.1|NG_007066.1,3765.0,136351.0,PA28181,9606.ENSP00000241453,1RJB|3QS7|3QS9|4RT7|4XUF|5X02|6IL3|6JQR|7QDP|7ZV9|8XB1,2.7.10.1,IPR000719|IPR001245|IPR001824|IPR008266|IPR011009|IPR013783|IPR017441|IPR020635|IPR050122|IPR007110,PF00047|PF07714,PS50011|PS50835,13,28003274.0,28100592.0,-1.0,993.0,Membrane|Endoplasmic reticulum lumen,9606.0,3040.0,CD135,kegg:hsa04010|kegg:hsa04014|kegg:hsa04151|kegg:hsa04640|kegg:hsa05200|reactome:R-HSA-109704|reactome:R-HSA-112399|reactome:R-HSA-1257604|reactome:R-HSA-1280215|reactome:R-HSA-1280215|wikipathways:WP3657|wikipathways:WP3658|wikipathways:WP4172|wikipathways:WP4223|wikipathways:WP4540,True,fms related receptor tyrosine kinase 3,166,49,RECOMBINANT TRANSFORMING GROWTH FACTOR-BETA 1|METHOTREXATE|CABOZANTINIB S-MALATE|HSP90 INHIBITOR LAM-003|DOVITINIB|QUIZARTINIB|IPATASERTIB|TRAMETINIB DIMETHYL SULFOXIDE|SORAFENIB|PD98059|AKN-028|ABIVERTINIB|SUNITINIB|CDX-301|TAZEMETOSTAT|PACRITINIB|ITACNOSERTIB|RG-1530|CRENOLANIB|PONATINIB,METHOTREXATE|CABOZANTINIB S-MALATE|QUIZARTINIB|TRAMETINIB DIMETHYL SULFOXIDE|SORAFENIB|SUNITINIB|TAZEMETOSTAT|PACRITINIB|PONATINIB|GILTERITINIB,QUIZARTINIB|MRX-2843|LESTAURTINIB|HSP90 INHIBITOR LAM-003|ITACNOSERTIB,KINASE|TYROSINE KINASE|DRUG RESISTANCE|CLINICALLY ACTIONABLE|DRUGGABLE GENOME,binder|agonist|inhibitor,"Catalogue Of Somatic Mutations In Cancer|NCI Cancer Gene Index|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|FDA Pharmacogenomic Biomarkers|OncoKB: A Precision Oncology Knowledge Base|The Clinical Knowledgebase|PharmGKB - The Pharmacogenomics Knowledgebase|Targeted Agents in Lung Cancer (Commentary, 2014)|Cancer Commons",True,CHEMBL2034796,SINGLE PROTEIN,0,0,16,16,31,True,1161,25,0,0,0,GILTERITINIB FUMARATE|MIDOSTAURIN|PEXIDARTINIB|SUNITINIB|MIDOSTAURIN|GILTERITINIB|FEDRATINIB|PACRITINIB|SORAFENIB TOSYLATE|SUNITINIB MALATE,Small molecule,Tyrosine-protein kinase receptor FLT3 inhibitor,True,False,True,HIGH - Approved drugs exist,Receptor-type tyrosine-protein kinase FLT3,"Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways",3D-structure|Alternative splicing|ATP-binding|Disease variant|Disulfide bond|Endoplasmic reticulum|Glycoprotein|Host-virus interaction|Immunoglobulin domain|Kinase|Membrane|Nucleotide-binding|Phosphoprotein|Proteomics identification|Proto-oncogene|Receptor|Reference proteome|Signal|Transferase|Transmembrane,Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily,PF00047:ig|PF07714:PK_Tyr_Ser-Thr,2,IPR007110:Ig-like_dom|IPR036179:Ig-like_dom_sf|IPR013783:Ig-like_fold|IPR013151:Immunoglobulin_dom|IPR011009:Kinase-like_dom_sf|IPR000719:Prot_kinase_dom|IPR017441:Protein_kinase_ATP_BS|IPR050122:RTK|IPR001245:Ser-Thr/Tyr_kinase_cat_dom|IPR008266:Tyr_kinase_AS|IPR020635:Tyr_kinase_cat_dom|IPR001824:Tyr_kinase_rcpt_3_CS,12,,active_site|domain|homologous_superfamily|conserved_site|family|binding_site,True,Kinase|T-cell Receptor|Transferase|Immune Checkpoint|Histone Acetyltransferase|Phosphatase,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: Keyword: mapk|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR017441|Kinase: InterPro: IPR020635|Kinase: Pfam: PF07714|Phosphatase: Keyword: ptp|Histone Acetyltransferase: Keyword: hat,Kinase,True,11,1RJB|3QS7|3QS9|4RT7|4XUF|5X02|6IL3|6JQR|7QDP|7ZV9,1RJB,2.1,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1RJB.pdb,False,,,,,PDB,protein_structures/pdb_experimental/1RJB.pdb,Good (2.0-2.5Å),True,17,6.0,415.721,0.461,22.5,0.095,True,15,Moderate,Low,Adequate volume (416A3),Low druggability (0.46),192|552|113|458|855|416|225|230|284|247|129|288|302|579|288|302|545,0.17|0.00|0.00|0.03|0.46|0.00|0.00|0.00|0.00|0.02,P1:Vol=192:Drug=0.17|P2:Vol=552:Drug=0.00|P3:Vol=113:Drug=0.00|P4:Vol=458:Drug=0.00|P5:Vol=855:Drug=0.03|P6:Vol=416:Drug=0.46|P7:Vol=225:Drug=0.00|P8:Vol=230:Drug=0.00|P9:Vol=284:Drug=0.00|P10:Vol=247:Drug=0.00
CDK4,CDK4,cyclin dependent kinase 4,"The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported. [provided by RefSeq, Jul 2008].",protein-coding,CMM3|PSK-J3,cell division protein kinase 4|cyclin-dependent kinase 4,ENSG00000135446,ENST00000257904|ENST00000546489|ENST00000547281|ENST00000547853|ENST00000549606|ENST00000550419|ENST00000551706|ENST00000551800|ENST00000551888|ENST00000552254,ENSP00000257904|ENSP00000446763|ENSP00000447005|ENSP00000447274|ENSP00000447779|ENSP00000448098|ENSP00000448885|ENSP00000448963|ENSP00000449179|ENSP00000449391,P11802,F8VZZ0|Q96BE9|F8VYH9|F8VZ51|F8VYY1,CDK4_HUMAN,1019.0,NM_000075.4|NM_052984.1,NP_000066.1,NC_000012.12|NC_060936.1|NG_007484.2,1773.0,123829.0,PA102,9606.ENSP00000257904,2W96|2W99|2W9F|2W9Z|3G33|5FWK|5FWL|5FWM|5FWP|6P8E|6P8F|6P8G|6P8H|7SJ3,2.7.11.22,IPR000719|IPR008271|IPR011009|IPR017441|IPR050108,PF00069,PS50011,12,57747722.0,57756013.0,-1.0,303.0,Cytoplasm|Nucleus|Nucleus membrane,9606.0,55429.0,Cyclin-dependent kinase 4,biocarta:cellcyclepathway|biocarta:efppathway|biocarta:g1pathway|biocarta:p53pathway|biocarta:raccycdpathway|kegg:hsa04110|kegg:hsa04115|kegg:hsa04151|kegg:hsa04218|kegg:hsa04530|netpath:Pathway_BCR|netpath:Pathway_TGF_beta_Receptor|pid:atf2_pathway|pid:foxm1pathway|pid:myc_activpathway|pid:nfat_tfpathway|pid:rb_1pathway|reactome:R-HSA-1266738|reactome:R-HSA-1280218|reactome:R-HSA-1474165|reactome:R-HSA-1500620|reactome:R-HSA-162582|wikipathways:WP1530|wikipathways:WP179|wikipathways:WP2032|wikipathways:WP2261|wikipathways:WP2431,True,cyclin dependent kinase 4,64,15,RIBOCICLIB|R547|PALBOCICLIB|RECOMBINANT TRANSFORMING GROWTH FACTOR|ATIRMOCICLIB|VORUCICLIB|SOMATROPIN (RECOMBINANT DNA ORIGIN)|TANESPIMYCIN|SU9516|BSJ-03-123|CP-10|RO-0505124|ALVOCIDIB|MKC-1|RIVICICLIB|NARAZACICLIB|MILCICLIB|ABEMACICLIB|CDK4 INHIBITOR III|BSJ-04-132,RIBOCICLIB|PALBOCICLIB|SOMATROPIN (RECOMBINANT DNA ORIGIN)|ABEMACICLIB|TRILACICLIB|TRILACICLIB DIHYDROCHLORIDE|CAMPTOTHECIN|NICOTINE POLACRILEX|APREMILAST|ASCORBIC ACID,CHEMBL:CHEMBL1956069|RO-0505124|FASCAPLYSIN|RIBOCICLIB SUCCINATE|LEROCICLIB,KINASE|SERINE THREONINE KINASE|DRUGGABLE GENOME|CLINICALLY ACTIONABLE|ENZYME|DRUG RESISTANCE|TRANSCRIPTION FACTOR|TRANSCRIPTION FACTOR COMPLEX|TUMOR SUPPRESSOR,inhibitor,"Clearity Foundation Biomarkers|NCI Cancer Gene Index|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|Cancer Commons|OncoKB: A Precision Oncology Knowledge Base|PharmGKB - The Pharmacogenomics Knowledgebase|Cancer Genome Interpreter|Guide to Pharmacology|Clearity Foundation Clinical Trial",True,CHEMBL3038517,PROTEIN FAMILY,0,0,6,6,6,True,466,19,6,0,0,PALBOCICLIB|ABEMACICLIB|RIBOCICLIB SUCCINATE|RIBOCICLIB SUCCINATE|ABEMACICLIB|PALBOCICLIB|TRILACICLIB DIHYDROCHLORIDE|PALBOCICLIB|PALBOCICLIB|ABEMACICLIB,Small molecule,Cyclin-dependent kinase 4 inhibitor|Cyclin-dependent kinase 4/cyclin D1 inhibitor,True,True,True,HIGH - Approved drugs exist,Cyclin-dependent kinase 4,"Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex",3D-structure|Acetylation|Alternative splicing|ATP-binding|Cell cycle|Cell division|Cytoplasm|Disease variant|Kinase|Membrane|Nucleotide-binding|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|Serine/threonine-protein kinase|Transferase,Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily,PF00069:Pkinase,1,IPR050108:CDK|IPR011009:Kinase-like_dom_sf|IPR000719:Prot_kinase_dom|IPR017441:Protein_kinase_ATP_BS|IPR008271:Ser/Thr_kinase_AS,5,,active_site|domain|homologous_superfamily|family|binding_site,True,Kinase|Histone Acetyltransferase|Transferase|Transcription Factor,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: Keyword: cdk|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR017441|Kinase: InterPro: IPR008271|Kinase: Pfam: PF00069|Histone Acetyltransferase: Keyword: hat|Transcription Factor: Keyword: transcription factor,Kinase,True,15,2W96|2W99|2W9F|2W9Z|3G33|5FWK|5FWL|5FWM|5FWP|6P8E,2W96,2.3,X-RAY DIFFRACTION,protein_structures/pdb_experimental/2W96.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/2W96.pdb,Good (2.0-2.5Å),True,52,2.0,377.156,0.521,13.444,0.238,True,41,Moderate,Low,Adequate volume (377A3),,614|377|522|109|360|517|186|1008|245|89|96|311|518|418|266|1004|362|326|444|178|213|208|491|322|390|288|251|419|731|640|229|284|572|176|271|181|254|439|292|112|398|155|178|195|332|245|265|282|208|203|235|635,0.00|0.52|0.41|0.33|0.00|0.01|0.34|0.00|0.03|0.00|0.22|0.02|0.07|0.00|0.00|0.04|0.00|0.01|0.00|0.00|0.12|0.01|0.02|0.00|0.02|0.01|0.00|0.01|0.24|0.00|0.15|0.02|0.00|0.00|0.00|0.00|0.06|0.01,P1:Vol=614:Drug=0.00|P2:Vol=377:Drug=0.52|P3:Vol=522:Drug=0.41|P4:Vol=109:Drug=0.33|P5:Vol=360:Drug=0.00|P6:Vol=517:Drug=0.00|P7:Vol=186:Drug=0.01|P8:Vol=1008:Drug=0.34|P9:Vol=245:Drug=0.00|P10:Vol=89:Drug=0.00
MAPK1,MAPK1,mitogen-activated protein kinase 1,"This gene encodes a member of the MAP kinase family. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. The activation of this kinase requires its phosphorylation by upstream kinases. Upon activation, this kinase translocates to the nucleus of the stimulated cells, where it phosphorylates nuclear targets. One study also suggests that this protein acts as a transcriptional repressor independent of its kinase activity. The encoded protein has been identified as a moonlighting protein based on its ability to perform mechanistically distinct functions. Two alternatively spliced transcript variants encoding the same protein, but differing in the UTRs, have been reported for this gene. [provided by RefSeq, Jan 2014].",protein-coding,ERK|ERK-2|ERK2|ERT1|MAPK2|NS13|P42MAPK|PRKM1|PRKM2|p38|p40|p41|p41mapk|p42-MAPK,MAP kinase 1|MAP kinase 2|MAPK 2|extracellular signal-regulated kinase 2|mitogen-activated protein kinase 1,ENSG00000100030,ENST00000215832|ENST00000398822|ENST00000491588|ENST00000544786|ENST00000879585|ENST00000879586|ENST00000879587|ENST00000962868|ENST00000962869|ENST00000962870,ENSP00000215832|ENSP00000381803|ENSP00000440842|ENSP00000549644|ENSP00000549645|ENSP00000549646|ENSP00000632927|ENSP00000632928|ENSP00000632929|ENSP00000632930,P28482,Q499G7|Q1HBJ4,MK01_HUMAN,5594.0,NM_002745.5|NM_138957.3,NP_002736.3|NP_620407.1,NC_000022.11|NC_060946.1|NG_023054.2,6871.0,176948.0,PA30616,9606.ENSP00000215832,1PME|1TVO|1WZY|2OJG|2OJI|2OJJ|2Y9Q|3D42|3D44|3I5Z|3I60|3SA0|3TEI|3W55|4FMQ|4FUX|4FUY|4FV0|4FV1|4FV2,2.7.11.24,IPR000719|IPR003527|IPR008271|IPR008349|IPR011009|IPR017441|IPR050117,PF00069,PS50011,22,21755537.0,21867680.0,-1.0,360.0,"Cytoplasm, cytoskeleton, spindle|Nucleus|Cytoplasm, cytoskeleton, microtubule organizing center, centrosome",9606.0,37670.0,MAPK1,biocarta:agrpathway|biocarta:at1rpathway|biocarta:barrestinsrcpathway|biocarta:barrmapkpathway|biocarta:biopeptidespathway|kegg:hsa04010|kegg:hsa04012|kegg:hsa04014|kegg:hsa04015|kegg:hsa04022|netpath:Pathway_Alpha6Beta4Integrin|netpath:Pathway_BCR|netpath:Pathway_BDNF|netpath:Pathway_CRH|netpath:Pathway_EGFR1|pid:alk1pathway|pid:angiopoietinreceptor_pathway|pid:anthraxpathway|pid:ar_nongenomic_pathway|pid:arf6downstreampathway|reactome:R-HSA-109581|reactome:R-HSA-109582|reactome:R-HSA-109606|reactome:R-HSA-111458|reactome:R-HSA-111461|smpdb:SMP00320|smpdb:SMP00321|smpdb:SMP00358|smpdb:SMP00391|wikipathways:WP127|wikipathways:WP1434|wikipathways:WP1449|wikipathways:WP1528|wikipathways:WP1539,True,mitogen-activated protein kinase 1,175,30,NAFTOPIDIL|INDIRUBIN-3'-MONOXIME|U-0126|LITHOCHOLIC ACID|LEVODOPA|SB203580|RELCOVAPTAN|SB220025|CHEMBL:CHEMBL222556|CHEMBL:CHEMBL1814509|TYRPHOSTIN AG 835|CHEMBL:CHEMBL580183|CHEMBL:CHEMBL429095|REFAMETINIB|RAVOXERTINIB|DAPH|WEDELOLACTONE|GF109203X|PHENYLMERCURIC ACETATE|URSODIOL,NAFTOPIDIL|LEVODOPA|URSODIOL|GLYBURIDE|HUMAN CHORIONIC GONADOTROPIN|DIPHENHYDRAMINE HYDROCHLORIDE|ECONAZOLE NITRATE|PROGESTERONE|BENZALKONIUM CHLORIDE|CHLORHEXIDINE HYDROCHLORIDE,SPINASAPONIN A METHYL ESTER|CIMIRACEMATE A|CHEMBL:CHEMBL329785|GDNF|CHEMBL:CHEMBL2088730,KINASE|SERINE THREONINE KINASE|DRUGGABLE GENOME|DRUG RESISTANCE|CLINICALLY ACTIONABLE|ENZYME|TRANSCRIPTION FACTOR,inhibitor,"Drug Target Commons|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|PharmGKB - The Pharmacogenomics Knowledgebase|NCI Cancer Gene Index|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL6051,SINGLE PROTEIN,0,0,3,3,3,True,19,0,0,5,12,ULIXERTINIB|TEMUTERKIB|ULIXERTINIB|ULIXERTINIB|TEMUTERKIB|ULIXERTINIB|ULIXERTINIB|TEMUTERKIB|ULIXERTINIB|MK-8353,Small molecule,Mitogen-activated protein kinase; ERK1/ERK2 inhibitor|MAP kinase ERK2 inhibitor,True,True,True,HIGH - Approved drugs exist,Mitogen-activated protein kinase 1,"Acts as a transcriptional repressor. Binds to a [GC]AAA[GC] consensus sequence. Repress the expression of interferon gamma-induced genes. Seems to bind to the promoter of CCL5, DMP1, IFIH1, IFITM1, IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 and STAT1. Transcriptional activity is independent of kinase activity",3D-structure|Acetylation|Alternative splicing|Apoptosis|ATP-binding|Cell cycle|Cell junction|Cytoplasm|Cytoskeleton|Direct protein sequencing|Disease variant|DNA-binding|Host-virus interaction|Kinase|Membrane|Nucleotide-binding|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome,Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. MAP kinase subfamily,PF00069:Pkinase,1,IPR011009:Kinase-like_dom_sf|IPR050117:MAP_kinase|IPR003527:MAP_kinase_CS|IPR008349:MAPK_ERK1/2|IPR000719:Prot_kinase_dom|IPR017441:Protein_kinase_ATP_BS|IPR008271:Ser/Thr_kinase_AS,7,,active_site|domain|homologous_superfamily|family|conserved_site|binding_site,True,Kinase|Transferase|Transcription Factor,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR017441|Kinase: InterPro: IPR008271|Kinase: Pfam: PF00069|Transcription Factor: Keyword: dna-binding|Transferase: Keyword: transferase,Kinase,True,157,1PME|1TVO|1WZY|2OJG|2OJI|2OJJ|2Y9Q|3D42|3D44|3I5Z,1PME,2.0,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1PME.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1PME.pdb,Excellent (<2.0Å),True,23,1.0,399.367,0.732,52.429,0.597,True,20,Excellent,High,Adequate volume (399A3)|High druggability (0.73),,399|435|238|558|313|96|1081|225|193|205|316|455|292|268|242|253|257|188|237|216|124|190|427,0.73|0.01|0.01|0.01|0.14|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00,P1:Vol=399:Drug=0.73|P2:Vol=435:Drug=0.01|P3:Vol=238:Drug=0.01|P4:Vol=558:Drug=0.01|P5:Vol=313:Drug=0.14|P6:Vol=96:Drug=0.00|P7:Vol=1081:Drug=0.00|P8:Vol=225:Drug=0.00|P9:Vol=193:Drug=0.00|P10:Vol=205:Drug=0.00
SCN5A,SCN5A,sodium voltage-gated channel alpha subunit 5,"The protein encoded by this gene is an integral membrane protein and tetrodotoxin-resistant voltage-gated sodium channel subunit. This protein is found primarily in cardiac muscle and is responsible for the initial upstroke of the action potential in an electrocardiogram. Defects in this gene have been associated with long QT syndrome type 3 (LQT3), atrial fibrillation, cardiomyopathy, and Brugada syndrome 1, all autosomal dominant cardiac diseases. Alternative splicing results in several transcript variants encoding different isoforms. [provided by RefSeq, May 2022].",protein-coding,CDCD2|CMD1E|CMPD2|HB1|HB2|HBBD|HH1|ICCD|IVF|LQT3|Nav1.5|PFHB1|SSS1|VF1,"cardiac tetrodotoxin-insensitive voltage-dependent sodium channel alpha subunit|sodium channel protein cardiac muscle subunit alpha|sodium channel protein type 5 subunit alpha|sodium channel, voltage-gated, type V, alpha subunit|voltage-gated sodium channel subunit alpha Nav1.5",ENSG00000183873,ENST00000327956|ENST00000333535|ENST00000413689|ENST00000414099|ENST00000423572|ENST00000449557|ENST00000450102|ENST00000455624|ENST00000464652|ENST00000476683,ENSP00000328968|ENSP00000333674|ENSP00000398266|ENSP00000398962|ENSP00000399524|ENSP00000403355|ENSP00000410257|ENSP00000413996|ENSP00000519034|ENSP00000519035,Q14524,H9KVD2|K4DIA1|E9PG18|E9PHB6|Q86V90,SCN5A_HUMAN,6331.0,NM_000335.5|NM_001099404.2|NM_001099405.2|NM_001160160.2|NM_001160161.2|NM_001354701.2|NM_001407185.1|NM_001407186.1|NM_001407187.1|NM_198056.3,NP_000326.2|NP_001092874.1|NP_001092875.1|NP_001153632.1|NP_001153633.1|NP_001341630.1|NP_001394114.1|NP_001394115.1|NP_001394116.1|NP_932173.1,NC_000003.12|NC_060927.1|NG_008934.1,10593.0,600163.0,PA304,9606.ENSP00000328968,2KBI|2L53|4DCK|4DJC|4JQ0|4OVN|5DBR|6LQA|6MUD|7DTC|7L83|8VYJ|8VYK,,IPR001696|IPR005821|IPR008053|IPR010526|IPR024583|IPR027359|IPR043203|IPR044564,PF00520|PF06512|PF11933|PF24609,,3,38548057.0,38649743.0,-1.0,2016.0,"Cell membrane|Cytoplasm, perinuclear region|Cell membrane, sarcolemma, T-tubule",9606.0,22738.0,Nav1.5,reactome:R-HSA-1266738|reactome:R-HSA-373760|reactome:R-HSA-397014|reactome:R-HSA-422475|reactome:R-HSA-445095|smpdb:SMP00296|smpdb:SMP00297|smpdb:SMP00298|smpdb:SMP00299|smpdb:SMP00300|wikipathways:WP2406|wikipathways:WP706,True,sodium voltage-gated channel alpha subunit 5,88,75,COCAINE|PROCAINAMIDE|CHLOROPROCAINE|DICHLOROBENZYL ALCOHOL|PHENACEMIDE|INDECAINIDE HYDROCHLORIDE|ETHOTOIN|PROPOXYCAINE HYDROCHLORIDE|RANOLAZINE|MORICIZINE|FOSPHENYTOIN|QUINIDINE|LIDOCAINE|FLECAINIDE ACETATE|LIDOCAINE HYDROCHLORIDE|PROCAINAMIDE HYDROCHLORIDE|QUINIDINE SULFATE|HEXYLCAINE|LACOSAMIDE|NKTR-171,COCAINE|PROCAINAMIDE|CHLOROPROCAINE|DICHLOROBENZYL ALCOHOL|PHENACEMIDE|INDECAINIDE HYDROCHLORIDE|ETHOTOIN|PROPOXYCAINE HYDROCHLORIDE|RANOLAZINE|MORICIZINE,BENZONATATE|INDECAINIDE|ENCAINIDE|MORICIZINE|HEXYLCAINE,DRUGGABLE GENOME|ION CHANNEL|CELL SURFACE,blocker|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL4523669,PROTEIN COMPLEX,0,0,6,6,6,True,1027,25,0,0,0,DRONEDARONE HYDROCHLORIDE|RANOLAZINE|PRENYLAMINE|PROPAFENONE HYDROCHLORIDE|VERNAKALANT HYDROCHLORIDE|OXCARBAZEPINE|OXCARBAZEPINE|CARBAMAZEPINE|CARBAMAZEPINE|MEPHENYTOIN,Small molecule,Sodium channel protein type V alpha subunit blocker|Sodium channel alpha subunit blocker,True,False,True,HIGH - Approved drugs exist,Sodium channel protein type 5 subunit alpha,"Pore-forming subunit of Nav1.5, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient. The influx of Na(+) ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues (PubMed:1309946, PubMed:21447824, PubMed:23085483, PubMed:23420830, PubMed:25370050, PubMed:26279430, PubMed:26392562, PubMed:26776555). Nav1.5 is the predominant sodium channel expressed in myocardial cells and it is responsible for the initial upstroke of the action potential in cardiac myocytes, thereby initiating the heartbeat (PubMed:11234013, PubMed:11804990, PubMed:12569159, PubMed:1309946). Required for normal electrical conduction including formation of the infranodal ventricular conduction system and normal action potential configuration, as a result of its interaction with XIRP2 (By similarity)",3D-structure|Alternative splicing|Atrial fibrillation|Brugada syndrome|Calmodulin-binding|Cardiomyopathy|Cell junction|Cell membrane|Cytoplasm|Disease variant|Disulfide bond|Glycoprotein|Ion channel|Ion transport|Long QT syndrome|Membrane|Methylation|Phosphoprotein|Proteomics identification|Reference proteome,Belongs to the sodium channel (TC 1.A.1.10) family. Nav1.5/SCN5A subfamily,PF00520:Ion_trans|PF24609:IQ_SCN5A_C|PF06512:Na_trans_assoc|PF11933:Na_trans_cytopl,4,IPR005821:Ion_trans_dom|IPR008053:Na_channel_a5su|IPR001696:Na_channel_asu|IPR044564:Na_chnl_inactivation_gate|IPR010526:Na_trans_assoc_dom|IPR024583:Na_trans_cytopl|IPR043203:VGCC_Ca_Na|IPR027359:Volt_channel_dom_sf,8,,domain|family|homologous_superfamily,True,Ion Channel|Histone Acetyltransferase,HIGH,Ion Channel: Keyword: ion channel|Ion Channel: Keyword: voltage-gated|Ion Channel: Keyword: sodium channel|Ion Channel: InterPro: IPR005821|Ion Channel: Pfam: PF00520|Histone Acetyltransferase: Keyword: hat,Ion Channel,True,14,2KBI|2L53|4DCK|4DJC|4JQ0|4OVN|5DBR|6LQA|6MUD|7DTC,2KBI,,SOLUTION NMR,protein_structures/pdb_experimental/2KBI.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/2KBI.pdb,,True,3,1.0,319.944,0.012,,0.409,True,2,Poor,Low,Adequate volume (320A3),Low druggability (0.01),320|193|299,0.01|0.00,P1:Vol=320:Drug=0.01|P2:Vol=193:Drug=0.00|P3:Vol=299:Drug=0.00
SCN9A,SCN9A,sodium voltage-gated channel alpha subunit 9,"This gene encodes a voltage-gated sodium channel which plays a significant role in nociception signaling. Mutations in this gene have been associated with primary erythermalgia, channelopathy-associated insensitivity to pain, and paroxysmal extreme pain disorder. [provided by RefSeq, Aug 2009].",protein-coding,ETHA|FEB3B|GEFSP7|HSAN2D|NE-NA|NENA|Nav1.7|PN1|SFNP,hNE-Na|neuroendocrine sodium channel|peripheral sodium channel 1|sodium channel protein type 9 subunit alpha|sodium channel protein type IX subunit alpha,ENSG00000169432,ENST00000303354|ENST00000409672|ENST00000452182|ENST00000454569|ENST00000472119|ENST00000642356|ENST00000643319|ENST00000645283|ENST00000645815|ENST00000645907,ENSP00000304748|ENSP00000386306|ENSP00000393141|ENSP00000413212|ENSP00000494071|ENSP00000495601|ENSP00000495983|ENSP00000496086|ENSP00000499341|ENSP00000499663,Q15858,A0A590UJB2|A0A2R8YCX9|A0A0C4DG82|A0A2R8Y7G0|A0A590UK23,SCN9A_HUMAN,6335.0,NM_001365536.1|NM_002977.4|XM_011511616.4|XM_011511617.3|XM_011511618.3|XM_011511619.3|XM_017004669.2|XM_054343320.1|XM_054343321.1|XM_054343322.1,NP_001352465.1|NP_002968.2|XP_011509918.1|XP_011509919.1|XP_011509920.1|XP_011509921.1|XP_016860158.1|XP_054199295.1|XP_054199296.1|XP_054199297.1,NC_000002.12|NC_060926.1|NG_012798.1,10597.0,603415.0,PA35010,9606.ENSP00000386306,5EK0|6J8G|6J8H|6J8I|6J8J|6N4Q|6N4R|6NT3|6NT4|6VXO|6W6O|7K48|7W9K|7W9L|7W9M|7W9P|7W9T|7XM9|7XMF|7XMG,,IPR005821|IPR027359|IPR043203|IPR024583|IPR000048|IPR001696|IPR010526|IPR044564,PF00520|PF11933|PF06512|PF24609,,2,166195185.0,166376001.0,-1.0,1988.0,"Cell membrane|Cell projection, neuron projection|Cell projection, axon",9606.0,2237.0,Nav1.7,reactome:R-HSA-1266738|reactome:R-HSA-373760|reactome:R-HSA-397014|reactome:R-HSA-422475|reactome:R-HSA-445095,True,sodium voltage-gated channel alpha subunit 9,84,54,MERETHOXYLLINE PROCAINE|ETIDOCAINE HYDROCHLORIDE|FOSPHENYTOIN|VERATRIDINE|ORPHENADRINE CITRATE|PHENACEMIDE|LACOSAMIDE|VIXOTRIGINE|DSP-2230|SAXITOXIN|ESLICARBAZEPINE ACETATE|SAFINAMIDE|LIDOCAINE|RILUZOLE|ROPIVACAINE HYDROCHLORIDE|FUNAPIDE|DYCLONINE HYDROCHLORIDE|EVENAMIDE|PROPOFOL|AM-6120,MERETHOXYLLINE PROCAINE|ETIDOCAINE HYDROCHLORIDE|FOSPHENYTOIN|ORPHENADRINE CITRATE|PHENACEMIDE|LACOSAMIDE|ESLICARBAZEPINE ACETATE|SAFINAMIDE|LIDOCAINE|RILUZOLE,RG7893|PF-05089771|VIXOTRIGINE|DSP-2230|RG6029,DRUGGABLE GENOME|ION CHANNEL,inhibitor|blocker|activator,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Guide to Pharmacology|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL4523670,PROTEIN COMPLEX,0,0,5,5,5,True,987,25,0,0,0,PROPAFENONE HYDROCHLORIDE|DRONEDARONE HYDROCHLORIDE|OXCARBAZEPINE|OXCARBAZEPINE|CARBAMAZEPINE|CARBAMAZEPINE|CARBAMAZEPINE|FOSPHENYTOIN|RUFINAMIDE|PHENACEMIDE,Small molecule,Sodium channel alpha subunit blocker,True,False,True,HIGH - Approved drugs exist,Sodium channel protein type 9 subunit alpha,"Pore-forming subunit of Nav1.7, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient. The influx of Na(+) ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues (PubMed:15385606, PubMed:16988069, PubMed:17145499, PubMed:17167479, PubMed:19369487, PubMed:24311784, PubMed:25240195, PubMed:26680203, PubMed:7720699). Nav1.7 plays a crucial role in controlling the excitability and action potential propagation from nociceptor neurons, thereby contributing to the sensory perception of pain (PubMed:17145499, PubMed:17167479, PubMed:19369487, PubMed:24311784)",3D-structure|Alternative splicing|Cell membrane|Cell projection|Disease variant|Disulfide bond|Epilepsy|Glycoprotein|Ion channel|Ion transport|Membrane|Phosphoprotein|Proteomics identification|Reference proteome|Repeat|Sodium|Sodium channel|Sodium transport|Transmembrane|Transmembrane helix,Belongs to the sodium channel (TC 1.A.1.10) family. Nav1.7/SCN9A subfamily,PF00520:Ion_trans|PF24609:IQ_SCN5A_C|PF06512:Na_trans_assoc|PF11933:Na_trans_cytopl,4,IPR005821:Ion_trans_dom|IPR000048:IQ_motif_EF-hand-BS|IPR001696:Na_channel_asu|IPR044564:Na_chnl_inactivation_gate|IPR010526:Na_trans_assoc_dom|IPR024583:Na_trans_cytopl|IPR043203:VGCC_Ca_Na|IPR027359:Volt_channel_dom_sf,8,,domain|family|binding_site|homologous_superfamily,True,Ion Channel|Histone Acetyltransferase,HIGH,Ion Channel: Keyword: ion channel|Ion Channel: Keyword: voltage-gated|Ion Channel: Keyword: sodium channel|Ion Channel: InterPro: IPR005821|Ion Channel: Pfam: PF00520|Histone Acetyltransferase: Keyword: hat,Ion Channel,True,41,5EK0|6J8G|6J8H|6J8I|6J8J|6N4Q|6N4R|6NT3|6NT4|6VXO,5EK0,3.53,X-RAY DIFFRACTION,protein_structures/pdb_experimental/5EK0.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/5EK0.pdb,Low (>3.5Å),True,71,2.0,2192.825,0.999,74.568,0.793,True,63,Excellent,High,Optimal volume (2193A3)|High druggability (1.00),,1868|2193|984|1971|1755|1033|826|1000|521|734|749|554|106|298|153|316|70|235|282|269|254|280|362|361|298|273|319|317|388|581|398|293|259|171|299|269|388|269|222|216|102|320|211|167|227|744|203|232|1160|262|319|157|219|185|227|210|161|493|265|292|202|106|811|207|361|472|383|277|322|354|238,1.00|1.00|0.88|1.00|0.99|0.93|0.87|0.97|0.14|0.39|0.01|0.06|0.00|0.01|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.03|0.00|0.01|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.02,P1:Vol=1868:Drug=1.00|P2:Vol=2193:Drug=1.00|P3:Vol=984:Drug=0.88|P4:Vol=1971:Drug=1.00|P5:Vol=1755:Drug=0.99|P6:Vol=1033:Drug=0.93|P7:Vol=826:Drug=0.87|P8:Vol=1000:Drug=0.97|P9:Vol=521:Drug=0.14|P10:Vol=734:Drug=0.39
KCNH2,KCNH2,potassium voltage-gated channel subfamily H member 2,"This gene encodes a component of a voltage-activated potassium channel found in cardiac muscle, nerve cells, and microglia. Four copies of this protein interact with one copy of the KCNE2 protein to form a functional potassium channel. Mutations in this gene can cause long QT syndrome type 2 (LQT2). Transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, May 2022].",protein-coding,ERG-1|ERG1|H-ERG|HERG|HERG1|Kv11.1|LQT2|SQT1,eag homolog|eag-related protein 1|ether-a-go-go-related gene potassium channel 1|ether-a-go-go-related potassium channel protein|ether-a-go-go-related protein 1,ENSG00000055118,ENST00000262186|ENST00000330883|ENST00000461280|ENST00000473610|ENST00000532957|ENST00000683359|ENST00000684116|ENST00000684241|ENST00000713700|ENST00000713701,ENSP00000262186|ENSP00000328531|ENSP00000519004|ENSP00000519013|ENSP00000615705|ENSP00000615706,Q12809,A0A090N7X5|A0A090N7W1|A0AAQ5BGQ9|Q15BH2|A0A090N8Q0,KCNH2_HUMAN,3757.0,NM_000238.4|NM_001204798.2|NM_001406753.1|NM_001406755.1|NM_001406756.1|NM_001406757.1|NM_172056.3|NM_172057.3|NR_176254.1|NR_176255.1,NP_000229.1|NP_001191727.1|NP_001393682.1|NP_001393684.1|NP_001393685.1|NP_001393686.1|NP_742053.1|NP_742054.1|XP_011514487.1|XP_016867684.1,NC_000007.14|NC_060931.1|NG_008916.1,6251.0,152427.0,PA212,9606.ENSP00000262186,1BYW|1UJL|2L0W|2L1M|2L4R|2LE7|2N7G|4HP9|4HQA|5VA1|5VA2|5VA3|6SYG|8IO4|8IO5|8IOB|8ZYN|8ZYO|8ZYP|8ZYQ,,IPR000014|IPR000595|IPR000700|IPR001610|IPR003938|IPR003967|IPR005821|IPR014710|IPR018490|IPR035965,PF00027|PF00520|PF13426,PS50042|PS50112|PS50113,7,150944064.0,150978394.0,-1.0,1159.0,Cell membrane,9606.0,201.0,HERG,reactome:R-HSA-112316|reactome:R-HSA-1296071|reactome:R-HSA-1296072|reactome:R-HSA-397014|reactome:R-HSA-5576890|smpdb:SMP00296|smpdb:SMP00297|smpdb:SMP00298|smpdb:SMP00299|smpdb:SMP00300|wikipathways:WP4754|wikipathways:WP706,True,potassium voltage-gated channel subfamily H member 2,351,110,CLARITHROMYCIN|PYRILAMINE MALEATE|CHEMBL:CHEMBL525106|CHEMBL:CHEMBL584829|TAMOXIFEN CITRATE|CHEMBL:CHEMBL529640|SPIPERONE HYDROCHLORIDE|NERISPIRDINE|CHEMBL:CHEMBL1437888|CHEMBL:CHEMBL602312|CHEMBL:CHEMBL49055|NISOXETINE HYDROCHLORIDE|CHEMBL:CHEMBL591887|SOTALOL|ATENOLOL|CHEMBL:CHEMBL601492|CHEMBL:CHEMBL1256726|N-AMINOHEXYL-5-CHLORO-1-NAPTHALENESULFONAMIDE HYDROCHLORIDE|KEPONE|PHENOXYBENZAMINE HYDROCHLORIDE,CLARITHROMYCIN|PYRILAMINE MALEATE|TAMOXIFEN CITRATE|SOTALOL|ATENOLOL|PHENOXYBENZAMINE HYDROCHLORIDE|PERPHENAZINE|BISOPROLOL|ROPINIROLE HYDROCHLORIDE|DROPERIDOL,GREPAFLOXACIN|TERODILINE|ANTIANXIETY AGENT|DARUISOLINE|LEVOMETHADYL,DRUGGABLE GENOME|ION CHANNEL|CELL SURFACE,blocker|inhibitor,"NCI Cancer Gene Index|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons|Therapeutic Target Database|The ChEMBL Bioactivity Database|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)",True,CHEMBL5557,SINGLE PROTEIN,0,0,24,24,24,True,147,25,0,0,0,DOFETILIDE|DOFETILIDE|SOTALOL|VERNAKALANT HYDROCHLORIDE|DOFETILIDE|DOFETILIDE|VERNAKALANT|IBUTILIDE|AMIODARONE HYDROCHLORIDE|DOFETILIDE,Small molecule,HERG blocker|Voltage-gated potassium channel blocker,True,False,True,HIGH - Approved drugs exist,Voltage-gated inwardly rectifying potassium channel KCNH2,"Has no inward rectifier potassium channel activity by itself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation",3D-structure|Alternative splicing|Cell membrane|Coiled coil|Deafness|Disease variant|Glycoprotein|Ion channel|Ion transport|Long QT syndrome|Membrane|Methylation|Phosphoprotein|Potassium|Potassium channel|Potassium transport|Proteomics identification|Reference proteome|Short QT syndrome|Transmembrane,Belongs to the potassium channel family. H (Eag) (TC 1.A.1.20) subfamily. Kv11.1/KCNH2 sub-subfamily,PF00027:cNMP_binding|PF00520:Ion_trans|PF13426:PAS_9,3,IPR000595:cNMP-bd_dom|IPR018490:cNMP-bd_dom_sf|IPR005821:Ion_trans_dom|IPR003938:K_chnl_volt-dep_EAG/ELK/ERG|IPR003967:K_chnl_volt-dep_ERG|IPR050818:KCNH_animal-type|IPR001610:PAC|IPR000014:PAS|IPR000700:PAS-assoc_C|IPR035965:PAS-like_dom_sf|IPR014710:RmlC-like_jellyroll,11,,domain|family|homologous_superfamily|repeat,True,Ion Channel,HIGH,Ion Channel: Keyword: ion channel|Ion Channel: Keyword: voltage-gated|Ion Channel: Keyword: potassium channel|Ion Channel: InterPro: IPR005821|Ion Channel: Pfam: PF00520|Ion Channel: Pfam: PF00027,Ion Channel,True,23,1BYW|1UJL|2L0W|2L1M|2L4R|2LE7|2N7G|4HP9|4HQA|5VA1,1BYW,2.6,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1BYW.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1BYW.pdb,Moderate (2.5-3.0Å),True,2,2.0,252.404,0.27,24.0,0.333,True,2,Moderate,Low,Adequate volume (252A3),Low druggability (0.27),374|252,0.00|0.27,P1:Vol=374:Drug=0.00|P2:Vol=252:Drug=0.27
CACNA1C,CACNA1C,calcium voltage-gated channel subunit alpha1 C,"This gene encodes an alpha-1 subunit of a voltage-dependent calcium channel. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization. The alpha-1 subunit consists of 24 transmembrane segments and forms the pore through which ions pass into the cell. The calcium channel consists of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. There are multiple isoforms of each of these proteins, either encoded by different genes or the result of alternative splicing of transcripts. The protein encoded by this gene binds to and is inhibited by dihydropyridine. Alternative splicing results in many transcript variants encoding different proteins. Some of the predicted proteins may not produce functional ion channel subunits. [provided by RefSeq, Oct 2012].",protein-coding,CACH2|CACN2|CACNA1C-IT2|CACNL1A1|CCHL1A1|CaV1.2|LQT8|NEDHLSS|TS|TS. LQT8,"CACNA1C intronic transcript 2|CACNA1C intronic transcript 2 (non-protein coding)|DHPR, alpha-1 subunit|calcium channel, cardic dihydropyridine-sensitive, alpha-1 subunit|calcium channel, voltage-dependent, L type, alpha 1C subunit",ENSG00000151067,ENST00000327702|ENST00000335762|ENST00000344100|ENST00000347598|ENST00000399591|ENST00000399595|ENST00000399597|ENST00000399601|ENST00000399603|ENST00000399606,ENSP00000266376|ENSP00000329877|ENSP00000336982|ENSP00000341092|ENSP00000382500|ENSP00000382504|ENSP00000382506|ENSP00000382510|ENSP00000382512|ENSP00000382515,Q13936,A0A804HIJ8|E9PDI6|A0A804HI37|A0A0A0MR67|A0A804HJB6,CAC1C_HUMAN,775.0,NM_000719.7|NM_001129827.2|NM_001129829.2|NM_001129830.3|NM_001129831.2|NM_001129832.2|NM_001129833.2|NM_001129834.2|NM_001129835.2|NM_001129836.2,NP_000710.5|NP_001123299.1|NP_001123301.1|NP_001123302.2|NP_001123303.1|NP_001123304.1|NP_001123305.1|NP_001123306.1|NP_001123307.1|NP_001123308.1,NC_000012.12|NC_060936.1|NG_008801.2|NW_018654718.1,1390.0,114205.0,PA83,9606.ENSP00000266376,1T0J|2BE6|2F3Y|2F3Z|2LQC|3G43|3OXQ|5V2P|5V2Q|6C0A|6DAD|6DAE|6DAF|6U39|6U3A|6U3B|6U3D|7L8V|8EOG|8EOI,,IPR005446|IPR005451|IPR005821|IPR027359|IPR050599|IPR002077|IPR014873|IPR031649|IPR031688,PF00520|PF08763|PF16885|PF16905,,12,1970772.0,2697950.0,1.0,2221.0,"Cell membrane|Cell membrane, sarcolemma|Perikaryon",9606.0,55484.0,Cav1.2,kegg:hsa04010|kegg:hsa04020|kegg:hsa04022|kegg:hsa04024|kegg:hsa04260|reactome:R-HSA-1266738|reactome:R-HSA-1430728|reactome:R-HSA-1430728|reactome:R-HSA-163685|reactome:R-HSA-163685|smpdb:SMP00296|smpdb:SMP00297|smpdb:SMP00298|smpdb:SMP00299|smpdb:SMP00300|wikipathways:WP1603|wikipathways:WP2059|wikipathways:WP2118|wikipathways:WP382|wikipathways:WP4539,True,calcium voltage-gated channel subunit alpha1 C,47,35,IMAGABALIN|PHLOROGLUCINOL|AMLODIPINE BESYLATE|LERCANIDIPINE HYDROCHLORIDE|AMLODIPINE BENZOATE|DEHYDRATED ALCOHOL|AZD1305|RAUWOLFIA SERPENTINA (USP)|PREGABALIN|CLEVIDIPINE|ELPETRIGINE|TERODILINE HYDROCHLORIDE|NIMODIPINE|NITRENDIPINE|FELODIPINE|AMLODIPINE MALEATE|IBUTILIDE|ATENOLOL|NICARDIPINE HYDROCHLORIDE|BENIDIPINE,PHLOROGLUCINOL|AMLODIPINE BESYLATE|LERCANIDIPINE HYDROCHLORIDE|AMLODIPINE BENZOATE|DEHYDRATED ALCOHOL|RAUWOLFIA SERPENTINA (USP)|PREGABALIN|CLEVIDIPINE|TERODILINE HYDROCHLORIDE|NIMODIPINE,CALCIUM CHANNEL BLOCKER|CLEVIDIPINE|IBUTILIDE|AMLODIPINE BESYLATE|AMLODIPINE BENZOATE,DRUGGABLE GENOME|ION CHANNEL,modulator|blocker,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL1940,SINGLE PROTEIN,0,0,713,713,1000,True,324,25,0,0,0,DILTIAZEM HYDROCHLORIDE|CLEVIDIPINE|NIMODIPINE|NICARDIPINE|NISOLDIPINE|DILTIAZEM|SULOCTIDIL|BEPRIDIL|FELODIPINE|AMLODIPINE,Small molecule,Voltage-gated L-type calcium channel blocker|Voltage-gated calcium channel blocker,True,False,True,HIGH - Approved drugs exist,Voltage-dependent L-type calcium channel subunit alpha-1C,(Microbial infection) Acts as a receptor for Influenzavirus (PubMed:29779930). May play a critical role in allowing virus entry when sialylated and expressed on lung tissues (PubMed:29779930),3D-structure|Alternative splicing|Autism|Autism spectrum disorder|Brugada syndrome|Calcium|Calcium channel|Calcium transport|Calmodulin-binding|Cell membrane|Cell projection|Disease variant|Disulfide bond|Epilepsy|Glycoprotein|Host-virus interaction|Intellectual disability|Ion channel|Ion transport|Long QT syndrome,Belongs to the calcium channel alpha-1 subunit (TC 1.A.1.11) family. CACNA1C subfamily,PF08763:Ca_chan_IQ|PF16885:CAC1F_C|PF16905:GPHH|PF00520:Ion_trans,4,IPR031688:CAC1F_C|IPR031649:GPHH_dom|IPR005821:Ion_trans_dom|IPR014873:VDCC_a1su_IQ|IPR050599:VDCC_alpha-1_subunit|IPR005451:VDCC_L_a1csu|IPR005446:VDCC_L_a1su|IPR002077:VDCCAlpha1|IPR027359:Volt_channel_dom_sf,9,,domain|family|homologous_superfamily,True,Ion Channel,HIGH,Ion Channel: Keyword: ion channel|Ion Channel: Keyword: voltage-gated|Ion Channel: Keyword: calcium channel|Ion Channel: InterPro: IPR005821|Ion Channel: Pfam: PF00520,Ion Channel,True,32,1T0J|2BE6|2F3Y|2F3Z|2LQC|3G43|3OXQ|5V2P|5V2Q|6C0A,1T0J,2.0,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1T0J.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1T0J.pdb,Excellent (<2.0Å),True,17,4.0,659.564,0.361,7.421,0.103,True,13,Moderate,Low,Optimal volume (660A3),Low druggability (0.36),499|330|531|660|737|328|804|293|167|250|255|401|253|781|157|297|204,0.18|0.12|0.36|0.36|0.02|0.00|0.04|0.00|0.00|0.04|0.00|0.02|0.04|0.00,P1:Vol=499:Drug=0.18|P2:Vol=330:Drug=0.12|P3:Vol=531:Drug=0.36|P4:Vol=660:Drug=0.36|P5:Vol=737:Drug=0.02|P6:Vol=328:Drug=0.00|P7:Vol=804:Drug=0.00|P8:Vol=293:Drug=0.04|P9:Vol=167:Drug=0.00|P10:Vol=250:Drug=0.00
TRPV1,TRPV1,transient receptor potential cation channel subfamily V member 1,"Capsaicin, the main pungent ingredient in hot chili peppers, elicits a sensation of burning pain by selectively activating sensory neurons that convey information about noxious stimuli to the central nervous system. The protein encoded by this gene is a receptor for capsaicin and is a non-selective cation channel that is structurally related to members of the TRP family of ion channels. This receptor is also activated by increases in temperature in the noxious range, suggesting that it functions as a transducer of painful thermal stimuli in vivo. Four transcript variants encoding the same protein, but with different 5' UTR sequence, have been described for this gene. [provided by RefSeq, Jul 2008].",protein-coding,VR1,OTRPC1|capsaicin receptor|osm-9-like TRP channel 1|transient receptor potential cation channel subfamily V member 1|transient receptor potential vanilloid 1a,ENSG00000196689,ENST00000310522|ENST00000399756|ENST00000399759|ENST00000425167|ENST00000570742|ENST00000571088|ENST00000572705|ENST00000574085|ENST00000576351|ENST00000650505,ENSP00000311692|ENSP00000382659|ENSP00000382661|ENSP00000409627|ENSP00000459042|ENSP00000459962|ENSP00000461007|ENSP00000497337|ENSP00000561231|ENSP00000636640,Q8NER1,I3L1R6|E7EQ78|A0A3B3ISI9|E7ESJ2,TRPV1_HUMAN,7442.0,NM_018727.5|NM_080704.4|NM_080705.4|NM_080706.3,NP_061197.4|NP_542435.2|NP_542436.2|NP_542437.2,NC_000017.11|NC_060941.1|NG_029716.2,12716.0,602076.0,PA37329,9606.ENSP00000459962,6L93|8GF8|8GF9|8GFA|8JQR|8X94|8YCP,,IPR002110|IPR005821|IPR008347|IPR024862|IPR036770,PF00023|PF00520|PF12796,PS50088|PS50297,17,3565444.0,3609411.0,-1.0,839.0,"Postsynaptic cell membrane|Cell projection, dendritic spine membrane|Cell membrane",9606.0,12920.0,TRPV1,kegg:hsa04080|kegg:hsa04750|pid:mapktrkpathway|pid:pi3kplctrkpathway|reactome:R-HSA-2672351|reactome:R-HSA-3295583|reactome:R-HSA-382551|reactome:R-HSA-983712|wikipathways:WP3947|wikipathways:WP4721,True,transient receptor potential cation channel subfamily V member 1,41,8,STREPTOZOCIN|BENZYL ISOTHIOCYANATE|ACETAMINOPHEN|POLYGODIAL|PROPOFOL|SAF312|GRC-15300|AZD1386|TIVANISIRAN|MAVATREP|MR-1817|FERRUGINENE B|CAPSAICIN|RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN|PHENETHYLISOTHIOCYANATE|VOACANGINE|RESINIFERATOXIN|DWP05195|XEN-D0501|PAC-14028,STREPTOZOCIN|ACETAMINOPHEN|PROPOFOL|CAPSAICIN|MASOPROCOL|RESERPINE|LEVODOPA|INDOMETHACIN,MR-1817|FERRUGINENE B|DWP05195|XEN-D0501|PAC-14028,DRUGGABLE GENOME|ION CHANNEL|KINASE|EXTERNAL SIDE OF PLASMA MEMBRANE,inhibitor|agonist|potentiator,"NCI Cancer Gene Index|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL5500263,NUCLEIC-ACID,0,0,0,0,0,True,343,25,0,0,0,ACETAMINOPHEN|ACETAMINOPHEN|ACETAMINOPHEN|ACETAMINOPHEN|ACETAMINOPHEN|ACETAMINOPHEN|CAPSAICIN|CAPSAICIN|ACETAMINOPHEN|CAPSAICIN,Small molecule,Vanilloid receptor opener,True,False,False,HIGH - Approved drugs exist,Transient receptor potential cation channel subfamily V member 1,"Non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli (PubMed:11050376, PubMed:11243859, PubMed:11226139, PubMed:12077606). Seems to mediate proton influx and may be involved in intracellular acidosis in nociceptive neurons. Involved in mediation of inflammatory pain and hyperalgesia. Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. Activated by vanilloids, like capsaicin, and temperatures higher than 42 degrees Celsius (PubMed:37117175). Upon activation, exhibits a time- and Ca(2+)-dependent outward rectification, followed by a long-lasting refractory state. Mild extracellular acidic pH (6.5) potentiates channel activation by noxious heat and vanilloids, whereas acidic conditions (pH <6) directly activate the channel. Can be activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. Acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. Triggers a form of long-term depression (TRPV1-LTD) mediated by the endocannabinoid anandamine in the hippocampus and nucleus accumbens by affecting AMPA receptors endocytosis",3D-structure|Alternative splicing|ANK repeat|ATP-binding|Calcium|Calcium channel|Calcium transport|Calmodulin-binding|Cell membrane|Cell projection|Glycoprotein|Ion channel|Ion transport|Membrane|Metal-binding|Nucleotide-binding|Phosphoprotein|Postsynaptic cell membrane|Reference proteome|Repeat,Belongs to the transient receptor (TC 1.A.4) family. TrpV subfamily. TRPV1 sub-subfamily,PF00023:Ank|PF12796:Ank_2|PF00520:Ion_trans,3,IPR002110:Ankyrin_rpt|IPR036770:Ankyrin_rpt-contain_sf|IPR005821:Ion_trans_dom|IPR024862:TRPV|IPR008347:TrpV1-4,5,,domain|family|homologous_superfamily|repeat,True,Kinase|Ion Channel|Histone Acetyltransferase,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: tyrosine kinase|Kinase: Keyword: receptor tyrosine kinase|Ion Channel: Keyword: ion channel|Ion Channel: Keyword: calcium channel|Ion Channel: Keyword: transient receptor potential|Ion Channel: InterPro: IPR005821|Ion Channel: Pfam: PF00520|Histone Acetyltransferase: Keyword: hat,Kinase,True,8,6L93|8GF8|8GF9|8GFA|8JQR|8X94|8YCP|9P6B,6L93,4.47,X-RAY DIFFRACTION,protein_structures/pdb_experimental/6L93.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/6L93.pdb,Low (>4.5Å),True,109,96.0,972.567,0.969,50.5,0.969,True,91,Excellent,High,Optimal volume (973A3)|High druggability (0.97),,86|381|188|396|103|458|2846|146|306|304|201|240|279|193|78|146|328|150|243|479|317|321|150|425|235|82|165|308|575|252|528|329|310|268|260|322|166|177|266|207|224|396|247|427|509|294|222|188|298|256|260|213|176|272|512|232|140|177|251|270|121|351|364|259|357|177|379|303|324|563|317|468|271|174|252|372|286|596|175|159|265|256|419|754|212|541|346|553|580|379|371|250|316|583|959|973|473|498|785|981|1011|903|807|1224|1428|895|5679|1405|1325,0.00|0.02|0.01|0.00|0.01|0.04|0.01|0.02|0.00|0.03|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.21|0.00|0.01|0.01|0.00|0.00|0.00|0.01|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.14|0.00|0.97|0.01|0.01|0.00|0.46|0.34|0.11|0.06|0.36|0.00|0.01,P1:Vol=86:Drug=0.00|P2:Vol=381:Drug=0.00|P3:Vol=188:Drug=0.02|P4:Vol=396:Drug=0.01|P5:Vol=103:Drug=0.00|P6:Vol=458:Drug=0.01|P7:Vol=2846:Drug=0.04|P8:Vol=146:Drug=0.01|P9:Vol=306:Drug=0.00|P10:Vol=304:Drug=0.02
KCNQ2,KCNQ2,potassium voltage-gated channel subfamily Q member 2,"The M channel is a slowly activating and deactivating potassium channel that plays a critical role in the regulation of neuronal excitability.  The M channel is formed by the association of the protein encoded by this gene and a related protein encoded by the KCNQ3 gene, both integral membrane proteins. M channel currents are inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 1 (BFNC), also known as epilepsy, benign neonatal type 1 (EBN1). At least five transcript variants encoding five different isoforms have been found for this gene. [provided by RefSeq, Jul 2008].",protein-coding,BFNC|DEE7|EBN|EBN1|ENB1|HNSPC|KCNA11|KV7.2,"neuroblastoma-specific potassium channel subunit alpha KvLQT2|potassium channel, voltage gated KQT-like subfamily Q, member 2|potassium voltage-gated channel subfamily KQT member 2|voltage-gated potassium channel subunit Kv7.2",ENSG00000281151,ENST00000625248|ENST00000625847|ENST00000626100|ENST00000626723|ENST00000626962|ENST00000627088|ENST00000627416|ENST00000627948|ENST00000628544|ENST00000628732,ENSP00000485756|ENSP00000485832|ENSP00000485872|ENSP00000486010|ENSP00000486451|ENSP00000486464|ENSP00000486557|ENSP00000486636|ENSP00000486949|ENSP00000487078,O43526,A0A9L9PXL0|Q53Y30|A0A0D9SGG3|A0A0D9SEV1|A0A0D9SGD4,KCNQ2_HUMAN,3785.0,NM_001382235.1|NM_001439003.1|NM_001439004.1|NM_004518.6|NM_172106.3|NM_172107.4|NM_172108.5|NM_172109.3|XM_011528811.3|XM_017027841.3,NP_001369164.1|NP_001425932.1|NP_001425933.1|NP_004509.2|NP_742104.1|NP_742105.1|NP_742106.1|NP_742107.1|XP_011527113.1|XP_016883330.1,NC_000020.11|NC_060944.1|NG_009004.2|NT_187625.1,6296.0,602235.0,PA30074,9606.ENSP00000352035,5J03|6FEG|6FEH|7CR0|7CR1|7CR2|7CR3|7CR4|7CR7|8IJK|8IZY|8J00|8J01|8J02|8J03|8J04|8J05|8W4U|8X43|8XO1,,IPR003937|IPR003947|IPR005821|IPR013821|IPR020969|IPR027359,PF00520|PF03520|PF11956|PF16642,,20,63400208.0,63472677.0,-1.0,872.0,Cell membrane,9606.0,26174.0,KvLQT2,reactome:R-HSA-112316|reactome:R-HSA-1266738|reactome:R-HSA-1296071|reactome:R-HSA-1296072|reactome:R-HSA-373760|wikipathways:WP4148|wikipathways:WP4698,True,potassium voltage-gated channel subfamily Q member 2,10,6,GUANIDINE HYDROCHLORIDE|TEDISAMIL|DALFAMPRIDINE|EZOGABINE|AMIFAMPRIDINE PHOSPHATE|NERISPIRDINE|ICA-105665|FLINDOKALNER|CELECOXIB|AMIFAMPRIDINE,GUANIDINE HYDROCHLORIDE|DALFAMPRIDINE|EZOGABINE|AMIFAMPRIDINE PHOSPHATE|CELECOXIB|AMIFAMPRIDINE,EZOGABINE|ICA-105665|FLINDOKALNER|CELECOXIB|TEDISAMIL,ION CHANNEL|DRUGGABLE GENOME,blocker|activator|potentiator,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|The ChEMBL Bioactivity Database|PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons",True,CHEMBL2985,SINGLE PROTEIN,0,0,53,53,95,False,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Potassium voltage-gated channel subfamily KQT member 2,"Pore-forming subunit of the voltage-gated potassium (Kv) M-channel which is responsible for the M-current, a key controller of neuronal excitability (PubMed:24277843, PubMed:28793216, PubMed:9836639). M-channel is composed of pore-forming subunits KCNQ2 and KCNQ3 assembled as heterotetramers (PubMed:10781098, PubMed:14534157, PubMed:32884139, PubMed:37857637, PubMed:9836639). The native M-current has a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs (PubMed:14534157, PubMed:28793216, PubMed:9836639). KCNQ2-KCNQ3 M-channel is selectively permeable in vitro to other cations besides potassium, in decreasing order of affinity K(+) > Rb(+) > Cs(+) > Na(+) (PubMed:28793216). M-channel association with SLC5A3/SMIT1 alters channel ion selectivity, increasing Na(+) and Cs(+) permeation relative to K(+) (PubMed:28793216). Suppressed by activation of the muscarinic acetylcholine receptor CHRM1 (PubMed:10684873, PubMed:10713961)",3D-structure|Alternative splicing|Cell membrane|Disease variant|Epilepsy|Intellectual disability|Ion channel|Ion transport|Membrane|Phosphoprotein|Potassium|Potassium channel|Potassium transport|Proteomics identification|Reference proteome|Transmembrane|Transmembrane helix|Transport|Ubl conjugation|Voltage-gated channel,Belongs to the potassium channel family. KQT (TC 1.A.1.15) subfamily. Kv7.2/KCNQ2 sub-subfamily,PF00520:Ion_trans|PF16642:KCNQ2_u3|PF03520:KCNQ_channel|PF11956:KCNQC3-Ank-G_bd,4,IPR020969:Ankyrin-G_BS|IPR005821:Ion_trans_dom|IPR003937:K_chnl_volt-dep_KCNQ|IPR003947:K_chnl_volt-dep_KCNQ2|IPR013821:K_chnl_volt-dep_KCNQ_C,5,,domain|family|binding_site,True,Ion Channel,HIGH,Ion Channel: Keyword: ion channel|Ion Channel: Keyword: voltage-gated|Ion Channel: Keyword: potassium channel|Ion Channel: InterPro: IPR005821|Ion Channel: Pfam: PF00520,Ion Channel,True,22,5J03|6FEG|6FEH|7CR0|7CR1|7CR2|7CR3|7CR4|7CR7|8IJK,5J03,2.0,X-RAY DIFFRACTION,protein_structures/pdb_experimental/5J03.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/5J03.pdb,Excellent (<2.0Å),True,13,10.0,637.244,0.629,,0.629,True,10,Good,Medium,Optimal volume (637A3),,942|895|461|317|298|237|331|187|321|637|222|228|207,0.02|0.05|0.28|0.00|0.00|0.01|0.00|0.01|0.00|0.63|0.01,P1:Vol=942:Drug=0.02|P2:Vol=895:Drug=0.05|P3:Vol=461:Drug=0.28|P4:Vol=317:Drug=0.00|P5:Vol=298:Drug=0.00|P6:Vol=237:Drug=0.01|P7:Vol=331:Drug=0.00|P8:Vol=187:Drug=0.01|P9:Vol=321:Drug=0.00|P10:Vol=637:Drug=0.63
GABRA1,GABRA1,gamma-aminobutyric acid type A receptor subunit alpha1,"This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. Mutations in this gene cause juvenile myoclonic epilepsy and childhood absence epilepsy type 4. Multiple transcript variants encoding the same protein have been identified for this gene. [provided by RefSeq, Jul 2008].",protein-coding,DEE19|ECA4|EIEE19|EJM|EJM5,"GABA(A) receptor subunit alpha-1|GABA(A) receptor, alpha 1|GABAAR subunit alpha-1|gamma-aminobutyric acid (GABA) A receptor, alpha 1|gamma-aminobutyric acid receptor subunit alpha-1",ENSG00000022355,ENST00000023897|ENST00000393943|ENST00000428797|ENST00000437025|ENST00000519542|ENST00000519621|ENST00000521339|ENST00000522651|ENST00000634335|ENST00000635096,ENSP00000023897|ENSP00000377517|ENSP00000393097|ENSP00000415441|ENSP00000430435|ENSP00000430507|ENSP00000430895|ENSP00000489033|ENSP00000489434|ENSP00000489738,P14867,A0A0U1RRB2|A8K177|A0A1B0GV38|A0A1B0GU82|A0A0U1RQJ3,GBRA1_HUMAN,2554.0,NM_000806.5|NM_001127643.2|NM_001127644.2|NM_001127645.2|NM_001127646.1|NM_001127647.1|NM_001127648.2,NP_000797.2|NP_001121115.1|NP_001121116.1|NP_001121117.1|NP_001121120.1,NC_000005.10|NC_060929.1|NG_011548.1,4075.0,137160.0,PA28489,9606.ENSP00000393097,6CDU|6D1S|6D6T|6D6U|6HUG|6HUJ|6HUK|6HUO|6HUP|6I53|6X3S|6X3T|6X3U|6X3V|6X3W|6X3X|6X3Z|6X40|7PBD|7PBZ,,IPR001390|IPR005431|IPR006028|IPR006029|IPR006201|IPR006202|IPR018000|IPR036719|IPR036734|IPR038050,PF02931|PF02932,,5,161847063.0,161899981.0,1.0,456.0,Postsynaptic cell membrane|Cell membrane|Cytoplasmic vesicle membrane,9606.0,629.0,Gamma-aminobutyric acid receptor subunit alpha-1,biocarta:flumazenilpathway|biocarta:gabapathway|kegg:hsa04080|kegg:hsa04723|kegg:hsa04727|kegg:hsa04742|kegg:hsa05032|reactome:R-HSA-112314|reactome:R-HSA-112314|reactome:R-HSA-112315|reactome:R-HSA-112315|reactome:R-HSA-112316|wikipathways:WP3947|wikipathways:WP4159|wikipathways:WP4549|wikipathways:WP4829|wikipathways:WP706,True,gamma-aminobutyric acid type A receptor subunit alpha1,130,73,CHLORDIAZEPOXIDE|ETIFOXINE|DIAZEPAM|METHARBITAL|L838417|GANAXOLONE|THIAMYLAL SODIUM|EVT 201|ADINAZOLAM|ZK-93423|AMOBARBITAL|ETHCHLORVYNOL|SECOBARBITAL SODIUM|MEPHOBARBITAL|ZOLPIDEM TARTRATE|METHAQUALONE|TOPIRAMATE|PAGOCLONE|THIOCOLCHICOSIDE|[3H]AZIETOMIDATE,CHLORDIAZEPOXIDE|DIAZEPAM|METHARBITAL|GANAXOLONE|THIAMYLAL SODIUM|AMOBARBITAL|ETHCHLORVYNOL|SECOBARBITAL SODIUM|MEPHOBARBITAL|ZOLPIDEM TARTRATE,INDIPLON|METHOHEXITAL|BICUCULLINE|AMOBARBITAL|BARBITURATE,DRUGGABLE GENOME|ION CHANNEL,negative modulator|modulator|inverse agonist|agonist|positive modulator|blocker|inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Guide to Pharmacology|Drug Target Commons|Therapeutic Target Database|The ChEMBL Bioactivity Database|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)",True,CHEMBL3139,SINGLE PROTEIN,0,0,3,3,3,True,810,25,0,0,0,DIAZEPAM|GANAXOLONE|TOPIRAMATE|TOPIRAMATE|CENOBAMATE|CLONAZEPAM|CLONAZEPAM|TOPIRAMATE|MIDAZOLAM|METHOXYFLURANE,Small molecule,GABA-A receptor; anion channel positive modulator|GABA-A receptor; anion channel positive allosteric modulator,True,False,True,HIGH - Approved drugs exist,Gamma-aminobutyric acid receptor subunit alpha-1,"Alpha subunit of the heteropentameric ligand-gated chloride channel gated by Gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:23909897, PubMed:25489750, PubMed:29950725, PubMed:30602789). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (PubMed:29950725, PubMed:30602789). When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient (PubMed:23909897, PubMed:29950725, PubMed:30602789). Alpha-1/GABRA1-containing GABAARs are largely synaptic (By similarity). Chloride influx into the postsynaptic neuron following GABAAR opening decreases the neuron ability to generate a new action potential, thereby reducing nerve transmission (By similarity). GABAARs containing alpha-1 and beta-2 or -3 subunits exhibit synaptogenic activity; the gamma-2 subunit being necessary but not sufficient to induce rapid synaptic contacts formation (PubMed:23909897, PubMed:25489750). GABAARs function also as histamine receptor where histamine binds at the interface of two neighboring beta subunits and potentiates GABA response (By similarity). GABAARs containing alpha, beta and epsilon subunits also permit spontaneous chloride channel activity while preserving the structural information required for GABA-gated openings (By similarity). Alpha-1-mediated plasticity in the orbitofrontal cortex regulates context-dependent action selection (By similarity). Together with rho subunits, may also control neuronal and glial GABAergic transmission in the cerebellum (By similarity)",3D-structure|Cell membrane|Chloride|Chloride channel|Cytoplasmic vesicle|Disease variant|Disulfide bond|Epilepsy|Glycoprotein|Ion channel|Ion transport|Ligand-gated ion channel|Membrane|Postsynaptic cell membrane|Proteomics identification|Receptor|Reference proteome|Signal|Synapse|Transmembrane,Belongs to the ligand-gated ion channel (TC 1.A.9) family. Gamma-aminobutyric acid receptor (TC 1.A.9.5) subfamily. GABRA1 sub-subfamily,PF02931:Neur_chan_LBD|PF02932:Neur_chan_memb,2,IPR006028:GABAA/Glycine_rcpt|IPR001390:GABAAa_rcpt|IPR005431:GABBAa1_rcpt|IPR047024:Gabra-1-6_TM|IPR047079:GABRA1_ECD|IPR006202:Neur_chan_lig-bd|IPR036734:Neur_chan_lig-bd_sf|IPR006201:Neur_channel|IPR036719:Neuro-gated_channel_TM_sf|IPR038050:Neuro_actylchol_rec|IPR006029:Neurotrans-gated_channel_TM|IPR018000:Neurotransmitter_ion_chnl_CS,12,,domain|family|homologous_superfamily|conserved_site,True,Ion Channel,HIGH,Ion Channel: Keyword: ion channel|Ion Channel: Keyword: ligand-gated|Ion Channel: Keyword: chloride channel|Ion Channel: InterPro: IPR006029,Ion Channel,True,83,6CDU|6D1S|6D6T|6D6U|6HUK|6HUO|6I53|6X3S|6X3T|6X3U,6CDU,3.45,X-RAY DIFFRACTION,protein_structures/pdb_experimental/6CDU.pdb,False,,,,,PDB,protein_structures/pdb_experimental/6CDU.pdb,Low (>3.5Å),True,243,53.0,479.455,0.783,43.167,0.033,True,211,Good,Medium,Adequate volume (479A3)|High druggability (0.78),,507|489|456|487|447|483|473|428|426|291|1263|1197|1450|341|391|565|1383|185|1510|106|1183|1615|1316|89|658|97|102|251|97|426|352|117|258|91|380|314|588|375|483|63|336|370|270|488|75|362|306|64|87|501|412|360|479|526|64|279|168|445|246|187|58|1443|343|69|531|277|124|105|386|146|265|71|951|221|167|191|466|250|202|172|194|291|472|420|236|155|136|371|262|211|805|307|203|234|223|269|225|391|302|482|1104|442|504|238|201|390|80|578|464|331|276|135|246|471|353|406|218|230|239|531|429|110|722|330|495|724|258|124|152|303|213|1056|233|179|562|286|552|462|268|241|172|421|469|228|415|195|252|196|353|297|179|300|579|319|234|154|236|97|813|318|258|342|396|380|197|182|458|190|135|337|295|364|210|542|396|303|276|1063|384|603|254|326|267|524|107|256|288|341|356|759|1853|316|245|352|143|322|691|194|930|359|255|307|1114|771|408|244|744|263|514|297|185|465|207|355|270|947|381|204|304|292|375|263|693|564|643|293|326|242|751|502|352|299|287|965|542|328|401|950|401|319|947|744|711,0.23|0.38|0.11|0.30|0.18|0.17|0.08|0.11|0.07|0.07|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.02|0.00|0.02|0.00|0.00|0.00|0.00|0.00|0.26|0.00|0.00|0.00|0.01|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.03|0.04|0.78|0.01|0.01|0.07|0.00|0.00|0.01|0.03|0.00|0.00|0.05|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.01|0.07|0.00|0.00|0.00|0.00|0.01|0.00|0.67|0.55|0.01|0.05|0.01|0.00|0.00|0.01|0.00|0.00|0.00|0.26|0.02|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.01|0.12|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.07|0.01|0.07|0.00|0.00|0.00|0.00|0.00|0.01|0.01|0.00|0.01|0.00|0.01|0.00|0.01|0.01|0.00|0.01|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00,P1:Vol=507:Drug=0.23|P2:Vol=489:Drug=0.38|P3:Vol=456:Drug=0.11|P4:Vol=487:Drug=0.30|P5:Vol=447:Drug=0.18|P6:Vol=483:Drug=0.17|P7:Vol=473:Drug=0.08|P8:Vol=428:Drug=0.11|P9:Vol=426:Drug=0.07|P10:Vol=291:Drug=0.07
GRIN1,GPRIN1,G protein regulated inducer of neurite outgrowth 1,"Predicted to enable phosphoprotein binding activity. Predicted to be involved in neuron projection development. Predicted to be located in growth cone. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022]",protein-coding,GRIN1,G protein-regulated inducer of neurite outgrowth 1,ENSG00000169258,ENST00000303991|ENST00000926001|ENST00000926002,ENSP00000305839|ENSP00000596060|ENSP00000596061,Q7Z2K8,,NMDZ1_HUMAN,114787.0,NM_052899.3,NP_443131.2,NC_000005.10|NC_060929.1,24835.0,611239.0,PA162390183,9606.ENSP00000360608,2HQW|2NR1|3BYA|5H8F|5H8H|5H8N|5H8Q|5I2K|5I2N|5KCJ|5KDT|5TP9|5TPA|6IRA|6IRF|6IRG|6IRH|7EOQ|7EOR|7EOS,,IPR026646|IPR032745,PF15235,,5,176595802.0,176610177.0,-1.0,938.0,Cell membrane|Postsynaptic cell membrane|Postsynaptic density membrane,9606.0,8072.0,,reactome:R-HSA-212436|reactome:R-HSA-73857|reactome:R-HSA-74160|reactome:R-HSA-8986944|reactome:R-HSA-9022699,True,glutamate ionotropic receptor NMDA type subunit 1,50,12,COMPOUND 53 [PMID: 33038794]|PAREGORIC|STING AGONIST 2|LATREPIRDINE|CNS-5161|MEMANTINE HYDROCHLORIDE|LANICEMINE|ULEVOSTINAG|ELIPRODIL|NBQX|RAPASTINEL|DEXANABINOL|NEBOGLAMINE|HALOPERIDOL DECANOATE|ORPHENADRINE|GW468816|ACAMPROSATE CALCIUM|AMANTADINE HYDROCHLORIDE|H-151|D-SERINE,PAREGORIC|MEMANTINE HYDROCHLORIDE|HALOPERIDOL DECANOATE|ORPHENADRINE|ACAMPROSATE CALCIUM|AMANTADINE HYDROCHLORIDE|KETAMINE HYDROCHLORIDE|FELBAMATE|ORPHENADRINE HYDROCHLORIDE|CYCLOSERINE,COMPOUND 53 [PMID: 33038794]|STING AGONIST 2|ULEVOSTINAG|RAPASTINEL|H-151,DRUGGABLE GENOME|ION CHANNEL|CELL SURFACE,negative modulator|agonist|positive modulator|blocker|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|NCI Cancer Gene Index|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Guide to Pharmacology|Drug Target Commons|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL5266,SINGLE PROTEIN,0,0,1,1,1,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,G protein-regulated inducer of neurite outgrowth 1,May be involved in neurite outgrowth,Alternative splicing|Cell membrane|Cell projection|Lipoprotein|Membrane|Palmitate|Phosphoprotein|Proteomics identification|Reference proteome,,PF15235:GRIN_C,1,IPR026646:GPRIN2-like/GPRIN3|IPR032745:GRIN_C,2,,domain|family,False,,NONE,,,False,0,,,,,,True,2025-08-01T00:00:00Z,,Unknown,,,,,False,0,,,,,,False,0,,,,,,,
ESR1,ESR1,estrogen receptor 1,"This gene encodes an estrogen receptor and ligand-activated transcription factor. The canonical protein contains an N-terminal ligand-independent transactivation domain, a central DNA binding domain, a hinge domain, and a C-terminal ligand-dependent transactivation domain. The protein localizes to the nucleus where it may form either a homodimer or a heterodimer with estrogen receptor 2. The protein encoded by this gene regulates the transcription of many estrogen-inducible genes that play a role in growth, metabolism, sexual development, gestation, and other reproductive functions and is expressed in many non-reproductive tissues. The receptor encoded by this gene plays a key role in breast cancer, endometrial cancer, and osteoporosis. This gene is reported to have dozens of transcript variants due to the use of alternate promoters and alternative splicing, however, the full-length nature of many of these variants remain uncertain. [provided by RefSeq, Jul 2020].",protein-coding,ER|ESR|ESRA|ESTRR|Era|NR3A1,E2 receptor alpha|ER-alpha|estradiol receptor|estrogen nuclear receptor alpha|estrogen receptor,ENSG00000091831,ENST00000206249|ENST00000338799|ENST00000404742|ENST00000406599|ENST00000415488|ENST00000427531|ENST00000440973|ENST00000443427|ENST00000446550|ENST00000456483,ENSP00000206249|ENSP00000342630|ENSP00000384064|ENSP00000385373|ENSP00000387500|ENSP00000394721|ENSP00000401995|ENSP00000405330|ENSP00000411105|ENSP00000415934,P03372,A0A125SXW3|Q9UBT1|G4XH65|A8KAF4|H0Y4W6,ESR1_HUMAN,2099.0,NM_000125.4|NM_001122740.2|NM_001122741.2|NM_001122742.2|NM_001291230.2|NM_001291241.2|NM_001328100.2|NM_001385568.1|NM_001385569.1|NM_001385570.1,NP_000116.2|NP_001116212.1|NP_001116213.1|NP_001116214.1|NP_001278159.1|NP_001278170.1|NP_001315029.1|NP_001372497.1|NP_001372498.1|NP_001372499.1,NC_000006.12|NC_060930.1|NG_008493.2,3467.0,133430.0,PA156,9606.ENSP00000405330,1A52|1ERE|1ERR|1G50|1GWQ|1GWR|1HCP|1HCQ|1L2I|1PCG|1QKT|1QKU|1R5K|1SJ0|1UOM|1X7E|1X7R|1XP1|1XP6|1XP9,,IPR000536|IPR001292|IPR001628|IPR001723|IPR013088|IPR024178|IPR024736|IPR035500|IPR046944|IPR050200,PF00104|PF00105|PF02159|PF12743,PS51030|PS51843,6,151651284.0,152129619.0,1.0,595.0,Nucleus|Cytoplasm|Cell membrane,9606.0,47906.0,Estrogen receptor alpha,biocarta:carmerpathway|biocarta:efppathway|biocarta:her2pathway|biocarta:mta3pathway|biocarta:pelp1pathway|kegg:hsa04915|kegg:hsa04917|kegg:hsa04919|kegg:hsa04961|kegg:hsa05200|netpath:Pathway_AndrogenReceptor|netpath:Pathway_Leptin|netpath:Pathway_Prolactin|netpath:Pathway_TGF_beta_Receptor|pid:ap1_pathway|pid:atf2_pathway|pid:er_nongenomic_pathway|pid:era_genomic_pathway|pid:foxm1pathway|smpdb:SMP00471|smpdb:SMP00606|wikipathways:WP170|wikipathways:WP1984|wikipathways:WP2034|wikipathways:WP2586|wikipathways:WP2814,True,estrogen receptor 1,216,109,"ESTRIOL|ERIBULIN MESYLATE|DIETHYLSTILBESTROL DIPHOSPHATE|EVEROLIMUS|FULVESTRANT|ESTROGENS, ESTERIFIED (USP)|LETROZOLE|SYNTHETIC CONJUGATED ESTROGENS, B|SELECTIVE ESTROGEN RECEPTOR MODULATOR CC-8490|CHEMBL:CHEMBL1091137|ALOE-EMODIN|ESTROGENS, CONJUGATED (USP)|BORIC ACID|ETONOGESTREL|FENRETINIDE|LASOFOXIFENE TARTRATE|ESTRADIOL VALERATE|GESTRINONE|AFIMOXIFENE|TESTOSTERONE","ESTRIOL|ERIBULIN MESYLATE|DIETHYLSTILBESTROL DIPHOSPHATE|EVEROLIMUS|FULVESTRANT|ESTROGENS, ESTERIFIED (USP)|LETROZOLE|SYNTHETIC CONJUGATED ESTROGENS, B|ESTROGENS, CONJUGATED (USP)|BORIC ACID",BRILANESTRANT|ELACESTRANT|CHEMBL:CHEMBL1091137|SELECTIVE ESTROGEN RECEPTOR DEGRADER AZD9496|4-TRIETHYLGERMYLPHENOL,NUCLEAR HORMONE RECEPTOR|DRUGGABLE GENOME|CLINICALLY ACTIONABLE|DRUG RESISTANCE|TRANSCRIPTION FACTOR|KINASE|TRANSCRIPTION FACTOR COMPLEX,modulator|cleavage|agonist|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|Clearity Foundation Biomarkers|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|FDA Pharmacogenomic Biomarkers|PharmGKB - The Pharmacogenomics Knowledgebase|Targeted Agents in Lung Cancer (Commentary, 2014)|Cancer Genome Interpreter|Clearity Foundation Clinical Trial|Guide to Pharmacology",True,CHEMBL206,SINGLE PROTEIN,0,0,606,606,1000,True,802,25,0,0,0,TOREMIFENE CITRATE|FULVESTRANT|CLOMIPHENE CITRATE|CLOMIPHENE CITRATE|CLOMIPHENE CITRATE|DIETHYLSTILBESTROL|FULVESTRANT|ETHINYL ESTRADIOL|TAMOXIFEN|DIETHYLSTILBESTROL DIPHOSPHATE,Unknown|Small molecule,Estrogen receptor antagonist|Estrogen receptor agonist|Estrogen receptor alpha degrader|Estrogen receptor modulator|Estrogen receptor alpha modulator|Estrogen receptor alpha agonist,True,False,True,HIGH - Approved drugs exist,Estrogen receptor,Involved in activation of NOS3 and endothelial nitric oxide production (PubMed:21937726). Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full-length receptor (PubMed:10970861). Binds to ERE and inhibits isoform 1 (PubMed:10970861),3D-structure|Activator|Alternative promoter usage|Alternative splicing|Cell membrane|Cytoplasm|Direct protein sequencing|Disease variant|DNA-binding|Glycoprotein|Golgi apparatus|Lipid-binding|Lipoprotein|Membrane|Metal-binding|Methylation|Nucleus|Osteoporosis|Palmitate|Phosphoprotein,Belongs to the nuclear hormone receptor family. NR3 subfamily,PF12743:ESR1_C|PF00104:Hormone_recep|PF02159:Oest_recep|PF00105:zf-C4,4,IPR024178:Est_rcpt/est-rel_rcp|IPR001292:Estr_rcpt|IPR046944:Estr_rcpt_N|IPR035500:NHR-like_dom_sf|IPR000536:Nucl_hrmn_rcpt_lig-bd|IPR050200:Nuclear_hormone_rcpt_NR3|IPR001723:Nuclear_hrmn_rcpt|IPR024736:Oestrogen-typ_rcpt_final_C_dom|IPR001628:Znf_hrmn_rcpt|IPR013088:Znf_NHR/GATA,10,,domain|family|homologous_superfamily,True,Transcription Factor|Nuclear Receptor,HIGH,Nuclear Receptor: Keyword: nuclear hormone receptor|Nuclear Receptor: Keyword: estrogen receptor|Nuclear Receptor: InterPro: IPR001628|Nuclear Receptor: InterPro: IPR000536|Nuclear Receptor: Pfam: PF00104|Nuclear Receptor: Pfam: PF00105|Transcription Factor: Keyword: dna-binding,Transcription Factor,True,475,1A52|1ERE|1ERR|1G50|1GWQ|1GWR|1HCP|1HCQ|1L2I|1PCG,1A52,2.8,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1A52.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1A52.pdb,Moderate (2.5-3.0Å),True,34,1.0,1206.586,0.995,56.281,0.788,True,31,Excellent,High,Optimal volume (1207A3)|High druggability (0.99),,1207|783|430|101|459|402|604|738|281|732|661|743|359|205|696|306|408|309|366|537|430|242|426|267|479|182|189|227|328|467|202|376|539|717,0.99|0.93|0.02|0.00|0.05|0.00|0.01|0.02|0.05|0.02|0.00|0.00|0.02|0.00|0.02|0.01|0.02|0.02|0.00|0.01|0.00|0.01|0.00|0.02,P1:Vol=1207:Drug=0.99|P2:Vol=783:Drug=0.93|P3:Vol=430:Drug=0.02|P4:Vol=101:Drug=0.00|P5:Vol=459:Drug=0.05|P6:Vol=402:Drug=0.00|P7:Vol=604:Drug=0.01|P8:Vol=738:Drug=0.02|P9:Vol=281:Drug=0.00|P10:Vol=732:Drug=0.05
NR3C1,NR3C1,nuclear receptor subfamily 3 group C member 1,"This gene encodes glucocorticoid receptor, which can function both as a transcription factor that binds to glucocorticoid response elements in the promoters of glucocorticoid responsive genes to activate their transcription, and as a regulator of other transcription factors. This receptor is typically found in the cytoplasm, but upon ligand binding, is transported into the nucleus. It is involved in inflammatory responses, cellular proliferation, and differentiation in target tissues. Mutations in this gene are associated with generalized glucocorticoid resistance. Alternative splicing of this gene results in transcript variants encoding either the same or different isoforms. Additional isoforms resulting from the use of alternate in-frame translation initiation sites have also been described, and shown to be functional, displaying diverse cytoplasm-to-nucleus trafficking patterns and distinct transcriptional activities (PMID:15866175). [provided by RefSeq, Feb 2011].",protein-coding,GCCR|GCR|GCRST|GR|GRL,"glucocorticoid receptor|nuclear receptor subfamily 3 group C member 1 variant hGR-B(54)|nuclear receptor subfamily 3 group C member 1 variant hGR-B(77)|nuclear receptor subfamily 3 group C member 1 variant hGR-B(93)|nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",ENSG00000113580,ENST00000231509|ENST00000343796|ENST00000394464|ENST00000394466|ENST00000415690|ENST00000424646|ENST00000502500|ENST00000502892|ENST00000503201|ENST00000503701,ENSP00000231509|ENSP00000343205|ENSP00000377977|ENSP00000377979|ENSP00000387672|ENSP00000405282|ENSP00000420856|ENSP00000422518|ENSP00000424747|ENSP00000425313,P04150,E5KQF6|E5KQF5|F1D8N4|Q3MSN4|A0A494C0P1,GCR_HUMAN,2908.0,NM_000176.3|NM_001018074.1|NM_001018075.1|NM_001018076.2|NM_001018077.1|NM_001020825.2|NM_001024094.2|NM_001204258.2|NM_001204259.2|NM_001204260.2,NP_000167.1|NP_001018084.1|NP_001018085.1|NP_001018086.1|NP_001018087.1|NP_001018661.1|NP_001019265.1|NP_001191187.1|NP_001191188.1|NP_001191189.1,NC_000005.10|NC_060929.1|NG_009062.1,7978.0,138040.0,PA181,9606.ENSP00000231509,1M2Z|1NHZ|1P93|3BQD|3CLD|3E7C|3H52|3K22|3K23|4CSJ|4HN5|4HN6|4LSJ|4MDD|4P6W|4P6X|4UDC|4UDD|5CBX|5CBY,,IPR000536|IPR001409|IPR001628|IPR001723|IPR013088|IPR035500|IPR050200,PF00104|PF00105|PF02155,PS51030|PS51843,5,143277931.0,143435512.0,-1.0,777.0,Cytoplasm|Nucleus|Mitochondrion,9606.0,30960.0,Glucocorticoid receptor,biocarta:carmerpathway|biocarta:gcrpathway|biocarta:hswisnfpathway|biocarta:nthipathway|biocarta:pcafpathway|pid:ap1_pathway|pid:ar_tf_pathway|pid:hdac_classii_pathway|pid:hnf3bpathway|pid:reg_gr_pathway|reactome:R-HSA-212436|reactome:R-HSA-383280|reactome:R-HSA-73857|reactome:R-HSA-74160|smpdb:SMP00441|smpdb:SMP00632|wikipathways:WP170|wikipathways:WP236|wikipathways:WP2817|wikipathways:WP2853|wikipathways:WP2880,True,nuclear receptor subfamily 3 group C member 1,134,88,PREDNISONE|FLUNISOLIDE ANHYDROUS|HYDROCORTAMATE|HE3286|DESOXIMETASONE|POTASSIUM DICHROMATE|MOMETASONE|APIGENIN|MIFEPRISTONE|BECLOMETHASONE|ESTRADIOL VALERATE|CORT 108297|BENZO(K)FLUORANTHENE|OUABAIN OCTAHYDRATE|METHYLPREDNISOLONE|RELACORILANT|CHEMBL:CHEMBL1275761|BAICALEIN|PREDNISOLONE ACETATE|TRIAMCINOLONE,PREDNISONE|FLUNISOLIDE ANHYDROUS|HYDROCORTAMATE|DESOXIMETASONE|MOMETASONE|APIGENIN|MIFEPRISTONE|BECLOMETHASONE|ESTRADIOL VALERATE|METHYLPREDNISOLONE,FLUTICASONE FUROATE|CORT 108297|RELACORILANT|CHEMBL:CHEMBL1275761|CHEMBL:CHEMBL1915270,NUCLEAR HORMONE RECEPTOR|DRUGGABLE GENOME|TRANSCRIPTION FACTOR|ENZYME,modulator|agonist|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|NCI Cancer Gene Index|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL2034,SINGLE PROTEIN,0,0,381,381,1000,True,3561,25,0,0,0,DESONIDE|DESONIDE|PREDNISOLONE|PREDNISOLONE|FLUTICASONE PROPIONATE|FLUTICASONE PROPIONATE|CORTISONE ACETATE|HYDROCORTISONE BUTYRATE|HYDROCORTISONE|HYDROCORTISONE,Small molecule,Glucocorticoid receptor agonist,True,False,True,HIGH - Approved drugs exist,Glucocorticoid receptor,"Has lowest transcriptional activation activity of all isoforms created by alternative initiation (PubMed:15866175, PubMed:23820903). Has transcriptional repression activity (PubMed:23303127)",3D-structure|Acetylation|Alternative initiation|Alternative splicing|Apoptosis|Cell cycle|Cell division|Chromatin regulator|Chromosome|Chromosome partition|Cytoplasm|Cytoskeleton|Disease variant|DNA-binding|Isopeptide bond|Lipid-binding|Metal-binding|Methylation|Mitochondrion|Mitosis,Belongs to the nuclear hormone receptor family. NR3 subfamily,PF02155:GCR|PF00104:Hormone_recep|PF00105:zf-C4,3,IPR001409:Glcrtcd_rcpt|IPR035500:NHR-like_dom_sf|IPR000536:Nucl_hrmn_rcpt_lig-bd|IPR050200:Nuclear_hormone_rcpt_NR3|IPR001723:Nuclear_hrmn_rcpt|IPR001628:Znf_hrmn_rcpt|IPR013088:Znf_NHR/GATA,7,,domain|family|homologous_superfamily,True,Transcription Factor|Nuclear Receptor,HIGH,Nuclear Receptor: Keyword: nuclear hormone receptor|Nuclear Receptor: Keyword: glucocorticoid receptor|Nuclear Receptor: InterPro: IPR001628|Nuclear Receptor: InterPro: IPR000536|Nuclear Receptor: Pfam: PF00104|Nuclear Receptor: Pfam: PF00105|Transcription Factor: Keyword: dna-binding,Transcription Factor,True,58,1M2Z|1NHZ|1P93|3BQD|3CLD|3E7C|3H52|3K22|3K23|4CSJ,1M2Z,2.5,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1M2Z.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1M2Z.pdb,Good (2.0-2.5Å),True,47,1.0,642.999,0.899,58.913,0.894,True,37,Excellent,High,Optimal volume (643A3)|High druggability (0.90),,643|665|903|363|346|843|251|893|435|438|476|90|357|400|133|497|243|260|252|233|176|141|338|187|252|279|215|243|191|212|241|366|205|303|274|219|191|237|286|428|309|321|213|262|273|379|426,0.90|0.83|0.63|0.24|0.01|0.03|0.01|0.02|0.06|0.00|0.00|0.07|0.00|0.00|0.01|0.01|0.02|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00,P1:Vol=643:Drug=0.90|P2:Vol=665:Drug=0.83|P3:Vol=903:Drug=0.63|P4:Vol=363:Drug=0.24|P5:Vol=346:Drug=0.01|P6:Vol=843:Drug=0.03|P7:Vol=251:Drug=0.00|P8:Vol=893:Drug=0.01|P9:Vol=435:Drug=0.02|P10:Vol=438:Drug=0.06
PPARG,PPARG,peroxisome proliferator activated receptor gamma,"This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008].",protein-coding,CIMT1|FPLD3|GLM1|NR1C3|PPARG1|PPARG2|PPARG5|PPARgamma,PPAR-gamma|nuclear receptor subfamily 1 group C member 3|peroxisome proliferator-activated receptor gamma|peroxisome proliferator-activated receptor-gamma 5|peroxisome proliferator-activated receptor-gamma splicing,ENSG00000132170,ENST00000287820|ENST00000309576|ENST00000396999|ENST00000397000|ENST00000397010|ENST00000397015|ENST00000397023|ENST00000397026|ENST00000397029|ENST00000438682,ENSP00000287820|ENSP00000312472|ENSP00000380195|ENSP00000380196|ENSP00000380205|ENSP00000380210|ENSP00000380218|ENSP00000380221|ENSP00000380224|ENSP00000392285,P37231,E9PFV2|A0A494C1F9|E9PFX5|D2KUA6|A0A3P3ZKM0,PPARG_HUMAN,5468.0,NM_001330615.4|NM_001354666.3|NM_001354667.3|NM_001354668.2|NM_001354669.2|NM_001354670.2|NM_001374261.3|NM_001374262.3|NM_001374263.2|NM_001374264.2,NP_001317544.2|NP_001341595.2|NP_001341596.2|NP_001341597.1|NP_001341598.1|NP_001341599.1|NP_001361190.2|NP_001361191.2|NP_001361192.2|NP_001361193.2,NC_000003.12|NC_060927.1|NG_011749.1,9236.0,601487.0,PA281,9606.ENSP00000287820,1FM6|1FM9|1I7I|1K74|1KNU|1NYX|1PRG|1RDT|1WM0|1ZEO|1ZGY|2ATH|2F4B|2FVJ|2G0G|2G0H|2GTK|2HFP|2HWQ|2HWR,,IPR000536|IPR001628|IPR001723|IPR003074|IPR003077|IPR013088|IPR022590|IPR035500|IPR050234,PF00104|PF00105|PF12577,PS51030|PS51843,3,12287368.0,12434574.0,1.0,505.0,Nucleus|Cytoplasm,9606.0,7899.0,Peroxisome proliferator-activated receptor gamma,biocarta:ppargpathway|biocarta:pparpathway|biocarta:vobesitypathway|kegg:hsa03320|kegg:hsa04152|kegg:hsa04211|kegg:hsa04380|kegg:hsa04714|netpath:Pathway_Gastrin|netpath:Pathway_Ghrelin|pid:hdac_classi_pathway|pid:nfat_tfpathway|pid:rb_1pathway|pid:rxr_vdr_pathway|pid:wnt_noncanonical_pathway|reactome:R-HSA-1266738|reactome:R-HSA-212165|reactome:R-HSA-212165|reactome:R-HSA-74160|reactome:R-HSA-74160|wikipathways:WP1541|wikipathways:WP170|wikipathways:WP1982|wikipathways:WP236|wikipathways:WP2456,True,peroxisome proliferator activated receptor gamma,125,31,METHOXYCHLOR|CHEMBL:CHEMBL2208197|PROPYLPYRAZOLETRIOL|LANIFIBRANOR|PROPYLPARABEN|ABIETIC ACID|KEPONE|SPIRONOLACTONE|FLUOXASTROBIN|ROSIGLITAZONE MALEATE|CHEMBL:CHEMBL2178583|NAVEGLITAZAR|CELECOXIB|SHINPTEROCARPIN|PSAMMAPLIN A|TECNAZENE|MYCOPHENOLATE|CHEMBL:CHEMBL1833984|IMIGLITAZAR|ROSIGLITAZONE,PROPYLPARABEN|SPIRONOLACTONE|ROSIGLITAZONE MALEATE|CELECOXIB|MYCOPHENOLATE|ROSIGLITAZONE|PIOGLITAZONE HYDROCHLORIDE|MESALAMINE|BEZAFIBRATE|TROGLITAZONE,CHEMBL:CHEMBL2208197|CHEMBL:CHEMBL2178583|SHINPTEROCARPIN|CHEMBL:CHEMBL1833984|CLX-0921,NUCLEAR HORMONE RECEPTOR|CLINICALLY ACTIONABLE|DRUGGABLE GENOME,modulator|agonist|inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Targeted Agents in Lung Cancer (Commentary, 2014)|Drug Target Commons|The ChEMBL Bioactivity Database|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)",True,CHEMBL235,SINGLE PROTEIN,0,0,520,520,1000,True,369,21,4,0,0,BEZAFIBRATE|ROSIGLITAZONE|ROSIGLITAZONE|TROGLITAZONE|PIOGLITAZONE|PIOGLITAZONE|PIOGLITAZONE|ROSIGLITAZONE MALEATE|PIOGLITAZONE|PIOGLITAZONE,Small molecule,Peroxisome proliferator-activated receptor agonist|Peroxisome proliferator-activated receptor gamma agonist,True,True,True,HIGH - Approved drugs exist,Peroxisome proliferator-activated receptor gamma,"(Microbial infection) Upon treatment with M.tuberculosis or its lipoprotein LpqH, phosphorylation of MAPK p38 and IL-6 production are modulated, probably via this protein",3D-structure|Activator|Alternative splicing|Biological rhythms|Cytoplasm|Diabetes mellitus|Disease variant|DNA-binding|Glycoprotein|Isopeptide bond|Metal-binding|Nucleus|Obesity|Phosphoprotein|Proteomics identification|Receptor|Reference proteome|Transcription|Transcription regulation|Ubl conjugation,Belongs to the nuclear hormone receptor family. NR1 subfamily,PF00104:Hormone_recep|PF12577:PPARgamma_N|PF00105:zf-C4,3,IPR003074:1Cnucl_rcpt|IPR035500:NHR-like_dom_sf|IPR000536:Nucl_hrmn_rcpt_lig-bd|IPR050234:Nuclear_hormone_rcpt_NR1|IPR001723:Nuclear_hrmn_rcpt|IPR003077:PPAR-gamma|IPR022590:PPARgamma_N|IPR001628:Znf_hrmn_rcpt|IPR013088:Znf_NHR/GATA,9,,domain|family|homologous_superfamily,True,Kinase|Transcription Factor|Nuclear Receptor,HIGH,Kinase: Keyword: mapk|Nuclear Receptor: Keyword: nuclear hormone receptor|Nuclear Receptor: Keyword: peroxisome proliferator|Nuclear Receptor: InterPro: IPR001628|Nuclear Receptor: InterPro: IPR000536|Nuclear Receptor: Pfam: PF00104|Nuclear Receptor: Pfam: PF00105|Transcription Factor: Keyword: dna-binding,Kinase,True,368,1FM6|1FM9|1I7I|1K74|1KNU|1NYX|1PRG|1RDT|1WM0|1ZEO,1FM6,2.1,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1FM6.pdb,False,,,,,PDB,protein_structures/pdb_experimental/1FM6.pdb,Good (2.0-2.5Å),True,92,1.0,1098.551,0.998,49.343,0.834,True,73,Excellent,High,Optimal volume (1099A3)|High druggability (1.00),,1099|1951|1454|460|379|236|380|341|130|317|406|307|121|294|210|96|115|209|518|461|176|333|109|250|91|227|204|448|366|573|139|132|191|396|576|363|300|183|411|197|711|333|199|400|201|259|209|382|197|139|478|232|227|197|129|90|226|182|385|159|259|238|254|263|222|302|279|344|248|180|715|609|155|336|222|635|575|716|463|195|167|264|390|514|261|1021|633|1240|1389|687|282|587,1.00|0.76|0.94|0.68|0.07|0.01|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.03|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.03|0.00|0.01,P1:Vol=1099:Drug=1.00|P2:Vol=1951:Drug=0.76|P3:Vol=1454:Drug=0.94|P4:Vol=460:Drug=0.68|P5:Vol=379:Drug=0.07|P6:Vol=236:Drug=0.01|P7:Vol=380:Drug=0.00|P8:Vol=341:Drug=0.00|P9:Vol=130:Drug=0.00|P10:Vol=317:Drug=0.00
THRB,THRB,thyroid hormone receptor beta,"The protein encoded by this gene is a nuclear hormone receptor for triiodothyronine. It is one of the several receptors for thyroid hormone, and has been shown to mediate the biological activities of thyroid hormone. Knockout studies in mice suggest that the different receptors, while having certain extent of redundancy, may mediate different functions of thyroid hormone. Mutations in this gene are known to be a cause of generalized thyroid hormone resistance (GTHR), a syndrome characterized by goiter and high levels of circulating thyroid hormone (T3-T4), with normal or slightly elevated thyroid stimulating hormone (TSH). Several alternatively spliced transcript variants encoding the same protein have been observed for this gene. [provided by RefSeq, Jul 2008].",protein-coding,C-ERBA-2|C-ERBA-BETA|ERBA2|GRTH|NR1A2|PRTH|THR1|THRB1|THRB2|THRbeta|THRbeta1|TRb|TRbeta|TRbeta1|Thrbeta2,"nuclear receptor subfamily 1 group A member 2|oncogene ERBA2|thyroid hormone receptor beta|thyroid hormone receptor, beta (erythroblastic leukemia viral (v-erb-a) oncogene homolog 2, avian)",ENSG00000151090,ENST00000280696|ENST00000356447|ENST00000396671|ENST00000413780|ENST00000416420|ENST00000418247|ENST00000428492|ENST00000431815|ENST00000447414|ENST00000447875,ENSP00000280696|ENSP00000348827|ENSP00000379904|ENSP00000388467|ENSP00000393932|ENSP00000395362|ENSP00000399573|ENSP00000404233|ENSP00000414100|ENSP00000414444,P10828,C9JJM3|A0A024R2I8|J3KR21|A0A2R8YF24|A0A0C4DG57,THB_HUMAN,7068.0,NM_000461.5|NM_001128176.3|NM_001128177.2|NM_001252634.2|NM_001354708.2|NM_001354709.2|NM_001354710.2|NM_001354711.2|NM_001354712.2|NM_001354713.2,NP_000452.2|NP_001121648.1|NP_001121649.1|NP_001239563.1|NP_001341637.1|NP_001341638.1|NP_001341639.1|NP_001341640.1|NP_001341641.1|NP_001341642.1,NC_000003.12|NC_060927.1|NG_009159.1,11799.0,190160.0,PA36508,9606.ENSP00000379904,1BSX|1N46|1NAX|1NQ0|1NQ1|1NQ2|1NUO|1Q4X|1R6G|1XZX|1Y0X|2J4A|2NLL|2PIN|3D57|3GWS|3IMY|3JZC|4ZO1|6KKB,,IPR000536|IPR001628|IPR001723|IPR001728|IPR013088|IPR035500|IPR050234,PF00104|PF00105,PS51030|PS51843,3,24117153.0,24495756.0,-1.0,461.0,Nucleus,9606.0,36025.0,Thyroid hormone receptor beta,kegg:hsa04080|kegg:hsa04919|wikipathways:WP170|wikipathways:WP3915|wikipathways:WP4746|wikipathways:WP706,True,thyroid hormone receptor beta,102,26,METHYL PARATHIONE|DIENOCHLOR|AXITIROME|3-METHYLCHOLANTHRENE|CHEMBL:CHEMBL577415|DYCLONINE HYDROCHLORIDE|LEVOTHYROXINE|ORTHO-PHTHALALDEHYDE|QUINALIZARIN|CHEMBL:CHEMBL297304|CHEMBL:CHEMBL1493528|RESMETIROM|CLOSANTEL|IDARUBICIN|FUMARPROTOCETRARIC ACID|DIPYRIDAMOLE|CHEMBL:CHEMBL1341830|CARUBICIN|ALBUTEROL SULFATE|PRIMAQUINE,DYCLONINE HYDROCHLORIDE|LEVOTHYROXINE|RESMETIROM|IDARUBICIN|DIPYRIDAMOLE|ALBUTEROL SULFATE|PRIMAQUINE|DEXTROTHYROXINE SODIUM|METHYLENE BLUE ANHYDROUS|HEXACHLOROPHENE,"AXITIROME|RESMETIROM|EPROTIROME|AMMONIA SOLUTION, STRONG|MB07811",NUCLEAR HORMONE RECEPTOR|DRUGGABLE GENOME,agonist|inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Guide to Pharmacology|Drug Target Commons|Therapeutic Target Database|The ChEMBL Bioactivity Database|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)",True,CHEMBL3917,SINGLE PROTEIN,0,0,104,104,299,True,81,14,11,0,0,DEXTROTHYROXINE|LEVOTHYROXINE SODIUM|LEVOTHYROXINE SODIUM|LIOTHYRONINE SODIUM|LEVOTHYROXINE SODIUM|LEVOTHYROXINE SODIUM|LEVOTHYROXINE SODIUM|LEVOTHYROXINE SODIUM|LIOTHYRONINE SODIUM|LIOTHYRONINE SODIUM,Small molecule,Thyroid hormone receptor agonist|Thyroid hormone receptor beta-1 agonist,True,True,True,HIGH - Approved drugs exist,Thyroid hormone receptor beta,"Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine",3D-structure|Alternative splicing|Deafness|Disease variant|DNA-binding|Metal-binding|Nucleus|Proteomics identification|Receptor|Reference proteome|Transcription|Transcription regulation|Zinc|Zinc-finger,Belongs to the nuclear hormone receptor family. NR1 subfamily,PF00104:Hormone_recep|PF00105:zf-C4,2,IPR035500:NHR-like_dom_sf|IPR000536:Nucl_hrmn_rcpt_lig-bd|IPR050234:Nuclear_hormone_rcpt_NR1|IPR001723:Nuclear_hrmn_rcpt|IPR001728:ThyrH_rcpt|IPR001628:Znf_hrmn_rcpt|IPR013088:Znf_NHR/GATA,7,,domain|family|homologous_superfamily,True,Histone Acetyltransferase|Transcription Factor|Nuclear Receptor,HIGH,Nuclear Receptor: Keyword: nuclear hormone receptor|Nuclear Receptor: Keyword: thyroid hormone receptor|Nuclear Receptor: InterPro: IPR001628|Nuclear Receptor: InterPro: IPR000536|Nuclear Receptor: Pfam: PF00104|Nuclear Receptor: Pfam: PF00105|Histone Acetyltransferase: Keyword: hat|Transcription Factor: Keyword: dna-binding,Histone Acetyltransferase,True,34,1BSX|1N46|1NAX|1NQ0|1NQ1|1NQ2|1NUO|1Q4X|1R6G|1XZX,1BSX,3.7,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1BSX.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1BSX.pdb,Low (>3.7Å),True,29,1.0,734.147,0.977,47.75,1.07,True,29,Excellent,High,Optimal volume (734A3)|High druggability (0.98),,734|729|500|241|237|287|290|639|260|193|505|285|348|446|255|471|633|463|276|194|457|229|255|228|259|340|227|194|198,0.98|0.97|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00,P1:Vol=734:Drug=0.98|P2:Vol=729:Drug=0.97|P3:Vol=500:Drug=0.01|P4:Vol=241:Drug=0.00|P5:Vol=237:Drug=0.00|P6:Vol=287:Drug=0.00|P7:Vol=290:Drug=0.00|P8:Vol=639:Drug=0.00|P9:Vol=260:Drug=0.00|P10:Vol=193:Drug=0.00
NR1I2,NR1I2,nuclear receptor subfamily 1 group I member 2,"This gene product belongs to the nuclear receptor superfamily, members of which are transcription factors characterized by a ligand-binding domain and a DNA-binding domain. The encoded protein is a transcriptional regulator of the cytochrome P450 gene CYP3A4, binding to the response element of the CYP3A4 promoter as a heterodimer with the 9-cis retinoic acid receptor RXR. It is activated by a range of compounds that induce CYP3A4, including dexamethasone and rifampicin. Several alternatively spliced transcripts encoding different isoforms, some of which use non-AUG (CUG) translation initiation codon, have been described for this gene. Additional transcript variants exist, however, they have not been fully characterized. [provided by RefSeq, Jul 2008].",protein-coding,BXR|ONR1|PAR|PAR1|PAR2|PARq|PRR|PXR|SAR|SXR,nuclear receptor subfamily 1 group I member 2|orphan nuclear receptor PAR1|orphan nuclear receptor PXR|pregnane X receptor|steroid and xenobiotic receptor,ENSG00000144852,ENST00000337940|ENST00000393716|ENST00000466380|ENST00000474090|ENST00000493757,ENSP00000336528|ENSP00000377319|ENSP00000420297,O75469,F1D8P9,NR1I2_HUMAN,8856.0,NM_003889.4|NM_022002.3|NM_033013.3,NP_003880.3|NP_071285.1|NP_148934.1,NC_000003.12|NC_060927.1|NG_011856.2,7968.0,603065.0,PA378,9606.ENSP00000336528,1ILG|1ILH|1M13|1NRL|1SKX|2O9I|2QNV|3CTB|3HVL|3R8D|4J5W|4J5X|4NY9|4S0S|4S0T|4X1F|4X1G|4XAO|4XHD|5A86,,IPR000536|IPR001628|IPR001723|IPR013088|IPR035500|IPR050234|IPR001728,PF00104|PF00105,PS51030|PS51843,3,119780484.0,119818487.0,1.0,434.0,Nucleus,9606.0,40757.0,Pregnane X receptor,reactome:R-HSA-212436|reactome:R-HSA-2990846|reactome:R-HSA-3108232|reactome:R-HSA-383280|reactome:R-HSA-392499|wikipathways:WP170|wikipathways:WP2289|wikipathways:WP2876|wikipathways:WP2880|wikipathways:WP2882,True,nuclear receptor subfamily 1 group I member 2,113,94,PAZOPANIB|BUDESONIDE|VORICONAZOLE|MINOCYCLINE|CARBOPLATIN|ADALIMUMAB|ISRADIPINE|RIFAPENTINE|CHLORPROMAZINE|ECONAZOLE NITRATE|METHADONE HYDROCHLORIDE|ATORVASTATIN CALCIUM TRIHYDRATE|CHENODEOXYCHOLIC ACID|TOPIRAMATE|CONICASTEROL E|RIFAXIMIN|SUNITINIB|MICONAZOLE NITRATE|FLUVASTATIN|NAVTEMADLIN,PAZOPANIB|BUDESONIDE|VORICONAZOLE|MINOCYCLINE|CARBOPLATIN|ADALIMUMAB|ISRADIPINE|RIFAPENTINE|CHLORPROMAZINE|ECONAZOLE NITRATE,RIFAXIMIN|SOLOMONSTEROL A|MENATETRENONE|SOLOMONSTEROL B|THEONELLASTEROL H,NUCLEAR HORMONE RECEPTOR|DRUGGABLE GENOME|TRANSCRIPTION FACTOR|TRANSCRIPTION FACTOR COMPLEX,,PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons,True,CHEMBL1743244,SINGLE PROTEIN,0,0,10,10,15,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Nuclear receptor subfamily 1 group I member 2,"Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and isoflavones. Response to specific ligands is species-specific. Activated by naturally occurring steroids, such as pregnenolone and progesterone. Binds to a response element in the promoters of the CYP3A4 and ABCB1/MDR1 genes",3D-structure|Activator|Alternative splicing|DNA-binding|Metal-binding|Nucleus|Proteomics identification|Receptor|Reference proteome|Transcription|Transcription regulation|Zinc|Zinc-finger,Belongs to the nuclear hormone receptor family. NR1 subfamily,PF00104:Hormone_recep|PF00105:zf-C4,2,IPR035500:NHR-like_dom_sf|IPR000536:Nucl_hrmn_rcpt_lig-bd|IPR050234:Nuclear_hormone_rcpt_NR1|IPR001723:Nuclear_hrmn_rcpt|IPR001628:Znf_hrmn_rcpt|IPR013088:Znf_NHR/GATA,6,,domain|family|homologous_superfamily,True,Histone Acetyltransferase|Transcription Factor|Nuclear Receptor,HIGH,Nuclear Receptor: Keyword: nuclear receptor|Nuclear Receptor: Keyword: nuclear hormone receptor|Nuclear Receptor: InterPro: IPR001628|Nuclear Receptor: InterPro: IPR000536|Nuclear Receptor: Pfam: PF00104|Nuclear Receptor: Pfam: PF00105|Histone Acetyltransferase: Keyword: hat|Transcription Factor: Keyword: transcription factor|Transcription Factor: Keyword: dna-binding,Histone Acetyltransferase,True,80,1ILG|1ILH|1M13|1NRL|1SKX|2O9I|2QNV|3CTB|3HVL|3R8D,1ILG,2.52,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1ILG.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1ILG.pdb,Moderate (2.5-3.0Å),True,22,1.0,1115.482,0.874,60.387,0.215,True,20,Good,Medium,Optimal volume (1115A3)|High druggability (0.87),,1115|556|305|507|332|286|331|325|442|361|151|343|460|430|444|1076|233|406|300|307|491|798,0.87|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.25|0.04,P1:Vol=1115:Drug=0.87|P2:Vol=556:Drug=0.00|P3:Vol=305:Drug=0.00|P4:Vol=507:Drug=0.00|P5:Vol=332:Drug=0.00|P6:Vol=286:Drug=0.00|P7:Vol=331:Drug=0.00|P8:Vol=325:Drug=0.00|P9:Vol=442:Drug=0.00|P10:Vol=361:Drug=0.00
ACE,ACE,angiotensin I converting enzyme,"This gene encodes an enzyme involved in blood pressure regulation and electrolyte balance. It catalyzes the conversion of angiotensin I into a physiologically active peptide angiotensin II. Angiotensin II is a potent vasopressor and aldosterone-stimulating peptide that controls blood pressure and fluid-electrolyte balance. This angiotensin converting enzyme (ACE) also inactivates the vasodilator protein, bradykinin. Accordingly, the encoded enzyme increases blood pressure and is a drug target of ACE inhibitors, which are often prescribed to reduce blood pressure. This enzyme additionally plays a role in fertility through its ability to cleave and release GPI-anchored membrane proteins in spermatozoa. Many studies have associated the presence or absence of a 287 bp Alu repeat element in this gene with the levels of circulating enzyme. This polymorphism, as well as mutations in this gene, have been implicated in a wide variety of diseases including cardiovascular pathophysiologies, psoriasis, renal disease, stroke, and Alzheimer's disease. Regulation of the homologous ACE2 gene may be involved in progression of disease caused by several human coronaviruses, including SARS-CoV and SARS-CoV-2. Alternative splicing results in multiple transcript variants encoding both somatic (sACE) and male-specific testicular (tACE) isoforms. [provided by RefSeq, Sep 2020].",protein-coding,ACE1|CD143|DCP|DCP1,CD143 antigen|angiotensin I converting enzyme (peptidyl-dipeptidase A) 1|angiotensin-converting enzyme|carboxycathepsin|dipeptidyl carboxypeptidase 1,ENSG00000159640,ENST00000290863|ENST00000290866|ENST00000413513|ENST00000428043|ENST00000577418|ENST00000578679|ENST00000578839|ENST00000579204|ENST00000579314|ENST00000579462,ENSP00000290863|ENSP00000290866|ENSP00000392247|ENSP00000397593|ENSP00000462002|ENSP00000462110|ENSP00000462280|ENSP00000462599|ENSP00000462909|ENSP00000462995,P12821,J3QSC7|B4DKH4|J3KRH5|A0A0A0MSN4|J3KTH9,ACE_HUMAN,1636.0,NM_000789.4|NM_001178057.2|NM_001382700.1|NM_001382701.1|NM_001382702.1|NM_152830.3|NM_152831.1|NR_168483.1|XM_006721737.4|XM_054315297.1,NP_000780.1|NP_001171528.1|NP_001369629.1|NP_001369630.1|NP_001369631.1|NP_690043.1|XP_006721800.3|XP_054171272.1,NC_000017.11|NC_060941.1|NG_011648.1,2707.0,106180.0,PA139,9606.ENSP00000290866,1O86|1O8A|1UZE|1UZF|2C6F|2C6N|2IUL|2IUX|2OC2|2XY9|2XYD|2YDM|3BKK|3BKL|3L3N|3NXQ|4APH|4APJ|4BXK|4BZR,3.4.15.1,IPR001548,PF01401,PS52011,17,63477058.0,63498380.0,1.0,1306.0,Cell membrane|Cytoplasm,9606.0,37351.0,Angiotensin-converting enzyme,kegg:hsa04614|kegg:hsa04924|kegg:hsa05142|kegg:hsa05171|kegg:hsa05410|reactome:R-HSA-2022377|reactome:R-HSA-2980736|reactome:R-HSA-392499|smpdb:SMP00145|smpdb:SMP00146|smpdb:SMP00147|smpdb:SMP00148|smpdb:SMP00149|wikipathways:WP4756|wikipathways:WP4818|wikipathways:WP4883|wikipathways:WP4969|wikipathways:WP554,True,angiotensin I converting enzyme,59,42,SALVIANOLIC ACID B|CANDOXATRIL|CILAZAPRIL|TP0556351|PRAVASTATIN SODIUM|SILDENAFIL|GEMFIBROZIL|RESCINNAMINE|SPIRAPRIL|INDOMETHACIN|HYDROCHLOROTHIAZIDE|ARGIPRESSIN|METOPROLOL|DELAPRIL|ACETYLCHOLINE|THERAPEUTIC GLUCOCORTICOID|IMIDAPRIL|MALATHION|MOEXIPRIL|VORINOSTAT,CANDOXATRIL|CILAZAPRIL|PRAVASTATIN SODIUM|SILDENAFIL|GEMFIBROZIL|RESCINNAMINE|SPIRAPRIL|INDOMETHACIN|HYDROCHLOROTHIAZIDE|ARGIPRESSIN,CILAZAPRIL|CAPTOPRIL|DELAPRIL|SPIRAPRIL|MOEXIPRIL,DRUGGABLE GENOME|PROTEASE|ENZYME|EXTERNAL SIDE OF PLASMA MEMBRANE|NEUTRAL ZINC METALLOPEPTIDASE,inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|Drug Target Commons|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Guide to Pharmacology|NCI Cancer Gene Index|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL3341583,SINGLE PROTEIN,0,0,9,9,9,True,274,25,0,0,0,TRANDOLAPRIL|LISINOPRIL|SPIRAPRIL|CILAZAPRIL|MOEXIPRIL|RAMIPRIL|RAMIPRIL|CAPTOPRIL|PERINDOPRIL|QUINAPRIL,Small molecule,Angiotensin-converting enzyme inhibitor,True,False,True,HIGH - Approved drugs exist,Angiotensin-converting enzyme,"Isoform produced by alternative promoter usage that is specifically expressed in spermatocytes and adult testis, and which is required for male fertility (PubMed:1651327, PubMed:1668266). In contrast to somatic isoforms, only contains one catalytic domain (PubMed:1651327, PubMed:1668266). Acts as a dipeptidyl carboxypeptidase that removes dipeptides from the C-terminus of substrates (PubMed:1668266, PubMed:24297181). The identity of substrates that are needed for male fertility is unknown (By similarity). May also have a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. The GPIase activity was reported to be essential for the egg-binding ability of the sperm (By similarity). This activity is however unclear and has been challenged by other groups, suggesting that it may be indirect (By similarity)",3D-structure|Alternative promoter usage|Alternative splicing|Calmodulin-binding|Carboxypeptidase|Cell membrane|Cytoplasm|Direct protein sequencing|Disulfide bond|Glycoprotein|Hydrolase|Membrane|Metal-binding|Metalloprotease|Phosphoprotein|Protease|Proteomics identification|Reference proteome|Repeat|Secreted,Belongs to the peptidase M2 family,PF01401:Peptidase_M2,1,IPR001548:Peptidase_M2,1,,family,True,Histone Acetyltransferase|Protease|Hydrolase,HIGH,Protease: Keyword: protease|Protease: Keyword: peptidase|Protease: Keyword: metalloprotease|Histone Acetyltransferase: Keyword: hat|Hydrolase: Keyword: hydrolase|Hydrolase: Keyword: glycosidase,Histone Acetyltransferase,True,92,1O86|1O8A|1UZE|1UZF|2C6F|2C6N|2IUL|2IUX|2OC2|2XY9,1O86,2.0,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1O86.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1O86.pdb,Excellent (<2.0Å),True,29,1.0,6068.781,0.588,22.319,3.804,True,23,Good,Medium,Optimal volume (6069A3),,6069|379|290|419|326|415|220|209|374|471|538|450|262|524|333|238|474|579|248|218|187|489|752|221|172|321|295|216|557,0.59|0.00|0.00|0.01|0.00|0.01|0.05|0.21|0.01|0.02|0.00|0.00|0.00|0.00|0.01|0.01|0.00|0.06|0.00,P1:Vol=6069:Drug=0.59|P2:Vol=379:Drug=0.00|P3:Vol=290:Drug=0.00|P4:Vol=419:Drug=0.00|P5:Vol=326:Drug=0.00|P6:Vol=415:Drug=0.01|P7:Vol=220:Drug=0.00|P8:Vol=209:Drug=0.00|P9:Vol=374:Drug=0.00|P10:Vol=471:Drug=0.01
HMGCR,HMGCR,3-hydroxy-3-methylglutaryl-CoA reductase,"HMG-CoA reductase is the rate-limiting enzyme for cholesterol synthesis and is regulated via a negative feedback mechanism mediated by sterols and non-sterol metabolites derived from mevalonate, the product of the reaction catalyzed by reductase. Normally in mammalian cells this enzyme is suppressed by cholesterol derived from the internalization and degradation of low density lipoprotein (LDL) via the LDL receptor. Competitive inhibitors of the reductase induce the expression of LDL receptors in the liver, which in turn increases the catabolism of plasma LDL and lowers the plasma concentration of cholesterol, an important determinant of atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2008].",protein-coding,LDLCQ3|LGMDR28|MYPLG,3-hydroxy-3-methylglutaryl CoA reductase (NADPH)|3-hydroxy-3-methylglutaryl-Coenzyme A reductase|HMG-CoA reductase|hydroxymethylglutaryl-CoA reductase,ENSG00000113161,ENST00000287936|ENST00000343975|ENST00000442032|ENST00000504466|ENST00000508070|ENST00000509085|ENST00000509431|ENST00000511206|ENST00000511986|ENST00000512053,ENSP00000287936|ENSP00000340816|ENSP00000409100|ENSP00000420871|ENSP00000421378|ENSP00000426745|ENSP00000505315|ENSP00000505561|ENSP00000505805|ENSP00000506232,P04035,H0Y8K6|A0A7P0TBP1|C9JKX7|H0Y8F6|A0A7P0Z481,HMDH_HUMAN,3156.0,NM_000859.3|NM_001130996.2|NM_001364187.1|XM_011543357.2|XM_011543358.2|XM_011543359.2|XM_054352484.1|XM_054352485.1|XM_054352486.1,NP_000850.1|NP_001124468.1|NP_001351116.1|XP_011541659.1|XP_011541660.1|XP_011541661.1|XP_054208459.1|XP_054208460.1|XP_054208461.1,NC_000005.10|NC_060929.1|NG_011449.1,5006.0,142910.0,PA189,9606.ENSP00000287936,1DQ8|1DQ9|1DQA|1HW8|1HW9|1HWI|1HWJ|1HWK|1HWL|2Q1L|2Q6B|2Q6C|2R4F|3BGL|3CCT|3CCW|3CCZ|3CD0|3CD5|3CD7,1.1.1.34,IPR000731|IPR002202|IPR004554|IPR004816|IPR009023|IPR009029|IPR023074|IPR023076|IPR023282|IPR053958,PF00368|PF12349,PS50065|PS50156,5,75336329.0,75364241.0,1.0,888.0,Endoplasmic reticulum membrane|Peroxisome membrane,9606.0,30994.0,HMG-CoA reductase,humancyc:PWY-5910|humancyc:PWY-922|humancyc:PWY66-5|kegg:hsa00900|kegg:hsa04152|kegg:hsa04976|reactome:R-HSA-1430728|reactome:R-HSA-1655829|reactome:R-HSA-191273|reactome:R-HSA-1989781|reactome:R-HSA-2426168|smpdb:SMP00023|smpdb:SMP00079|smpdb:SMP00082|smpdb:SMP00089|smpdb:SMP00092|wikipathways:WP1403|wikipathways:WP1471|wikipathways:WP197|wikipathways:WP1982|wikipathways:WP1984,True,3-hydroxy-3-methylglutaryl-CoA reductase,18,14,LOVASTATIN|SIMVASTATIN|ROSUVASTATIN|ATORVASTATIN CALCIUM TRIHYDRATE|FLUVASTATIN|PRAVASTATIN SODIUM|CERIVASTATIN SODIUM|PITAVASTATIN CALCIUM|PITAVASTATIN|TOCOTRIENOLS|CRILVASTATIN|ASPIRIN|PITAVASTATIN MAGNESIUM|PITAVASTATIN SODIUM|CERIVASTATIN|LAROPIPRANT|TERIFLUNOMIDE|HMG-COA REDUCTASE INHIBITOR,LOVASTATIN|SIMVASTATIN|ROSUVASTATIN|ATORVASTATIN CALCIUM TRIHYDRATE|FLUVASTATIN|PRAVASTATIN SODIUM|CERIVASTATIN SODIUM|PITAVASTATIN CALCIUM|PITAVASTATIN|ASPIRIN,PITAVASTATIN CALCIUM|TOCOTRIENOLS|CRILVASTATIN|PITAVASTATIN MAGNESIUM|PITAVASTATIN SODIUM,DRUGGABLE GENOME|ENZYME,inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Clearity Foundation Clinical Trial|Drug Target Commons|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL402,SINGLE PROTEIN,0,0,615,615,1000,True,787,25,0,0,0,PRAVASTATIN|CERIVASTATIN|ATORVASTATIN|ATORVASTATIN|ATORVASTATIN|ROSUVASTATIN|ROSUVASTATIN|ROSUVASTATIN|PRAVASTATIN SODIUM|SIMVASTATIN,Small molecule,HMG-CoA reductase inhibitor,True,False,True,HIGH - Approved drugs exist,3-hydroxy-3-methylglutaryl-coenzyme A reductase,"Catalyzes the conversion of (3S)-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonic acid, the rate-limiting step in the synthesis of cholesterol and other isoprenoids, thus plays a critical role in cellular cholesterol homeostasis (PubMed:21357570, PubMed:2991281, PubMed:36745799, PubMed:6995544). HMGCR is the main target of statins, a class of cholesterol-lowering drugs (PubMed:11349148, PubMed:18540668, PubMed:36745799)",3D-structure|Alternative splicing|Cholesterol biosynthesis|Cholesterol metabolism|Disease variant|Endoplasmic reticulum|Glycoprotein|Isopeptide bond|Limb-girdle muscular dystrophy|Lipid biosynthesis|Lipid metabolism|Membrane|NADP|Oxidoreductase|Peroxisome|Phosphoprotein|Proteomics identification|Reference proteome|Steroid biosynthesis|Steroid metabolism,Belongs to the HMG-CoA reductase family,PF00368:HMG-CoA_red|PF12349:Sterol-sensing,2,IPR002202:HMG_CoA_Rdtase|IPR023074:HMG_CoA_Rdtase_cat_sf|IPR023076:HMG_CoA_Rdtase_CS|IPR004554:HMG_CoA_Rdtase_eu_arc|IPR004816:HMG_CoA_Rdtase_metazoan|IPR023282:HMG_CoA_Rdtase_N|IPR009023:HMG_CoA_Rdtase_NAD(P)-bd_sf|IPR009029:HMG_CoA_Rdtase_sub-bd_dom_sf|IPR053958:HMGCR/SNAP/NPC1-like_SSD|IPR000731:SSD,10,,domain|family|conserved_site|homologous_superfamily,True,Oxidoreductase,MEDIUM,Oxidoreductase: Keyword: oxidoreductase|Oxidoreductase: Keyword: reductase,Oxidoreductase,True,24,1DQ8|1DQ9|1DQA|1HW8|1HW9|1HWI|1HWJ|1HWK|1HWL|2Q1L,1DQ8,2.1,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1DQ8.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1DQ8.pdb,Good (2.0-2.5Å),True,106,1.0,2803.42,0.972,12.033,1.206,True,88,Excellent,High,Optimal volume (2803A3)|High druggability (0.97),,2803|1913|2151|1080|765|1118|572|244|250|301|337|219|427|1671|572|401|1275|442|322|234|267|298|188|412|217|270|269|290|343|359|313|357|197|344|306|294|369|199|316|432|220|265|151|250|132|226|150|205|195|291|265|158|160|277|158|187|284|239|390|237|425|416|398|264|297|531|287|254|404|273|306|400|229|231|611|209|294|492|338|291|186|407|285|241|188|363|168|414|244|156|300|241|170|530|477|595|416|244|448|206|618|463|1191|934|625|458,0.97|0.96|0.34|0.49|0.92|0.73|0.07|0.03|0.45|0.00|0.00|0.00|0.61|0.00|0.07|0.01|0.00|0.00|0.00|0.03|0.02|0.02|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.03|0.00|0.00|0.12|0.00|0.00|0.01|0.00|0.00|0.03|0.00|0.01|0.00|0.08|0.00|0.00|0.00|0.00|0.01|0.00|0.01|0.00|0.00|0.00|0.14|0.11|0.00|0.00|0.00|0.00|0.00|0.00|0.36|0.00|0.00|0.04|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.02|0.00,P1:Vol=2803:Drug=0.97|P2:Vol=1913:Drug=0.96|P3:Vol=2151:Drug=0.34|P4:Vol=1080:Drug=0.49|P5:Vol=765:Drug=0.92|P6:Vol=1118:Drug=0.73|P7:Vol=572:Drug=0.00|P8:Vol=244:Drug=0.07|P9:Vol=250:Drug=0.03|P10:Vol=301:Drug=0.45
CYP2D6,LOC107987479,cytochrome P450 2D6,,protein-coding,CYP2D6,cytochrome P450 2D6|cytochrome P4502D6,,,,P10635,Q38LG2,CP2D6_HUMAN,107987479.0,XM_017030331.2,XP_016885820.1,NW_014040931.1,,,,9606.ENSP00000496150,2F9Q|3QM4|3TBG|3TDA|4WNT|4WNU|4WNV|4WNW|4XRY|4XRZ|5TFT|5TFU|6CSB|6CSD,,,,,,,,,497.0,Endoplasmic reticulum membrane|Microsome membrane,9606.0,,,kegg:hsa00980|kegg:hsa00982|kegg:hsa04726,True,cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene),594,328,"CHEMBL:CHEMBL244707|TROLEANDOMYCIN|HYCANTHONE|DEXTROAMPHETAMINE SULFATE|PSEUDOEPHEDRINE|ZOXAZOLAMINE|YOHIMBINE|CIPROFLOXACIN|PALIPERIDONE|COLCHICINE|REMOXIPRIDE|L-733,060|GUAIFENESIN|DYCLONINE|DEXPROPRANOLOL|TERAZOSIN|E324|PROTRIPTYLINE|TRIFLUOPERAZINE|MECLIZINE",TROLEANDOMYCIN|DEXTROAMPHETAMINE SULFATE|PSEUDOEPHEDRINE|YOHIMBINE|CIPROFLOXACIN|PALIPERIDONE|COLCHICINE|REMOXIPRIDE|GUAIFENESIN|DYCLONINE,SPARTEINE|ETHYLMORPHINE|ELIGLUSTAT|SOLANIDINE|MEPHEDRONE,DRUGGABLE GENOME|CYTOCHROME P450|ENZYME|CLINICALLY ACTIONABLE,,Drug Target Commons|FDA Pharmacogenomic Biomarkers|PharmGKB - The Pharmacogenomics Knowledgebase|NCI Cancer Gene Index|Therapeutic Target Database,True,CHEMBL289,SINGLE PROTEIN,0,0,834,834,1000,False,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Cytochrome P450 2D6,"A cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroids and retinoids (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:19965576, PubMed:20972997). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE-EA) and 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:18698000, PubMed:21289075). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Catalyzes the oxidative transformations of all-trans retinol to all-trans retinal, a precursor for the active form all-trans-retinoic acid (PubMed:10681376). Also involved in the oxidative metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants",3D-structure|Alternative splicing|Cholesterol metabolism|Endoplasmic reticulum|Fatty acid metabolism|Heme|Iron|Lipid metabolism|Membrane|Metal-binding|Microsome|Monooxygenase|Oxidoreductase|Proteomics identification|Reference proteome|Steroid metabolism|Sterol metabolism,Belongs to the cytochrome P450 family,PF00067:p450,1,IPR001128:Cyt_P450|IPR017972:Cyt_P450_CS|IPR002401:Cyt_P450_E_grp-I|IPR008069:Cyt_P450_E_grp-I_CYP2D-like|IPR036396:Cyt_P450_sf|IPR050182:Cytochrome_P450_fam2,6,,conserved_site|family|homologous_superfamily,True,Oxidoreductase,HIGH,Oxidoreductase: Keyword: oxidoreductase|Oxidoreductase: Keyword: reductase|Oxidoreductase: Keyword: monooxygenase,Oxidoreductase,True,14,2F9Q|3QM4|3TBG|3TDA|4WNT|4WNU|4WNV|4WNW|4XRY|4XRZ,2F9Q,3.002,X-RAY DIFFRACTION,protein_structures/pdb_experimental/2F9Q.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/2F9Q.pdb,Low (>3.0Å),True,134,30.0,1066.524,0.99,37.788,0.99,True,116,Excellent,High,Optimal volume (1067A3)|High druggability (0.99),,118|102|99|104|102|92|1076|272|84|304|91|369|203|96|461|342|230|1050|104|267|234|2399|387|362|183|1108|187|272|252|1067|910|234|484|868|221|341|202|214|371|353|995|191|256|232|232|172|486|302|201|282|219|366|234|303|356|175|343|198|424|186|458|218|441|325|533|644|167|1669|207|241|220|206|260|152|3228|389|328|343|180|199|386|149|281|399|225|205|315|279|211|268|243|231|509|209|235|272|187|526|385|832|690|389|235|791|325|283|352|281|642|678|472|435|536|186|516|618|349|340|603|390|405|701|770|506|528|416|554|1410|738|934|287|1003|3029|1010,0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.04|0.00|0.00|0.99|0.00|0.30|0.01|0.00|0.99|0.01|0.99|0.45|0.00|0.00|0.02|0.00|0.00|0.03|0.97|0.00|0.00|0.02|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.01|0.03|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.19|0.00|0.00|0.01|0.00|0.02|0.00|0.01|0.00|0.01|0.00|0.00|0.04|0.03|0.00|0.00|0.00|0.12|0.02|0.05|0.01,P1:Vol=118:Drug=0.00|P2:Vol=102:Drug=0.00|P3:Vol=99:Drug=0.00|P4:Vol=104:Drug=0.00|P5:Vol=102:Drug=0.00|P6:Vol=92:Drug=0.00|P7:Vol=1076:Drug=0.01|P8:Vol=272:Drug=0.00|P9:Vol=84:Drug=0.00|P10:Vol=304:Drug=0.00
PTGS2,PTGS2,prostaglandin-endoperoxide synthase 2,"Prostaglandin-endoperoxide synthase (PTGS), also known as cyclooxygenase, is the key enzyme in prostaglandin biosynthesis, and acts both as a dioxygenase and as a peroxidase. There are two isozymes of PTGS: a constitutive PTGS1 and an inducible PTGS2, which differ in their regulation of expression and tissue distribution. This gene encodes the inducible isozyme. It is regulated by specific stimulatory events, suggesting that it is responsible for the prostanoid biosynthesis involved in inflammation and mitogenesis. [provided by RefSeq, Feb 2009].",protein-coding,COX-2|COX2|GRIPGHS|PGG/HS|PGHS-2|PHS-2|hCox-2,PGH synthase 2|PHS II|cyclooxygenase 2|cyclooxygenase 2b|prostaglandin G/H synthase 2,ENSG00000073756,ENST00000367468|ENST00000466691|ENST00000490885|ENST00000559627|ENST00000680451|ENST00000681605,ENSP00000356438|ENSP00000454130|ENSP00000504900|ENSP00000506242,P35354,A0A7P0T828|Q6ZYK7,PGH2_HUMAN,5743.0,NM_000963.4,NP_000954.1,NC_000001.11|NC_060925.1|NG_028206.2,9605.0,600262.0,PA293,9606.ENSP00000356438,5F19|5F1A|5IKQ|5IKR|5IKT|5IKV|5KIR,1.14.99.1,IPR000742|IPR010255|IPR019791|IPR037120|IPR050783,PF03098,PS50026|PS50292,1,186671791.0,186680922.0,-1.0,604.0,Microsome membrane|Endoplasmic reticulum membrane|Nucleus inner membrane,9606.0,31000.0,Prostaglandin-endoperoxide synthase 2,humancyc:PWY66-374|humancyc:PWY66-393|humancyc:PWY66-394|humancyc:PWY66-395|kegg:hsa00590|kegg:hsa04064|kegg:hsa04370|kegg:hsa04625|kegg:hsa04657|pid:cmyb_pathway|pid:nfat_tfpathway|pid:p38alphabetadownstreampathway|pid:s1p_s1p1_pathway|pid:tcrcalciumpathway|reactome:R-HSA-1280215|reactome:R-HSA-1430728|reactome:R-HSA-168256|reactome:R-HSA-2142753|reactome:R-HSA-2142770|smpdb:SMP00075|smpdb:SMP00077|smpdb:SMP00083|smpdb:SMP00084|smpdb:SMP00085|wikipathways:WP15|wikipathways:WP167|wikipathways:WP2431|wikipathways:WP2586|wikipathways:WP2880,True,prostaglandin-endoperoxide synthase 2,117,82,"CARPROFEN|INDOMETHACIN SODIUM|DARBUFELONE|MEFENAMIC ACID|MECLOFENAMATE SODIUM|DICLOFENAC SODIUM|CAPECITABINE|PIRPROFEN|ESFLURBIPROFEN|SULFASALAZINE|BROMFENAC|IBUPROFEN, SODIUM SALT|ALOXIPRIN|TENOXICAM|FLURBIPROFEN|SALICYLIC ACID|ATENOLOL|DEXKETOPROFEN|ETORICOXIB|LUMIRACOXIB",CARPROFEN|INDOMETHACIN SODIUM|MEFENAMIC ACID|MECLOFENAMATE SODIUM|DICLOFENAC SODIUM|CAPECITABINE|PIRPROFEN|ESFLURBIPROFEN|SULFASALAZINE|BROMFENAC,ETORICOXIB|CIMICOXIB|CARPROFEN|APRICOXIB|(R)-IBUPROPHEN,ENZYME|DRUGGABLE GENOME,inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|NCI Cancer Gene Index|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|PharmGKB - The Pharmacogenomics Knowledgebase|MyCancerGenome Clinical Trial|Drug Target Commons|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL4033,SINGLE PROTEIN,0,0,133,133,160,True,1925,25,0,0,0,IBUPROFEN|INDOMETHACIN|ASPIRIN|ASPIRIN|ASPIRIN|CELECOXIB|DICLOFENAC SODIUM|NABUMETONE|CELECOXIB|CELECOXIB,Small molecule,Cyclooxygenase-2 inhibitor|Cyclooxygenase inhibitor,True,False,True,HIGH - Approved drugs exist,Prostaglandin G/H synthase 2,"Dual cyclooxygenase and peroxidase in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response (PubMed:11939906, PubMed:16373578, PubMed:19540099, PubMed:22942274, PubMed:26859324, PubMed:27226593, PubMed:7592599, PubMed:7947975, PubMed:9261177). The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes (PubMed:16373578, PubMed:22942274, PubMed:26859324, PubMed:27226593, PubMed:7592599, PubMed:7947975, PubMed:9261177). This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons (PubMed:16373578, PubMed:22942274, PubMed:26859324, PubMed:27226593, PubMed:7592599, PubMed:7947975, PubMed:9261177). Similarly catalyzes successive cyclooxygenation and peroxidation of dihomo-gamma-linoleate (DGLA, C20:3(n-6)) and eicosapentaenoate (EPA, C20:5(n-3)) to corresponding PGH1 and PGH3, the precursors of 1- and 3-series prostaglandins (PubMed:11939906, PubMed:19540099). In an alternative pathway of prostanoid biosynthesis, converts 2-arachidonoyl lysophopholipids to prostanoid lysophopholipids, which are then hydrolyzed by intracellular phospholipases to release free prostanoids (PubMed:27642067). Metabolizes 2-arachidonoyl glycerol yielding the glyceryl ester of PGH2, a process that can contribute to pain response (PubMed:22942274). Generates lipid mediators from n-3 and n-6 polyunsaturated fatty acids (PUFAs) via a lipoxygenase-type mechanism. Oxygenates PUFAs to hydroperoxy compounds and then reduces them to corresponding alcohols (PubMed:11034610, PubMed:11192938, PubMed:9048568, PubMed:9261177). Plays a role in the generation of resolution phase interaction products (resolvins) during both sterile and infectious inflammation (PubMed:12391014). Metabolizes docosahexaenoate (DHA, C22:6(n-3)) to 17R-HDHA, a precursor of the D-series resolvins (RvDs) (PubMed:12391014). As a component of the biosynthetic pathway of E-series resolvins (RvEs), converts eicosapentaenoate (EPA, C20:5(n-3)) primarily to 18S-HEPE that is further metabolized by ALOX5 and LTA4H to generate 18S-RvE1 and 18S-RvE2 (PubMed:21206090). In vascular endothelial cells, converts docosapentaenoate (DPA, C22:5(n-3)) to 13R-HDPA, a precursor for 13-series resolvins (RvTs) shown to activate macrophage phagocytosis during bacterial infection (PubMed:26236990). In activated leukocytes, contributes to oxygenation of hydroxyeicosatetraenoates (HETE) to diHETES (5,15-diHETE and 5,11-diHETE) (PubMed:22068350, PubMed:26282205). Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity). During neuroinflammation, plays a role in neuronal secretion of specialized preresolving mediators (SPMs) 15R-lipoxin A4 that regulates phagocytic microglia (By similarity)",3D-structure|Acetylation|Dioxygenase|Disulfide bond|Endoplasmic reticulum|Fatty acid biosynthesis|Fatty acid metabolism|Glycoprotein|Heme|Iron|Lipid biosynthesis|Lipid metabolism|Membrane|Metal-binding|Microsome|Nucleus|Oxidoreductase|Peroxidase|Prostaglandin biosynthesis|Prostaglandin metabolism,Belongs to the prostaglandin G/H synthase family,PF03098:An_peroxidase,1,IPR000742:EGF-like_dom|IPR019791:Haem_peroxidase_animal|IPR010255:Haem_peroxidase_sf|IPR037120:Haem_peroxidase_sf_animal|IPR050783:Oxylipin_biosynth_metab,5,,domain|family|homologous_superfamily,True,Oxidoreductase|Histone Acetyltransferase|Hydrolase|Lyase|Cyclooxygenase,HIGH,Histone Acetyltransferase: Keyword: hat|Cyclooxygenase: Keyword: cyclooxygenase|Cyclooxygenase: Keyword: prostaglandin|Oxidoreductase: Keyword: oxidoreductase|Oxidoreductase: Keyword: oxidase|Oxidoreductase: Keyword: reductase|Oxidoreductase: Keyword: peroxidase|Oxidoreductase: Keyword: dioxygenase|Hydrolase: Keyword: lipase|Lyase: Keyword: synthase,Oxidoreductase,True,7,5F19|5F1A|5IKQ|5IKR|5IKT|5IKV|5KIR,5F19,2.04,X-RAY DIFFRACTION,protein_structures/pdb_experimental/5F19.pdb,False,,,,,PDB,protein_structures/pdb_experimental/5F19.pdb,Good (2.0-2.5Å),True,71,1.0,607.144,0.944,52.043,0.586,True,58,Excellent,High,Optimal volume (607A3)|High druggability (0.94),,607|2510|2110|138|133|133|448|294|190|367|140|136|224|320|240|317|440|518|490|1919|196|251|320|138|366|368|105|290|260|274|140|353|305|350|321|379|278|388|252|239|270|165|217|531|98|448|217|341|126|1255|519|271|251|567|356|307|198|321|366|782|510|333|172|690|252|386|748|308|430|710|557,0.94|0.43|0.00|0.01|0.01|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.03|0.00|0.02|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.06|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.01|0.00|0.00|0.08|0.00,P1:Vol=607:Drug=0.94|P2:Vol=2510:Drug=0.43|P3:Vol=2110:Drug=0.00|P4:Vol=138:Drug=0.01|P5:Vol=133:Drug=0.01|P6:Vol=133:Drug=0.01|P7:Vol=448:Drug=0.00|P8:Vol=294:Drug=0.00|P9:Vol=190:Drug=0.00|P10:Vol=367:Drug=0.00
PDE5A,PDE5A,phosphodiesterase 5A,"This gene encodes a cGMP-binding, cGMP-specific phosphodiesterase, a member of the cyclic nucleotide phosphodiesterase family. This phosphodiesterase specifically hydrolyzes cGMP to 5'-GMP. It is involved in the regulation of intracellular concentrations of cyclic nucleotides and is important for smooth muscle relaxation in the cardiovascular system. Alternative splicing of this gene results in three transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2008].",protein-coding,CGB-PDE|CN5A|PDE5,"cGMP-binding cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase|cGMP-specific 3',5'-cyclic phosphodiesterase|cGMP-specific phosphodiesterase PDE5A2|cGMP-specific phosphodiesterase type 5A|phosphodiesterase 5A, cGMP-specific",ENSG00000138735,ENST00000264805|ENST00000354960|ENST00000394439|ENST00000420633|ENST00000502912|ENST00000503412|ENST00000508914|ENST00000509612|ENST00000512450|ENST00000512494,ENSP00000264805|ENSP00000347046|ENSP00000377957|ENSP00000416309|ENSP00000425810|ENSP00000595666|ENSP00000595667,O76074,H0YA14|G5E9C5|C9JGT3,PDE5A_HUMAN,8654.0,NM_001083.4|NM_033430.3|NM_033437.4|XM_017008791.3|XM_054351150.1,NP_001074.2|NP_236914.2|NP_246273.2|XP_016864280.1|XP_054207125.1,NC_000004.12|NC_060928.1,8784.0,603310.0,PA33132,9606.ENSP00000347046,1RKP|1T9R|1T9S|1TBF|1UDT|1UDU|1UHO|1XOZ|1XP0|2CHM|2H40|2H42|2H44|2XSS|3B2R|3BJC|3HC8|3HDZ|3JWQ|3JWR,3.1.4.35,IPR002073|IPR003018|IPR003607|IPR023088|IPR023174|IPR029016|IPR036971,PF00233|PF01590,PS51845,4,119494397.0,119628804.0,-1.0,875.0,,9606.0,842.0,CGMP-specific phosphodiesterase type 5,kegg:hsa00230|kegg:hsa04022|reactome:R-HSA-109582|reactome:R-HSA-162582|reactome:R-HSA-194315|reactome:R-HSA-392154|reactome:R-HSA-397014,True,phosphodiesterase 5A,32,13,DIPYRIDAMOLE|SILDENAFIL|OSI-461|ZAPRINAST|PENTOXIFYLLINE|PF-00489791|ENALAPRIL MALEATE|PF-00489791|CHEMBL:CHEMBL460293|IBUDILAST|RHUCIN|EXISULIND|PAPAVERINE|TUNODAFIL|VARDENAFIL|ROLIPRAM|ICARIIN|MILRINONE|LORNEIC ACID A|SCH51866,DIPYRIDAMOLE|SILDENAFIL|PENTOXIFYLLINE|ENALAPRIL MALEATE|IBUDILAST|PAPAVERINE|VARDENAFIL|MILRINONE|TADALAFIL|UDENAFIL,UDENAFIL|AVANAFIL|PF-00489791|VARDENAFIL|LORNEIC ACID A,DRUGGABLE GENOME|ENZYME,inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|Drug Target Commons|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|Guide to Pharmacology|NCI Cancer Gene Index|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL4523626,CHIMERIC PROTEIN,0,0,2,2,2,True,439,25,0,0,0,TADALAFIL|TADALAFIL|PENTOXIFYLLINE|DIPYRIDAMOLE|DIPYRIDAMOLE|TADALAFIL|TADALAFIL|DIPYRIDAMOLE|DIPYRIDAMOLE|SILDENAFIL CITRATE,Small molecule,"3',5'-cyclic phosphodiesterase inhibitor|Phosphodiesterase 5A inhibitor",True,False,True,HIGH - Approved drugs exist,"cGMP-specific 3',5'-cyclic phosphodiesterase","Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:15489334, PubMed:9714779). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334)",3D-structure|Allosteric enzyme|Alternative splicing|cGMP|cGMP-binding|Hydrolase|Metal-binding|Nucleotide-binding|Phosphoprotein|Proteomics identification|Reference proteome|Repeat|Zinc,Belongs to the cyclic nucleotide phosphodiesterase family,PF01590:GAF|PF00233:PDEase_I,2,IPR003018:GAF|IPR029016:GAF-like_dom_sf|IPR003607:HD/PDEase_dom|IPR023088:PDEase|IPR002073:PDEase_catalytic_dom|IPR036971:PDEase_catalytic_dom_sf|IPR023174:PDEase_CS,7,,domain|family|homologous_superfamily|conserved_site,True,Hydrolase,MEDIUM,Hydrolase: Keyword: hydrolase|Hydrolase: Keyword: esterase,Hydrolase,True,49,1RKP|1T9R|1T9S|1TBF|1UDT|1UDU|1UHO|1XOZ|1XP0|2CHM,1RKP,2.05,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1RKP.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1RKP.pdb,Good (2.0-2.5Å),True,19,1.0,677.934,0.954,39.609,0.611,True,17,Excellent,High,Optimal volume (678A3)|High druggability (0.95),,678|760|263|426|395|453|104|221|265|398|282|259|655|245|258|513|293|295|735,0.95|0.45|0.03|0.00|0.00|0.06|0.00|0.00|0.00|0.00|0.02|0.03|0.00|0.00|0.00|0.00,P1:Vol=678:Drug=0.95|P2:Vol=760:Drug=0.45|P3:Vol=263:Drug=0.03|P4:Vol=426:Drug=0.00|P5:Vol=395:Drug=0.00|P6:Vol=453:Drug=0.06|P7:Vol=104:Drug=0.00|P8:Vol=221:Drug=0.00|P9:Vol=265:Drug=0.00|P10:Vol=398:Drug=0.00
ACHE,ACHE,acetylcholinesterase (Yt blood group),"Acetylcholinesterase hydrolyzes the neurotransmitter, acetylcholine at neuromuscular junctions and brain cholinergic synapses, and thus terminates signal transmission. It is also found on the red blood cell membranes, where it constitutes the Yt blood group antigen. Acetylcholinesterase exists in multiple molecular forms which possess similar catalytic properties, but differ in their oligomeric assembly and mode of cell attachment to the cell surface. It is encoded by the single ACHE gene, and the structural diversity in the gene products arises from alternative mRNA splicing, and post-translational associations of catalytic and structural subunits. The major form of acetylcholinesterase found in brain, muscle and other tissues is the hydrophilic species, which forms disulfide-linked oligomers with collagenous, or lipid-containing structural subunits. The other, alternatively spliced form, expressed primarily in the erythroid tissues, differs at the C-terminal end, and contains a cleavable hydrophobic peptide with a GPI-anchor site. It associates with the membranes through the phosphoinositide (PI) moieties added post-translationally. AChE activity may constitute a sensitive biomarker of RBC ageing in vivo, and thus, may be of aid in understanding the effects of transfusion[provided by RefSeq, Sep 2019].",protein-coding,ACEE|ARACHE|N-ACHE|YT,Yt blood group|acetylcholinesterase|acetylcholinesterase (Cartwright blood group)|apoptosis-related acetylcholinesterase,ENSG00000087085,ENST00000241069|ENST00000302913|ENST00000411582|ENST00000412389|ENST00000419336|ENST00000426415|ENST00000428317|ENST00000430554|ENST00000440755|ENST00000441605,ENSP00000241069|ENSP00000303211|ENSP00000390004|ENSP00000394976|ENSP00000396360|ENSP00000397143|ENSP00000399725|ENSP00000400933|ENSP00000403474|ENSP00000404865,P22303,F8WD68|A0A498U6H7|C9JZL6|C9J2S3|C9JD78,ACES_HUMAN,43.0,NM_000665.5|NM_001282449.2|NM_001302621.3|NM_001302622.2|NM_001367915.1|NM_001367917.1|NM_001367918.1|NM_001367919.2|NM_015831.2|NR_160407.1,NP_000656.1|NP_001269378.1|NP_001289550.1|NP_001289551.1|NP_001354844.1|NP_001354846.1|NP_001354847.1|NP_001354848.1,NC_000007.14|NC_060931.1|NG_007474.2,108.0,100740.0,PA20,9606.ENSP00000303211,1B41|1F8U|1VZJ|2X8B|3LII|4BDT|4EY4|4EY5|4EY6|4EY7|4EY8|4M0E|4M0F|4PQE|5FOQ|5FPQ|5HF5|5HF6|5HF8|5HF9,3.1.1.7,IPR000997|IPR002018|IPR014788|IPR019819|IPR019826|IPR029058|IPR050654,PF00135|PF08674,,7,100889994.0,100897022.0,-1.0,614.0,Synapse|Secreted|Cell membrane,9606.0,543.0,Acetylcholinesterase,kegg:hsa00564|kegg:hsa04725|reactome:R-HSA-112311|reactome:R-HSA-112315|reactome:R-HSA-112316|reactome:R-HSA-1430728|reactome:R-HSA-1483191|wikipathways:WP3298|wikipathways:WP528|wikipathways:WP550|wikipathways:WP727,True,acetylcholinesterase (Yt blood group),69,35,EDROPHONIUM CATION|PYRIDOSTIGMINE|ACOTIAMIDE HYDROCHLORIDE|EPTASTIGMINE|ISOFLUROPHATE|METHADONE HYDROCHLORIDE|AMBENONIUM CHLORIDE|AMBENONIUM|PRALIDOXIME CHLORIDE|NEOSTIGMINE|MIMOPEZIL|SKIMMIANINE|ADRENOMEDULLIN|TACRINE|HUMAN CALCITONIN|HUPERZINE A|&BETA;-CGRP|SALMON CALCITONIN|GALACTITOL|GALANTAMINE,EDROPHONIUM CATION|PYRIDOSTIGMINE|ISOFLUROPHATE|METHADONE HYDROCHLORIDE|AMBENONIUM CHLORIDE|AMBENONIUM|PRALIDOXIME CHLORIDE|NEOSTIGMINE|TACRINE|HUMAN CALCITONIN,AMBENONIUM|HUPERZINE A|ACOTIAMIDE HYDROCHLORIDE|PRALIDOXIME CHLORIDE|GALACTITOL,DRUGGABLE GENOME|ENZYME|CELL SURFACE,agonist|activator|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|Drug Target Commons|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|Guide to Pharmacology|NCI Cancer Gene Index|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL4780,SINGLE PROTEIN,0,0,395,395,659,True,259,25,0,0,0,NEOSTIGMINE METHYLSULFATE|PRALIDOXIME CHLORIDE|PYRIDOSTIGMINE BROMIDE|RIVASTIGMINE TARTRATE|DONEPEZIL|RIVASTIGMINE|RIVASTIGMINE|GALANTAMINE|GALANTAMINE|PRALIDOXIME CHLORIDE,Small molecule,Cholinesterases; ACHE & BCHE inhibitor|Acetylcholinesterase inhibitor|Acetylcholinesterase activator,True,False,True,HIGH - Approved drugs exist,Acetylcholinesterase,Hydrolyzes rapidly the acetylcholine neurotransmitter released into the synaptic cleft allowing to terminate the signal transduction at the neuromuscular junction. Role in neuronal apoptosis,3D-structure|Alternative splicing|Blood group antigen|Cell membrane|Direct protein sequencing|Disulfide bond|Glycoprotein|GPI-anchor|Hydrolase|Lipoprotein|Membrane|Neurotransmitter degradation|Nucleus|Proteomics identification|Reference proteome|Secreted|Serine esterase|Signal|Synapse,Belongs to the type-B carboxylesterase/lipase family,PF08674:AChE_tetra|PF00135:COesterase,2,IPR029058:AB_hydrolase_fold|IPR050654:AChE-related_enzymes|IPR014788:AChE_tetra|IPR002018:CarbesteraseB|IPR019826:Carboxylesterase_B_AS|IPR019819:Carboxylesterase_B_CS|IPR000997:Cholinesterase,7,,active_site|domain|homologous_superfamily|family|conserved_site,True,Protease|Hydrolase,HIGH,Protease: InterPro: IPR029058|Hydrolase: Keyword: hydrolase|Hydrolase: Keyword: esterase|Hydrolase: Keyword: lipase,Protease,True,78,1B41|1F8U|1VZJ|2X8B|3LII|4BDT|4EY4|4EY5|4EY6|4EY7,1B41,2.76,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1B41.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1B41.pdb,Moderate (2.5-3.0Å),True,27,1.0,620.372,0.925,34.926,0.378,True,21,Good,Medium,Optimal volume (620A3)|High druggability (0.93),,620|116|262|596|396|289|170|73|238|421|241|413|314|400|225|258|273|291|256|232|206|711|281|1155|352|941|234,0.93|0.01|0.00|0.00|0.01|0.01|0.00|0.01|0.01|0.07|0.00|0.00|0.01|0.00|0.00|0.01|0.00|0.91|0.00|0.02,P1:Vol=620:Drug=0.93|P2:Vol=116:Drug=0.01|P3:Vol=262:Drug=0.00|P4:Vol=596:Drug=0.00|P5:Vol=396:Drug=0.01|P6:Vol=289:Drug=0.01|P7:Vol=170:Drug=0.00|P8:Vol=73:Drug=0.00|P9:Vol=238:Drug=0.00|P10:Vol=421:Drug=0.01
DPP4TNF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,False,,0,0,,,,,,,False,,,0,0,0,0,0,False,0,0,0,0,0,,,,False,False,False,NONE - No known drug interactions,,,,,,0,,0,,,False,,NONE,,,False,0,,,,,,False,,,,,,,,False,0,,,,,,False,0,,,,,,,
IL1B,IL1B,interleukin 1 beta,"The protein encoded by this gene is a member of the interleukin 1 cytokine family. This cytokine is produced by activated macrophages as a proprotein, which is proteolytically processed to its active form by caspase 1 (CASP1/ICE). This cytokine is an important mediator of the inflammatory response, and is involved in a variety of cellular activities, including cell proliferation, differentiation, and apoptosis. The induction of cyclooxygenase-2 (PTGS2/COX2) by this cytokine in the central nervous system (CNS) is found to contribute to inflammatory pain hypersensitivity. Similarly, IL-1B has been implicated in human osteoarthritis pathogenesis. Patients with severe Coronavirus Disease 2019 (COVID-19) present elevated levels of pro-inflammatory cytokines such as IL-1B in bronchial alveolar lavage fluid samples. The lung damage induced by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is to a large extent, a result of the inflammatory response promoted by cytokines such as IL-1B. This gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2. [provided by RefSeq, Jul 2020].",protein-coding,IL-1|IL1-BETA|IL1F2|IL1beta,IL-1 beta|catabolin|interleukin 1beta|interleukin-1 beta|preinterleukin 1 beta,ENSG00000125538,ENST00000263341|ENST00000416750|ENST00000418817|ENST00000432018|ENST00000477398|ENST00000487639|ENST00000491056|ENST00000496280,ENSP00000263341|ENSP00000400854|ENSP00000407219|ENSP00000409680,P01584,C9JWV2|C9JSC2|C9JVK0,IL1B_HUMAN,3553.0,NM_000576.3|XM_047444175.1|XM_054341810.1,NP_000567.1|XP_047300131.1|XP_054197785.1,NC_000002.12|NC_060926.1|NG_008851.1,5992.0,147720.0,PA29808,9606.ENSP00000263341,1HIB|1I1B|1IOB|1ITB|1L2H|1S0L|1T4Q|1TOO|1TP0|1TWE|1TWM|21BI|2I1B|2KH2|2NVH|31BI|3LTQ|3O4O|3POK|41BI,,IPR003502|IPR000975|IPR008996|IPR020877,PF00340|PF02394,,2,112829751.0,112836816.0,-1.0,269.0,"Cytoplasm, cytosol|Secreted|Lysosome",9606.0,481.0,IL1B,biocarta:il1rpathway|biocarta:nthipathway|kegg:hsa04010|kegg:hsa04060|kegg:hsa04064|kegg:hsa04217|kegg:hsa04380|pid:anthraxpathway|pid:ifngpathway|pid:il12_2pathway|pid:il1pathway|pid:il23pathway|reactome:R-HSA-1280215|reactome:R-HSA-1643685|reactome:R-HSA-168249|reactome:R-HSA-168256|reactome:R-HSA-446652|wikipathways:WP1433|wikipathways:WP1449|wikipathways:WP1455|wikipathways:WP15|wikipathways:WP1533,True,interleukin 1 beta,51,37,ASPIRIN|MAFOSFAMIDE|DIACETYLRHEIN|INFLIXIMAB|LANSOPRAZOLE|TILUDRONIC ACID|GEVOKIZUMAB|LUTIKIZUMAB|CELASTROL|CYTARABINE|RILONACEPT|TT-301|METFORMIN|ANTICONVULSANT AGENT|ANTIDEPRESSANT AGENT|ACITRETIN|ERYTHROMYCIN|ALTEPLASE|OFLOXACIN|PENTOXIFYLLINE,ASPIRIN|DIACETYLRHEIN|INFLIXIMAB|LANSOPRAZOLE|TILUDRONIC ACID|CYTARABINE|RILONACEPT|METFORMIN|ACITRETIN|ERYTHROMYCIN,GEVOKIZUMAB|CANAKINUMAB|TT-301|PENTAMIDINE|POLYVALENT VACCINE,DRUGGABLE GENOME|KINASE,negative modulator|immunotherapy|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|NCI Cancer Gene Index|The ChEMBL Bioactivity Database|Therapeutic Target Database|My Cancer Genome",True,CHEMBL5069361,SINGLE PROTEIN,0,0,2,2,2,True,109,12,13,0,0,RILONACEPT|CANAKINUMAB|CANAKINUMAB|CANAKINUMAB|RILONACEPT|RILONACEPT|CANAKINUMAB|CANAKINUMAB|RILONACEPT|RILONACEPT,Antibody|Protein,Interleukin-1 beta inhibitor|Interleukin-1 beta negative allosteric modulator,True,True,True,HIGH - Approved drugs exist,Interleukin-1 beta,"Potent pro-inflammatory cytokine (PubMed:10653850, PubMed:12794819, PubMed:28331908, PubMed:3920526). Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production (PubMed:3920526). Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells (PubMed:10653850). Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6 (PubMed:12794819). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33377178, PubMed:33883744). Acts as a sensor of S.pyogenes infection in skin: cleaved and activated by pyogenes SpeB protease, leading to an inflammatory response that prevents bacterial growth during invasive skin infection (PubMed:28331908)",3D-structure|Cytokine|Cytoplasm|Direct protein sequencing|Inflammatory response|Lysosome|Mitogen|Proteomics identification|Pyrogen|Reference proteome|Secreted,Belongs to the IL-1 family,PF00340:IL1|PF02394:IL1_propep,2,IPR020877:IL-1_CS|IPR000975:IL-1_fam|IPR003502:IL-1_propep|IPR008996:IL1/FGF,4,,domain|family|conserved_site|homologous_superfamily,True,Cyclooxygenase|Histone Acetyltransferase|Protease,HIGH,Protease: Keyword: protease|Histone Acetyltransferase: Keyword: hat|Cyclooxygenase: Keyword: prostaglandin,Cyclooxygenase,True,64,1HIB|1I1B|1IOB|1ITB|1L2H|1S0L|1T4Q|1TOO|1TP0|1TWE,1HIB,2.4,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1HIB.pdb,False,,,,,PDB,protein_structures/pdb_experimental/1HIB.pdb,Good (2.0-2.5Å),True,8,6.0,241.698,0.317,47.0,0.125,True,7,Moderate,Low,Adequate volume (242A3),Low druggability (0.32),495|214|423|273|96|242|190|214,0.00|0.00|0.03|0.32,P1:Vol=495:Drug=0.00|P2:Vol=214:Drug=0.00|P3:Vol=423:Drug=0.00|P4:Vol=273:Drug=0.03|P5:Vol=96:Drug=0.00|P6:Vol=242:Drug=0.32|P7:Vol=190:Drug=0.00|P8:Vol=214:Drug=0.00
IL6,IL6,interleukin 6,"This gene encodes a cytokine that functions in inflammation and the maturation of B cells. In addition, the encoded protein has been shown to be an endogenous pyrogen capable of inducing fever in people with autoimmune diseases or infections. The protein is primarily produced at sites of acute and chronic inflammation, where it is secreted into the serum and induces a transcriptional inflammatory response through interleukin 6 receptor, alpha. The functioning of this gene is implicated in a wide variety of inflammation-associated disease states, including suspectibility to diabetes mellitus and systemic juvenile rheumatoid arthritis. Elevated levels of the encoded protein have been found in virus infections, including COVID-19 (disease caused by SARS-CoV-2). [provided by RefSeq, Aug 2020].",protein-coding,BSF-2|BSF2|CDF|HGF|HSF|IFN-beta-2|IFNB2|IL-6,B-cell differentiation factor|B-cell stimulatory factor 2|CTL differentiation factor|hybridoma growth factor|interferon beta-2,ENSG00000136244,ENST00000258743|ENST00000401630|ENST00000401651|ENST00000404625|ENST00000406575|ENST00000407492|ENST00000426291|ENST00000464710|ENST00000485300|ENST00000964192,ENSP00000258743|ENSP00000384928|ENSP00000385043|ENSP00000385227|ENSP00000385675|ENSP00000385718|ENSP00000405150|ENSP00000512964|ENSP00000634251,P05231,B5MC21|Q75MH2|B4DVM1|B4DNQ5|B5MCZ3,IL6_HUMAN,3569.0,NM_000600.5|NM_001318095.2|NM_001371096.1|XM_005249745.6|XM_054358145.1|XM_054358146.1,NP_000591.1|NP_001305024.1|NP_001358025.1|XP_005249802.1|XP_054214120.1|XP_054214121.1,NC_000007.14|NC_060931.1|NG_011640.1,6018.0,147620.0,PA198,9606.ENSP00000385675,1ALU|1IL6|1P9M|2IL6|4CNI|4J4L|4NI7|4NI9|4O9H|4ZS7|5FUC|7NXZ|8D82|8QY5|8QY6|8YWQ|8YWR,,IPR003574|IPR009079|IPR030473|IPR030474,PF00489,,7,22725884.0,22732002.0,1.0,212.0,Secreted,9606.0,502.0,Interleukin 6,biocarta:her2pathway|biocarta:il10pathway|biocarta:il1rpathway|biocarta:il6pathway|kegg:hsa04060|kegg:hsa04061|kegg:hsa04066|kegg:hsa04068|kegg:hsa04151|pid:amb2_neutrophils_pathway|pid:ap1_pathway|pid:atf2_pathway|pid:fra_pathway|pid:il23pathway|reactome:R-HSA-1059683|reactome:R-HSA-110056|reactome:R-HSA-112409|reactome:R-HSA-112411|reactome:R-HSA-1280215|wikipathways:WP1449|wikipathways:WP15|wikipathways:WP1533|wikipathways:WP176|wikipathways:WP2036,True,interleukin 6,49,29,"CISPLATIN|ZILTIVEKIMAB|CHINESE HERBS|PF-04236921|MRA 003 US|SIGNAL TRANSDUCTION INHIBITOR|BINETRAKIN|IBUDILAST|INSULIN, REGULAR, HUMAN|SILTUXIMAB|METRONIDAZOLE|CLAZAKIZUMAB|GALLIUM NITRATE|INTERFERON ALFA-2B|DULOXETINE HYDROCHLORIDE|MEDI-5117|GEMFIBROZIL|BIAFINE CREAM|ETANERCEPT|ELSILIMOMAB","CISPLATIN|IBUDILAST|INSULIN, REGULAR, HUMAN|SILTUXIMAB|METRONIDAZOLE|GALLIUM NITRATE|INTERFERON ALFA-2B|DULOXETINE HYDROCHLORIDE|GEMFIBROZIL|ETANERCEPT",CLAZAKIZUMAB|OLOKIZUMAB|SILTUXIMAB|BIAFINE CREAM|IMIPENEM-CILASTATIN SODIUM,DRUGGABLE GENOME|DRUG RESISTANCE|GROWTH FACTOR,binder|antibody|inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|Targeted Agents in Lung Cancer (Commentary, 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|NCI Cancer Gene Index|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL1795129,SINGLE PROTEIN,0,0,144,144,412,True,65,2,9,14,0,SILTUXIMAB|SILTUXIMAB|SIRUKUMAB|OLOKIZUMAB|OLOKIZUMAB|SIRUKUMAB|SILTUXIMAB|SIRUKUMAB|SIRUKUMAB|SILTUXIMAB,Antibody,Interleukin-6 inhibitor,True,True,True,HIGH - Approved drugs exist,Interleukin-6,"Acts as an essential factor in bone homeostasis and on vessels directly or indirectly by induction of VEGF, resulting in increased angiogenesis activity and vascular permeability (PubMed:12794819, PubMed:17075861). Induces, through 'trans-signaling' and synergistically with IL1B and TNF, the production of VEGF (PubMed:12794819). Involved in metabolic controls, is discharged into the bloodstream after muscle contraction increasing lipolysis and improving insulin resistance (PubMed:20823453). 'Trans-signaling' in central nervous system also regulates energy and glucose homeostasis (By similarity). Mediates, through GLP-1, crosstalk between insulin-sensitive tissues, intestinal L cells and pancreatic islets to adapt to changes in insulin demand (By similarity). Also acts as a myokine (Probable). Plays a protective role during liver injury, being required for maintenance of tissue regeneration (By similarity). Also has a pivotal role in iron metabolism by regulating HAMP/hepcidin expression upon inflammation or bacterial infection (PubMed:15124018). Through activation of IL6ST-YAP-NOTCH pathway, induces inflammation-induced epithelial regeneration (By similarity)",3D-structure|Acute phase|Cytokine|Direct protein sequencing|Disulfide bond|Glycoprotein|Growth factor|Phosphoprotein|Proteomics identification|Reference proteome|Secreted|Signal,Belongs to the IL-6 superfamily,PF00489:IL6,1,IPR009079:4_helix_cytokine-like_core|IPR003574:IL-6-like|IPR030474:IL-6/GCSF/MGF|IPR030473:IL6/GCSF/MGF_CS,4,,homologous_superfamily|family|conserved_site,False,,NONE,,,True,17,1ALU|1IL6|1P9M|2IL6|4CNI|4J4L|4NI7|4NI9|4O9H|4ZS7,1ALU,1.9,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1ALU.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1ALU.pdb,Excellent (<2.0Å),True,10,6.0,379.511,0.323,26.125,0.21,True,7,Moderate,Low,Adequate volume (380A3),Low druggability (0.32),449|585|548|365|371|380|276|298|364|270,0.07|0.12|0.03|0.00|0.01|0.32|0.01|0.00|0.02,P1:Vol=449:Drug=0.07|P2:Vol=585:Drug=0.12|P3:Vol=548:Drug=0.03|P4:Vol=365:Drug=0.00|P5:Vol=371:Drug=0.01|P6:Vol=380:Drug=0.32|P7:Vol=276:Drug=0.01|P8:Vol=298:Drug=0.00|P9:Vol=364:Drug=0.00|P10:Vol=270:Drug=0.02
IL10,IL10,interleukin 10,"The protein encoded by this gene is a cytokine produced primarily by monocytes and to a lesser extent by lymphocytes. This cytokine has pleiotropic effects in immunoregulation and inflammation. It down-regulates the expression of Th1 cytokines, MHC class II Ags, and costimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production. This cytokine can block NF-kappa B activity, and is involved in the regulation of the JAK-STAT signaling pathway. Knockout studies in mice suggested the function of this cytokine as an essential immunoregulator in the intestinal tract. Mutations in this gene are associated with an increased susceptibility to HIV-1 infection and rheumatoid arthritis. [provided by RefSeq, May 2020].",protein-coding,CSIF|GVHDS|IL-10|IL10A|TGIF,T-cell growth inhibitory factor|cytokine synthesis inhibitory factor|interleukin-10,ENSG00000136634,ENST00000367099|ENST00000423557|ENST00000471071|ENST00000640756|ENST00000659065|ENST00000659642|ENST00000664374,ENSP00000412237|ENSP00000493073|ENSP00000499509|ENSP00000499588|ENSP00000499664,P22301,A0A286YEX3|Q6FGW4|A0A590UK12,IL10_HUMAN,3586.0,NM_000572.3|NM_001382624.1|NR_168466.1|NR_168467.1,NP_000563.1|NP_001369553.1,NC_000001.11|NC_060925.1|NG_012088.1,5962.0,124092.0,PA29778,9606.ENSP00000412237,1ILK|1INR|1J7V|1LK3|1Y6K|2H24|2ILK|6X93|8SVE,,IPR000098|IPR009079|IPR020423|IPR020443,PF00726,,1,206767602.0,206774541.0,-1.0,178.0,Secreted,9606.0,478.0,Interleukin 10,kegg:hsa04060|kegg:hsa04061|kegg:hsa04068|kegg:hsa04625|kegg:hsa04630|pid:ap1_pathway|pid:il4_2pathway|pid:smad2_3nuclearpathway|reactome:R-HSA-1280215|reactome:R-HSA-1643685|reactome:R-HSA-168256|reactome:R-HSA-447115|reactome:R-HSA-449147|wikipathways:WP2328|wikipathways:WP3863|wikipathways:WP4141|wikipathways:WP4298|wikipathways:WP4329,True,interleukin 10,20,12,EFAVIRENZ|ANESTHETIC AGENT|ACYCLOVIR|MACROLIDE ANTIBIOTIC|LISOFYLLINE|PROTON PUMP INHIBITOR|SCH-708980|SIROLIMUS|SHO-SAIKO-TO|RABEPRAZOLE|AMOXICILLIN ANHYDROUS|CLARITHROMYCIN|ILODECAKIN|FLUTICASONE|TRETINOIN|MESALAMINE|ROFECOXIB|ETANERCEPT|PEGILODECAKIN|ZIDOVUDINE,EFAVIRENZ|ACYCLOVIR|SIROLIMUS|RABEPRAZOLE|AMOXICILLIN ANHYDROUS|CLARITHROMYCIN|FLUTICASONE|TRETINOIN|MESALAMINE|ROFECOXIB,LISOFYLLINE|SCH-708980|ILODECAKIN|MACROLIDE ANTIBIOTIC|PROTON PUMP INHIBITOR,DRUGGABLE GENOME|GROWTH FACTOR|CLINICALLY ACTIONABLE,inhibitor,The ChEMBL Bioactivity Database|Therapeutic Target Database|PharmGKB - The Pharmacogenomics Knowledgebase|NCI Cancer Gene Index,True,CHEMBL3712920,SINGLE PROTEIN,0,0,0,0,0,True,1,0,0,0,1,SCH-708980,Antibody,Interleukin-10 inhibitor,True,True,False,HIGH - Approved drugs exist,Interleukin-10,"Major immune regulatory cytokine that acts on many cells of the immune system where it has profound anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. Mechanistically, IL10 binds to its heterotetrameric receptor comprising IL10RA and IL10RB leading to JAK1 and STAT2-mediated phosphorylation of STAT3 (PubMed:16982608). In turn, STAT3 translocates to the nucleus where it drives expression of anti-inflammatory mediators (PubMed:18025162). Targets antigen-presenting cells (APCs) such as macrophages and monocytes and inhibits their release of pro-inflammatory cytokines including granulocyte-macrophage colony-stimulating factor /GM-CSF, granulocyte colony-stimulating factor/G-CSF, IL-1 alpha, IL-1 beta, IL-6, IL-8 and TNF-alpha (PubMed:11564774, PubMed:1940799, PubMed:7512027). Also interferes with antigen presentation by reducing the expression of MHC-class II and co-stimulatory molecules, thereby inhibiting their ability to induce T cell activation (PubMed:8144879). In addition, controls the inflammatory response of macrophages by reprogramming essential metabolic pathways including mTOR signaling (By similarity)",3D-structure|Cytokine|Direct protein sequencing|Disulfide bond|Glycoprotein|Proteomics identification|Reference proteome|Secreted|Signal,Belongs to the IL-10 family,PF00726:IL10,1,IPR009079:4_helix_cytokine-like_core|IPR000098:IL-10|IPR020443:IL-10/19/20/24/26|IPR020423:IL-10_CS,4,,homologous_superfamily|family|conserved_site,True,Histone Acetyltransferase,LOW,Histone Acetyltransferase: Keyword: hat,Histone Acetyltransferase,True,9,1ILK|1INR|1J7V|1LK3|1Y6K|2H24|2ILK|6X93|8SVE,1ILK,1.8,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1ILK.pdb,False,,,,,PDB,protein_structures/pdb_experimental/1ILK.pdb,Excellent (<2.0Å),True,11,8.0,616.833,0.843,63.9,0.166,True,11,Good,Medium,Optimal volume (617A3)|High druggability (0.84),,601|333|288|236|345|274|240|617|230|305|298,0.49|0.00|0.36|0.04|0.01|0.06|0.84|0.00|0.00,P1:Vol=601:Drug=0.00|P2:Vol=333:Drug=0.49|P3:Vol=288:Drug=0.00|P4:Vol=236:Drug=0.36|P5:Vol=345:Drug=0.04|P6:Vol=274:Drug=0.01|P7:Vol=240:Drug=0.06|P8:Vol=617:Drug=0.84|P9:Vol=230:Drug=0.00|P10:Vol=305:Drug=0.00
IL17A,IL17F,interleukin 17F,"The protein encoded by this gene is a cytokine that shares sequence similarity with IL17. This cytokine is expressed by activated T cells, and has been shown to stimulate the production of several other cytokines, including IL6, IL8, and CSF2/GM_CSF. This cytokine is also found to inhibit the angiogenesis of endothelial cells and induce endothelial cells to produce IL2, TGFB1/TGFB, and monocyte chemoattractant protein-1. [provided by RefSeq, Jul 2008].",protein-coding,CANDF6|IL-17F|IL17A|ML-1|ML1,cytokine ML-1|interleukin-17F,ENSG00000112116,ENST00000336123|ENST00000478427|ENST00000699946,ENSP00000337432|ENSP00000514702,Q96PD4,,IL17_HUMAN,112744.0,NM_052872.4|NM_172343.1|XM_011514276.1|XM_054354142.1,NP_443104.1|XP_011512578.1|XP_054210117.1,NC_000006.12|NC_060930.1|NG_031869.1,16404.0,606496.0,PA29800,9606.ENSP00000497968,1JPY|3JVF|5N92|5NAN|6HG4|6HG9|6HGO|6PPG|8RUU,,IPR010345|IPR020440|IPR029034,PF06083,,6,52236681.0,52245689.0,-1.0,155.0,Secreted,9606.0,17115.0,,kegg:hsa04060|kegg:hsa04657|kegg:hsa04659|kegg:hsa05321|reactome:R-HSA-1280215|reactome:R-HSA-1643685|reactome:R-HSA-168256|reactome:R-HSA-448424|reactome:R-HSA-449147,True,interleukin 17A,26,11,SIMVASTATIN|IL-12|SECUKINUMAB|TIBULIZUMAB|BIMEKIZUMAB|ANTI-IL17A MONOCLONAL ANTIBODY CJM112|VUNAKIZUMAB|M-1095|AFASEVIKUMAB|PERAKIZUMAB|SIROLIMUS|GENTAMICIN|AZATHIOPRINE|VIDOFLUDIMUS|VUNAKIZUMAB|COVA322|BRODALUMAB|IXEKIZUMAB|IZOKIBEP|REMTOLUMAB,SIMVASTATIN|SECUKINUMAB|BIMEKIZUMAB|SIROLIMUS|GENTAMICIN|AZATHIOPRINE|BRODALUMAB|IXEKIZUMAB|TETRACYCLINE|ERYTHROMYCIN,IXEKIZUMAB|SECUKINUMAB|BIMEKIZUMAB|ANTI-IL17A MONOCLONAL ANTIBODY CJM112|VUNAKIZUMAB,DRUGGABLE GENOME|EXTERNAL SIDE OF PLASMA MEMBRANE|KINASE,binder|inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|The ChEMBL Bioactivity Database|Therapeutic Target Database|NCI Cancer Gene Index",True,CHEMBL3390822,SINGLE PROTEIN,0,0,117,117,305,True,26,5,10,9,1,BIMEKIZUMAB|BIMEKIZUMAB|BIMEKIZUMAB|BIMEKIZUMAB|BIMEKIZUMAB|BIMEKIZUMAB|BIMEKIZUMAB|BIMEKIZUMAB|BIMEKIZUMAB|BIMEKIZUMAB,Unknown|Antibody,Interleukin-17F inhibitor,True,True,True,HIGH - Approved drugs exist,Interleukin-17F,"Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity (PubMed:21350122). IL17A-IL17F signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter through SEFIR domains. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation (PubMed:11574464, PubMed:11591732, PubMed:11591768, PubMed:17911633, PubMed:18684971, PubMed:21350122, PubMed:28827714). IL17A-IL17F is primarily involved in host defense against extracellular bacteria and fungi by inducing neutrophilic inflammation (By similarity). As signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites (By similarity). Stimulates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers (By similarity). IL17F homodimer can signal via IL17RC homodimeric receptor complex, triggering downstream activation of TRAF6 and NF-kappa-B signaling pathway (PubMed:32187518). Via IL17RC induces transcriptional activation of IL33, a potent cytokine that stimulates group 2 innate lymphoid cells and adaptive T-helper 2 cells involved in pulmonary allergic response to fungi. Likely via IL17RC, promotes sympathetic innervation of peripheral organs by coordinating the communication between gamma-delta T cells and parenchymal cells. Stimulates sympathetic innervation of thermogenic adipose tissue by driving TGFB1 expression (By similarity). Regulates the composition of intestinal microbiota and immune tolerance by inducing antimicrobial proteins that specifically control the growth of commensal Firmicutes and Bacteroidetes (By similarity)",3D-structure|Adaptive immunity|Cytokine|Direct protein sequencing|Disease variant|Disulfide bond|Glycoprotein|Immunity|Inflammatory response|Innate immunity|Proteomics identification|Reference proteome|Secreted|Signal,Belongs to the IL-17 family,PF06083:IL17,1,IPR029034:Cystine-knot_cytokine|IPR020440:IL-17_chr|IPR010345:IL-17_fam,3,,homologous_superfamily|family,True,Kinase|Histone Acetyltransferase|Protease,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: mapk|Protease: Keyword: proteinase|Protease: Keyword: matrix metalloproteinase|Histone Acetyltransferase: Keyword: hat,Kinase,True,9,1JPY|3JVF|5N92|5NAN|6HG4|6HG9|6HGO|6PPG|8RUU,1JPY,2.85,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1JPY.pdb,False,,,,,PDB,protein_structures/pdb_experimental/1JPY.pdb,Moderate (2.5-3.0Å),True,28,25.0,594.746,0.829,23.333,0.829,True,27,Excellent,High,Optimal volume (595A3)|High druggability (0.83),,722|60|426|254|302|287|243|259|278|387|340|1580|227|549|519|510|489|232|416|473|860|275|214|266|595|467|525|2072,0.10|0.01|0.00|0.00|0.06|0.00|0.01|0.41|0.00|0.00|0.21|0.11|0.00|0.00|0.48|0.00|0.83|0.01|0.00|0.01,P1:Vol=722:Drug=0.10|P2:Vol=60:Drug=0.01|P3:Vol=426:Drug=0.00|P4:Vol=254:Drug=0.00|P5:Vol=302:Drug=0.06|P6:Vol=287:Drug=0.00|P7:Vol=243:Drug=0.00|P8:Vol=259:Drug=0.00|P9:Vol=278:Drug=0.00|P10:Vol=387:Drug=0.00
TSLP,TSLP,thymic stromal lymphopoietin,"This gene encodes a hemopoietic cytokine proposed to signal through a heterodimeric receptor complex composed of the thymic stromal lymphopoietin receptor and the IL-7R alpha chain. It mainly impacts myeloid cells and induces the release of T cell-attracting chemokines from monocytes and enhances the maturation of CD11c(+) dendritic cells. The protein promotes T helper type 2 (TH2) cell responses that are associated with immunity in various inflammatory diseases, including asthma, allergic inflammation and chronic obstructive pulmonary disease. The protein is therefore considered a potential therapeutic target for the treatment of such diseases. In addition, the shorter (predominant) isoform is an antimicrobial protein, displaying antibacterial and antifungal activity against B. cereus, E. coli, E. faecalis, S. mitis, S. epidermidis, and C. albicans. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Jul 2020].",protein-coding,,thymic stroma-derived lymphopoietin|thymic stromal lymphopoietin,ENSG00000145777,ENST00000344895|ENST00000379706|ENST00000420978,ENSP00000339804|ENSP00000399099|ENSP00000427827,Q969D9,A0A0C4DG43,TSLP_HUMAN,85480.0,NM_033035.5|NM_138551.5|NR_045089.2|XM_011543698.2|XM_047417846.1|XM_047417847.1|XM_054353732.1|XM_054353733.1,NP_149024.1|NP_612561.2|XP_011542000.1|XP_047273802.1|XP_047273803.1|XP_054209707.1|XP_054209708.1,NC_000005.10|NC_060929.1,30743.0,607003.0,PA162407159,9606.ENSP00000339804,5J11|5J12|5J13|8QFZ,,IPR029189|IPR038329,PF15216,,5,111070062.0,111078026.0,1.0,159.0,Secreted,9606.0,81957.0,Thymic stromal lymphopoietin,kegg:hsa04060|kegg:hsa04630|reactome:R-HSA-1266695|reactome:R-HSA-1266695|reactome:R-HSA-1280215|reactome:R-HSA-1280215|reactome:R-HSA-168256|wikipathways:WP2203|wikipathways:WP3893,True,thymic stromal lymphopoietin,2,1,TEZEPELUMAB|AMG-157,TEZEPELUMAB,TEZEPELUMAB|AMG-157,DRUGGABLE GENOME,inhibitor,The ChEMBL Bioactivity Database|Therapeutic Target Database,True,CHEMBL3712931,SINGLE PROTEIN,0,0,69,69,114,True,17,2,5,7,3,TEZEPELUMAB|TEZEPELUMAB|TEZEPELUMAB|TEZEPELUMAB|TEZEPELUMAB|TEZEPELUMAB|TEZEPELUMAB|TEZEPELUMAB|TEZEPELUMAB|TEZEPELUMAB,Antibody,Thymic stromal lymphopoietin inhibitor,True,True,True,HIGH - Approved drugs exist,Thymic stromal lymphopoietin,May act as an antimicrobial peptide in the oral cavity and on the skin,3D-structure|Alternative splicing|Cytokine|Disulfide bond|Glycoprotein|Reference proteome|Secreted|Signal,,PF15216:TSLP,1,IPR029189:TSLP|IPR038329:TSLP_sf,2,,homologous_superfamily|family,False,,NONE,,,True,5,5J11|5J12|5J13|8QFZ|8ZEU,5J11,2.56,X-RAY DIFFRACTION,protein_structures/pdb_experimental/5J11.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/5J11.pdb,Moderate (2.5-3.0Å),True,31,25.0,2860.091,0.302,17.431,0.302,True,25,Moderate,Low,Optimal volume (2860A3),Low druggability (0.30),520|386|299|275|370|191|210|249|243|336|206|187|398|280|181|160|255|267|273|204|636|324|316|625|2860|338|184|322|417|260|226,0.00|0.00|0.00|0.01|0.00|0.00|0.30|0.00|0.01|0.00|0.00|0.00|0.05|0.03|0.10|0.09|0.30|0.00|0.00|0.12,P1:Vol=520:Drug=0.00|P2:Vol=386:Drug=0.00|P3:Vol=299:Drug=0.00|P4:Vol=275:Drug=0.00|P5:Vol=370:Drug=0.01|P6:Vol=191:Drug=0.00|P7:Vol=210:Drug=0.00|P8:Vol=249:Drug=0.30|P9:Vol=243:Drug=0.00|P10:Vol=336:Drug=0.01
IFNG,IFNG,interferon gamma,"This gene encodes a soluble cytokine that is a member of the type II interferon class. The encoded protein is secreted by cells of both the innate and adaptive immune systems. The active protein is a homodimer that binds to the interferon gamma receptor which triggers a cellular response to viral and microbial infections. Mutations in this gene are associated with an increased susceptibility to viral, bacterial and parasitic infections and to several autoimmune diseases. [provided by RefSeq, Dec 2015].",protein-coding,IFG|IFI|IMD69,IFN-gamma|immune interferon|interferon gamma,ENSG00000111537,ENST00000229135,ENSP00000229135,P01579,,IFNG_HUMAN,3458.0,NM_000619.3,NP_000610.2,NC_000012.12|NC_060936.1|NG_015840.1,5438.0,147570.0,PA29674,9606.ENSP00000229135,1EKU|1FG9|1FYH|1HIG|3BES|6E3K|6E3L,,IPR002069|IPR009079,PF00714,PS51257,12,68154768.0,68159740.0,-1.0,166.0,Secreted,9606.0,55526.0,Interferon-gamma,biocarta:41bbpathway|biocarta:ifngpathway|biocarta:il12pathway|biocarta:no2il12pathway|biocarta:tidpathway|kegg:hsa03050|kegg:hsa04060|kegg:hsa04066|kegg:hsa04217|kegg:hsa04350|pid:ap1_pathway|pid:atf2_pathway|pid:cd8tcrdownstreampathway|pid:ifngpathway|pid:il12_2pathway|reactome:R-HSA-1266738|reactome:R-HSA-1280215|reactome:R-HSA-1280215|reactome:R-HSA-168256|reactome:R-HSA-168256|wikipathways:WP15|wikipathways:WP1533|wikipathways:WP176|wikipathways:WP183|wikipathways:WP2328,True,interferon gamma,28,20,"TRETINOIN|URSODIOL|TRASTUZUMAB|FUMARIC ACID|IBUPROFEN, SODIUM SALT|RECOMBINANT INTERLEUKIN-1-BETA|METHYLPREDNISOLONE|EMAPALUMAB|MELPHALAN|FONTOLIZUMAB|AMITRIPTYLINE HYDROCHLORIDE|BLEOMYCIN|SURAMIN|DOXIFLURIDINE|THERAPEUTIC AUTOLOGOUS LYMPHOCYTES|AMG-811|PREDNISONE|EDRECOLOMAB|INTERFERON ALFA-2B|CISPLATIN","TRETINOIN|URSODIOL|TRASTUZUMAB|FUMARIC ACID|IBUPROFEN, SODIUM SALT|METHYLPREDNISOLONE|EMAPALUMAB|MELPHALAN|AMITRIPTYLINE HYDROCHLORIDE|BLEOMYCIN",FONTOLIZUMAB|THERAPEUTIC AUTOLOGOUS LYMPHOCYTES|FUMARIC ACID|RECOMBINANT INTERLEUKIN-1-BETA|AMG-811,DRUGGABLE GENOME,inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|The ChEMBL Bioactivity Database|Therapeutic Target Database|NCI Cancer Gene Index",True,CHEMBL3286073,SINGLE PROTEIN,0,0,3,3,3,True,15,3,5,5,2,EMAPALUMAB|EMAPALUMAB|EMAPALUMAB|EMAPALUMAB|EMAPALUMAB|EMAPALUMAB|EMAPALUMAB|EMAPALUMAB|EMAPALUMAB|FONTOLIZUMAB,Antibody,Interferon gamma inhibitor,True,True,True,HIGH - Approved drugs exist,Interferon gamma,"Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation (PubMed:16914093, PubMed:8666937). Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation (PubMed:8349687). Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription (PubMed:16914093). Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits (PubMed:8666937). In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading (PubMed:8163024). Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference (PubMed:11112687). Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL (PubMed:7729559). Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation (By similarity)",3D-structure|Antiviral defense|Cleavage on pair of basic residues|Cytokine|Direct protein sequencing|Glycoprotein|Growth regulation|Pharmaceutical|Proteomics identification|Pyrrolidone carboxylic acid|Reference proteome|Secreted|Signal,Belongs to the type II (or gamma) interferon family,PF00714:IFN-gamma,1,IPR009079:4_helix_cytokine-like_core|IPR002069:Interferon_gamma,2,,homologous_superfamily|family,True,E3 Ubiquitin Ligase|Protease|Transcription Factor|Histone Acetyltransferase,HIGH,Protease: Keyword: cathepsin|E3 Ubiquitin Ligase: Keyword: proteasome|Histone Acetyltransferase: Keyword: hat|Transcription Factor: Keyword: transcription factor,E3 Ubiquitin Ligase,True,7,1EKU|1FG9|1FYH|1HIG|3BES|6E3K|6E3L,1EKU,2.9,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1EKU.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1EKU.pdb,Moderate (2.5-3.0Å),True,35,1.0,2314.443,0.889,13.857,0.636,True,22,Excellent,High,Optimal volume (2314A3)|High druggability (0.89),,2314|2522|380|488|192|341|207|233|452|292|225|358|256|256|253|342|280|201|305|184|424|339|249|329|211|781|532|173|346|278|128|454|534|448|587,0.89|0.88|0.00|0.00|0.00|0.00|0.02|0.01|0.00|0.00|0.00|0.01|0.00|0.00|0.01|0.05|0.00|0.00|0.01|0.00|0.00|0.00|0.01|0.01|0.03|0.01,P1:Vol=2314:Drug=0.89|P2:Vol=2522:Drug=0.88|P3:Vol=380:Drug=0.00|P4:Vol=488:Drug=0.00|P5:Vol=192:Drug=0.00|P6:Vol=341:Drug=0.00|P7:Vol=207:Drug=0.02|P8:Vol=233:Drug=0.01|P9:Vol=452:Drug=0.00|P10:Vol=292:Drug=0.00
BDNF,BDNF-AS,BDNF antisense RNA,,ncRNA,ANTI-BDNF|BDNF|BDNF-AS1|BDNFAS|BDNFOS|NCRNA00049,BDNF antisense RNA (non-protein coding)|BDNF antisense RNA 1 (non-protein coding)|BDNF opposite strand (non-protein coding)|brain-derived neurotrophic factor opposite strand,ENSG00000245573,ENST00000499008|ENST00000499568|ENST00000500662|ENST00000501176|ENST00000501663|ENST00000502161|ENST00000530313|ENST00000530686|ENST00000532965|ENST00000650703,,P23560,,BDNF_HUMAN,497258.0,NR_002832.2|NR_033312.1|NR_033313.1|NR_033314.1|NR_033315.1,,NC_000011.10|NC_060935.1,20608.0,611468.0,PA134953249,9606.ENSP00000414303,1B8M|1BND,,,,,11,27506808.0,27698231.0,1.0,247.0,Secreted,9606.0,,,,True,brain derived neurotrophic factor,123,76,TRAMADOL|FLUTICASONE|IONOMYCIN|MONOAMINE OXIDASE INHIBITOR|FREUND'S ADJUVANT|LITHIUM|ZINC SULFATE ANHYDROUS|CAPSAICIN|PROPRANOLOL HYDROCHLORIDE|MARIJUANA|NORTRIPTYLINE|BORTEZOMIB|GLUCAGON (RDNA)|COLCHICINE|DOXEPIN HYDROCHLORIDE|DRONABINOL|TANAPROGET|CYCLOOXYGENASE INHIBITOR|VERTEPORFIN|ANTIOXIDANT,TRAMADOL|FLUTICASONE|LITHIUM|ZINC SULFATE ANHYDROUS|CAPSAICIN|PROPRANOLOL HYDROCHLORIDE|NORTRIPTYLINE|BORTEZOMIB|GLUCAGON (RDNA)|COLCHICINE,VERTEPORFIN|RNA POLYMERASE INHIBITOR|NORMAL SALINE|POLYSIALIC ACID|TANAPROGET,DRUGGABLE GENOME|GROWTH FACTOR,agonist|inhibitor,Guide to Pharmacology|PharmGKB - The Pharmacogenomics Knowledgebase|NCI Cancer Gene Index,True,CHEMBL4523205,SINGLE PROTEIN,0,0,6,6,6,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Neurotrophic factor BDNF precursor form,"Important signaling molecule that activates signaling cascades downstream of NTRK2. Activates signaling cascades via the heterodimeric receptor formed by NGFR and SORCS2 (PubMed:24908487, PubMed:29909994). Signaling via NGFR and SORCS2 plays a role in synaptic plasticity and long-term depression (LTD). Binding to NGFR and SORCS2 promotes neuronal apoptosis. Promotes neuronal growth cone collapse (By similarity)",3D-structure|Alternative promoter usage|Alternative splicing|Cleavage on pair of basic residues|Direct protein sequencing|Disulfide bond|Glycoprotein|Growth factor|Proteomics identification|Reference proteome|Secreted|Signal,Belongs to the NGF-beta family,PF00243:NGF,1,IPR020430:Brain-der_neurotrophic_factor|IPR029034:Cystine-knot_cytokine|IPR020408:Nerve_growth_factor-like|IPR002072:Nerve_growth_factor-rel|IPR019846:Nerve_growth_factor_CS,5,,domain|family|homologous_superfamily|conserved_site,True,Histone Acetyltransferase,LOW,Histone Acetyltransferase: Keyword: hat,Histone Acetyltransferase,True,2,1B8M|1BND,1B8M,2.75,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1B8M.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1B8M.pdb,Moderate (2.5-3.0Å),True,11,8.0,788.654,0.719,48.583,0.091,True,9,Good,Medium,Optimal volume (789A3)|High druggability (0.72),,252|472|180|425|108|215|253|789|242|211|213,0.66|0.03|0.23|0.02|0.00|0.72|0.04|0.00,P1:Vol=252:Drug=0.66|P2:Vol=472:Drug=0.03|P3:Vol=180:Drug=0.23|P4:Vol=425:Drug=0.00|P5:Vol=108:Drug=0.02|P6:Vol=215:Drug=0.00|P7:Vol=253:Drug=0.00|P8:Vol=789:Drug=0.72|P9:Vol=242:Drug=0.04|P10:Vol=211:Drug=0.00
NGF,NGF,nerve growth factor,"This gene is a member of the NGF-beta family and encodes a secreted protein which homodimerizes and is incorporated into a larger complex. This protein has nerve growth stimulating activity and the complex is involved in the regulation of growth and the differentiation of sympathetic and certain sensory neurons. Mutations in this gene have been associated with hereditary sensory and autonomic neuropathy, type 5 (HSAN5), and dysregulation of this gene's expression is associated with allergic rhinitis. [provided by RefSeq, Jul 2008].",protein-coding,Beta-NGF|HSAN5|NGFB,"beta-nerve growth factor|nerve growth factor (beta polypeptide)|nerve growth factor, beta subunit|pro-nerve growth factor long",ENSG00000134259,ENST00000369512|ENST00000675637|ENST00000676038|ENST00000679806|ENST00000680116|ENST00000680540|ENST00000680752|ENST00000681124|ENST00000871201|ENST00000871202,ENSP00000358525|ENSP00000502380|ENSP00000502831|ENSP00000505558|ENSP00000505694|ENSP00000506364|ENSP00000506492|ENSP00000506569|ENSP00000541260|ENSP00000541261,P01138,A0A7P0TAZ6|A0A346FYQ1,NGF_HUMAN,4803.0,NM_001437545.1|NM_002506.3|XM_011541518.3|XM_054336789.1,NP_001424474.1|NP_002497.2|XP_011539820.1|XP_054192764.1,NC_000001.11|NC_060925.1|NG_007944.1,7808.0,162030.0,PA162397475,9606.ENSP00000358525,1SG1|1WWW|2IFG|4EDW|4EDX|4ZBN|5JZ7|6YW8,,IPR002072|IPR019846|IPR020408|IPR020425|IPR020437|IPR029034,PF00243,PS50270,1,115285904.0,115338770.0,-1.0,241.0,Secreted|Endosome lumen,9606.0,1876.0,Nerve growth factor,biocarta:cdk5pathway|biocarta:erk5pathway|biocarta:erkpathway|biocarta:ngfpathway|biocarta:trkapathway|kegg:hsa04010|kegg:hsa04014|kegg:hsa04015|kegg:hsa04020|kegg:hsa04060|pid:p75ntrpathway|pid:pi3kplctrkpathway|pid:shp2_pathway|pid:trkrpathway|wikipathways:WP2380|wikipathways:WP382|wikipathways:WP3932|wikipathways:WP3998|wikipathways:WP4172,True,nerve growth factor,9,0,MEDI-578|CERE-110|FASINUMAB|TANEZUMAB|FRUNEVETMAB|FULRANUMAB|FASINUMAB|BEDINVETMAB|PG-110,,TANEZUMAB|MEDI-578|CERE-110|FASINUMAB|FRUNEVETMAB,DRUGGABLE GENOME|KINASE|GROWTH FACTOR,binder|inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL1649058,SINGLE PROTEIN,0,0,7,7,8,True,43,0,11,14,0,TANEZUMAB|FASINUMAB|TANEZUMAB|FASINUMAB|TANEZUMAB|TANEZUMAB|TANEZUMAB|TANEZUMAB|TANEZUMAB|TANEZUMAB,Antibody,Beta-nerve growth factor inhibitor,False,True,True,MEDIUM - Clinical stage compounds exist,Beta-nerve growth factor,"Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems (PubMed:14976160, PubMed:20978020). Extracellular ligand for the NTRK1 and NGFR receptors, activates cellular signaling cascades to regulate neuronal proliferation, differentiation and survival (Probable) (PubMed:20978020). The immature NGF precursor (proNGF) functions as a ligand for the heterodimeric receptor formed by SORCS2 and NGFR, and activates cellular signaling cascades that lead to inactivation of RAC1 and/or RAC2, reorganization of the actin cytoskeleton and neuronal growth cone collapse. In contrast to mature NGF, the precursor form (proNGF) promotes neuronal apoptosis (in vitro) (By similarity). Inhibits metalloproteinase-dependent proteolysis of platelet glycoprotein VI (PubMed:20164177). Binds lysophosphatidylinositol and lysophosphatidylserine between the two chains of the homodimer. The lipid-bound form promotes histamine relase from mast cells, contrary to the lipid-free form (By similarity)",3D-structure|Cleavage on pair of basic residues|Disease variant|Disulfide bond|Endosome|Glycoprotein|Growth factor|Lipid-binding|Metalloenzyme inhibitor|Metalloprotease inhibitor|Neurodegeneration|Neuropathy|Protease inhibitor|Proteomics identification|Reference proteome|Secreted|Signal,Belongs to the NGF-beta family,PF00243:NGF,1,IPR029034:Cystine-knot_cytokine|IPR020408:Nerve_growth_factor-like|IPR002072:Nerve_growth_factor-rel|IPR020425:Nerve_growth_factor_bsu|IPR020437:Nerve_growth_factor_bsu_mml|IPR019846:Nerve_growth_factor_CS,6,,domain|family|homologous_superfamily|conserved_site,True,Actin|Histone Acetyltransferase|Protease|Metalloenzyme,HIGH,Protease: Keyword: protease|Protease: Keyword: proteinase|Protease: Keyword: metalloprotease|Histone Acetyltransferase: Keyword: hat|Actin: Keyword: actin|Metalloenzyme: Keyword: metalloenzyme,Actin,True,8,1SG1|1WWW|2IFG|4EDW|4EDX|4ZBN|5JZ7|6YW8,1SG1,2.4,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1SG1.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1SG1.pdb,Good (2.0-2.5Å),True,25,1.0,1062.762,0.971,64.467,0.425,True,22,Good,Medium,Optimal volume (1063A3)|High druggability (0.97),,1063|388|367|112|102|217|526|333|136|383|209|247|208|226|219|510|426|372|212|306|429|253|314|576|996,0.97|0.01|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00,P1:Vol=1063:Drug=0.97|P2:Vol=388:Drug=0.01|P3:Vol=367:Drug=0.00|P4:Vol=112:Drug=0.00|P5:Vol=102:Drug=0.01|P6:Vol=217:Drug=0.00|P7:Vol=526:Drug=0.00|P8:Vol=333:Drug=0.00|P9:Vol=136:Drug=0.00|P10:Vol=383:Drug=0.00
VEGFA,VEGFA,vascular endothelial growth factor A,"This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines. [provided by RefSeq, Jun 2020].",protein-coding,L-VEGF|MVCD1|VEGF|VPF,"vascular endothelial growth factor A, long form|vascular endothelial growth factor A121|vascular endothelial growth factor A165|vascular permeability factor",ENSG00000112715,ENST00000230480|ENST00000324450|ENST00000372055|ENST00000372064|ENST00000372067|ENST00000372077|ENST00000413642|ENST00000417285|ENST00000425836|ENST00000457104,ENSP00000230480|ENSP00000317598|ENSP00000361125|ENSP00000361134|ENSP00000361137|ENSP00000361148|ENSP00000388465|ENSP00000388663|ENSP00000389864|ENSP00000409911,P15692,A0A0Y0IMM4|A2A2V4|A0A0A0MSH5|H0YBI8|H0YBZ0,VEGFA_HUMAN,7422.0,NM_001025366.3|NM_001025367.3|NM_001025368.3|NM_001025369.3|NM_001025370.3|NM_001033756.3|NM_001171622.2|NM_001171623.2|NM_001171624.2|NM_001171625.2,NP_001020537.2|NP_001020538.2|NP_001020539.2|NP_001020540.2|NP_001020541.2|NP_001028928.1|NP_001165093.1|NP_001165094.1|NP_001165095.1|NP_001165096.1,NC_000006.12|NC_060930.1|NG_008732.1|NG_028283.4,12680.0,192240.0,PA37302,,1BJ1|1CZ8|1FLT|1KAT|1KMX|1MJV|1MKG|1MKK|1QTY|1TZH|1TZI|1VGH|1VPF|1VPP|2FJG|2FJH|2QR0|2VGH|2VPF|3BDY,,IPR000072|IPR023581|IPR027928|IPR029034|IPR050507|IPR036841,PF00341|PF14554,PS50278,6,43770184.0,43786487.0,1.0,395.0,Cytoplasm|Nucleus,9606.0,2534.0,Vascular endothelial growth factor A,biocarta:hifpathway|biocarta:no1pathway|biocarta:vegfpathway|kegg:hsa04010|kegg:hsa04014|kegg:hsa04015|kegg:hsa04020|kegg:hsa04066|pid:avb3_integrin_pathway|pid:glypican_1pathway|pid:hif1_tfpathway|pid:hif2pathway|pid:integrin1_pathway|wikipathways:WP1591|wikipathways:WP1984|wikipathways:WP2328|wikipathways:WP2374|wikipathways:WP2586,True,vascular endothelial growth factor A,53,27,PTC299|PEGAPTANIB|BROLUCIZUMAB|GENTAMICIN|AFLIBERCEPT|VANUCIZUMAB|PEGAPTANIB OCTASODIUM|VEGF/HGF-TARGETING DARPIN MP0250|PEMETREXED DISODIUM|EW-A-401|ENDOSTATIN|ABICIPAR PEGOL|LENALIDOMIDE|SUNITINIB|RISUTEGANIB|PHENETHYL ISOTHIOCYANATE|SILDENAFIL|CARBOPLATIN|SELECTIVE CYTOKINE INHIBITORY DRUG CC-1088|ALBUTEROL SULFATE,PEGAPTANIB|BROLUCIZUMAB|GENTAMICIN|AFLIBERCEPT|PEMETREXED DISODIUM|LENALIDOMIDE|SUNITINIB|SILDENAFIL|CARBOPLATIN|ALBUTEROL SULFATE,PEGAPTANIB|ABICIPAR PEGOL|VANUCIZUMAB|AFLIBERCEPT|RANIBIZUMAB,DRUGGABLE GENOME|CLINICALLY ACTIONABLE|DRUG RESISTANCE|GROWTH FACTOR|CELL SURFACE,binder|antibody|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|PharmGKB - The Pharmacogenomics Knowledgebase|Targeted Agents in Lung Cancer (Commentary, 2014)|Clearity Foundation Clinical Trial|Cancer Genome Interpreter|MyCancerGenome Clinical Trial|NCI Cancer Gene Index|The ChEMBL Bioactivity Database",True,CHEMBL1783,SINGLE PROTEIN,0,0,313,313,1000,True,1191,25,0,0,0,BEVACIZUMAB|BEVACIZUMAB|AFLIBERCEPT|BEVACIZUMAB|BEVACIZUMAB|BEVACIZUMAB|BEVACIZUMAB|AFLIBERCEPT|BEVACIZUMAB|BEVACIZUMAB,Antibody|Protein,Vascular endothelial growth factor A inhibitor,True,False,True,HIGH - Approved drugs exist,"Vascular endothelial growth factor A, long form","Binds to the KDR receptor but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth",3D-structure|Alternative initiation|Alternative promoter usage|Alternative splicing|Angiogenesis|Cytoplasm|Developmental protein|Differentiation|Direct protein sequencing|Disulfide bond|Endoplasmic reticulum|Extracellular matrix|Glycoprotein|Golgi apparatus|Growth factor|Heparin-binding|Mitogen|Nucleus|Proteomics identification|Reference proteome,Belongs to the PDGF/VEGF growth factor family,PF00341:PDGF|PF14554:VEGF_C,2,IPR029034:Cystine-knot_cytokine|IPR023581:PD_growth_factor_CS|IPR000072:PDGF/VEGF_dom|IPR050507:PDGF/VEGF_growth_factor|IPR027928:VEGF_C|IPR036841:VEGF_C_sf,6,,domain|family|homologous_superfamily|conserved_site,False,,NONE,,,True,56,1BJ1|1CZ8|1FLT|1KAT|1KMX|1MJV|1MKG|1MKK|1QTY|1TZH,1BJ1,2.4,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1BJ1.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1BJ1.pdb,Good (2.0-2.5Å),True,54,51.0,1322.692,0.155,,0.155,True,47,Moderate,Low,Optimal volume (1323A3),Low druggability (0.15),135|434|257|267|293|284|478|252|733|312|670|292|381|406|209|143|295|324|300|819|244|463|636|264|365|304|309|116|132|414|149|151|193|429|226|344|296|472|572|332|328|403|1044|653|481|340|170|363|389|412|1323|586|316|356,0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.01|0.00|0.00|0.01|0.00|0.01|0.00|0.00|0.08|0.00|0.15|0.00|0.03|0.04|0.00|0.15|0.04,P1:Vol=135:Drug=0.00|P2:Vol=434:Drug=0.00|P3:Vol=257:Drug=0.00|P4:Vol=267:Drug=0.00|P5:Vol=293:Drug=0.00|P6:Vol=284:Drug=0.00|P7:Vol=478:Drug=0.00|P8:Vol=252:Drug=0.00|P9:Vol=733:Drug=0.00|P10:Vol=312:Drug=0.00
TP53,TP53,tumor protein p53,"This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons from identical transcript variants (PMIDs: 12032546, 20937277). [provided by RefSeq, Dec 2016].",protein-coding,BCC7|BMFS5|LFS1|P53|TRP53,antigen NY-CO-13|cellular tumor antigen p53|mutant tumor protein 53|phosphoprotein p53|transformation-related protein 53,ENSG00000141510,ENST00000269305|ENST00000359597|ENST00000413465|ENST00000420246|ENST00000445888|ENST00000455263|ENST00000503591|ENST00000504290|ENST00000504937|ENST00000505014,ENSP00000269305|ENSP00000352610|ENSP00000391127|ENSP00000391478|ENSP00000398846|ENSP00000410739|ENSP00000423862|ENSP00000424104|ENSP00000425104|ENSP00000426252,P04637,H2EHT1|K7PPA8|Q53GA5|A0A087X1Q1|A0A087WT22,P53_HUMAN,7157.0,NM_000546.6|NM_001126112.3|NM_001126113.3|NM_001126114.3|NM_001126115.2|NM_001126116.2|NM_001126117.2|NM_001126118.2|NM_001276695.3|NM_001276696.3,NP_000537.3|NP_001119584.1|NP_001119585.1|NP_001119586.1|NP_001119587.1|NP_001119588.1|NP_001119589.1|NP_001119590.1|NP_001263624.1|NP_001263625.1,NC_000017.11|NC_060941.1|NG_017013.2,11998.0,191170.0,PA36679,9606.ENSP00000269305,1A1U|1AIE|1C26|1DT7|1GZH|1H26|1HS5|1JSP|1KZY|1MA3|1OLG|1OLH|1PES|1PET|1SAE|1SAF|1SAK|1SAL|1TSR|1TUP,,IPR002117|IPR008967|IPR010991|IPR011615|IPR012346|IPR013872|IPR036674|IPR040926,PF00870|PF07710|PF08563|PF18521,,17,7661779.0,7687546.0,-1.0,393.0,"Cytoplasm|Nucleus|Nucleus, PML body",9606.0,460.0,P53,biocarta:arfpathway|biocarta:atmpathway|biocarta:atrbrcapathway|biocarta:btg2pathway|biocarta:chemicalpathway|kegg:hsa04010|kegg:hsa04071|kegg:hsa04110|kegg:hsa04115|kegg:hsa04137|netpath:Pathway_EGFR1|netpath:Pathway_Oncostatin_M|netpath:Pathway_TGF_beta_Receptor|pid:ap1_pathway|pid:aurora_a_pathway|pid:bard1pathway|pid:hdac_classiii_pathway|pid:hif1apathway|smpdb:SMP00436|smpdb:SMP00437|smpdb:SMP00438|smpdb:SMP00439|wikipathways:WP1403|wikipathways:WP1530|wikipathways:WP1545|wikipathways:WP1601|wikipathways:WP1742,True,tumor protein p53,452,152,VEMURAFENIB|CHEMBL:CHEMBL602150|CHEMBL:CHEMBL201325|CHK1 INHIBITOR GDC-0575|FENTICLOR|PACLITAXEL|CHEMBL:CHEMBL85194|ERLOTINIB|CHEMBL:CHEMBL408563|HEXACHLOROPHENE|BORTEZOMIB|IL-27 SUBUNIT &ALPHA;|CHEMBL:CHEMBL195350|PHA-680632|CHEMBL:CHEMBL1389794|SERTRALINE HYDROCHLORIDE|CHEMBL:CHEMBL99408|THIMEROSAL|ABIRATERONE ACETATE|TRICLOCARBAN,VEMURAFENIB|PACLITAXEL|ERLOTINIB|HEXACHLOROPHENE|BORTEZOMIB|SERTRALINE HYDROCHLORIDE|THIMEROSAL|ABIRATERONE ACETATE|ENZALUTAMIDE|VENETOCLAX,EPRENETAPOPT|REBEMADLIN|THIOUREIDOBUTYRONITRILE|NUTLIN-3|P53-HDM2 INTERACTION INHIBITOR MI-773,DRUGGABLE GENOME|KINASE|TRANSCRIPTION FACTOR COMPLEX|TUMOR SUPPRESSOR|CLINICALLY ACTIONABLE|TRANSPORTER|DRUG RESISTANCE,modulator|vaccine|activator|inhibitor,"Drug Target Commons|CIViC: Clinical Interpretation of Variants in Cancer|FDA Pharmacogenomic Biomarkers|The Clinical Knowledgebase|PharmGKB - The Pharmacogenomics Knowledgebase|Targeted Agents in Lung Cancer (Commentary, 2014)|Cancer Genome Interpreter|Clearity Foundation Clinical Trial|NCI Cancer Gene Index|The ChEMBL Bioactivity Database",True,CHEMBL2424509,SINGLE PROTEIN,0,0,133,133,162,True,79,0,2,20,3,EPRENETAPOPT|IDASANUTLIN|CENERSEN SODIUM|CENERSEN|CENERSEN|NAVTEMADLIN|SIREMADLIN|IDASANUTLIN|NAVTEMADLIN|IDASANUTLIN,Gene|Oligonucleotide|Small molecule,p53 mRNA RNAi inhibitor|Tumour suppressor p53/oncoprotein Mdm2 inhibitor|Cellular tumor antigen p53 stabiliser|Cellular tumor antigen p53 exogenous gene|p53 mRNA antisense inhibitor,True,True,True,HIGH - Approved drugs exist,Cellular tumor antigen p53,"Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17189187, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:38653238, PubMed:9840937). Negatively regulates cell division by controlling expression of a set of genes required for this process (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:9840937). One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression (PubMed:12524540, PubMed:17189187). Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this activity is inhibited when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492)",3D-structure|Acetylation|Activator|Alternative promoter usage|Alternative splicing|Apoptosis|Biological rhythms|Cell cycle|Cytoplasm|Cytoskeleton|Direct protein sequencing|Disease variant|DNA-binding|Endoplasmic reticulum|Glycoprotein|Host-virus interaction|Isopeptide bond|Li-Fraumeni syndrome|Metal-binding|Methylation,Belongs to the p53 family,PF00870:P53|PF08563:P53_TAD|PF07710:P53_tetramer|PF18521:TAD2,4,IPR008967:p53-like_TF_DNA-bd_sf|IPR012346:p53/RUNT-type_TF_DNA-bd_sf|IPR011615:p53_DNA-bd|IPR040926:p53_TAD2|IPR036674:p53_tetramer_sf|IPR010991:p53_tetrameristn|IPR013872:p53_transactivation_domain|IPR002117:p53_tumour_suppressor,8,,homologous_superfamily|family|domain|conserved_site,True,Kinase|Histone Acetyltransferase|Transcription Factor,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: cdk|Histone Acetyltransferase: Keyword: hat|Transcription Factor: Keyword: transcription factor|Transcription Factor: Keyword: dna-binding,Kinase,True,298,1A1U|1AIE|1C26|1DT7|1GZH|1H26|1HS5|1JSP|1KZY|1MA3,1A1U,,SOLUTION NMR,protein_structures/pdb_experimental/1A1U.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1A1U.pdb,,True,4,2.0,172.617,0.077,28.2,0.299,True,3,Poor,Low,,Small volume (173A3)|Low druggability (0.08),340|173|276|255,0.00|0.08|0.00|0.02,P1:Vol=340:Drug=0.00|P2:Vol=173:Drug=0.08|P3:Vol=276:Drug=0.00|P4:Vol=255:Drug=0.02
MYC,MYC,"MYC proto-oncogene, bHLH transcription factor","This gene is a proto-oncogene and encodes a nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. The encoded protein forms a heterodimer with the related transcription factor MAX. This complex binds to the E box DNA consensus sequence and regulates the transcription of specific target genes. Amplification of this gene is frequently observed in numerous human cancers. Translocations involving this gene are associated with Burkitt lymphoma and multiple myeloma in human patients. There is evidence to show that translation initiates both from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site, resulting in the production of two isoforms with distinct N-termini. [provided by RefSeq, Aug 2017].",protein-coding,MRTL|MYCC|bHLHe39|c-Myc,avian myelocytomatosis viral oncogene homolog|class E basic helix-loop-helix protein 39|myc proto-oncogene protein|myc-related translation/localization regulatory factor|proto-oncogene c-Myc,ENSG00000136997,ENST00000259523|ENST00000377970|ENST00000517291|ENST00000520751|ENST00000524013|ENST00000621592|ENST00000641036|ENST00000641252|ENST00000651626|ENST00000652288,ENSP00000259523|ENSP00000367207|ENSP00000429441|ENSP00000430235|ENSP00000478887|ENSP00000493139|ENSP00000493145|ENSP00000499105|ENSP00000499182|ENSP00000516742,P01106,A0A0B4J1R1|Q16591|Q14899|A0A494C1T8|H0YBG3,MYC_HUMAN,4609.0,NM_001354870.1|NM_002467.6,NP_001341799.1|NP_002458.2,NC_000008.11|NC_060932.1|NG_007161.2,7553.0,190080.0,PA31353,9606.ENSP00000478887,1A93|1EE4|1MV0|1NKP|2A93|2OR9|4Y7R|5I4Z|5I50|6C4U|6E16|6E24|6G6J|6G6K|6G6L|7T1Y|7T1Z|8J2Q|8OTS|8OTT,,IPR002418|IPR003327|IPR011598|IPR012682|IPR036638|IPR050433,PF00010|PF01056|PF02344,PS50888,8,127735434.0,127742951.0,1.0,454.0,"Nucleus, nucleoplasm|Nucleus, nucleolus|Nucleus",9606.0,31092.0,Myc,biocarta:arfpathway|biocarta:cardiacegfpathway|biocarta:cdmacpathway|biocarta:ctcfpathway|biocarta:erkpathway|kegg:hsa04010|kegg:hsa04012|kegg:hsa04110|kegg:hsa04151|kegg:hsa04218|netpath:Pathway_EGFR1|netpath:Pathway_TGF_beta_Receptor|pid:ap1_pathway|pid:betacatenin_nuc_pathway|pid:cd40_pathway|pid:ceramide_pathway|pid:cmyb_pathway|reactome:R-HSA-1266738|reactome:R-HSA-1280215|reactome:R-HSA-1280218|reactome:R-HSA-1362277|reactome:R-HSA-1500931|wikipathways:WP127|wikipathways:WP1530|wikipathways:WP1545|wikipathways:WP1742|wikipathways:WP179,True,"MYC proto-oncogene, bHLH transcription factor",70,29,UBENIMEX|DIETHYLSTILBESTROL|METHYLPREDNISOLONE|PERILLYL ALCOHOL|RONICICLIB|OLAPARIB|DINACICLIB|BRYOSTATIN 1|TETRADECANOYLPHORBOL ACETATE|LIF|AMINOPTERIN|LOBAPLATIN|PREXASERTIB|CISPLATIN|AN-9|POLATUZUMAB VEDOTIN|PREGNANT MARE SERUM GONADOTROPIN|MELATONIN|PROTEASOME INHIBITOR|VORINOSTAT,DIETHYLSTILBESTROL|METHYLPREDNISOLONE|OLAPARIB|CISPLATIN|POLATUZUMAB VEDOTIN|MELATONIN|VORINOSTAT|BROMOCRIPTINE|ESTRONE|SULINDAC,AMINOPTERIN|LOBAPLATIN|AN-9|BIZELESIN|COBALT CO-60,CLINICALLY ACTIONABLE|TRANSCRIPTION FACTOR,,"Clearity Foundation Biomarkers|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|PharmGKB - The Pharmacogenomics Knowledgebase|Cancer Genome Interpreter|NCI Cancer Gene Index",True,CHEMBL1250349,SINGLE PROTEIN,0,0,2,2,2,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Myc proto-oncogene protein,"Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3' (PubMed:24940000, PubMed:25956029). Activates the transcription of growth-related genes (PubMed:24940000, PubMed:25956029). Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis (PubMed:24940000, PubMed:25956029). Regulator of somatic reprogramming, controls self-renewal of embryonic stem cells (By similarity). Functions with TAF6L to activate target gene expression through RNA polymerase II pause release (By similarity). Positively regulates transcription of HNRNPA1, HNRNPA2 and PTBP1 which in turn regulate splicing of pyruvate kinase PKM by binding repressively to sequences flanking PKM exon 9, inhibiting exon 9 inclusion and resulting in exon 10 inclusion and production of the PKM M2 isoform (PubMed:20010808)",3D-structure|Acetylation|Activator|Alternative initiation|Alternative splicing|Chromosomal rearrangement|Chromosome|Cytoplasm|DNA-binding|Glycoprotein|Isopeptide bond|Nucleus|Phosphoprotein|Proteomics identification|Proto-oncogene|Reference proteome|Transcription|Transcription regulation|Ubl conjugation,,PF00010:HLH|PF02344:Myc-LZ|PF01056:Myc_N,3,IPR011598:bHLH_dom|IPR036638:HLH_DNA-bd_sf|IPR003327:Myc-LZ|IPR050433:Myc_transcription_factors|IPR002418:Tscrpt_reg_Myc|IPR012682:Tscrpt_reg_Myc_N,6,,domain|family|homologous_superfamily,True,Kinase|Histone Acetyltransferase|Transcription Factor,HIGH,Kinase: Keyword: kinase|Histone Acetyltransferase: Keyword: hat|Transcription Factor: Keyword: transcription factor|Transcription Factor: Keyword: dna-binding|Transcription Factor: Pfam: PF00010,Kinase,True,25,1A93|1EE4|1MV0|1NKP|2A93|2OR9|4Y7R|5I4Z|5I50|6C4U,1A93,,SOLUTION NMR,protein_structures/pdb_experimental/1A93.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1A93.pdb,,True,8,1.0,355.608,0.624,57.0,0.316,True,6,Moderate,Low,Adequate volume (356A3),,356|279|393|212|326|385|299|262,0.62|0.07|0.01|0.01|0.00,P1:Vol=356:Drug=0.62|P2:Vol=279:Drug=0.07|P3:Vol=393:Drug=0.00|P4:Vol=212:Drug=0.00|P5:Vol=326:Drug=0.01|P6:Vol=385:Drug=0.01|P7:Vol=299:Drug=0.00|P8:Vol=262:Drug=0.00
JUN,JUN,"Jun proto-oncogene, AP-1 transcription factor subunit","This gene is the putative transforming gene of avian sarcoma virus 17. It encodes a protein which is highly similar to the viral protein, and which interacts directly with specific target DNA sequences to regulate gene expression. This gene is intronless and is mapped to 1p32-p31, a chromosomal region involved in both translocations and deletions in human malignancies. [provided by RefSeq, Jul 2008].",protein-coding,AP-1|AP1|c-Jun|cJUN|p39,Jun activation domain binding protein|activator protein 1|enhancer-binding protein AP1|jun oncogene|proto-oncogene c-Jun,ENSG00000177606,ENST00000371222|ENST00000678696|ENST00000710273,ENSP00000360266|ENSP00000503132|ENSP00000518166,P05412,A0AA34QVR9,JUN_HUMAN,3725.0,NM_002228.4,NP_002219.1,NC_000001.11|NC_060925.1|NG_047027.2,6204.0,165160.0,PA30006,9606.ENSP00000360266,1A02|1FOS|1JNM|1JUN|1S9K|1T2K|5FV8|5T01|6Y3V|8SOS,,IPR002112|IPR004827|IPR005643|IPR008917|IPR046347|IPR050946,PF00170|PF03957,PS50217,1,58776845.0,58784048.0,-1.0,331.0,Nucleus,9606.0,1679.0,C-jun,biocarta:41bbpathway|biocarta:agrpathway|biocarta:arenrf2pathway|biocarta:at1rpathway|biocarta:atmpathway|kegg:hsa04010|kegg:hsa04012|kegg:hsa04024|kegg:hsa04137|kegg:hsa04210|netpath:Pathway_Alpha6Beta4Integrin|netpath:Pathway_AndrogenReceptor|netpath:Pathway_BCR|netpath:Pathway_EGFR1|netpath:Pathway_Gastrin|pid:ap1_pathway|pid:ar_tf_pathway|pid:atf2_pathway|pid:avb3_opn_pathway|pid:bcr_5pathway|reactome:R-HSA-1257604|reactome:R-HSA-1257604|reactome:R-HSA-1266738|reactome:R-HSA-1280215|reactome:R-HSA-1280218|smpdb:SMP00320|smpdb:SMP00321|wikipathways:WP127|wikipathways:WP138|wikipathways:WP1449|wikipathways:WP1528|wikipathways:WP1772,True,"Jun proto-oncogene, AP-1 transcription factor subunit",46,24,NEOCHAMAEJASMIN A|NAFRONYL OXALATE|BRUCEANTIN|ATOMOXETINE HYDROCHLORIDE|IRISOLIDONE|MECHLORETHAMINE HYDROCHLORIDE|CINNARIZINE|(-)-CAMPHOR|QUINAPRIL HYDROCHLORIDE|TRIFLUPROMAZINE HYDROCHLORIDE|CHEMBL:CHEMBL477052|CRIDANIMOD|TROPISETRON|EFLORNITHINE|9-ANTHROIC ACID|COLCHICINE|METHIMAZOLE|CARBOXYMETHYL-TRIMETHYL-ARSONIUM|PATULIN|BENZO[B]FLUORANTHENE,BRUCEANTIN|ATOMOXETINE HYDROCHLORIDE|MECHLORETHAMINE HYDROCHLORIDE|CINNARIZINE|QUINAPRIL HYDROCHLORIDE|TRIFLUPROMAZINE HYDROCHLORIDE|TROPISETRON|EFLORNITHINE|COLCHICINE|METHIMAZOLE,NEOCHAMAEJASMIN A|BRUCEANTIN|IRISOLIDONE|CHEMBL:CHEMBL477052|SERGEOLIDE,TRANSCRIPTION FACTOR COMPLEX|TUMOR SUPPRESSOR|CLINICALLY ACTIONABLE|DRUGGABLE GENOME|TRANSCRIPTION FACTOR,,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|NCI Cancer Gene Index|Drug Target Commons",True,CHEMBL1075084,SINGLE PROTEIN,0,0,7,7,7,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Transcription factor Jun,"(Microbial infection) Upon Epstein-Barr virus (EBV) infection, binds to viral BZLF1 Z promoter and activates viral BZLF1 expression",3D-structure|Acetylation|Activator|Direct protein sequencing|DNA-binding|Isopeptide bond|Nucleus|Phosphoprotein|Proteomics identification|Proto-oncogene|Reference proteome|Transcription|Transcription regulation|Ubl conjugation,Belongs to the bZIP family. Jun subfamily,PF00170:bZIP_1|PF03957:Jun,2,IPR050946:AP-1_TF_bZIP|IPR004827:bZIP|IPR046347:bZIP_sf|IPR005643:JNK|IPR002112:Leuzip_Jun|IPR008917:TF_DNA-bd_sf,6,,domain|family|homologous_superfamily,True,Transcription Factor,MEDIUM,Transcription Factor: Keyword: transcription factor|Transcription Factor: Keyword: dna-binding,Transcription Factor,True,10,1A02|1FOS|1JNM|1JUN|1S9K|1T2K|5FV8|5T01|6Y3V|8SOS,1A02,2.7,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1A02.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1A02.pdb,Moderate (2.5-3.0Å),True,49,4.0,1176.151,0.846,,0.125,True,34,Good,Medium,Optimal volume (1176A3)|High druggability (0.85),,198|499|495|1176|472|688|570|353|584|369|310|368|425|270|215|194|388|156|468|482|250|392|234|326|469|874|145|416|144|416|626|353|473|270|354|342|199|358|362|255|154|577|534|440|307|491|470|267|1402,0.00|0.60|0.00|0.85|0.10|0.01|0.02|0.02|0.02|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.01|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.01,P1:Vol=198:Drug=0.00|P2:Vol=499:Drug=0.60|P3:Vol=495:Drug=0.00|P4:Vol=1176:Drug=0.85|P5:Vol=472:Drug=0.10|P6:Vol=688:Drug=0.01|P7:Vol=570:Drug=0.02|P8:Vol=353:Drug=0.02|P9:Vol=584:Drug=0.00|P10:Vol=369:Drug=0.02
FOS,FOS,"Fos proto-oncogene, AP-1 transcription factor subunit","The Fos gene family consists of 4 members: FOS, FOSB, FOSL1, and FOSL2.  These genes encode leucine zipper proteins that can dimerize with proteins of the JUN family, thereby forming the transcription factor complex AP-1.  As such, the FOS proteins have been implicated as regulators of cell proliferation, differentiation, and transformation.  In some cases, expression of the FOS gene has also been associated with apoptotic cell death. [provided by RefSeq, Jul 2008].",protein-coding,AP-1|C-FOS|p55,"FBJ murine osteosarcoma viral (v-fos) oncogene homolog (oncogene FOS)|FBJ murine osteosarcoma viral oncogene homolog|Fos proto-oncogene, AP-1 trancription factor subunit|G0/G1 switch regulatory protein 7|activator protein 1",ENSG00000170345,ENST00000303562|ENST00000535987|ENST00000554212|ENST00000554617|ENST00000555242|ENST00000555347|ENST00000555672|ENST00000555686|ENST00000556324|ENST00000557139,ENSP00000306245|ENSP00000442268|ENSP00000450519|ENSP00000450886|ENSP00000451786|ENSP00000452386|ENSP00000452440|ENSP00000452443|ENSP00000452590|ENSP00000542046,P01100,G3V5J9|Q6FG41|G3V289|G3V2V7|G3V5N7,FOS_HUMAN,2353.0,NM_005252.4,NP_005243.1,NC_000014.9|NC_060938.1|NG_029673.1,3796.0,164810.0,PA28212,9606.ENSP00000306245,1A02|1FOS|1S9K,,IPR000837|IPR004827|IPR046347,PF00170,PS50217,14,75278826.0,75283190.0,1.0,380.0,"Nucleus|Endoplasmic reticulum|Cytoplasm, cytosol",9606.0,3844.0,C-Fos,biocarta:arenrf2pathway|biocarta:at1rpathway|biocarta:bcrpathway|biocarta:cardiacegfpathway|biocarta:ccr5pathway|kegg:hsa04010|kegg:hsa04024|kegg:hsa04210|kegg:hsa04380|kegg:hsa04620|netpath:Pathway_Alpha6Beta4Integrin|netpath:Pathway_BCR|netpath:Pathway_EGFR1|netpath:Pathway_IL6|netpath:Pathway_Oncostatin_M|pid:ap1_pathway|pid:ar_nongenomic_pathway|pid:atf2_pathway|pid:avb3_opn_pathway|pid:bcr_5pathway|reactome:R-HSA-1280215|reactome:R-HSA-1280218|reactome:R-HSA-162582|reactome:R-HSA-162582|reactome:R-HSA-166016|wikipathways:WP127|wikipathways:WP1449|wikipathways:WP1528|wikipathways:WP1772|wikipathways:WP2018,True,"Fos proto-oncogene, AP-1 transcription factor subunit",26,10,MAGNESIUM SULFATE ANHYDROUS|DEHYDRATED ALCOHOL|ANTIBIOTIC|RECOMBINANT INTERLEUKIN-1-BETA|LHVS|VBY-825|PACLITAXEL|URSODIOL|PILOCARPINE HYDROCHLORIDE|THROMBIN|BROMOCRIPTINE|NIMODIPINE|COMPOUND (R)-26 [PMID: 22686657]|PETESICATIB|ODANACATIB|COMPOUND 4D [PMID: 38746883]|SAPONIN|K777|PROTEIN KINASE A INHIBITOR|DAIDZEIN,MAGNESIUM SULFATE ANHYDROUS|DEHYDRATED ALCOHOL|PACLITAXEL|URSODIOL|PILOCARPINE HYDROCHLORIDE|THROMBIN|BROMOCRIPTINE|NIMODIPINE|PHENOBARBITAL|BACLOFEN,PROTEIN KINASE A INHIBITOR|RECOMBINANT INTERLEUKIN-1-BETA|RECOMBINANT INTERFERON BETA|MAGNESIUM SULFATE ANHYDROUS|COMPOUND (R)-26 [PMID: 22686657],DRUGGABLE GENOME|TRANSCRIPTION FACTOR,inhibitor,Guide to Pharmacology|NCI Cancer Gene Index,True,CHEMBL5029,SINGLE PROTEIN,0,0,1,1,1,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Protein c-Fos,"Nuclear phosphoprotein which forms a tight but non-covalently linked complex with the JUN/AP-1 transcription factor. In the heterodimer, FOS and JUN/AP-1 basic regions each seems to interact with symmetrical DNA half sites. On TGF-beta activation, forms a multimeric SMAD3/SMAD4/JUN/FOS complex at the AP1/SMAD-binding site to regulate TGF-beta-mediated signaling. Has a critical function in regulating the development of cells destined to form and maintain the skeleton. It is thought to have an important role in signal transduction, cell proliferation and differentiation. In growing cells, activates phospholipid synthesis, possibly by activating CDS1 and PI4K2A. This activity requires Tyr-dephosphorylation and association with the endoplasmic reticulum",3D-structure|Alternative splicing|Cytoplasm|DNA-binding|Endoplasmic reticulum|Isopeptide bond|Nucleus|Phosphoprotein|Proteomics identification|Proto-oncogene|Reference proteome|Ubl conjugation,Belongs to the bZIP family. Fos subfamily,PF00170:bZIP_1,1,IPR000837:AP-1|IPR004827:bZIP|IPR046347:bZIP_sf,3,,domain|family|homologous_superfamily,True,Transcription Factor,MEDIUM,Transcription Factor: Keyword: transcription factor|Transcription Factor: Keyword: dna-binding,Transcription Factor,True,3,1A02|1FOS|1S9K,1A02,2.7,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1A02.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1A02.pdb,Moderate (2.5-3.0Å),True,49,4.0,1163.745,0.846,,0.125,True,37,Good,Medium,Optimal volume (1164A3)|High druggability (0.85),,203|503|515|1164|479|695|560|354|575|375|304|370|410|262|214|205|383|152|472|492|245|382|236|325|463|864|150|407|147|432|622|358|455|267|352|348|199|353|356|257|151|587|556|426|307|485|479|271|1487,0.00|0.60|0.00|0.85|0.10|0.01|0.02|0.02|0.02|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.01|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.01,P1:Vol=203:Drug=0.00|P2:Vol=503:Drug=0.60|P3:Vol=515:Drug=0.00|P4:Vol=1164:Drug=0.85|P5:Vol=479:Drug=0.10|P6:Vol=695:Drug=0.01|P7:Vol=560:Drug=0.02|P8:Vol=354:Drug=0.02|P9:Vol=575:Drug=0.00|P10:Vol=375:Drug=0.02
STAT3,STAT3,signal transducer and activator of transcription 3,"The protein encoded by this gene is a member of the STAT protein family. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein is activated through phosphorylation in response to various cytokines and growth factors including IFNs, EGF, IL5, IL6, HGF, LIF and BMP2. This protein mediates the expression of a variety of genes in response to cell stimuli, and thus plays a key role in many cellular processes such as cell growth and apoptosis. The small GTPase Rac1 has been shown to bind and regulate the activity of this protein. PIAS3 protein is a specific inhibitor of this protein. This gene also plays a role in regulating host response to viral and bacterial infections. Mutations in this gene are associated with infantile-onset multisystem autoimmune disease and hyper-immunoglobulin E syndrome. [provided by RefSeq, Aug 2020].",protein-coding,ADMIO|ADMIO1|APRF|HIES,DNA-binding protein APRF|acute-phase response factor|signal transducer and activator of transcription 3,ENSG00000168610,ENST00000264657|ENST00000389272|ENST00000404395|ENST00000462269|ENST00000462286|ENST00000471989|ENST00000478276|ENST00000491272|ENST00000498330|ENST00000585360,ENSP00000264657|ENSP00000373923|ENSP00000384943|ENSP00000467000|ENSP00000467985|ENSP00000502874|ENSP00000503059|ENSP00000503102|ENSP00000503105|ENSP00000503181,P40763,A0A7I2V395|A0A7I2V4C8|A0A7I2V4R3|A0A7I2YQD2|A0A7I2V552,STAT3_HUMAN,6774.0,NM_001369512.1|NM_001369513.1|NM_001369514.1|NM_001369516.1|NM_001369517.1|NM_001369518.1|NM_001369519.1|NM_001369520.1|NM_001384984.1|NM_001384985.1,NP_001356441.1|NP_001356442.1|NP_001356443.1|NP_001356445.1|NP_001356446.1|NP_001356447.1|NP_001356448.1|NP_001356449.1|NP_001371913.1|NP_001371914.1,NC_000017.11|NC_060941.1|NG_007370.1,11364.0,102582.0,PA337,9606.ENSP00000264657,5AX3|5U5S|6NJS|6NUQ|6QHD|6TLC,,IPR001217|IPR008967|IPR012345|IPR013799|IPR013800|IPR013801|IPR015988|IPR036535|IPR048988|IPR000980,PF01017|PF02864|PF02865|PF21354|PF00017,PS50001,17,42313324.0,42388568.0,-1.0,770.0,Cytoplasm|Nucleus,9606.0,7960.0,STAT3,biocarta:biopeptidespathway|biocarta:egfpathway|biocarta:erkpathway|biocarta:her2pathway|biocarta:il22bppathway|kegg:hsa04062|kegg:hsa04066|kegg:hsa04068|kegg:hsa04217|kegg:hsa04550|netpath:Pathway_AndrogenReceptor|netpath:Pathway_BCR|netpath:Pathway_EGFR1|netpath:Pathway_Fibroblast__growth__factor-1|netpath:Pathway_Gastrin|pid:cxcr4_pathway|pid:erbb1_downstream_pathway|pid:erbb2erbb3pathway|pid:fgf_pathway|pid:gmcsf_pathway|wikipathways:WP127|wikipathways:WP138|wikipathways:WP1528|wikipathways:WP1544|wikipathways:WP1559,True,signal transducer and activator of transcription 3,30,8,OUABAIN|COSMOMYCIN C|DIGITOXIN|RECOMBINANT INTERLEUKIN|CELECOXIB|CUCURBITACIN E|STAT3 INHIBITOR OPB-51602|ACITRETIN|CHEMBL:CHEMBL2062862|OSIMERTINIB|OCHROMYCINONE|CHEMBL:CHEMBL2062869|CURCUMIN/DOXORUBICIN-ENCAPSULATING NANOPARTICLE IMX-110|GOLOTIMOD|WP-1066|CHEMBL:CHEMBL1687979|CHEMBL:CHEMBL2062868|RECOMBINANT INTERFERON|CHEMBL:CHEMBL2062863|DIGOXIN,DIGITOXIN|CELECOXIB|ACITRETIN|OSIMERTINIB|DIGOXIN|CUCURBITACIN B|NICLOSAMIDE|PYRIMETHAMINE,COSMOMYCIN C|CUCURBITACIN E|STAT3 INHIBITOR OPB-51602|CHEMBL:CHEMBL2062862|OCHROMYCINONE,KINASE|TRANSCRIPTION FACTOR COMPLEX|NUCLEAR HORMONE RECEPTOR|TUMOR SUPPRESSOR|CLINICALLY ACTIONABLE|DRUGGABLE GENOME,,"Drug Target Commons|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|NCI Cancer Gene Index|Therapeutic Target Database",True,CHEMBL4296101,PROTEIN-PROTEIN INTERACTION,0,0,1,1,12,True,11,0,0,3,8,DANVATIRSEN|DANVATIRSEN|DANVATIRSEN|DANVATIRSEN|DANVATIRSEN|DANVATIRSEN|DANVATIRSEN|DANVATIRSEN|DANVATIRSEN|DANVATIRSEN,Oligonucleotide,STAT-3 mRNA 3'UTR antisense inhibitor,True,True,True,HIGH - Approved drugs exist,Signal transducer and activator of transcription 3,"Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors (PubMed:10688651, PubMed:12359225, PubMed:12873986, PubMed:15194700, PubMed:15653507, PubMed:16285960, PubMed:17344214, PubMed:18242580, PubMed:18782771, PubMed:22306293, PubMed:23084476, PubMed:28262505, PubMed:32929201, PubMed:38404237). Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene (PubMed:15653507, PubMed:16285960, PubMed:17344214, PubMed:18782771, PubMed:28262505, PubMed:32929201). May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4 (PubMed:12873986). Upon activation of IL6ST/gp130 signaling by interleukin-6 (IL6), binds to the IL6-responsive elements identified in the promoters of various acute-phase protein genes (PubMed:12359225). Activated by IL31 through IL31RA (PubMed:15194700). Acts as a regulator of inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): acetylation promotes its transcription activity and cell differentiation while deacetylation and oxidation of lysine residues by LOXL3 inhibits differentiation (PubMed:28065600, PubMed:28262505). Involved in cell cycle regulation by inducing the expression of key genes for the progression from G1 to S phase, such as CCND1 (PubMed:17344214). Mediates the effects of LEP on melanocortin production, body energy homeostasis and lactation (By similarity). May play an apoptotic role by transctivating BIRC5 expression under LEP activation (PubMed:18242580). Cytoplasmic STAT3 represses macroautophagy by inhibiting EIF2AK2/PKR activity (PubMed:23084476). Plays a crucial role in basal beta cell functions, such as regulation of insulin secretion (By similarity). Following JAK/STAT signaling activation and as part of a complex with NFATC3 and NFATC4, binds to the alpha-beta E4 promoter region of CRYAB and activates transcription in cardiomyocytes (By similarity)",3D-structure|Acetylation|Activator|Alternative splicing|Cytoplasm|Diabetes mellitus|Disease variant|DNA-binding|Dwarfism|Host-virus interaction|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|SH2 domain|Transcription|Transcription regulation,Belongs to the transcription factor STAT family,PF00017:SH2|PF01017:STAT_alpha|PF02864:STAT_bind|PF02865:STAT_int|PF21354:STAT_linker,5,IPR008967:p53-like_TF_DNA-bd_sf|IPR000980:SH2|IPR036860:SH2_dom_sf|IPR001217:STAT|IPR035855:STAT3_SH2|IPR048988:STAT_linker|IPR036535:STAT_N_sf|IPR013800:STAT_TF_alpha|IPR015988:STAT_TF_coiled-coil|IPR013801:STAT_TF_DNA-bd|IPR012345:STAT_TF_DNA-bd_N|IPR013799:STAT_TF_prot_interaction,12,,domain|family|homologous_superfamily,True,T-cell Receptor|Histone Acetyltransferase|Transcription Factor,HIGH,Histone Acetyltransferase: Keyword: hat|T-cell Receptor: Keyword: cd4|Transcription Factor: Keyword: transcription factor|Transcription Factor: Keyword: dna-binding,T-cell Receptor,True,6,5AX3|5U5S|6NJS|6NUQ|6QHD|6TLC,5AX3,2.984,X-RAY DIFFRACTION,protein_structures/pdb_experimental/5AX3.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/5AX3.pdb,Moderate (2.5-3.0Å),True,34,7.0,375.631,0.698,61.4,0.09,True,31,Moderate,Low,Adequate volume (376A3),,605|744|910|511|587|350|376|603|369|82|180|356|370|174|305|457|390|533|493|256|230|224|169|255|407|150|239|307|236|119|305|419|227|214,0.55|0.01|0.00|0.00|0.70|0.00|0.00|0.01|0.01|0.03|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.03,P1:Vol=605:Drug=0.55|P2:Vol=744:Drug=0.01|P3:Vol=910:Drug=0.00|P4:Vol=511:Drug=0.00|P5:Vol=587:Drug=0.00|P6:Vol=350:Drug=0.00|P7:Vol=376:Drug=0.70|P8:Vol=603:Drug=0.00|P9:Vol=369:Drug=0.00|P10:Vol=82:Drug=0.00
NFKB1,NFKB1,nuclear factor kappa B subunit 1,"This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. NFKB is a critical regulator of the immediate-early response to viral infection. Alternative splicing results in multiple transcript variants encoding different isoforms, at least one of which is proteolytically processed. [provided by RefSeq, Aug 2020].",protein-coding,CVID12|EBP-1|KBF1|NF-kB|NF-kB1|NF-kappa-B1|NF-kappaB|NF-kappabeta|NFKB-p105|NFKB-p50|NFkappaB,DNA-binding factor KBF1|nuclear factor NF-kappa-B p105 subunit|nuclear factor NF-kappa-B p50 subunit|nuclear factor kappa-B DNA binding subunit|nuclear factor of kappa light polypeptide gene enhancer in B-cells 1,ENSG00000109320,ENST00000226574|ENST00000394820|ENST00000502367|ENST00000504044|ENST00000505458|ENST00000507079|ENST00000508584|ENST00000509165|ENST00000510638|ENST00000513803,ENSP00000226574|ENSP00000378297|ENSP00000423877|ENSP00000424790|ENSP00000426147|ENSP00000498904|ENSP00000499031|ENSP00000513443|ENSP00000548398|ENSP00000548399,P19838,A0A8V8TLB2|A0A494C157|D6RH30|A0A494C1E9,NFKB1_HUMAN,4790.0,NM_001165412.2|NM_001319226.2|NM_001382625.1|NM_001382626.1|NM_001382627.1|NM_001382628.1|NM_003998.4|XM_024454068.1|XM_024454069.2|XM_047415742.1,NP_001158884.1|NP_001306155.1|NP_001369554.1|NP_001369555.1|NP_001369556.1|NP_001369557.1|NP_003989.2|XP_024309836.1|XP_024309837.1|XP_047271698.1,NC_000004.12|NC_060928.1|NG_050628.1,7794.0,164011.0,PA248,9606.ENSP00000226574,1MDI|1MDJ|1MDK|1NFI|1SVC|2DBF|2O61|3GUT|7LEQ|7LET|7LF4|7LFC|7RG4|7RG5|8TQD,,IPR000451|IPR000488|IPR002110|IPR002909|IPR008967|IPR011029|IPR011539|IPR013783|IPR014756|IPR030492,PF00023|PF00531|PF00554|PF12796|PF16179,PS50088|PS50254|PS50297,4,102500937.0,102617302.0,1.0,968.0,Cytoplasm,9606.0,2971.0,NFKB1,kegg:hsa04010|kegg:hsa04014|kegg:hsa04024|kegg:hsa04062|kegg:hsa04064|netpath:Pathway_BDNF|netpath:Pathway_CRH|netpath:Pathway_EGFR1|netpath:Pathway_Fibroblast__growth__factor-1|netpath:Pathway_Gastrin|pid:amb2_neutrophils_pathway|pid:angiopoietinreceptor_pathway|pid:avb3_opn_pathway|pid:bcr_5pathway|pid:cd40_pathway|smpdb:SMP00320|smpdb:SMP00321|wikipathways:WP1434|wikipathways:WP1449|wikipathways:WP15|wikipathways:WP1533|wikipathways:WP1544,True,nuclear factor kappa B subunit 1,96,24,TYRPHOSTIN 47|CHLORPROPAMIDE|QUERCETIN|DEHYDROXYMETHYLEPOXYQUINOMICIN|CHLORAMBUCIL|ANDROGRAPHOLIDE|CHEMBL:CHEMBL260560|THALIDOMIDE|LAPACHONE|AG 9|TYRPHOSTIN 23|GW5074|DIHYDREXIDINE|KAEMPFERIDE|(R)-NITRENDIPINE|ISORHAMNETIN|FLUPENTHIXOL|KAEMPHEROL|CHEMBL:CHEMBL578741|CHEMBL:CHEMBL201325,CHLORPROPAMIDE|QUERCETIN|CHLORAMBUCIL|THALIDOMIDE|PROTRIPTYLINE|INDOPROFEN|BORTEZOMIB|ARTESUNATE|BACLOFEN|HYDROCORTISONE BUTYRATE,DEHYDROXYMETHYLEPOXYQUINOMICIN|DYRENE|KAEMPFERIDE|ISORHAMNETIN|TAMARIXETIN,DRUGGABLE GENOME|TRANSCRIPTION FACTOR|KINASE|TRANSCRIPTION FACTOR COMPLEX,inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Clearity Foundation Clinical Trial|Drug Target Commons|The ChEMBL Bioactivity Database|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)",True,CHEMBL3251,SINGLE PROTEIN,0,0,603,603,1000,True,4,0,2,0,2,EDASALONEXENT|EDASALONEXENT|EDASALONEXENT|EDASALONEXENT,Small molecule,Nuclear factor NF-kappa-B complex inhibitor,True,True,True,HIGH - Approved drugs exist,Nuclear factor NF-kappa-B p105 subunit,"Constitutes the active form, which associates with RELA/p65 to form the NF-kappa-B p65-p50 complex to form a transcription factor (PubMed:1740106, PubMed:7830764). Together with RELA/p65, binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions (PubMed:1740106, PubMed:7830764)",3D-structure|Acetylation|Activator|Alternative splicing|ANK repeat|Apoptosis|Cytoplasm|Direct protein sequencing|DNA-binding|Hydroxylation|Isopeptide bond|Lipoprotein|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|Repeat|S-nitrosylation|Transcription|Transcription regulation,,PF00023:Ank|PF12796:Ank_2|PF00531:Death|PF16179:RHD_dimer|PF00554:RHD_DNA_bind,5,IPR002110:Ankyrin_rpt|IPR036770:Ankyrin_rpt-contain_sf|IPR011029:DEATH-like_dom_sf|IPR000488:Death_dom|IPR013783:Ig-like_fold|IPR014756:Ig_E-set|IPR002909:IPT_dom|IPR033926:IPT_NFkappaB|IPR047096:NF-kB_p105_DD|IPR030503:NF-kB_p105_RHD_N|IPR000451:NFkB/Dor|IPR008967:p53-like_TF_DNA-bd_sf|IPR030492:RHD_CS|IPR032397:RHD_dimer|IPR011539:RHD_DNA_bind_dom,16,,domain|conserved_site|family|homologous_superfamily|repeat,True,Immune Checkpoint|Transcription Factor,HIGH,Immune Checkpoint: InterPro: IPR013783|Transcription Factor: Keyword: transcription factor|Transcription Factor: Keyword: dna-binding,Immune Checkpoint,True,15,1MDI|1MDJ|1MDK|1NFI|1SVC|2DBF|2O61|3GUT|7LEQ|7LET,1MDI,,SOLUTION NMR,protein_structures/pdb_experimental/1MDI.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1MDI.pdb,,True,7,5.0,341.632,0.206,24.364,0.06,True,4,Moderate,Low,Adequate volume (342A3),Low druggability (0.21),448|253|273|308|342|159|256,0.02|0.00|0.00|0.21|0.01,P1:Vol=448:Drug=0.02|P2:Vol=253:Drug=0.00|P3:Vol=273:Drug=0.00|P4:Vol=308:Drug=0.00|P5:Vol=342:Drug=0.21|P6:Vol=159:Drug=0.00|P7:Vol=256:Drug=0.01
SOX2,SOX2,SRY-box transcription factor 2,"This intronless gene encodes a member of the SRY-related HMG-box (SOX) family of transcription factors involved in the regulation of embryonic development and in the determination of cell fate. The product of this gene is required for stem-cell maintenance in the central nervous system, and also regulates gene expression in the stomach. Mutations in this gene have been associated with optic nerve hypoplasia and with syndromic microphthalmia, a severe form of structural eye malformation. This gene lies within an intron of another gene called SOX2 overlapping transcript (SOX2OT). [provided by RefSeq, Jul 2008].",protein-coding,ANOP3|MCOPS3,SRY (sex determining region Y)-box 2|SRY-box 2|SRY-related HMG-box gene 2|sex determining region Y-box 2|transcription factor SOX-2,ENSG00000181449,ENST00000325404,ENSP00000323588,P48431,A0A0U3FYV6,SOX2_HUMAN,6657.0,NM_003106.4,NP_003097.1,NC_000003.12|NC_060927.1|NG_009080.1,11195.0,184429.0,PA36032,9606.ENSP00000323588,1O4X|2LE4|6T7B|6T90|6WX7|6WX8|6WX9|6YOV,,IPR009071|IPR022097|IPR036910|IPR050140,PF00505|PF12336,PS50118,3,181711925.0,181714436.0,1.0,317.0,Nucleus speckle|Cytoplasm|Nucleus,9606.0,68298.0,SOX2,kegg:hsa04390|kegg:hsa04550|reactome:R-HSA-1266738|reactome:R-HSA-1266738|reactome:R-HSA-1280215|reactome:R-HSA-162582|reactome:R-HSA-168256|wikipathways:WP2023|wikipathways:WP2406|wikipathways:WP2853|wikipathways:WP2855|wikipathways:WP2857,True,SRY-box transcription factor 2,0,0,,,,TRANSCRIPTION FACTOR COMPLEX|CLINICALLY ACTIONABLE|TRANSCRIPTION FACTOR,,,True,CHEMBL4649919,NUCLEIC-ACID,0,0,1,1,50,True,0,0,0,0,0,,,,False,False,True,LOW - Bioactive compounds or interactions reported,Transcription factor SOX-2,"Transcription factor that forms a trimeric complex with OCT4 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206 (By similarity). Binds to the proximal enhancer region of NANOG (By similarity). Critical for early embryogenesis and for embryonic stem cell pluripotency (PubMed:18035408). Downstream SRRT target that mediates the promotion of neural stem cell self-renewal (By similarity). Keeps neural cells undifferentiated by counteracting the activity of proneural proteins and suppresses neuronal differentiation (By similarity). May function as a switch in neuronal development (By similarity)",3D-structure|Activator|Cytoplasm|Developmental protein|Disease variant|DNA-binding|Isopeptide bond|Methylation|Microphthalmia|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|Transcription|Transcription regulation|Ubl conjugation,,PF00505:HMG_box|PF12336:SOXp,2,IPR009071:HMG_box_dom|IPR036910:HMG_box_dom_sf|IPR022097:SOX_fam|IPR050140:SRY-related_HMG-box_TF-like,4,,domain|family|homologous_superfamily,True,Actin|Histone Acetyltransferase|Transcription Factor,HIGH,Histone Acetyltransferase: Keyword: hat|Actin: Keyword: actin|Transcription Factor: Keyword: transcription factor|Transcription Factor: Keyword: dna-binding,Actin,True,9,1O4X|2LE4|6T7B|6T90|6WX7|6WX8|6WX9|6YOV|9QPF,1O4X,,SOLUTION NMR,protein_structures/pdb_experimental/1O4X.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1O4X.pdb,,True,30,1.0,1602.125,0.857,0.818,0.291,True,21,Good,Medium,Optimal volume (1602A3)|High druggability (0.86),,1602|222|436|766|588|264|477|291|336|376|306|339|350|259|280|340|303|309|220|330|480|200|177|266|335|200|336|283|251|1164,0.86|0.71|0.21|0.83|0.00|0.04|0.00|0.08|0.04|0.01|0.00|0.00|0.00|0.04|0.02|0.04|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.00,P1:Vol=1602:Drug=0.86|P2:Vol=222:Drug=0.71|P3:Vol=436:Drug=0.21|P4:Vol=766:Drug=0.83|P5:Vol=588:Drug=0.00|P6:Vol=264:Drug=0.04|P7:Vol=477:Drug=0.00|P8:Vol=291:Drug=0.08|P9:Vol=336:Drug=0.00|P10:Vol=376:Drug=0.00
NANOG,NANOG,Nanog homeobox,"The protein encoded by this gene is a DNA binding homeobox transcription factor involved in embryonic stem (ES) cell proliferation, renewal, and pluripotency. The encoded protein can block ES cell differentiation and can also autorepress its own expression in differentiating cells. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2015].",protein-coding,,homeobox protein NANOG|homeobox transcription factor Nanog|homeobox transcription factor Nanog-delta 48,ENSG00000111704,ENST00000229307|ENST00000526286|ENST00000526434|ENST00000541267|ENST00000933164|ENST00000933165,ENSP00000229307|ENSP00000435288|ENSP00000444434|ENSP00000603223|ENSP00000603224,Q9H9S0,F5GZI2|A8K4D1,NANOG_HUMAN,79923.0,NM_001297698.2|NM_024865.4,NP_001284627.1|NP_079141.2,NC_000012.12|NC_060936.1,20857.0,607937.0,PA134864904,9606.ENSP00000229307,2KT0|4RBO,,IPR001356|IPR009057|IPR017970|IPR050460,PF00046,PS50071,12,7787794.0,7799146.0,1.0,305.0,Nucleus,9606.0,78027.0,Homeobox protein NANOG,kegg:hsa04550|kegg:hsa05205|reactome:R-HSA-1266738|reactome:R-HSA-1266738|reactome:R-HSA-1280215|reactome:R-HSA-1474165|reactome:R-HSA-168256|wikipathways:WP2406|wikipathways:WP2853|wikipathways:WP2857|wikipathways:WP3527|wikipathways:WP399,True,Nanog homeobox,0,0,,,,TRANSCRIPTION FACTOR,,,True,CHEMBL3580527,SINGLE PROTEIN,0,0,18,18,18,True,0,0,0,0,0,,,,False,False,True,LOW - Bioactive compounds or interactions reported,Homeobox protein NANOG,"Transcription regulator involved in inner cell mass and embryonic stem (ES) cells proliferation and self-renewal. Imposes pluripotency on ES cells and prevents their differentiation towards extraembryonic endoderm and trophectoderm lineages. Blocks bone morphogenetic protein-induced mesoderm differentiation of ES cells by physically interacting with SMAD1 and interfering with the recruitment of coactivators to the active SMAD transcriptional complexes. Acts as a transcriptional activator or repressor. Binds optimally to the DNA consensus sequence 5'-TAAT[GT][GT]-3' or 5'-[CG][GA][CG]C[GC]ATTAN[GC]-3'. Binds to the POU5F1/OCT4 promoter (PubMed:25825768). Able to autorepress its expression in differentiating (ES) cells: binds to its own promoter following interaction with ZNF281/ZFP281, leading to recruitment of the NuRD complex and subsequent repression of expression. When overexpressed, promotes cells to enter into S phase and proliferation",3D-structure|Activator|Alternative splicing|Developmental protein|DNA-binding|Homeobox|Nucleus|Reference proteome|Repeat|Repressor|Transcription|Transcription regulation,Belongs to the Nanog homeobox family,PF00046:Homeodomain,1,IPR050460:Distal-less_Homeobox_TF|IPR001356:HD|IPR017970:Homeobox_CS|IPR009057:Homeodomain-like_sf,4,,domain|family|conserved_site|homologous_superfamily,True,Actin|Transcription Factor,HIGH,Actin: Keyword: actin|Transcription Factor: Keyword: dna-binding|Transcription Factor: Keyword: homeobox|Transcription Factor: InterPro: IPR001356|Transcription Factor: InterPro: IPR009057|Transcription Factor: InterPro: IPR017970|Transcription Factor: Pfam: PF00046,Actin,True,2,2KT0|4RBO,2KT0,,SOLUTION NMR,protein_structures/pdb_experimental/2KT0.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/2KT0.pdb,,True,9,4.0,517.235,0.353,66.364,0.123,True,7,Moderate,Low,Optimal volume (517A3),Low druggability (0.35),586|356|266|517|216|259|316|175|131,0.02|0.03|0.01|0.35|0.00|0.00|0.00,P1:Vol=586:Drug=0.02|P2:Vol=356:Drug=0.03|P3:Vol=266:Drug=0.01|P4:Vol=517:Drug=0.35|P5:Vol=216:Drug=0.00|P6:Vol=259:Drug=0.00|P7:Vol=316:Drug=0.00|P8:Vol=175:Drug=0.00|P9:Vol=131:Drug=0.00
POU5F1,POU5F1,POU class 5 homeobox 1,"This gene encodes a transcription factor containing a POU homeodomain that plays a key role in embryonic development and stem cell pluripotency. Aberrant expression of this gene in adult tissues is associated with tumorigenesis. This gene can participate in a translocation with the Ewing's sarcoma gene on chromosome 21, which also leads to tumor formation. Alternative splicing, as well as usage of alternative AUG and non-AUG translation initiation codons, results in multiple isoforms. One of the AUG start codons is polymorphic in human populations. Related pseudogenes have been identified on chromosomes 1, 3, 8, 10, and 12. [provided by RefSeq, Oct 2013].",protein-coding,OCT3|OCT4|OCT4Borf1|OTF-3|OTF3|OTF4|Oct-3|Oct-4|Oct3/4,"POU domain transcription factor OCT4|POU domain, class 5, transcription factor 1|POU-type homeodomain-containing DNA-binding protein|octamer-binding protein 3|octamer-binding protein 4",ENSG00000235068,ENST00000419095|ENST00000433063|ENST00000483880|ENST00000498800,ENSP00000405041|ENSP00000413622,Q01860,F2Z381|M1S623|D2IYK3|A0A1W2PP83,PO5F1_HUMAN,5460.0,NM_001173531.3|NM_001285986.2|NM_001285987.1|NM_002701.6|NM_203289.6,NP_001167002.1|NP_001272915.1|NP_001272916.1|NP_002692.2|NP_976034.4,NC_000006.12|NC_060930.1|NT_113891.3|NT_167245.2|NT_167246.2,9221.0,164177.0,PA33545,9606.ENSP00000259915,6T90|6YOV|7U0G|7U0I|8G87|8G88|8G8B|8G8E|8G8G|8OTS|8SPS|8SPU,,IPR000327|IPR001356|IPR009057|IPR010982|IPR013847|IPR017970|IPR050255,PF00046|PF00157,PS50071|PS51179,HSCHR6_MHC_QBL_CTG1,2422370.0,2428743.0,-1.0,360.0,Cytoplasm|Nucleus,9606.0,8422.0,Oct-4,reactome:R-HSA-1266738|reactome:R-HSA-1266738|reactome:R-HSA-1474165|reactome:R-HSA-2892245|reactome:R-HSA-2892247|wikipathways:WP2406|wikipathways:WP2853|wikipathways:WP2857|wikipathways:WP2880|wikipathways:WP2882,True,POU class 5 homeobox 1,4,4,PHENYTOIN SODIUM|CARBAMAZEPINE|DEHYDRATED ALCOHOL|ALLOPURINOL,PHENYTOIN SODIUM|CARBAMAZEPINE|DEHYDRATED ALCOHOL|ALLOPURINOL,ALLOPURINOL|PHENYTOIN SODIUM|CARBAMAZEPINE|DEHYDRATED ALCOHOL,TRANSCRIPTION FACTOR COMPLEX|CLINICALLY ACTIONABLE|TRANSCRIPTION FACTOR,,PharmGKB - The Pharmacogenomics Knowledgebase|NCI Cancer Gene Index,True,CHEMBL3580526,SINGLE PROTEIN,0,0,46,46,111,False,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,"POU domain, class 5, transcription factor 1","Transcription factor that binds to the octamer motif (5'-ATTTGCAT-3'). Forms a trimeric complex with SOX2 or SOX15 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206. Critical for early embryogenesis and for embryonic stem cell pluripotency",3D-structure|Alternative splicing|Cytoplasm|Developmental protein|DNA-binding|Homeobox|Isopeptide bond|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|Transcription|Transcription regulation|Ubl conjugation,Belongs to the POU transcription factor family. Class-5 subfamily,PF00046:Homeodomain|PF00157:Pou,2,IPR001356:HD|IPR017970:Homeobox_CS|IPR009057:Homeodomain-like_sf|IPR010982:Lambda_DNA-bd_dom_sf|IPR013847:POU|IPR000327:POU_dom|IPR050255:POU_domain_TF,7,,domain|family|conserved_site|homologous_superfamily,True,Histone Acetyltransferase|Transcription Factor,HIGH,Histone Acetyltransferase: Keyword: hat|Transcription Factor: Keyword: transcription factor|Transcription Factor: Keyword: dna-binding|Transcription Factor: Keyword: homeobox|Transcription Factor: InterPro: IPR001356|Transcription Factor: InterPro: IPR009057|Transcription Factor: InterPro: IPR017970|Transcription Factor: Pfam: PF00046,Histone Acetyltransferase,True,12,6T90|6YOV|7U0G|7U0I|8G87|8G88|8G8B|8G8E|8G8G|8OTS,6T90,3.05,ELECTRON MICROSCOPY,protein_structures/pdb_experimental/6T90.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/6T90.pdb,Low (>3.0Å),True,118,22.0,567.327,0.928,9.05,0.928,True,92,Excellent,High,Optimal volume (567A3)|High druggability (0.93),,379|236|304|394|94|87|1838|416|1232|112|319|87|86|441|225|997|1826|352|203|124|282|567|347|193|301|353|228|263|285|194|1300|291|399|115|206|1270|767|188|410|213|348|265|264|258|487|368|246|177|489|1243|334|327|101|283|696|232|269|476|1248|566|281|258|279|332|247|1547|410|526|234|669|488|181|464|206|451|314|658|451|537|210|636|339|425|371|338|163|668|438|592|408|293|376|301|912|310|345|339|747|781|290|248|1512|556|1178|1408|1020|605|541|782|577|1277|935|1060|765|1134|701|1011|1607,0.00|0.02|0.01|0.00|0.00|0.01|0.26|0.01|0.10|0.00|0.03|0.00|0.00|0.00|0.03|0.14|0.00|0.00|0.00|0.93|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.13|0.01|0.00|0.01|0.00|0.00|0.02|0.00|0.00|0.33|0.00|0.00|0.00|0.01|0.00|0.00|0.07|0.08|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.25|0.00|0.06|0.00|0.00|0.02|0.00|0.01|0.29|0.03|0.00|0.00|0.00|0.06|0.00|0.00|0.00,P1:Vol=379:Drug=0.00|P2:Vol=236:Drug=0.02|P3:Vol=304:Drug=0.01|P4:Vol=394:Drug=0.00|P5:Vol=94:Drug=0.00|P6:Vol=87:Drug=0.01|P7:Vol=1838:Drug=0.26|P8:Vol=416:Drug=0.01|P9:Vol=1232:Drug=0.10|P10:Vol=112:Drug=0.00
HIF1A,HIF1A,hypoxia inducible factor 1 subunit alpha,"This gene encodes the alpha subunit of transcription factor hypoxia-inducible factor-1 (HIF-1), which is a heterodimer composed of an alpha and a beta subunit. HIF-1 functions as a master regulator of cellular and systemic homeostatic response to hypoxia by activating transcription of many genes, including those involved in energy metabolism, angiogenesis, apoptosis, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. HIF-1 thus plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. Alternatively spliced transcript variants encoding different isoforms have been identified for this gene. [provided by RefSeq, Jul 2011].",protein-coding,HIF-1-alpha|HIF-1A|HIF-1alpha|HIF1|HIF1-ALPHA|MOP1|PASD8|bHLHe78,ARNT interacting protein|PAS domain-containing protein 8|basic-helix-loop-helix-PAS protein MOP1|class E basic helix-loop-helix protein 78|hypoxia inducible factor 1 alpha subunit,ENSG00000100644,ENST00000323441|ENST00000337138|ENST00000394997|ENST00000539097|ENST00000547430|ENST00000553999|ENST00000555014|ENST00000556237|ENST00000556827|ENST00000557206,ENSP00000323326|ENSP00000338018|ENSP00000378446|ENSP00000437955|ENSP00000578790|ENSP00000578791|ENSP00000588901|ENSP00000588902|ENSP00000588903|ENSP00000588904,Q16665,A8MYV6|D0VY79,HIF1A_HUMAN,3091.0,NM_001243084.2|NM_001530.4|NM_181054.3,NP_001230013.1|NP_001521.1|NP_851397.1,NC_000014.9|NC_060938.1|NG_029606.1,4910.0,603348.0,PA29283,9606.ENSP00000437955,1H2K|1H2L|1H2M|1L3E|1L8C|1LM8|1LQB|2ILM|3HQR|3HQU|4AJY|4H6J|5JWP|5L9B|5L9V|5LA9|5LAS|6GFX|6GMR|6YW3,,IPR000014|IPR001321|IPR001610|IPR011598|IPR013655|IPR013767|IPR014887|IPR035965|IPR036638|IPR021537,PF00989|PF08447|PF08778|PF23171|PF11413,PS50112|PS50888,14,61695456.0,61748263.0,1.0,826.0,Cytoplasm|Nucleus|Nucleus speckle,9606.0,1171.0,HIF1A,biocarta:eponfkbpathway|biocarta:hifpathway|biocarta:p53hypoxiapathway|biocarta:vegfpathway|kegg:hsa04066|kegg:hsa04137|kegg:hsa04140|kegg:hsa04659|kegg:hsa04919|pid:ap1_pathway|pid:hes_heypathway|pid:hif1_tfpathway|pid:hif1apathway|pid:vegfr1_pathway|reactome:R-HSA-1234158|reactome:R-HSA-1234174|reactome:R-HSA-1234176|reactome:R-HSA-1280215|reactome:R-HSA-1280218|smpdb:SMP02292|smpdb:SMP02295|wikipathways:WP1539|wikipathways:WP2324|wikipathways:WP236|wikipathways:WP2374|wikipathways:WP2456,True,hypoxia inducible factor 1 subunit alpha,145,47,AMCINONIDE|EMETINE|FLUFENAMIC ACID|CHEMBL:CHEMBL458765|TIRATRICOL|ELLIPTECINE|SB-415286|CATECHOL|QUERCETIN|CYCLOHEXIMIDE|NOSCAPINE|IODOQUINOL|OXATOMIDE|CGS 15943|ISOCEPHAELINE|MECLOFENAMATE SODIUM|BENZAMIL|FUSARIC ACID|VINCRISTINE SULFATE|HESPERETIN,AMCINONIDE|QUERCETIN|IODOQUINOL|OXATOMIDE|MECLOFENAMATE SODIUM|VINCRISTINE SULFATE|HESPERETIN|LORATADINE|HYDROQUINONE|SULFASALAZINE,PX-478|ISOCEPHAELINE|ENMD-1198|ANTI-HIF-1ALPHA LNA ANTISENSE OLIGONUCLEOTIDE EZN-2968|KLUGINE,TRANSPORTER|TRANSCRIPTION FACTOR|ENZYME|DRUGGABLE GENOME|CLINICALLY ACTIONABLE,inhibitor,"Drug Target Commons|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|Targeted Agents in Lung Cancer (Commentary, 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Cancer Genome Interpreter|MyCancerGenome Clinical Trial|NCI Cancer Gene Index|Therapeutic Target Database",True,CHEMBL6046,SINGLE PROTEIN,0,0,16,16,24,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Hypoxia-inducible factor 1-alpha,"(Microbial infection) Upon infection by human coronavirus SARS-CoV-2, is required for induction of glycolysis in monocytes and the consequent pro-inflammatory state (PubMed:32697943). In monocytes, induces expression of ACE2 and cytokines such as IL1B, TNF, IL6, and interferons (PubMed:32697943). Promotes human coronavirus SARS-CoV-2 replication and monocyte inflammatory response (PubMed:32697943)",3D-structure|Acetylation|Activator|Alternative splicing|Cytoplasm|Direct protein sequencing|DNA-binding|Glycoprotein|Host-virus interaction|Hydroxylation|Isopeptide bond|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|Repeat|S-nitrosylation|Transcription|Transcription regulation|Ubl conjugation,,PF23171:bHLH_HIF1A|PF11413:HIF-1|PF08778:HIF-1a_CTAD|PF00989:PAS|PF08447:PAS_3,5,IPR011598:bHLH_dom|IPR001321:HIF-1_alpha|IPR014887:HIF-1_CTAD|IPR021537:HIF_alpha-like|IPR036638:HLH_DNA-bd_sf|IPR001610:PAC|IPR000014:PAS|IPR035965:PAS-like_dom_sf|IPR013767:PAS_fold|IPR013655:PAS_fold_3,10,,domain|family|homologous_superfamily|repeat,True,Transcription Factor,LOW,Transcription Factor: Keyword: dna-binding,Transcription Factor,True,26,1H2K|1H2L|1H2M|1L3E|1L8C|1LM8|1LQB|2ILM|3HQR|3HQU,1H2K,2.15,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1H2K.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1H2K.pdb,Good (2.0-2.5Å),True,28,2.0,1241.034,0.921,23.0,0.261,True,20,Good,Medium,Optimal volume (1241A3)|High druggability (0.92),,257|1241|391|373|109|231|372|262|78|202|921|238|371|314|409|286|274|144|274|408|301|295|190|226|298|265|351|336,0.53|0.92|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.04|0.00|0.27|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.02|0.00|0.02|0.01,P1:Vol=257:Drug=0.53|P2:Vol=1241:Drug=0.92|P3:Vol=391:Drug=0.00|P4:Vol=373:Drug=0.00|P5:Vol=109:Drug=0.01|P6:Vol=231:Drug=0.00|P7:Vol=372:Drug=0.00|P8:Vol=262:Drug=0.00|P9:Vol=78:Drug=0.00|P10:Vol=202:Drug=0.00
COL1A1,COL1A1,collagen type I alpha 1 chain,"This gene encodes the pro-alpha1 chains of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon. Mutations in this gene are associated with osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIA, Ehlers-Danlos syndrome Classical type, Caffey Disease and idiopathic osteoporosis. Reciprocal translocations between chromosomes 17 and 22, where this gene and the gene for platelet-derived growth factor beta are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans, resulting from unregulated expression of the growth factor. Two transcripts, resulting from the use of alternate polyadenylation signals, have been identified for this gene. [provided by R. Dalgleish, Feb 2008].",protein-coding,CAFYD|EDSARTH1|EDSC|OI1|OI2|OI3|OI4,alpha-1 type I collagen|alpha1(I) procollagen|collagen Col1-ColIII-1|collagen Col1-ColIII-2|collagen alpha 1 chain type I,ENSG00000108821,ENST00000225964|ENST00000463440|ENST00000471344|ENST00000474644|ENST00000476387|ENST00000485870|ENST00000486572|ENST00000494334|ENST00000495677|ENST00000504289,ENSP00000225964|ENSP00000460459|ENSP00000531392|ENSP00000531393|ENSP00000531394|ENSP00000531395|ENSP00000531396|ENSP00000531397|ENSP00000531398|ENSP00000531399,P02452,I3L3H7,CO1A1_HUMAN,1277.0,NM_000088.4|XM_005257058.5|XM_005257059.5|XM_011524341.2|XM_054315081.1|XM_054315082.1|XM_054315083.1,NP_000079.2|XP_005257115.2|XP_005257116.2|XP_011522643.1|XP_054171056.1|XP_054171057.1|XP_054171058.1,NC_000017.11|NC_060941.1|NG_007400.1,2197.0,120150.0,PA35041,9606.ENSP00000225964,1Q7D|2LLP|3EJH|3GXE|5CTD|5CTI|5CVA|5CVB|5K31|5OU8|5OU9|7E7B|7E7D,,IPR000885|IPR001007|IPR008160|IPR050149|IPR050938|IPR052624,PF00093|PF01391|PF01410,PS50184|PS51461,17,50184101.0,50201634.0,-1.0,1464.0,"Secreted, extracellular space, extracellular matrix",9606.0,73874.0,"Collagen, type I, alpha 1",kegg:hsa04151|kegg:hsa04510|kegg:hsa04512|kegg:hsa04611|kegg:hsa04926|pid:avb3_integrin_pathway|pid:il4_2pathway|pid:integrin1_pathway|pid:integrin3_pathway|pid:lymphangiogenesis_pathway|reactome:R-HSA-109582|reactome:R-HSA-109582|reactome:R-HSA-114604|reactome:R-HSA-1266738|reactome:R-HSA-1280218|smpdb:SMP00268|smpdb:SMP00269|smpdb:SMP00270|smpdb:SMP00271|smpdb:SMP00272|wikipathways:WP306|wikipathways:WP322|wikipathways:WP3932|wikipathways:WP3967|wikipathways:WP4172,True,collagen type I alpha 1 chain,7,7,PAMIDRONATE|OCRIPLASMIN|ZOLEDRONIC ACID ANHYDROUS|ETIDRONIC ACID|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|VALPROIC ACID|SOMATROPIN (RECOMBINANT DNA ORIGIN),PAMIDRONATE|OCRIPLASMIN|ZOLEDRONIC ACID ANHYDROUS|ETIDRONIC ACID|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|VALPROIC ACID|SOMATROPIN (RECOMBINANT DNA ORIGIN),PAMIDRONATE|ETIDRONIC ACID|ZOLEDRONIC ACID ANHYDROUS|SOMATROPIN (RECOMBINANT DNA ORIGIN)|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,CLINICALLY ACTIONABLE|DRUGGABLE GENOME,cleavage,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|The ChEMBL Bioactivity Database|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|PharmGKB - The Pharmacogenomics Knowledgebase",True,CHEMBL4845624,NUCLEIC-ACID,0,0,62,62,117,True,38,13,6,6,0,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,Protein|Enzyme,Collagen hydrolytic enzyme,True,True,True,HIGH - Approved drugs exist,Collagen alpha-1(I) chain,Type I collagen is a member of group I collagen (fibrillar forming collagen),3D-structure|Calcium|Chromosomal rearrangement|Collagen|Direct protein sequencing|Disease variant|Disulfide bond|Dwarfism|Ehlers-Danlos syndrome|Extracellular matrix|Glycoprotein|Hydroxylation|Metal-binding|Osteogenesis imperfecta|Osteoporosis|Phosphoprotein|Proteomics identification|Pyrrolidone carboxylic acid|Reference proteome|Repeat,Belongs to the fibrillar collagen family,PF01410:COLFI|PF01391:Collagen|PF00093:VWC,3,IPR008160:Collagen|IPR050149:Collagen_superfamily|IPR000885:Fib_collagen_C|IPR001007:VWF_dom,4,,domain|family|repeat,False,,NONE,,,True,14,1Q7D|2LLP|3EJH|3GXE|5CTD|5CTI|5CVA|5CVB|5K31|5OU8,1Q7D,1.8,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1Q7D.pdb,False,,,,,PDB,protein_structures/pdb_experimental/1Q7D.pdb,Excellent (<2.0Å),True,0,,,,,,False,0,,,,,,,
COL1A2,COL1A2,collagen type I alpha 2 chain,"This gene encodes the pro-alpha2 chain of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon. Mutations in this gene are associated with osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIB, recessive Ehlers-Danlos syndrome Classical type, idiopathic osteoporosis, and atypical Marfan syndrome. Symptoms associated with mutations in this gene, however, tend to be less severe than mutations in the gene for the alpha1 chain of type I collagen (COL1A1) reflecting the different role of alpha2 chains in matrix integrity. Three transcripts, resulting from the use of alternate polyadenylation signals, have been identified for this gene. [provided by R. Dalgleish, Feb 2008].",protein-coding,EDSARTH2|EDSCV|OI4,"alpha 2 type I procollagen|alpha 2(I) procollagen|alpha 2(I)-collagen|alpha-2 type I collagen|collagen I, alpha-2 polypeptide",ENSG00000164692,ENST00000297268|ENST00000461525|ENST00000464916|ENST00000467931|ENST00000469732|ENST00000473573|ENST00000478215|ENST00000481570|ENST00000488121|ENST00000488298,ENSP00000297268|ENSP00000629436|ENSP00000629437|ENSP00000629438|ENSP00000629439|ENSP00000629440|ENSP00000629441|ENSP00000629442,P08123,A0A0S2Z3H5,CO1A2_HUMAN,1278.0,NM_000089.4,NP_000080.2,NC_000007.14|NC_060931.1|NG_007405.1,2198.0,120160.0,PA35042,9606.ENSP00000297268,5CTD|5CTI|5CVA|6JEC,,IPR000885|IPR008160|IPR050149,PF01391|PF01410,PS51461,7,94394820.0,94431227.0,1.0,1366.0,"Secreted, extracellular space, extracellular matrix",9606.0,69.0,COL1A2,kegg:hsa04151|kegg:hsa04510|kegg:hsa04512|kegg:hsa04611|kegg:hsa04926|pid:ap1_pathway|pid:avb3_integrin_pathway|pid:cmyb_pathway|pid:endothelinpathway|pid:fra_pathway|reactome:R-HSA-109582|reactome:R-HSA-109582|reactome:R-HSA-114604|reactome:R-HSA-1266738|reactome:R-HSA-1280215|wikipathways:WP2911|wikipathways:WP306|wikipathways:WP366|wikipathways:WP3932|wikipathways:WP4172,True,collagen type I alpha 2 chain,9,4,TNF-ALPHA|ST034307|RECOMBINANT TRANSFORMING GROWTH FACTOR-BETA-2|RECOMBINANT INTERFERON|DAUNORUBICIN LIPOSOMAL|RECOMBINANT TRANSFORMING GROWTH FACTOR|OCRIPLASMIN|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|DOXORUBICIN HYDROCHLORIDE,DAUNORUBICIN LIPOSOMAL|OCRIPLASMIN|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|DOXORUBICIN HYDROCHLORIDE,ST034307|RECOMBINANT TRANSFORMING GROWTH FACTOR-BETA-2|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|RECOMBINANT TRANSFORMING GROWTH FACTOR|TNF-ALPHA,DRUGGABLE GENOME,cleavage|inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|Guide to Pharmacology|NCI Cancer Gene Index|The ChEMBL Bioactivity Database|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)",True,CHEMBL2685,SINGLE PROTEIN,0,0,1,1,4,True,38,13,6,6,0,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,Protein|Enzyme,Collagen hydrolytic enzyme,True,True,True,HIGH - Approved drugs exist,Collagen alpha-2(I) chain,Type I collagen is a member of group I collagen (fibrillar forming collagen),3D-structure|Calcium|Chromosomal rearrangement|Collagen|Direct protein sequencing|Disease variant|Disulfide bond|Dwarfism|Ehlers-Danlos syndrome|Extracellular matrix|Glycoprotein|Hydroxylation|Metal-binding|Osteogenesis imperfecta|Proteomics identification|Pyrrolidone carboxylic acid|Reference proteome|Repeat|Secreted|Signal,Belongs to the fibrillar collagen family,PF01410:COLFI|PF01391:Collagen,2,IPR008160:Collagen|IPR050149:Collagen_superfamily|IPR000885:Fib_collagen_C,3,,domain|family|repeat,False,,NONE,,,True,5,5CTD|5CTI|5CVA|6JEC|8YV3,5CTD,1.5991,X-RAY DIFFRACTION,protein_structures/pdb_experimental/5CTD.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/5CTD.pdb,Excellent (<2.0Å),True,8,1.0,686.868,0.298,16.818,0.271,True,7,Moderate,Low,Optimal volume (687A3),Low druggability (0.30),687|440|276|291|289|256|292|261,0.30|0.01|0.04|0.17|0.11|0.01,P1:Vol=687:Drug=0.30|P2:Vol=440:Drug=0.01|P3:Vol=276:Drug=0.04|P4:Vol=291:Drug=0.17|P5:Vol=289:Drug=0.11|P6:Vol=256:Drug=0.00|P7:Vol=292:Drug=0.01|P8:Vol=261:Drug=0.00
COL3A1,COL3A1,collagen type III alpha 1 chain,"This gene encodes the pro-alpha1 chains of type III collagen, a fibrillar collagen that is found in extensible connective tissues such as skin, lung, uterus, intestine and the vascular system, frequently in association with type I collagen. Mutations in this gene are associated with Ehlers-Danlos syndrome type IV, and with aortic and arterial aneurysms. [provided by R. Dalgleish, Feb 2008].",protein-coding,EDS4A|EDSVASC|PMGEDSV,"Ehlers-Danlos syndrome type IV, autosomal dominant|alpha-1 type III collagen|alpha1 (III) collagen|collagen alpha-1(III) chain|collagen, fetal",ENSG00000291748,ENST00000708566|ENST00000708568|ENST00000708569|ENST00000708570|ENST00000708571,ENSP00000517283|ENSP00000517285,P02461,A0AAG2UUZ6|A0AAG2UVC5|A0AAQ5BGS2|H7C435|A0AAQ5BGR9,CO3A1_HUMAN,1281.0,NM_000090.4|NM_001376916.1,NP_000081.2,NC_000002.12|NC_060926.1|NG_007404.1|NW_025791764.1,2201.0,120180.0,PA26716,9606.ENSP00000304408,2V53|3DMW|4AE2|4AEJ|4AK3|4GYX|6FZV|6FZW|7WWR|7WWS|7XAN,,IPR000885|IPR001007|IPR008160|IPR050149|IPR050938,PF00093|PF01391|PF01410,PS50184|PS51461,2,188974371.0,189012746.0,1.0,1466.0,"Secreted, extracellular space, extracellular matrix",9606.0,55433.0,"Collagen, type III, alpha 1",kegg:hsa04611|kegg:hsa04926|kegg:hsa04933|kegg:hsa04974|kegg:hsa05146|pid:avb3_integrin_pathway|pid:endothelinpathway|pid:integrin1_pathway|pid:syndecan_1_pathway|wikipathways:WP2911|wikipathways:WP3932|wikipathways:WP3967|wikipathways:WP453|wikipathways:WP4754,True,collagen type III alpha 1 chain,2,2,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN,DRUGGABLE GENOME,cleavage,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|The ChEMBL Bioactivity Database|Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)",True,CHEMBL2364188,PROTEIN COMPLEX GROUP,0,0,0,0,0,False,0,0,0,0,0,,,,True,False,False,HIGH - Approved drugs exist,Collagen alpha-1(III) chain,Collagen type III occurs in most soft connective tissues along with type I collagen. Involved in regulation of cortical development. Is the major ligand of ADGRG1 in the developing brain and binding to ADGRG1 inhibits neuronal migration and activates the RhoA pathway by coupling ADGRG1 to GNA13 and possibly GNA12,3D-structure|Alternative splicing|Aortic aneurysm|Calcium|Collagen|Direct protein sequencing|Disease variant|Disulfide bond|Ehlers-Danlos syndrome|Extracellular matrix|Glycoprotein|Hydroxylation|Metal-binding|Proteomics identification|Reference proteome|Repeat|Secreted|Signal,Belongs to the fibrillar collagen family,PF01410:COLFI|PF01391:Collagen|PF00093:VWC,3,IPR008160:Collagen|IPR050149:Collagen_superfamily|IPR000885:Fib_collagen_C|IPR001007:VWF_dom,4,,domain|family|repeat,False,,NONE,,,True,11,2V53|3DMW|4AE2|4AEJ|4AK3|4GYX|6FZV|6FZW|7WWR|7WWS,2V53,3.2,X-RAY DIFFRACTION,protein_structures/pdb_experimental/2V53.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/2V53.pdb,Low (>3.2Å),True,21,7.0,531.901,0.531,27.583,0.123,True,17,Good,Medium,Optimal volume (532A3),,324|637|374|255|562|459|532|439|401|352|357|271|393|295|322|235|304|286|176|333|278,0.01|0.01|0.00|0.00|0.05|0.01|0.53|0.00|0.00|0.09|0.00|0.01|0.01|0.00|0.00|0.00|0.01,P1:Vol=324:Drug=0.01|P2:Vol=637:Drug=0.01|P3:Vol=374:Drug=0.00|P4:Vol=255:Drug=0.00|P5:Vol=562:Drug=0.05|P6:Vol=459:Drug=0.01|P7:Vol=532:Drug=0.53|P8:Vol=439:Drug=0.00|P9:Vol=401:Drug=0.00|P10:Vol=352:Drug=0.00
COL4A1,COL4A1,collagen type IV alpha 1 chain,"This gene encodes a type IV collagen alpha protein. Type IV collagen proteins are integral components of basement membranes. This gene shares a bidirectional promoter with a paralogous gene on the opposite strand. The protein consists of an amino-terminal 7S domain, a triple-helix forming collagenous domain, and a carboxy-terminal non-collagenous domain. It functions as part of a heterotrimer and interacts with other extracellular matrix components such as perlecans, proteoglycans, and laminins. In addition, proteolytic cleavage of the non-collagenous carboxy-terminal domain results in a biologically active fragment known as arresten, which has anti-angiogenic and tumor suppressor properties. Mutations in this gene cause porencephaly, cerebrovascular disease, and renal and muscular defects. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2014].",protein-coding,BSVD|BSVD1|COL4A1s|PADMAL|RATOR,"COL4A1 NC1 domain|arresten|collagen IV, alpha-1 polypeptide|collagen alpha-1(IV) chain|collagen of basement membrane, alpha-1 chain",ENSG00000187498,ENST00000375820|ENST00000467182|ENST00000474391|ENST00000543140|ENST00000615732|ENST00000647632|ENST00000647797|ENST00000648170|ENST00000648695|ENST00000648966,ENSP00000364979|ENSP00000443348|ENSP00000478222|ENSP00000497355|ENSP00000497477|ENSP00000497533|ENSP00000497713|ENSP00000497756|ENSP00000498007|ENSP00000498030,P02462,A0AAQ5BHV6|A5PKV2|A0A3B3IUD0|A0A087WTY5|A0A3B3ISZ8,CO4A1_HUMAN,1282.0,NM_001303110.2|NM_001845.6,NP_001290039.1|NP_001836.3,NC_000013.11|NC_060937.1|NG_011544.2,2202.0,120130.0,PA26717,9606.ENSP00000364979,1LI1|5NAX|5NAY|6MPX,,IPR001442|IPR008160|IPR016187|IPR036954|IPR050149,PF01391|PF01413,PS51403,13,110148963.0,110307202.0,-1.0,1669.0,"Secreted, extracellular space, extracellular matrix, basement membrane",9606.0,20437.0,"Collagen, type IV, alpha 1",biocarta:intrinsicpathway|biocarta:npp1pathway|kegg:hsa04151|kegg:hsa04510|kegg:hsa04512|kegg:hsa04926|kegg:hsa04933|pid:avb3_integrin_pathway|pid:integrin1_pathway|pid:integrin3_pathway|pid:syndecan_1_pathway|reactome:R-HSA-1266738|reactome:R-HSA-1442490|reactome:R-HSA-1442490|reactome:R-HSA-1474228|reactome:R-HSA-1474228|wikipathways:WP2431|wikipathways:WP2911|wikipathways:WP306|wikipathways:WP3287|wikipathways:WP3932,True,collagen type IV alpha 1 chain,4,2,FD6|OCRIPLASMIN|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|NKY80,OCRIPLASMIN|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,FD6|NKY80|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN,DRUGGABLE GENOME,cleavage|inhibitor|activator,The ChEMBL Bioactivity Database|Guide to Pharmacology,True,CHEMBL2364188,PROTEIN COMPLEX GROUP,0,0,0,0,0,True,38,13,6,6,0,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,Protein|Enzyme,Collagen hydrolytic enzyme,True,True,False,HIGH - Approved drugs exist,Collagen alpha-1(IV) chain,"Arresten, comprising the C-terminal NC1 domain, inhibits angiogenesis and tumor formation. The C-terminal half is found to possess the anti-angiogenic activity. Specifically inhibits endothelial cell proliferation, migration and tube formation",3D-structure|Alternative splicing|Angiogenesis|Basement membrane|Collagen|Direct protein sequencing|Disease variant|Disulfide bond|Extracellular matrix|Glycoprotein|Hydroxylation|Proteomics identification|Reference proteome|Repeat|Secreted|Signal,Belongs to the type IV collagen family,PF01413:C4|PF01391:Collagen,2,IPR008160:Collagen|IPR001442:Collagen_IV_NC|IPR036954:Collagen_IV_NC_sf|IPR050149:Collagen_superfamily|IPR016187:CTDL_fold,5,,domain|family|homologous_superfamily|repeat,False,,NONE,,,True,4,1LI1|5NAX|5NAY|6MPX,1LI1,1.9,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1LI1.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1LI1.pdb,Excellent (<2.0Å),True,103,29.0,552.693,0.589,39.933,0.05,True,71,Good,Medium,Optimal volume (553A3),,117|456|393|403|137|137|357|107|85|356|138|145|300|105|333|114|91|464|218|434|362|99|57|100|430|98|96|424|553|340|59|169|104|345|215|403|183|578|262|666|278|345|275|211|571|195|205|209|240|493|186|208|477|209|554|231|292|637|275|298|302|190|402|230|231|259|779|279|281|134|348|226|309|283|636|95|479|321|231|196|248|598|406|304|251|299|322|315|1044|359|305|332|272|335|337|276|487|325|197|495|327|335|367,0.00|0.30|0.39|0.00|0.00|0.00|0.01|0.00|0.02|0.00|0.00|0.00|0.00|0.01|0.00|0.01|0.00|0.01|0.43|0.03|0.59|0.15|0.01|0.03|0.00|0.00|0.00|0.00|0.06|0.21|0.00|0.00|0.00|0.22|0.00|0.17|0.02|0.01|0.00|0.01|0.00|0.01|0.00|0.16|0.01|0.00|0.05|0.17|0.00|0.00|0.00|0.00|0.24|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00,P1:Vol=117:Drug=0.00|P2:Vol=456:Drug=0.30|P3:Vol=393:Drug=0.39|P4:Vol=403:Drug=0.00|P5:Vol=137:Drug=0.00|P6:Vol=137:Drug=0.00|P7:Vol=357:Drug=0.01|P8:Vol=107:Drug=0.00|P9:Vol=85:Drug=0.00|P10:Vol=356:Drug=0.02
COL5A1,COL5A1,collagen type V alpha 1 chain,"This gene encodes an alpha chain for one of the low abundance fibrillar collagens. Fibrillar collagen molecules are trimers that can be composed of one or more types of alpha chains. Type V collagen is found in tissues containing type I collagen and appears to regulate the assembly of heterotypic fibers composed of both type I and type V collagen. This gene product is closely related to type XI collagen and it is possible that the collagen chains of types V and XI constitute a single collagen type with tissue-specific chain combinations. The encoded procollagen protein occurs commonly as the heterotrimer pro-alpha1(V)-pro-alpha1(V)-pro-alpha2(V). Mutations in this gene are associated with Ehlers-Danlos syndrome, types I and II. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2013].",protein-coding,EDSC|EDSCL1|FMDMF,"collagen alpha-1(V) chain|collagen, type V, alpha 1",ENSG00000130635,ENST00000371817|ENST00000371820|ENST00000460264|ENST00000463925|ENST00000464187|ENST00000465877|ENST00000469093|ENST00000950240,ENSP00000360882|ENSP00000360885|ENSP00000620299,P20908,Q59EE7|B2ZZ86|H7BY82,CO5A1_HUMAN,1289.0,NM_000093.5|NM_001278074.1|XM_017014266.3|XM_054361962.1,NP_000084.3|NP_001265003.1|XP_016869755.1|XP_054217937.1,NC_000009.12|NC_060933.1|NG_008030.1,2209.0,120215.0,PA26724,9606.ENSP00000360882,7Y37,,IPR000885|IPR001791|IPR008160|IPR013320|IPR048287|IPR050149,PF01391|PF01410|PF02210,PS51461,9,134641803.0,134844843.0,1.0,1838.0,"Secreted, extracellular space, extracellular matrix",9606.0,55434.0,"Collagen, type V, alpha 1",pid:avb3_integrin_pathway|pid:deltanp63pathway|pid:integrin1_pathway|pid:syndecan_1_pathway|reactome:R-HSA-1266738|reactome:R-HSA-1442490|reactome:R-HSA-1474228|reactome:R-HSA-1474244|reactome:R-HSA-1474244|wikipathways:WP2328|wikipathways:WP2911|wikipathways:WP3932|wikipathways:WP3967,True,collagen type V alpha 1 chain,2,2,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN,DRUGGABLE GENOME,cleavage,The ChEMBL Bioactivity Database,True,CHEMBL2364188,PROTEIN COMPLEX GROUP,0,0,0,0,0,True,38,13,6,6,0,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|OCRIPLASMIN|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,Protein|Enzyme,Collagen hydrolytic enzyme,True,True,False,HIGH - Approved drugs exist,Collagen alpha-1(V) chain,"Type V collagen is a member of group I collagen (fibrillar forming collagen). It is a minor connective tissue component of nearly ubiquitous distribution. Type V collagen binds to DNA, heparan sulfate, thrombospondin, heparin, and insulin",3D-structure|Alternative splicing|Calcium|Collagen|Direct protein sequencing|Disease variant|Disulfide bond|Ehlers-Danlos syndrome|Extracellular matrix|Heparin-binding|Hydroxylation|Metal-binding|Proteomics identification|Reference proteome|Repeat|Secreted|Signal|Sulfation,Belongs to the fibrillar collagen family,PF01410:COLFI|PF01391:Collagen|PF02210:Laminin_G_2,3,IPR008160:Collagen|IPR050149:Collagen_superfamily|IPR013320:ConA-like_dom_sf|IPR000885:Fib_collagen_C|IPR001791:Laminin_G|IPR048287:TSPN-like_N,6,,domain|family|homologous_superfamily|repeat,False,,NONE,,,True,1,7Y37,7Y37,1.45,X-RAY DIFFRACTION,protein_structures/pdb_experimental/7Y37.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/7Y37.pdb,Excellent (<2.0Å),True,1,1.0,228.367,0.0,1.167,0.388,True,1,Moderate,Low,Adequate volume (228A3),,228,,P1:Vol=228:Drug=0.00
ACTB,POTEF,POTE ankyrin domain family member F,"Involved in retina homeostasis. Located in blood microparticle and extracellular exosome. [provided by Alliance of Genome Resources, Apr 2022]",protein-coding,A26C1B|ACTB|POTE2alpha|POTEACTIN,ANKRD26-like family C member 1B|POTE ankyrin domain family member F|POTE-2 alpha-actin|beta actin|chimeric POTE-actin protein,ENSG00000196604,ENST00000361163|ENST00000409914,ENSP00000355012|ENSP00000386786,A5A3E0,A6NC16,ACTB_HUMAN,728378.0,NM_001099771.2|XM_017004833.2|XM_017004834.2|XM_017004835.2|XM_047445721.1|XM_054332885.1|XM_054343705.1|XM_054343706.1,NP_001093241.1|XP_016860322.1|XP_016860323.1|XP_016860324.1|XP_047301677.1|XP_054188860.1|XP_054199680.1|XP_054199681.1,NC_000002.12|NC_060926.1|NW_025791762.1,33905.0,,PA164724818,9606.ENSP00000494750,3BYH|3D2U|3J82|3LUE|6ANU|6ICT|6ICV|6LTJ|6MBJ|6MBK|6MBL|6NBW|6OX0|6OX1|6OX2|6OX3|6OX4|6OX5|6V62|6V63,,IPR002110|IPR036770|IPR050657|IPR004000|IPR004001|IPR020902|IPR039497|IPR043129,PF00022|PF12796|PF14915,PS50088|PS50297,2,130073535.0,130129222.0,-1.0,375.0,"Cytoplasm, cytoskeleton|Nucleus",9606.0,133745.0,,,True,actin beta,35,2,UCB35625|CCL28|MET-CK&BETA;7|[125I]CCL7 (HUMAN)|CCL11|CCL26|RO116-4875/608|GW766994|HIV-TAT|CXCL9|ETHINYL ESTRADIOL|CXCL11|[3H]BANYU (I)|YM-355179|CCL2|LAZUCIRNON|RO330-0802/001|BMS COMPOUND 87B|CYCLOPHOSPHAMIDE ANHYDROUS|CCL18,ETHINYL ESTRADIOL|CYCLOPHOSPHAMIDE ANHYDROUS,MET-CK&BETA;7|RO116-4875/608|GW766994|[3H]BANYU (I)|LAZUCIRNON,TUMOR SUPPRESSOR|CLINICALLY ACTIONABLE,agonist|inhibitor,Guide to Pharmacology|NCI Cancer Gene Index,True,CHEMBL5170,SINGLE PROTEIN,0,0,5,5,5,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,POTE ankyrin domain family member F,,ANK repeat|Coiled coil|Cytoplasm|Proteomics identification|Reference proteome|Repeat,In the N-terminal section; belongs to the POTE family|In the C-terminal section; belongs to the actin family,PF00022:Actin|PF12796:Ank_2|PF14915:CCDC144C,3,IPR004000:Actin|IPR020902:Actin/actin-like_CS|IPR004001:Actin_CS|IPR002110:Ankyrin_rpt|IPR036770:Ankyrin_rpt-contain_sf|IPR043129:ATPase_NBD|IPR039497:CC144C-like_CC_dom,7,,conserved_site|domain|family|homologous_superfamily|repeat,True,Actin,HIGH,Actin: Keyword: actin|Actin: InterPro: IPR004000|Actin: Pfam: PF00022,Actin,False,0,,,,,,False,,,,,,,,False,0,,,,,,False,0,,,,,,,
TUBB,TUBB2A,tubulin beta 2A class IIa,"Microtubules, key participants in processes such as mitosis and intracellular transport, are composed of heterodimers of alpha- and beta-tubulins. The protein encoded by this gene is a beta-tubulin. Defects in this gene are associated with complex cortical dysplasia with other brain malformations-5. Two transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Jul 2015].",protein-coding,CDCBM5|TUBB|TUBB2,"class IIa beta-tubulin|tubulin beta-2A chain|tubulin, beta 2A|tubulin, beta polypeptide 2",ENSG00000137267,ENST00000333628|ENST00000489942|ENST00000679400|ENST00000679907|ENST00000680036|ENST00000680967|ENST00000940056,ENSP00000369703|ENSP00000610115,Q13885,,TBB5_HUMAN,7280.0,NM_001069.3|NM_001310315.2,NP_001060.1|NP_001297244.1,NC_000006.12|NC_060930.1|NG_042223.1,12412.0,615101.0,PA142670670,9606.ENSP00000339001,7NVN|8V3O|8V3P,,IPR000217|IPR002453|IPR003008|IPR008280|IPR013838|IPR017975|IPR018316|IPR023123|IPR036525|IPR037103,PF00091|PF03953,,6,3153497.0,3157544.0,-1.0,444.0,"Cytoplasm, cytoskeleton",9606.0,134314.0,TUBB2A,kegg:hsa04145|kegg:hsa04540|kegg:hsa05010|kegg:hsa05012|kegg:hsa05014|pid:hdac_classii_pathway|pid:hdac_classiii_pathway|reactome:R-HSA-109582|reactome:R-HSA-112314|reactome:R-HSA-112315|reactome:R-HSA-112316|reactome:R-HSA-1169410|wikipathways:WP2272|wikipathways:WP2359,True,tubulin beta class I,99,27,VANDORTUZUMAB VEDOTIN|VORINOSTAT|CROLIBULIN|OMBRABULIN|PHOMOPSIN A|VINORELBINE|VINCRISTINE|LORVOTUZUMAB MERTANSINE|VINORELBINE TARTRATE|VINCRISTINE SULFATE|VASCULAR DISRUPTING AGENT BNC105|ANG1005|VINBLASTINE|ASG-5ME|PACLITAXEL DOCOSAHEXAENOIC ACID|CHEMBL:CHEMBL1935538|PATUPILONE|VALECOBULIN|RG-7841|PACLITAXEL,VORINOSTAT|VINORELBINE|VINCRISTINE|VINORELBINE TARTRATE|VINCRISTINE SULFATE|VINBLASTINE|PACLITAXEL|CABAZITAXEL|MEBENDAZOLE|EPOTHILONE D,PHOMOPSIN A|VASCULAR DISRUPTING AGENT BNC105|VALECOBULIN|TUBULIN INHIBITOR ALB 109564 DIHYDROCHLORIDE|SIMOTAXEL,DRUGGABLE GENOME,modulator|negative modulator|inhibitor,"Trends in the exploitation of novel drug targets (Rask-Andersen, et al., 2011)|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|Drug Target Commons|The ChEMBL Bioactivity Database|Therapeutic Target Database",True,CHEMBL5444,SINGLE PROTEIN,0,0,27,27,48,True,3947,25,0,0,0,BRENTUXIMAB VEDOTIN|BRENTUXIMAB VEDOTIN|VINBLASTINE SULFATE|DOCETAXEL|DOCETAXEL|PACLITAXEL|IXABEPILONE|ERIBULIN MESYLATE|TRASTUZUMAB EMTANSINE|PACLITAXEL,Small molecule|Antibody drug conjugate,Tubulin inhibitor,True,False,True,HIGH - Approved drugs exist,Tubulin beta-2A chain,"Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin",3D-structure|Acetylation|Cytoplasm|Cytoskeleton|Direct protein sequencing|Disease variant|GTP-binding|Isopeptide bond|Magnesium|Metal-binding|Methylation|Microtubule|Nucleotide-binding|Phosphoprotein|Proteomics identification|Reference proteome|Ubl conjugation,Belongs to the tubulin family,PF00091:Tubulin|PF03953:Tubulin_C,2,IPR013838:Beta-tubulin_BS|IPR002453:Beta_tubulin|IPR008280:Tub_FtsZ_C|IPR000217:Tubulin|IPR037103:Tubulin/FtsZ-like_C|IPR018316:Tubulin/FtsZ_2-layer-sand-dom|IPR036525:Tubulin/FtsZ_GTPase_sf|IPR023123:Tubulin_C|IPR017975:Tubulin_CS|IPR003008:Tubulin_FtsZ_GTPase,10,,domain|conserved_site|family|homologous_superfamily|binding_site,True,Tubulin|GTPase,HIGH,Tubulin: Keyword: tubulin|Tubulin: Keyword: alpha-tubulin|Tubulin: Keyword: beta-tubulin|Tubulin: Keyword: microtubule|Tubulin: InterPro: IPR000217|Tubulin: InterPro: IPR003008|Tubulin: Pfam: PF00091|Tubulin: Pfam: PF03953|GTPase: Keyword: gtpase,Tubulin,True,3,7NVN|8V3O|8V3P,7NVN,3.0,ELECTRON MICROSCOPY,protein_structures/pdb_experimental/7NVN.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/7NVN.pdb,Moderate (2.5-3.0Å),False,0,,,,,,False,0,,,,,,,
VIM,VIM,vimentin,"This gene encodes a type III intermediate filament protein. Intermediate filaments, along with microtubules and actin microfilaments, make up the cytoskeleton. The encoded protein is responsible for maintaining cell shape and integrity of the cytoplasm, and stabilizing cytoskeletal interactions. This protein is involved in neuritogenesis and cholesterol transport and functions as an organizer of a number of other critical proteins involved in cell attachment, migration, and signaling. Bacterial and viral pathogens have been shown to attach to this protein on the host cell surface. Mutations in this gene are associated with congenital cataracts in human patients. [provided by RefSeq, Aug 2017].",protein-coding,,epididymis secretory sperm binding protein|vimentin,ENSG00000026025,ENST00000224237|ENST00000421459|ENST00000469543|ENST00000478746|ENST00000485947|ENST00000487938|ENST00000495528|ENST00000497849|ENST00000544301|ENST00000637053,ENSP00000224237|ENSP00000431702|ENSP00000435613|ENSP00000446007|ENSP00000489830|ENSP00000490509|ENSP00000552020|ENSP00000552021|ENSP00000552022|ENSP00000616843,P08670,B0YJC5|V9HWE1|B0YJC4|A0A1B0GVG8|A0A1B0GTT5,VIME_HUMAN,7431.0,NM_003380.5,NP_003371.2,NC_000010.11|NC_060934.1|NG_012413.1,12692.0,193060.0,PA37311,9606.ENSP00000446007,1GK4|1GK6|1GK7|3G1E|3KLT|3S4R|3SSU|3SWK|3TRT|3UF1|4MCY|4MCZ|4MD0|4MD5|4MDI|4MDJ|4YPC|4YV3|5WHF|6ATF,,IPR006821|IPR018039|IPR039008|IPR050405,PF00038|PF04732,PS51842,10,17228241.0,17237593.0,1.0,466.0,"Cytoplasm|Cytoplasm, cytoskeleton|Nucleus matrix",9606.0,2538.0,Vimentin,kegg:hsa05169|kegg:hsa05206|netpath:Pathway_Alpha6Beta4Integrin|netpath:Pathway_EGFR1|pid:aurora_b_pathway|pid:caspase_pathway|reactome:R-HSA-109581|reactome:R-HSA-111465|reactome:R-HSA-1266738|reactome:R-HSA-1280215|reactome:R-HSA-162582|wikipathways:WP2328|wikipathways:WP2431|wikipathways:WP2572|wikipathways:WP2814|wikipathways:WP2864,True,vimentin,5,2,ALDESLEUKIN|DIMETHYL SULFOXIDE|GELDANAMYCIN|PRITUMUMAB|GANGLIOSIDE GM2,ALDESLEUKIN|DIMETHYL SULFOXIDE,GANGLIOSIDE GM2|PRITUMUMAB|GELDANAMYCIN|DIMETHYL SULFOXIDE|ALDESLEUKIN,DRUGGABLE GENOME,other/unknown,The ChEMBL Bioactivity Database|NCI Cancer Gene Index,True,CHEMBL3712854,SINGLE PROTEIN,0,0,12,12,30,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Vimentin,Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2,3D-structure|Acetylation|Cataract|Cell membrane|Coiled coil|Cytoplasm|Cytoskeleton|Direct protein sequencing|Disease variant|Glycoprotein|Host-virus interaction|Intermediate filament|Isopeptide bond|Membrane|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|S-nitrosylation|Ubl conjugation,Belongs to the intermediate filament family,PF00038:Filament|PF04732:Filament_head,2,IPR018039:IF_conserved|IPR039008:IF_rod_dom|IPR006821:Intermed_filament_DNA-bd|IPR050405:Intermediate_filament,4,,domain|family|conserved_site,False,,NONE,,,True,27,1GK4|1GK6|1GK7|3G1E|3KLT|3S4R|3SSU|3SWK|3TRT|3UF1,1GK4,2.3,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1GK4.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1GK4.pdb,Good (2.0-2.5Å),True,43,9.0,1117.173,0.862,21.7,0.049,True,35,Good,Medium,Optimal volume (1117A3)|High druggability (0.86),,617|398|389|572|545|473|483|474|1117|180|370|266|143|408|555|516|306|319|193|229|224|447|192|320|349|252|215|253|163|218|221|223|246|320|111|204|166|309|331|349|274|365|611,0.01|0.06|0.00|0.01|0.07|0.03|0.00|0.86|0.00|0.00|0.07|0.04|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01,P1:Vol=617:Drug=0.01|P2:Vol=398:Drug=0.06|P3:Vol=389:Drug=0.00|P4:Vol=572:Drug=0.01|P5:Vol=545:Drug=0.07|P6:Vol=473:Drug=0.03|P7:Vol=483:Drug=0.00|P8:Vol=474:Drug=0.00|P9:Vol=1117:Drug=0.86|P10:Vol=180:Drug=0.00
LMNA,LMNA,lamin A/C,"The protein encoded by this gene is part of the nuclear lamina, a two-dimensional matrix of proteins located next to the inner nuclear membrane. The lamin family of proteins make up the matrix and are highly conserved in evolution. During mitosis, the lamina matrix is reversibly disassembled as the lamin proteins are phosphorylated. Lamin proteins are thought to be involved in nuclear stability, chromatin structure and gene expression. Vertebrate lamins consist of two types, A and B. Alternative splicing results in multiple transcript variants. Mutations in this gene lead to several diseases: Emery-Dreifuss muscular dystrophy, familial partial lipodystrophy, limb girdle muscular dystrophy, dilated cardiomyopathy, Charcot-Marie-Tooth disease, and Hutchinson-Gilford progeria syndrome. [provided by RefSeq, May 2022].",protein-coding,CDCD1|CDDC|CMD1A|CMT2B1|EMD2|FPL|FPLD|FPLD2|HGPS|IDC|LDP1|LFP|LGMD1B|LMN1|LMNC|LMNL1|MADA|PRO1,70 kDa lamin|epididymis secretory sperm binding protein|lamin|lamin A/C-like 1|lamin C,ENSG00000160789,ENST00000361308|ENST00000368297|ENST00000368298|ENST00000368299|ENST00000368300|ENST00000368301|ENST00000448611|ENST00000459904|ENST00000469565|ENST00000470199,ENSP00000355292|ENSP00000357280|ENSP00000357282|ENSP00000357283|ENSP00000357284|ENSP00000395597|ENSP00000421821|ENSP00000424518|ENSP00000426535|ENSP00000501648,P02545,Q5TCI8|H0YAB0|A0A384MQX1|A0A6Q8PF80|A0A6Q8PF59,LMNA_HUMAN,4000.0,NM_001257374.3|NM_001282624.2|NM_001282625.2|NM_001282626.2|NM_001406983.1|NM_001406984.1|NM_001406985.1|NM_001406986.1|NM_001406987.1|NM_001406988.1,NP_001244303.1|NP_001269553.1|NP_001269554.1|NP_001269555.1|NP_001393912.1|NP_001393913.1|NP_001393914.1|NP_001393915.1|NP_001393916.1|NP_001393917.1,NC_000001.11|NC_060925.1|NG_008692.2,6636.0,150330.0,PA231,9606.ENSP00000357283,1IFR|1IVT|1X8Y|2XV5|2YPT|3GEF|3V4Q|3V4W|3V5B|6GHD|6JLB|6RPR|6SNZ|6YF5|6YJD|7CRG|7D9N|7WZZ|7X1B|7X5D,,IPR001322|IPR018039|IPR036415|IPR039008,PF00038|PF00932,PS51841|PS51842,1,156082572.0,156140081.0,1.0,664.0,"Nucleus lamina|Nucleus envelope|Nucleus, nucleoplasm",9606.0,41321.0,LMNA,biocarta:caspasepathway|biocarta:deathpathway|biocarta:hivnefpathway|biocarta:tnfr1pathway|kegg:hsa04210|kegg:hsa05410|kegg:hsa05412|kegg:hsa05414|wikipathways:WP2118|wikipathways:WP236|wikipathways:WP314|wikipathways:WP4299|wikipathways:WP4758,True,lamin A/C,3,2,CHEMBL:CHEMBL328710|LONAFARNIB|HISTAMINE,LONAFARNIB|HISTAMINE,LONAFARNIB|CHEMBL:CHEMBL328710|HISTAMINE,DRUGGABLE GENOME|CLINICALLY ACTIONABLE,,PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons,True,CHEMBL1293235,SINGLE PROTEIN,0,0,999,999,1000,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Prelamin-A/C,"Prelamin-A/C can accelerate smooth muscle cell senescence (PubMed:20458013). It acts to disrupt mitosis and induce DNA damage in vascular smooth muscle cells (VSMCs), leading to mitotic failure, genomic instability, and premature senescence (PubMed:20458013)",3D-structure|Acetylation|Alternative splicing|Cardiomyopathy|Charcot-Marie-Tooth disease|Coiled coil|Congenital muscular dystrophy|Direct protein sequencing|Disease variant|Emery-Dreifuss muscular dystrophy|Glycoprotein|Intermediate filament|Isopeptide bond|Limb-girdle muscular dystrophy|Lipoprotein|Methylation|Neurodegeneration|Neuropathy|Nucleus|Phosphoprotein,Belongs to the intermediate filament family,PF00038:Filament|PF00932:LTD,2,IPR018039:IF_conserved|IPR039008:IF_rod_dom|IPR001322:Lamin_tail_dom|IPR036415:Lamin_tail_dom_sf,4,,domain|homologous_superfamily|conserved_site,False,,NONE,,,True,27,1IFR|1IVT|1X8Y|2XV5|2YPT|3GEF|3V4Q|3V4W|3V5B|6GHD,1IFR,1.4,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1IFR.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1IFR.pdb,Excellent (<2.0Å),True,2,2.0,212.107,0.341,17.143,0.297,True,2,Moderate,Low,Adequate volume (212A3),Low druggability (0.34),337|212,0.03|0.34,P1:Vol=337:Drug=0.03|P2:Vol=212:Drug=0.34
KRT1,KRT1,keratin 1,"The protein encoded by this gene is a member of the keratin gene family. The type II cytokeratins consist of basic or neutral proteins which are arranged in pairs of heterotypic keratin chains coexpressed during differentiation of simple and stratified epithelial tissues. This type II cytokeratin is specifically expressed in the spinous and granular layers of the epidermis with family member KRT10 and mutations in these genes have been associated with bullous congenital ichthyosiform erythroderma. The type II cytokeratins are clustered in a region of chromosome 12q12-q13. [provided by RefSeq, Jul 2008].",protein-coding,AEI2|CK1|EHK|EHK1|EPPK|K1|KRT1A|NEPPK,67 kDa cytokeratin|CK-1|cytokeratin 1|epidermolytic hyperkeratosis 1|hair alpha protein,ENSG00000167768,ENST00000252244|ENST00000548765,ENSP00000252244,P04264,,K2C1_HUMAN,3848.0,NM_006121.4,NP_006112.3,NC_000012.12|NC_060936.1|NG_008364.2,6412.0,139350.0,PA30199,9606.ENSP00000252244,4ZRY|6E2J|6UUI,,IPR003054|IPR018039|IPR032444|IPR032449|IPR039008,PF00038|PF16208|PF16210,PS51842,12,52674736.0,52680407.0,-1.0,644.0,Cell membrane|Cytoplasm,9606.0,38146.0,Keratin 1,reactome:R-HSA-1266738|reactome:R-HSA-168249|reactome:R-HSA-168256|reactome:R-HSA-6798695|reactome:R-HSA-6805567,True,keratin 1,0,0,,,,KINASE,,,False,,,0,0,0,0,0,True,0,0,0,0,0,,,,False,False,False,NONE - No known drug interactions,"Keratin, type II cytoskeletal 1",May regulate the activity of kinases such as PKC and SRC via binding to integrin beta-1 (ITB1) and the receptor of activated protein C kinase 1 (RACK1). In complex with C1QBP is a high affinity receptor for kininogen-1/HMWK,3D-structure|Cell membrane|Citrullination|Coiled coil|Cytoplasm|Direct protein sequencing|Disease variant|Ichthyosis|Intermediate filament|Keratin|Membrane|Methylation|Palmoplantar keratoderma|Phosphoprotein|Proteomics identification|Reference proteome,Belongs to the intermediate filament family,PF00038:Filament|PF16208:Keratin_2_head|PF16210:Keratin_2_tail,3,IPR018039:IF_conserved|IPR039008:IF_rod_dom|IPR032449:Keratin_2_1_tail|IPR032444:Keratin_2_head|IPR003054:Keratin_II,5,,conserved_site|family|domain,True,Kinase|Integrin,HIGH,Kinase: Keyword: kinase|Integrin: Keyword: integrin|Integrin: Keyword: integrin beta,Kinase,True,3,4ZRY|6E2J|6UUI,4ZRY,3.30012502044,X-RAY DIFFRACTION,protein_structures/pdb_experimental/4ZRY.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/4ZRY.pdb,Low (>3.3Å),True,9,4.0,381.679,0.626,46.875,0.249,True,8,Moderate,Low,Adequate volume (382A3),,544|346|425|382|203|337|300|231|159,0.00|0.00|0.01|0.63|0.01|0.00|0.00,P1:Vol=544:Drug=0.00|P2:Vol=346:Drug=0.00|P3:Vol=425:Drug=0.01|P4:Vol=382:Drug=0.63|P5:Vol=203:Drug=0.01|P6:Vol=337:Drug=0.00|P7:Vol=300:Drug=0.00|P8:Vol=231:Drug=0.00|P9:Vol=159:Drug=0.00
GRB2,GRB2,growth factor receptor bound protein 2,"The protein encoded by this gene binds the epidermal growth factor receptor and contains one SH2 domain and two SH3 domains. Its two SH3 domains direct complex formation with proline-rich regions of other proteins, and its SH2 domain binds tyrosine phosphorylated sequences. This gene is similar to the Sem5 gene of C.elegans, which is involved in the signal transduction pathway. Two alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008].",protein-coding,ASH|EGFRBP-GRB2|Grb3-3|MST084|MSTP084|NCKAP2,HT027|SH2/SH3 adapter GRB2|abundant SRC homology|epidermal growth factor receptor-binding protein GRB2|epididymis secretory sperm binding protein,ENSG00000177885,ENST00000316615|ENST00000316804|ENST00000392562|ENST00000392563|ENST00000392564|ENST00000462266|ENST00000577711|ENST00000578961|ENST00000581959|ENST00000582582,ENSP00000317360|ENSP00000339007|ENSP00000376345|ENSP00000376346|ENSP00000376347|ENSP00000462785|ENSP00000463525|ENSP00000464279|ENSP00000496913|ENSP00000574827,P62993,J3QRL5|B0LPF3|J3KT38|J3QLF6,GRB2_HUMAN,2885.0,NM_002086.5|NM_203506.3,NP_002077.1|NP_987102.1,NC_000017.11|NC_060941.1|NG_029556.1,4566.0,108355.0,PA28962,9606.ENSP00000376345,1AZE|1BM2|1BMB|1CJ1|1FHS|1FYR|1GCQ|1GFC|1GFD|1GHU|1GRI|1IO6|1JYQ|1JYR|1JYU|1QG1|1TZE|1X0N|1ZFP|2AOA,,IPR000980|IPR001452|IPR035641|IPR035643|IPR036028|IPR036860|IPR043539,PF00017|PF00018|PF14604,PS50001|PS50002,17,75318076.0,75405709.0,-1.0,217.0,Nucleus|Cytoplasm|Endosome,9606.0,1576.0,GRB2,biocarta:at1rpathway|biocarta:bcrpathway|biocarta:biopeptidespathway|biocarta:cardiacegfpathway|biocarta:cblpathway|kegg:hsa04010|kegg:hsa04012|kegg:hsa04014|kegg:hsa04062|kegg:hsa04068|netpath:Pathway_Alpha6Beta4Integrin|netpath:Pathway_BCR|netpath:Pathway_BDNF|netpath:Pathway_EGFR1|netpath:Pathway_Fibroblast__growth__factor-1|pid:a6b1_a6b4_integrin_pathway|pid:angiopoietinreceptor_pathway|pid:bcr_5pathway|pid:cd8tcrpathway|pid:epha2_fwdpathway|reactome:R-HSA-109582|reactome:R-HSA-109704|reactome:R-HSA-112399|reactome:R-HSA-112399|reactome:R-HSA-112412|smpdb:SMP00358|smpdb:SMP00391|wikipathways:WP127|wikipathways:WP185|wikipathways:WP2034|wikipathways:WP2037|wikipathways:WP22,True,growth factor receptor bound protein 2,7,3,ANTINEOPLASTIC AGENT|RECOMBINANT HEREGULIN|VORASIDENIB|TCDD|LY3410738|ENASIDENIB|DACTINOMYCIN,VORASIDENIB|ENASIDENIB|DACTINOMYCIN,RECOMBINANT HEREGULIN|VORASIDENIB|LY3410738|ENASIDENIB|ANTINEOPLASTIC AGENT,,inhibitor,Guide to Pharmacology|NCI Cancer Gene Index,True,CHEMBL4830,SINGLE PROTEIN,0,0,14,14,49,True,1,0,0,1,0,PREXIGEBERSEN,Oligonucleotide,Growth factor receptor-bound protein 2 mRNA antisense inhibitor,True,True,True,HIGH - Approved drugs exist,Growth factor receptor-bound protein 2,"Does not bind to phosphorylated epidermal growth factor receptor (EGFR) but inhibits EGF-induced transactivation of a RAS-responsive element. Acts as a dominant negative protein over GRB2 and by suppressing proliferative signals, may trigger active programmed cell death. Mechanistically, inhibits RAS-ERK signaling and downstream cell proliferation by competing with GRB2 for SOS1 binding and thus by regulating SOS1 membrane recruitment (PubMed:36171279)",3D-structure|Acetylation|Alternative splicing|Cytoplasm|Direct protein sequencing|Endosome|Golgi apparatus|Host-virus interaction|Isopeptide bond|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|Repeat|SH2 domain|SH3 domain|Ubl conjugation,Belongs to the GRB2/sem-5/DRK family,PF00017:SH2|PF00018:SH3_1,2,IPR043539:Grb2-like|IPR035643:GRB2_C_SH3|IPR035641:GRB2_N_SH3|IPR000980:SH2|IPR036860:SH2_dom_sf|IPR036028:SH3-like_dom_sf|IPR001452:SH3_domain,7,,domain|family|homologous_superfamily,False,,NONE,,,True,55,1AZE|1BM2|1BMB|1CJ1|1FHS|1FYR|1GCQ|1GFC|1GFD|1GHU,1AZE,,SOLUTION NMR,protein_structures/pdb_experimental/1AZE.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1AZE.pdb,,True,3,1.0,227.139,0.179,13.833,0.326,True,2,Moderate,Low,Adequate volume (227A3),Low druggability (0.18),227|236|167,0.18|0.02|0.00,P1:Vol=227:Drug=0.18|P2:Vol=236:Drug=0.02|P3:Vol=167:Drug=0.00
SHC1,SHC1,SHC adaptor protein 1,"This gene encodes three main isoforms that differ in activities and subcellular location. While all three are adapter proteins in signal transduction pathways, the longest (p66Shc) may be involved in regulating life span and the effects of reactive oxygen species. The other two isoforms, p52Shc and p46Shc, link activated receptor tyrosine kinases to the Ras pathway by recruitment of the GRB2/SOS complex. p66Shc is not involved in Ras activation. Unlike the other two isoforms, p46Shc is targeted to the mitochondrial matrix. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2011].",protein-coding,SHC|SHCA,SH2 domain protein C1|SHC (Src homology 2 domain containing) transforming protein 1|SHC-transforming protein 1|SHC-transforming protein 3|SHC-transforming protein A,ENSG00000160691,ENST00000366442|ENST00000368445|ENST00000368449|ENST00000368450|ENST00000368453|ENST00000412170|ENST00000414115|ENST00000444179|ENST00000444664|ENST00000448116,ENSP00000357430|ENSP00000357434|ENSP00000357435|ENSP00000357438|ENSP00000396162|ENSP00000396333|ENSP00000398441|ENSP00000398864|ENSP00000401303|ENSP00000404908,P29353,Q5T182|H0Y539|X6R6D0|Q5T187|Q5T188,SHC1_HUMAN,6464.0,NM_001130040.2|NM_001130041.2|NM_001202859.2|NM_003029.5|NM_183001.5|XM_005245449.6|XM_005245451.5|XM_011509892.4|XM_011509893.4|XM_011509894.4,NP_001123512.1|NP_001123513.1|NP_001189788.1|NP_003020.2|NP_892113.4|XP_005245506.1|XP_005245508.1|XP_011508194.1|XP_011508195.1|XP_011508196.1,NC_000001.11|NC_060925.1|NG_029028.1,10840.0,600560.0,PA35746,9606.ENSP00000401303,1MIL|1N3H|1OY2|1QG1|1SHC|1TCE|2L1C|4JMH|4XWX|5CZI|6DM4,,IPR000980|IPR006019|IPR006020|IPR011993|IPR035676|IPR036860|IPR051235,PF00017|PF00640,PS01179|PS50001,1,154962284.0,154974395.0,-1.0,583.0,"Cytoplasm|Cell junction, focal adhesion",9606.0,7934.0,SHC1,biocarta:at1rpathway|biocarta:bcrpathway|biocarta:biopeptidespathway|biocarta:cardiacegfpathway|biocarta:cdk5pathway|kegg:hsa04012|kegg:hsa04014|kegg:hsa04062|kegg:hsa04072|kegg:hsa04510|netpath:Pathway_Alpha6Beta4Integrin|netpath:Pathway_BCR|netpath:Pathway_BDNF|netpath:Pathway_EGFR1|netpath:Pathway_Fibroblast__growth__factor-1|pid:a6b1_a6b4_integrin_pathway|pid:angiopoietinreceptor_pathway|pid:bcr_5pathway|pid:cd8tcrpathway|pid:epha2_fwdpathway|wikipathways:WP127|wikipathways:WP185|wikipathways:WP2034|wikipathways:WP2037|wikipathways:WP23,True,SHC adaptor protein 1,0,0,,,,KINASE,,,True,CHEMBL5626,SINGLE PROTEIN,0,0,65,65,70,True,0,0,0,0,0,,,,False,False,True,LOW - Bioactive compounds or interactions reported,SHC-transforming protein 1,"Signaling adapter that couples activated growth factor receptors to signaling pathways. Participates in a signaling cascade initiated by activated KIT and KITLG/SCF. Isoform p46Shc and isoform p52Shc, once phosphorylated, couple activated receptor tyrosine kinases to Ras via the recruitment of the GRB2/SOS complex and are implicated in the cytoplasmic propagation of mitogenic signals. Isoform p46Shc and isoform p52Shc may thus function as initiators of the Ras signaling cascade in various non-neuronal systems. Isoform p66Shc does not mediate Ras activation, but is involved in signal transduction pathways that regulate the cellular response to oxidative stress and life span. Isoform p66Shc acts as a downstream target of the tumor suppressor p53 and is indispensable for the ability of stress-activated p53 to induce elevation of intracellular oxidants, cytochrome c release and apoptosis. The expression of isoform p66Shc has been correlated with life span (By similarity). Participates in signaling downstream of the angiopoietin receptor TEK/TIE2, and plays a role in the regulation of endothelial cell migration and sprouting angiogenesis",3D-structure|Acetylation|Alternative promoter usage|Alternative splicing|Angiogenesis|Cell junction|Cytoplasm|Growth regulation|Host-virus interaction|Mitochondrion|Phosphoprotein|Proteomics identification|Reference proteome|SH2 domain,,PF00640:PID|PF00017:SH2,2,IPR051235:CEP152/SHC-Transforming|IPR011993:PH-like_dom_sf|IPR006019:PID_Shc-like|IPR006020:PTB/PI_dom|IPR000980:SH2|IPR036860:SH2_dom_sf|IPR035676:SHC_SH2,7,,domain|family|homologous_superfamily,True,Kinase|Histone Acetyltransferase,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: tyrosine kinase|Kinase: Keyword: receptor tyrosine kinase|Histone Acetyltransferase: Keyword: hat,Kinase,True,11,1MIL|1N3H|1OY2|1QG1|1SHC|1TCE|2L1C|4JMH|4XWX|5CZI,1MIL,2.7,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1MIL.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1MIL.pdb,Moderate (2.5-3.0Å),True,5,5.0,248.5,0.3,25.4,0.073,True,4,Moderate,Low,Adequate volume (248A3),Low druggability (0.30),239|72|263|286|248,0.01|0.02|0.00|0.30,P1:Vol=239:Drug=0.00|P2:Vol=72:Drug=0.01|P3:Vol=263:Drug=0.02|P4:Vol=286:Drug=0.00|P5:Vol=248:Drug=0.30
GAB1,PIGU,phosphatidylinositol glycan anchor biosynthesis class U,"The protein encoded by this gene shares similarity with Saccharomyces cerevisiae Cdc91, a predicted integral membrane protein that may function in cell division control. The protein encoded by this gene is the fifth subunit of GPI transamidase that attaches GPI-anchors to proteins. [provided by RefSeq, Jul 2008].",protein-coding,CDC91L1|GAB1|GPIBD21|NEDBSS|PIG-U,"CDC91 (cell division cycle 91, S. cerevisiae, homolog)-like 1|GPI and Actin Bar homolog|GPI transamidase component PIG-U|GPI transamidase subunit|GPI transamidase subunit PIGU",ENSG00000101464,ENST00000217446|ENST00000374820|ENST00000438215|ENST00000462389|ENST00000480175|ENST00000628281|ENST00000897591|ENST00000897592|ENST00000897593|ENST00000897594,ENSP00000217446|ENSP00000363953|ENSP00000395755|ENSP00000567650|ENSP00000567651|ENSP00000567652|ENSP00000567653|ENSP00000567654|ENSP00000610127|ENSP00000610128,Q9H490,Q5JWU1,GAB1_HUMAN,128869.0,NM_080476.5|XM_011528542.2|XM_017027664.2|XM_054322981.1|XM_054322982.1,NP_536724.1|XP_011526844.1|XP_016883153.1|XP_054178956.1|XP_054178957.1,NC_000020.11|NC_060944.1|NG_011497.1,15791.0,608528.0,PA162399506,9606.ENSP00000262995,7W72|7WLD|8IMX|8IMY,,IPR009600,PF06728,,20,34560542.0,34698790.0,-1.0,694.0,,9606.0,6553.0,PIGU,reactome:R-HSA-162791|reactome:R-HSA-163125|reactome:R-HSA-392499|reactome:R-HSA-597592,True,GRB2 associated binding protein 1,1,0,A1120,,A1120,KINASE,inhibitor,Guide to Pharmacology,True,CHEMBL4523286,SINGLE PROTEIN,0,0,22,22,44,True,0,0,0,0,0,,,,False,False,True,LOW - Bioactive compounds or interactions reported,GPI-anchor transamidase component PIGU,"Component of the glycosylphosphatidylinositol-anchor (GPI-anchor) transamidase (GPI-T) complex that catalyzes the formation of the linkage between a proprotein and a GPI-anchor and participates in GPI anchored protein biosynthesis (PubMed:12802054, PubMed:31353022, PubMed:34576938, PubMed:35165458, PubMed:35551457, PubMed:37684232). Binds the lipid portion of GPI-anchor (PubMed:37684232). May act as an organizer in the transmembrane layer to recruit other subunits, and thus is essential for assembly of the complex (PubMed:35165458, PubMed:35551457)",3D-structure|Alternative splicing|Direct protein sequencing|Disease variant|Endoplasmic reticulum|Epilepsy|GPI-anchor biosynthesis|Intellectual disability|Membrane|Proteomics identification|Reference proteome|Transmembrane|Transmembrane helix,Belongs to the PIGU family,PF06728:PIG-U,1,IPR009600:PIG-U,1,,family,True,Histone Acetyltransferase|Hydrolase,MEDIUM,Histone Acetyltransferase: Keyword: hat|Hydrolase: Keyword: amidase,Histone Acetyltransferase,True,3,7W72|7WLD|8IMX,7W72,3.1,ELECTRON MICROSCOPY,protein_structures/pdb_experimental/7W72.pdb,False,,,,,PDB,protein_structures/pdb_experimental/7W72.pdb,Low (>3.1Å),True,160,67.0,1413.08,0.986,47.057,0.986,True,133,Excellent,High,Optimal volume (1413A3)|High druggability (0.99),,102|547|203|1582|837|310|444|153|91|167|100|483|427|137|335|342|260|60|302|233|126|633|175|114|173|289|2064|866|603|79|276|266|220|238|526|298|205|953|226|248|445|169|169|224|240|78|390|279|315|533|669|205|250|406|233|603|149|187|126|209|935|315|261|202|203|265|1413|172|459|253|357|479|382|234|270|340|335|192|447|65|734|190|345|208|557|311|136|311|469|292|173|407|294|120|401|317|416|630|226|225|265|355|242|244|454|159|185|244|423|292|442|190|389|256|247|424|392|335|621|493|229|433|326|253|396|247|562|306|421|173|226|314|239|135|264|481|376|499|576|557|200|595|238|240|1007|209|427|272|889|359|1638|624|715|1161|246|525|875|682|585|933,0.06|0.00|0.40|0.25|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00|0.01|0.00|0.00|0.01|0.93|0.01|0.09|0.00|0.00|0.01|0.01|0.00|0.00|0.02|0.00|0.01|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.02|0.00|0.01|0.07|0.00|0.00|0.98|0.00|0.00|0.99|0.00|0.00|0.06|0.00|0.00|0.01|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.14|0.00|0.00|0.00|0.02|0.00|0.00|0.00|0.06|0.00|0.04|0.01|0.03|0.00|0.01|0.01|0.00|0.00|0.03|0.01|0.01|0.03|0.04|0.00|0.00|0.00|0.00|0.00|0.01|0.68|0.00|0.00|0.00|0.00|0.00|0.08|0.00|0.01|0.00|0.00|0.02|0.58|0.00|0.03|0.01|0.09|0.05|0.04|0.00|0.00,P1:Vol=102:Drug=0.00|P2:Vol=547:Drug=0.06|P3:Vol=203:Drug=0.00|P4:Vol=1582:Drug=0.40|P5:Vol=837:Drug=0.25|P6:Vol=310:Drug=0.00|P7:Vol=444:Drug=0.00|P8:Vol=153:Drug=0.00|P9:Vol=91:Drug=0.00|P10:Vol=167:Drug=0.00
IRS1,IRS1,insulin receptor substrate 1,"This gene encodes a protein which is phosphorylated by insulin receptor tyrosine kinase. Mutations in this gene are associated with type II diabetes and susceptibility to insulin resistance. [provided by RefSeq, Nov 2009].",protein-coding,HIRS-1,insulin receptor substrate 1,ENSG00000169047,ENST00000305123|ENST00000498335|ENST00000918829,ENSP00000304895|ENSP00000588888,P35568,,IRS1_HUMAN,3667.0,NM_005544.3|XM_047444223.1|XM_047444224.1|XM_054341875.1,NP_005535.1|XP_047300179.1|XP_047300180.1|XP_054197850.1,NC_000002.12|NC_060926.1|NG_015830.1,6125.0,147545.0,PA203,9606.ENSP00000304895,1IRS|1K3A|1QQG|2Z8C|5U1M|6BNT|7PPL|7PPM,,IPR001849|IPR002404|IPR011993|IPR039011,PF00169|PF02174,PS50003|PS51064,2,226731312.0,226799820.0,-1.0,1242.0,Cytoplasm|Nucleus,9606.0,4049.0,IRS1,biocarta:eif4pathway|biocarta:ghpathway|biocarta:igf1pathway|biocarta:igf1rpathway|biocarta:il2rbpathway|kegg:hsa04022|kegg:hsa04068|kegg:hsa04140|kegg:hsa04150|kegg:hsa04151|netpath:Pathway_Alpha6Beta4Integrin|netpath:Pathway_BDNF|netpath:Pathway_Ghrelin|netpath:Pathway_IL-7|netpath:Pathway_IL2|pid:avb3_integrin_pathway|pid:igf1_pathway|pid:il2_1pathway|pid:il4_2pathway|pid:insulin_pathway|reactome:R-HSA-109704|reactome:R-HSA-112399|reactome:R-HSA-112399|reactome:R-HSA-112412|reactome:R-HSA-112412|smpdb:SMP00391|smpdb:SMP00682|wikipathways:WP1584|wikipathways:WP1984|wikipathways:WP2034|wikipathways:WP2037|wikipathways:WP2261,True,insulin receptor substrate 1,8,7,AGANIRSEN|CYCLOPHOSPHAMIDE ANHYDROUS|FLUOROURACIL|DEHYDRATED ALCOHOL|PRASTERONE|EPIRUBICIN|INOSITOL|GLIMEPIRIDE,CYCLOPHOSPHAMIDE ANHYDROUS|FLUOROURACIL|DEHYDRATED ALCOHOL|PRASTERONE|EPIRUBICIN|INOSITOL|GLIMEPIRIDE,AGANIRSEN|GLIMEPIRIDE|INOSITOL|PRASTERONE|EPIRUBICIN,CLINICALLY ACTIONABLE|KINASE,,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|PharmGKB - The Pharmacogenomics Knowledgebase|NCI Cancer Gene Index",True,CHEMBL1163110,SINGLE PROTEIN,0,0,4,4,6,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Insulin receptor substrate 1,"Signaling adapter protein that participates in the signal transduction from two prominent receptor tyrosine kinases, insulin receptor/INSR and insulin-like growth factor I receptor/IGF1R (PubMed:7541045, PubMed:33991522, PubMed:38625937). Plays therefore an important role in development, growth, glucose homeostasis as well as lipid metabolism (PubMed:19639489). Upon phosphorylation by the insulin receptor, functions as a signaling scaffold that propagates insulin action through binding to SH2 domain-containing proteins including the p85 regulatory subunit of PI3K, NCK1, NCK2, GRB2 or SHP2 (PubMed:11171109, PubMed:8265614). Recruitment of GRB2 leads to the activation of the guanine nucleotide exchange factor SOS1 which in turn triggers the Ras/Raf/MEK/MAPK signaling cascade (By similarity). Activation of the PI3K/AKT pathway is responsible for most of insulin metabolic effects in the cell, and the Ras/Raf/MEK/MAPK is involved in the regulation of gene expression and in cooperation with the PI3K pathway regulates cell growth and differentiation. Acts a positive regulator of the Wnt/beta-catenin signaling pathway through suppression of DVL2 autophagy-mediated degradation leading to cell proliferation (PubMed:24616100)",3D-structure|Cytoplasm|Diabetes mellitus|Disease variant|Isopeptide bond|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|Repeat|S-nitrosylation|Transducer|Ubl conjugation,,PF02174:IRS|PF00169:PH,2,IPR039011:IRS|IPR002404:IRS_PTB|IPR011993:PH-like_dom_sf|IPR001849:PH_domain,4,,domain|family|homologous_superfamily,True,Kinase|Histone Acetyltransferase|Lipid Kinase,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: tyrosine kinase|Kinase: Keyword: receptor tyrosine kinase|Kinase: Keyword: mapk|Histone Acetyltransferase: Keyword: hat|Lipid Kinase: Keyword: pi3k,Kinase,True,8,1IRS|1K3A|1QQG|2Z8C|5U1M|6BNT|7PPL|7PPM,1IRS,,SOLUTION NMR,protein_structures/pdb_experimental/1IRS.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1IRS.pdb,,True,7,2.0,101.411,0.337,88.833,0.302,True,5,Poor,Low,,Small volume (101A3)|Low druggability (0.34),400|101|235|508|319|255|186,0.00|0.34|0.00,P1:Vol=400:Drug=0.00|P2:Vol=101:Drug=0.34|P3:Vol=235:Drug=0.00|P4:Vol=508:Drug=0.00|P5:Vol=319:Drug=0.00|P6:Vol=255:Drug=0.00|P7:Vol=186:Drug=0.00
TRAF6,TRAF6,TNF receptor associated factor 6,"The protein encoded by this gene is a member of the TNF receptor associated factor (TRAF) protein family. TRAF proteins are associated with, and mediate signal transduction from, members of the TNF receptor superfamily. This protein has an amino terminal RING domain which is followed by four zinc-finger motifs, a central coiled-coil region and a highly conserved carboxyl terminal domain, known as the TRAF-C domain and mediates signaling from members of the TNF receptor superfamily as well as the Toll/IL-1 family. Signals from receptors such as CD40, TNFSF11/RANCE and IL-1 have been shown to be mediated by this protein. This protein also interacts with various protein kinases including IRAK1/IRAK, SRC and PKCzeta, which provides a link between distinct signaling pathways. This protein functions as a signal transducer in the NF-kappaB pathway that activates IkappaB kinase (IKK) in response to proinflammatory cytokines. The interaction of this protein with UBE2N/UBC13, and UBE2V1/UEV1A, which are ubiquitin conjugating enzymes catalyzing the formation of polyubiquitin chains, has been found to be required for IKK activation by this protein. This protein also interacts with the transforming growth factor (TGF) beta receptor complex and is required for Smad-independent activation of the JNK and p38 kinases. The protein encoded by this gene is a key molecule in antiviral innate and antigen-specific immune responses. [provided by RefSeq, Nov 2021].",protein-coding,MGC:3310|RNF85,"E3 ubiquitin-protein ligase TRAF6|RING finger protein 85|RING-type E3 ubiquitin transferase TRAF6|TNF receptor-associated factor 6|TNF receptor-associated factor 6, E3 ubiquitin protein ligase",ENSG00000175104,ENST00000348124|ENST00000526995|ENST00000529150|ENST00000876418|ENST00000876419|ENST00000876420,ENSP00000337853|ENSP00000433623|ENSP00000546477|ENSP00000546478|ENSP00000546479,Q9Y4K3,,TRAF6_HUMAN,7189.0,NM_004620.4|NM_145803.3,NP_004611.1|NP_665802.1,NC_000011.10|NC_060935.1,12036.0,602355.0,PA36713,9606.ENSP00000433623,1LB4|1LB5|1LB6|2ECI|2JMD|3HCS|3HCT|3HCU|4Z8M|5ZUJ|6A33|7L3L|8HZ2,2.3.2.27,IPR001293|IPR001841|IPR002083|IPR008974|IPR012227|IPR013083|IPR017907|IPR027139|IPR037309|IPR041310,PF02176|PF13923|PF18048|PF21355,PS50089|PS50144|PS50145,11,36483769.0,36510292.0,-1.0,522.0,"Cytoplasm|Cytoplasm, cell cortex|Nucleus",9606.0,3395.0,TRAF6,biocarta:cd40pathway|biocarta:il1rpathway|biocarta:nfkbpathway|biocarta:ranklpathway|biocarta:tall1pathway|kegg:hsa04010|kegg:hsa04064|kegg:hsa04120|kegg:hsa04140|kegg:hsa04144|netpath:Pathway_BDNF|netpath:Pathway_IL1|netpath:Pathway_RANKL|netpath:Pathway_TNFalpha|pid:bcr_5pathway|pid:cd40_pathway|pid:cd8tcrpathway|pid:il1pathway|pid:nfkappabcanonicalpathway|reactome:R-HSA-1257604|reactome:R-HSA-1280215|reactome:R-HSA-1280218|reactome:R-HSA-162582|reactome:R-HSA-162582|wikipathways:WP1449|wikipathways:WP1772|wikipathways:WP195|wikipathways:WP2018|wikipathways:WP2112,True,TNF receptor associated factor 6,0,0,,,,KINASE|ENZYME|SERINE THREONINE KINASE,,,True,CHEMBL3588728,SINGLE PROTEIN,0,0,14,14,20,True,0,0,0,0,0,,,,False,False,True,LOW - Bioactive compounds or interactions reported,TNF receptor-associated factor 6,"E3 ubiquitin ligase that, together with UBE2N and UBE2V1, mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains conjugated to proteins, such as ECSIT, IKBKG, IRAK1, AKT1 and AKT2 (PubMed:11057907, PubMed:18347055, PubMed:19465916, PubMed:19713527, PubMed:27746020, PubMed:31620128). Also mediates ubiquitination of free/unanchored polyubiquitin chain that leads to MAP3K7 activation (PubMed:19675569). Leads to the activation of NF-kappa-B and JUN (PubMed:16378096, PubMed:17135271, PubMed:17703191). Seems to also play a role in dendritic cells (DCs) maturation and/or activation (By similarity). Represses c-Myb-mediated transactivation, in B-lymphocytes (PubMed:18093978, PubMed:18758450). Adapter protein that seems to play a role in signal transduction initiated via TNF receptor, IL-1 receptor and IL-17 receptor (PubMed:12140561, PubMed:19825828, PubMed:8837778). Regulates osteoclast differentiation by mediating the activation of adapter protein complex 1 (AP-1) and NF-kappa-B, in response to RANK-L stimulation (By similarity). Together with MAP3K8, mediates CD40 signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production (By similarity). Acts as a regulator of the JNK and NF-kappa-B signaling pathways by initiating assembly of heterotypic 'Lys-63'-/'Lys-48'-linked branched ubiquitin chains that are then recognized by TAB2: TRAF6 catalyzes initial 'Lys-63'-linked-polyubiquitin chains that are then branched via 'Lys-48'-linked polyubiquitin by HUWE1 (PubMed:27746020). 'Lys-63'-/'Lys-48'-linked branched ubiquitin chains protect 'Lys-63'-linkages from CYLD deubiquitination (PubMed:27746020). Participates also in the TCR signaling by ubiquitinating LAT (PubMed:23514740, PubMed:25907557)",3D-structure|Coiled coil|Cytoplasm|DNA damage|Immunity|Isopeptide bond|Lipid droplet|Metal-binding|Nucleus|Osteogenesis|Proteomics identification|Reference proteome|Repeat|Transferase|Ubl conjugation|Ubl conjugation pathway|Zinc|Zinc-finger,Belongs to the TNF receptor-associated factor family. A subfamily,PF21355:TRAF-mep_MATH|PF18048:TRAF6_Z2|PF13923:zf-C3HC4_2|PF02176:zf-TRAF,4,IPR002083:MATH/TRAF_dom|IPR012227:TNF_rcpt-assoc_TRAF_met|IPR008974:TRAF-like|IPR049342:TRAF1-6_MATH_dom|IPR037309:TRAF6_MATH|IPR027139:TRAF6_RING-HC|IPR041310:TRAF6_Z2|IPR001841:Znf_RING|IPR013083:Znf_RING/FYVE/PHD|IPR017907:Znf_RING_CS|IPR001293:Znf_TRAF,11,,domain|family|conserved_site|homologous_superfamily,True,T-cell Receptor|E3 Ubiquitin Ligase|Transferase|Cytokine Receptor|Ligase|Histone Acetyltransferase,HIGH,E3 Ubiquitin Ligase: Keyword: e3 ubiquitin ligase|E3 Ubiquitin Ligase: Keyword: ubiquitin ligase|E3 Ubiquitin Ligase: Keyword: ubiquitination|E3 Ubiquitin Ligase: InterPro: IPR001841|E3 Ubiquitin Ligase: InterPro: IPR013083|Histone Acetyltransferase: Keyword: hat|Cytokine Receptor: Keyword: tnf receptor|T-cell Receptor: Keyword: tcr|T-cell Receptor: Keyword: cd4|Transferase: Keyword: transferase,T-cell Receptor,True,13,1LB4|1LB5|1LB6|2ECI|2JMD|3HCS|3HCT|3HCU|4Z8M|5ZUJ,1LB4,2.4,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1LB4.pdb,False,,,,,PDB,protein_structures/pdb_experimental/1LB4.pdb,Good (2.0-2.5Å),True,13,8.0,216.758,0.039,20.125,0.25,True,11,Moderate,Low,Adequate volume (217A3),Low druggability (0.04),316|359|322|316|234|245|501|217|210|204|254|308|183,0.00|0.01|0.00|0.00|0.00|0.00|0.04|0.01|0.00|0.00|0.02,P1:Vol=316:Drug=0.00|P2:Vol=359:Drug=0.01|P3:Vol=322:Drug=0.00|P4:Vol=316:Drug=0.00|P5:Vol=234:Drug=0.00|P6:Vol=245:Drug=0.00|P7:Vol=501:Drug=0.00|P8:Vol=217:Drug=0.04|P9:Vol=210:Drug=0.01|P10:Vol=204:Drug=0.00
MYD88,MYD88,MYD88 innate immune signal transduction adaptor,"This gene encodes a cytosolic adapter protein that plays a central role in the innate and adaptive immune response. This protein functions as an essential signal transducer in the interleukin-1 and Toll-like receptor signaling pathways. These pathways regulate that activation of numerous proinflammatory genes. The encoded protein consists of an N-terminal death domain and a C-terminal Toll-interleukin1 receptor domain. Patients with defects in this gene have an increased susceptibility to pyogenic bacterial infections. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Feb 2010].",protein-coding,IMD68|MYD88D|WM1,TLR adaptor MYD88|mutant myeloid differentiation primary response 88|myeloid differentiation primary response 88|myeloid differentiation primary response gene (88)|myeloid differentiation primary response protein MyD88,ENSG00000172936,ENST00000416282|ENST00000417037|ENST00000421516|ENST00000460295|ENST00000463956|ENST00000481122|ENST00000484513|ENST00000650112|ENST00000650905|ENST00000651800,ENSP00000391753|ENSP00000401399|ENSP00000497991|ENSP00000498360|ENSP00000498576|ENSP00000499012|ENSP00000514121|ENSP00000533054|ENSP00000639126|ENSP00000639127,Q99836,A0A0A0MSI9|A0A3F2YP85|A0A494C0J8|A0A3B3ITY3|A0A8V8TP38,MYD88_HUMAN,4615.0,NM_001172566.2|NM_001172567.2|NM_001172568.2|NM_001172569.3|NM_001365876.1|NM_001365877.1|NM_001374787.1|NM_001374788.1|NM_002468.5|NR_164663.1,NP_001166037.2|NP_001166038.2|NP_001166039.2|NP_001166040.2|NP_001352805.1|NP_001352806.1|NP_001361716.1|NP_002459.3,NC_000003.12|NC_060927.1|NG_016964.1,7562.0,602170.0,PA31361,9606.ENSP00000498321,2JS7|2Z5V|3MOP|4DOM|4EO7|6I3N|7BEQ|7BER|7L6W|8S78|8W8M,,IPR000157|IPR000488|IPR011029|IPR017281|IPR034249|IPR035897,PF00531|PF13676|PF01582,PS50017|PS50104,3,38138552.0,38143024.0,1.0,296.0,Cytoplasm|Nucleus,9606.0,1849.0,MYD88,biocarta:gsk3pathway|biocarta:il1rpathway|biocarta:nfkbpathway|biocarta:nthipathway|biocarta:tollpathway|kegg:hsa04010|kegg:hsa04064|kegg:hsa04620|kegg:hsa04621|kegg:hsa05130|netpath:Pathway_IL1|netpath:Pathway_RAGE|pid:il1pathway|pid:p75ntrpathway|pid:toll_endogenous_pathway|wikipathways:WP1449|wikipathways:WP1772|wikipathways:WP195|wikipathways:WP2324|wikipathways:WP2637,True,MYD88 innate immune signal transduction adaptor,3,3,ZANUBRUTINIB|FENTANYL CITRATE|IBRUTINIB,ZANUBRUTINIB|FENTANYL CITRATE|IBRUTINIB,ZANUBRUTINIB|IBRUTINIB|FENTANYL CITRATE,SERINE THREONINE KINASE|CELL SURFACE|CLINICALLY ACTIONABLE,,CIViC: Clinical Interpretation of Variants in Cancer|Cancer Genome Interpreter|PharmGKB - The Pharmacogenomics Knowledgebase,True,CHEMBL5919,SINGLE PROTEIN,0,0,16,16,36,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Myeloid differentiation primary response protein MyD88,"Adapter protein involved in the Toll-like receptor and IL-1 receptor signaling pathway in the innate immune response (PubMed:15361868, PubMed:18292575, PubMed:33718825, PubMed:37971847). Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:15361868, PubMed:19506249, PubMed:24316379). Increases IL-8 transcription (PubMed:9013863). Involved in IL-18-mediated signaling pathway. Activates IRF1 resulting in its rapid migration into the nucleus to mediate an efficient induction of IFN-beta, NOS2/INOS, and IL12A genes. Upon TLR8 activation by GU-rich single-stranded RNA (GU-rich RNA) derived from viruses such as SARS-CoV-2, SARS-CoV and HIV-1, induces IL1B release through NLRP3 inflammasome activation (PubMed:33718825). MyD88-mediated signaling in intestinal epithelial cells is crucial for maintenance of gut homeostasis and controls the expression of the antimicrobial lectin REG3G in the small intestine (By similarity)",3D-structure|Alternative splicing|Antiviral defense|Cytoplasm|Disease variant|Immunity|Inflammatory response|Innate immunity|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|Ubl conjugation,,PF00531:Death|PF13676:TIR_2,2,IPR011029:DEATH-like_dom_sf|IPR000488:Death_dom|IPR034249:MyD88_Death|IPR017281:Myelin_different_resp_MyD88|IPR000157:TIR_dom|IPR035897:Toll_tir_struct_dom_sf,6,,domain|family|homologous_superfamily,False,,NONE,,,True,14,2JS7|2Z5V|3MOP|4DOM|4EO7|6I3N|7BEQ|7BER|7L6W|8S78,2JS7,,SOLUTION NMR,protein_structures/pdb_experimental/2JS7.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/2JS7.pdb,,True,12,1.0,822.844,0.282,34.0,0.383,True,9,Moderate,Low,Optimal volume (823A3),Low druggability (0.28),823|552|362|237|219|207|343|197|129|312|167|162,0.28|0.02|0.00|0.00|0.04|0.01|0.02,P1:Vol=823:Drug=0.28|P2:Vol=552:Drug=0.02|P3:Vol=362:Drug=0.00|P4:Vol=237:Drug=0.00|P5:Vol=219:Drug=0.00|P6:Vol=207:Drug=0.00|P7:Vol=343:Drug=0.04|P8:Vol=197:Drug=0.00|P9:Vol=129:Drug=0.00|P10:Vol=312:Drug=0.01
TIRAP,TIRAP,TIR domain containing adaptor protein,"The innate immune system recognizes microbial pathogens through Toll-like receptors (TLRs), which identify pathogen-associated molecular patterns. Different TLRs recognize different pathogen-associated molecular patterns and all TLRs have a Toll-interleukin 1 receptor (TIR) domain, which is responsible for signal transduction. The protein encoded by this gene is a TIR adaptor protein involved in the TLR4 signaling pathway of the immune system. It activates NF-kappa-B, MAPK1, MAPK3 and JNK, which then results in cytokine secretion and the inflammatory response. Alternative splicing of this gene results in several transcript variants; however, not all variants have been fully described. [provided by RefSeq, Jul 2008].",protein-coding,BACTS1|Mal|MyD88-2|wyatt,MyD88 adapter-like protein|Toll-like receptor adaptor protein|adapter protein wyatt|adaptor protein Wyatt|toll-interleukin 1 receptor (TIR) domain containing adaptor protein,ENSG00000150455,ENST00000392678|ENST00000392679|ENST00000392680|ENST00000462401|ENST00000467006|ENST00000479770|ENST00000488598|ENST00000700488|ENST00000700489|ENST00000700490,ENSP00000376445|ENSP00000376446|ENSP00000376447|ENSP00000436967|ENSP00000446213|ENSP00000515016|ENSP00000515017|ENSP00000515018|ENSP00000515019|ENSP00000515020,P58753,F5H2K1|A0A8V8TPR1,TIRAP_HUMAN,114609.0,NM_001039661.2|NM_001318776.2|NM_001318777.2|NM_052887.2|NM_148910.3,NP_001034750.1|NP_001305705.1|NP_001305706.1|NP_683708.1,NC_000011.10|NC_060935.1|NG_011523.1,17192.0,606252.0,PA134972842,9606.ENSP00000376445,2NDH|2Y92|3UB2|3UB3|3UB4|4FZ5|4LQD|5T7Q|5UZB|8JZM,,IPR000157|IPR017279|IPR035897,PF13676,PS50104,11,126282497.0,126298845.0,1.0,221.0,Cytoplasm|Cell membrane|Membrane,9606.0,14285.0,,biocarta:gsk3pathway|biocarta:tollpathway|kegg:hsa04064|kegg:hsa04620|kegg:hsa05130|kegg:hsa05132|kegg:hsa05133|wikipathways:WP1449|wikipathways:WP2324|wikipathways:WP3851|wikipathways:WP3858|wikipathways:WP4136,True,TIR domain containing adaptor protein,1,1,USTEKINUMAB,USTEKINUMAB,USTEKINUMAB,CELL SURFACE,,PharmGKB - The Pharmacogenomics Knowledgebase,False,,,0,0,0,0,0,True,0,0,0,0,0,,,,True,False,False,HIGH - Approved drugs exist,Toll/interleukin-1 receptor domain-containing adapter protein,"Adapter involved in TLR2, TLR4 and RAGE signaling pathways in the innate immune response. Acts via IRAK2 and TRAF-6, leading to the activation of NF-kappa-B, MAPK1, MAPK3 and JNK, and resulting in cytokine secretion and the inflammatory response. Positively regulates the production of TNF-alpha (TNF) and interleukin-6 (IL6)",3D-structure|Alternative splicing|Cell membrane|Cytoplasm|Disulfide bond|Immunity|Inflammatory response|Innate immunity|Membrane|Phosphoprotein|Proteomics identification|Reference proteome|Ubl conjugation,,PF13676:TIR_2,1,IPR000157:TIR_dom|IPR017279:Tol-interleuk_rcpt_adapt_Tirap|IPR035897:Toll_tir_struct_dom_sf,3,,domain|family|homologous_superfamily,True,Kinase,LOW,Kinase: Keyword: mapk,Kinase,True,11,2NDH|2Y92|3UB2|3UB3|3UB4|4FZ5|4LQD|5T7Q|5UZB|8JZM,2NDH,,SOLUTION NMR,protein_structures/pdb_experimental/2NDH.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/2NDH.pdb,,True,13,4.0,653.325,0.837,24.211,0.143,True,10,Good,Medium,Optimal volume (653A3)|High druggability (0.84),,1199|296|385|653|867|225|300|117|155|159|495|267|772,0.62|0.71|0.00|0.84|0.22|0.01|0.00|0.00|0.02|0.00,P1:Vol=1199:Drug=0.62|P2:Vol=296:Drug=0.71|P3:Vol=385:Drug=0.00|P4:Vol=653:Drug=0.84|P5:Vol=867:Drug=0.22|P6:Vol=225:Drug=0.01|P7:Vol=300:Drug=0.00|P8:Vol=117:Drug=0.00|P9:Vol=155:Drug=0.00|P10:Vol=159:Drug=0.00
RIPK1,RIPK1,receptor interacting serine/threonine kinase 1,"This gene encodes a member of the receptor-interacting protein (RIP) family of serine/threonine protein kinases. The encoded protein plays a role in inflammation and cell death in response to tissue damage, pathogen recognition, and as part of developmental regulation. RIPK1/RIPK3 kinase-mediated necrosis is referred to as necroptosis. Genetic disruption of this gene in mice results in death shortly after birth. [provided by RefSeq, Aug 2017].",protein-coding,AIEFL|IMD57|RIP|RIP-1|RIP1,cell death protein RIP|receptor (TNFRSF)-interacting serine-threonine kinase 1|receptor-interacting protein 1|receptor-interacting protein kinase 1|receptor-interacting serine/threonine-protein kinase 1,ENSG00000137275,ENST00000259808|ENST00000380409|ENST00000479389|ENST00000676591|ENST00000676618|ENST00000676758|ENST00000676965|ENST00000676995|ENST00000677261|ENST00000677361,ENSP00000259808|ENSP00000369773|ENSP00000502975|ENSP00000503002|ENSP00000503154|ENSP00000503708|ENSP00000503978|ENSP00000504232|ENSP00000504592|ENSP00000504823,Q13546,A0A7I2V404|A0A7I2V5Y1,RIPK1_HUMAN,8737.0,NM_001317061.3|NM_001354930.2|NM_001354931.2|NM_001354932.2|NM_001354933.2|NM_001354934.2|NM_003804.6|XM_006715237.4|XM_017011403.2|XM_017011404.3,NP_001303990.1|NP_001341859.1|NP_001341860.1|NP_001341861.1|NP_001341862.1|NP_001341863.1|NP_003795.2|XP_006715300.2|XP_016866892.1|XP_016866893.1,NC_000006.12|NC_060930.1|NG_063914.1,10019.0,603453.0,PA34394,9606.ENSP00000259808,4ITH|4ITI|4ITJ|4NEU|5HX6|5TX5|5V7Z|6AC5|6C3E|6C4D|6HHO|6NW2|6NYH|6OCQ|6R5F|6RLN|7CJB|7FCZ|7FD0|7XMK,2.7.11.1,IPR000488|IPR000719|IPR001245|IPR008271|IPR011009|IPR011029|IPR037934|IPR051681,PF00531|PF07714|PF00069,PS50011|PS50017,6,3063824.0,3115187.0,1.0,671.0,Cytoplasm|Cell membrane,9606.0,2820.0,RIPK1,biocarta:ceramidepathway|biocarta:deathpathway|biocarta:hivnefpathway|biocarta:keratinocytepathway|biocarta:nfkbpathway|kegg:hsa04064|kegg:hsa04210|kegg:hsa04217|kegg:hsa04620|kegg:hsa04621|netpath:Pathway_EGFR1|netpath:Pathway_TNFalpha|netpath:Pathway_TWEAK|pid:caspase_pathway|pid:ceramide_pathway|pid:faspathway|pid:hivnefpathway|pid:p38alphabetapathway|reactome:R-HSA-109581|reactome:R-HSA-140534|reactome:R-HSA-1606322|reactome:R-HSA-162582|reactome:R-HSA-1643685|wikipathways:WP1449|wikipathways:WP1772|wikipathways:WP2036|wikipathways:WP231|wikipathways:WP2513,True,receptor interacting serine/threonine kinase 1,2,1,GSK2982772|RESVERATROL,RESVERATROL,GSK2982772|RESVERATROL,DRUGGABLE GENOME|KINASE|ENZYME|SERINE THREONINE KINASE,inhibitor,The ChEMBL Bioactivity Database|Therapeutic Target Database|NCI Cancer Gene Index,True,CHEMBL4523112,SINGLE PROTEIN,0,0,1,1,1,True,6,0,0,3,3,GSK2982772|GSK2982772|GSK2982772|GSK2982772|GSK2982772|GSK2982772,Small molecule,Receptor-interacting serine/threonine-protein kinase 1 inhibitor,True,True,True,HIGH - Approved drugs exist,Receptor-interacting serine/threonine-protein kinase 1,"Serine-threonine kinase which is a key regulator of TNF-mediated apoptosis, necroptosis and inflammatory pathways (PubMed:17703191, PubMed:24144979, PubMed:31827280, PubMed:31827281, PubMed:32657447, PubMed:35831301). Exhibits kinase activity-dependent functions that regulate cell death and kinase-independent scaffold functions regulating inflammatory signaling and cell survival (PubMed:11101870, PubMed:19524512, PubMed:19524513, PubMed:29440439, PubMed:30988283). Has kinase-independent scaffold functions: upon binding of TNF to TNFR1, RIPK1 is recruited to the TNF-R1 signaling complex (TNF-RSC also known as complex I) where it acts as a scaffold protein promoting cell survival, in part, by activating the canonical NF-kappa-B pathway (By similarity). Kinase activity is essential to regulate necroptosis and apoptosis, two parallel forms of cell death: upon activation of its protein kinase activity, regulates assembly of two death-inducing complexes, namely complex IIa (RIPK1-FADD-CASP8), which drives apoptosis, and the complex IIb (RIPK1-RIPK3-MLKL), which drives necroptosis (By similarity). RIPK1 is required to limit CASP8-dependent TNFR1-induced apoptosis (By similarity). In normal conditions, RIPK1 acts as an inhibitor of RIPK3-dependent necroptosis, a process mediated by RIPK3 component of complex IIb, which catalyzes phosphorylation of MLKL upon induction by ZBP1 (PubMed:19524512, PubMed:19524513, PubMed:29440439, PubMed:30988283). Inhibits RIPK3-mediated necroptosis via FADD-mediated recruitment of CASP8, which cleaves RIPK1 and limits TNF-induced necroptosis (PubMed:19524512, PubMed:19524513, PubMed:29440439, PubMed:30988283). Required to inhibit apoptosis and necroptosis during embryonic development: acts by preventing the interaction of TRADD with FADD thereby limiting aberrant activation of CASP8 (By similarity). In addition to apoptosis and necroptosis, also involved in inflammatory response by promoting transcriptional production of pro-inflammatory cytokines, such as interleukin-6 (IL6) (PubMed:31827280, PubMed:31827281). Phosphorylates RIPK3: RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation (PubMed:19524513). Phosphorylates DAB2IP at 'Ser-728' in a TNF-alpha-dependent manner, and thereby activates the MAP3K5-JNK apoptotic cascade (PubMed:15310755, PubMed:17389591). Required for ZBP1-induced NF-kappa-B activation in response to DNA damage (By similarity)",3D-structure|Alternative splicing|Apoptosis|ATP-binding|Cell membrane|Cytoplasm|Disease variant|Glycoprotein|Host-virus interaction|Inflammatory response|Isopeptide bond|Kinase|Membrane|Necrosis|Nucleotide-binding|Phosphoprotein|Proteomics identification|Reference proteome|Serine/threonine-protein kinase|Transferase,Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family,PF00531:Death|PF07714:PK_Tyr_Ser-Thr,2,IPR011029:DEATH-like_dom_sf|IPR000488:Death_dom|IPR011009:Kinase-like_dom_sf|IPR000719:Prot_kinase_dom|IPR037934:RIP1_Death|IPR001245:Ser-Thr/Tyr_kinase_cat_dom|IPR008271:Ser/Thr_kinase_AS|IPR051681:Ser/Thr_Kinases-Pseudokinases,8,,domain|family|active_site|homologous_superfamily,True,Kinase|Histone Acetyltransferase|Transferase|Actin,HIGH,Kinase: Keyword: kinase|Kinase: Keyword: protein kinase|Kinase: InterPro: IPR000719|Kinase: InterPro: IPR011009|Kinase: InterPro: IPR008271|Kinase: Pfam: PF07714|Histone Acetyltransferase: Keyword: hat|Actin: Keyword: actin|Transferase: Keyword: transferase,Kinase,True,33,4ITH|4ITI|4ITJ|4NEU|5HX6|5TX5|5V7Z|5ZMZ|6AC5|6C3E,4ITH,2.25,X-RAY DIFFRACTION,protein_structures/pdb_experimental/4ITH.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/4ITH.pdb,Good (2.0-2.5Å),True,30,1.0,381.734,0.706,67.412,0.817,True,23,Excellent,High,Adequate volume (382A3)|High druggability (0.71),,382|369|677|277|406|868|436|229|243|292|270|518|88|190|373|228|294|307|210|326|292|393|195|341|373|110|272|115|228|369,0.71|0.50|0.60|0.01|0.06|0.00|0.00|0.01|0.01|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.01|0.00|0.00|0.00,P1:Vol=382:Drug=0.71|P2:Vol=369:Drug=0.50|P3:Vol=677:Drug=0.60|P4:Vol=277:Drug=0.01|P5:Vol=406:Drug=0.06|P6:Vol=868:Drug=0.00|P7:Vol=436:Drug=0.00|P8:Vol=229:Drug=0.01|P9:Vol=243:Drug=0.01|P10:Vol=292:Drug=0.00
KRAS,NRAS,"NRAS proto-oncogene, GTPase","This is an N-ras oncogene encoding a membrane protein that shuttles between the Golgi apparatus and the plasma membrane. This shuttling is regulated through palmitoylation and depalmitoylation by the ZDHHC9-GOLGA7 complex. The encoded protein, which has intrinsic GTPase activity, is activated by a guanine nucleotide-exchange factor and inactivated by a GTPase activating protein. Mutations in this gene have been associated with somatic rectal cancer, follicular thyroid cancer, autoimmune lymphoproliferative syndrome, Noonan syndrome, and juvenile myelomonocytic leukemia. [provided by RefSeq, Jun 2011].",protein-coding,ALPS4|CMNS|KRAS|N-ras|NCMS|NRAS1|NS6,GTPase NRas|N-ras protein part 4|neuroblastoma RAS viral (v-ras) oncogene homolog|neuroblastoma RAS viral oncogene homolog|proto-oncogene GTPase,ENSG00000213281,ENST00000369535|ENST00000899430|ENST00000931009|ENST00000931010,ENSP00000358548|ENSP00000569489|ENSP00000601068|ENSP00000601069,P01111,Q5U091,RASK_HUMAN,4893.0,NM_002524.5,NP_002515.1,NC_000001.11|NC_060925.1|NG_007572.1,7989.0,164790.0,PA31768,9606.ENSP00000256078,2N9C|3CON|5UHV|6E6H|6MPP|6ULI|6ULK|6ULN|6ULR|6UON|6WGH|6ZIO|6ZIR|6ZIZ|7F68|7OW3|7OW4|7OW5|7OW6|7PB2,3.6.5.2,IPR001806|IPR005225|IPR020849|IPR027417,PF00071,PS51419|PS51420|PS51421,1,114704469.0,114716771.0,-1.0,189.0,"Cell membrane|Endomembrane system|Cytoplasm, cytosol",9606.0,55661.0,Neuroblastoma RAS viral oncogene homolog,kegg:hsa04010|kegg:hsa04012|kegg:hsa04014|kegg:hsa04015|kegg:hsa04062|pid:cd8tcrdownstreampathway|pid:cd8tcrpathway|pid:cmyb_pathway|pid:cxcr3pathway|pid:ephbfwdpathway|reactome:R-HSA-109582|reactome:R-HSA-112314|reactome:R-HSA-112315|reactome:R-HSA-112316|reactome:R-HSA-112399|wikipathways:WP2261|wikipathways:WP2290|wikipathways:WP231|wikipathways:WP2586|wikipathways:WP2828,True,"KRAS proto-oncogene, GTPase",96,56,ABEMACICLIB|BEVACIZUMAB|PD98059|DANOPREVIR|PELAREOREP|GEMCITABINE|DECITABINE|TRASTUZUMAB|ALISERTIB|SALIRASIB|CRIZOTINIB|PEMETREXED DISODIUM|SORAFENIB|AFATINIB|TEPROTUMUMAB|NARLAPREVIR|ERLOTINIB|RAMUCIRUMAB|LAPATINIB|REGORAFENIB,ABEMACICLIB|BEVACIZUMAB|GEMCITABINE|DECITABINE|TRASTUZUMAB|CRIZOTINIB|PEMETREXED DISODIUM|SORAFENIB|AFATINIB|TEPROTUMUMAB,PANITUMUMAB|ADAGRASIB|DANOPREVIR|NARLAPREVIR|GLECAPREVIR,ENZYME|CLINICALLY ACTIONABLE|DRUG RESISTANCE,vaccine|inhibitor,"Clearity Foundation Biomarkers|The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|Cancer Commons|PharmGKB - The Pharmacogenomics Knowledgebase|Targeted Agents in Lung Cancer (Commentary, 2014)|Cancer Genome Interpreter|MyCancerGenome Clinical Trial|Database of Curated Mutations|The ChEMBL Bioactivity Database",True,CHEMBL2189121,SINGLE PROTEIN,0,0,297,297,1000,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,GTPase NRas,Ras proteins bind GDP/GTP and possess intrinsic GTPase activity,3D-structure|Acetylation|Cell membrane|Disease variant|Glycoprotein|Golgi apparatus|GTP-binding|Hydrolase|Isopeptide bond|Lipoprotein|Membrane|Methylation|Nucleotide-binding|Palmitate|Phosphoprotein|Prenylation|Proteomics identification|Proto-oncogene|Reference proteome|Ubl conjugation,Belongs to the small GTPase superfamily. Ras family,PF00071:Ras,1,IPR027417:P-loop_NTPase|IPR005225:Small_GTP-bd|IPR001806:Small_GTPase|IPR020849:Small_GTPase_Ras-type,4,,domain|family|homologous_superfamily,True,GTPase|Motor Protein|Hydrolase,HIGH,Motor Protein: InterPro: IPR027417|GTPase: Keyword: gtpase|GTPase: Keyword: ras protein|GTPase: Keyword: small gtpase|GTPase: InterPro: IPR001806|GTPase: InterPro: IPR005225|GTPase: InterPro: IPR027417|GTPase: Pfam: PF00071|Hydrolase: Keyword: hydrolase,GTPase,True,27,2N9C|3CON|5UHV|6E6H|6MPP|6ULI|6ULK|6ULN|6ULR|6UON,2N9C,,SOLUTION NMR,protein_structures/pdb_experimental/2N9C.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/2N9C.pdb,,True,1,1.0,218.637,0.185,41.6,0.456,True,1,Moderate,Low,Adequate volume (219A3),Low druggability (0.18),219,0.18,P1:Vol=219:Drug=0.18
NRAS,NRAS,"NRAS proto-oncogene, GTPase","This is an N-ras oncogene encoding a membrane protein that shuttles between the Golgi apparatus and the plasma membrane. This shuttling is regulated through palmitoylation and depalmitoylation by the ZDHHC9-GOLGA7 complex. The encoded protein, which has intrinsic GTPase activity, is activated by a guanine nucleotide-exchange factor and inactivated by a GTPase activating protein. Mutations in this gene have been associated with somatic rectal cancer, follicular thyroid cancer, autoimmune lymphoproliferative syndrome, Noonan syndrome, and juvenile myelomonocytic leukemia. [provided by RefSeq, Jun 2011].",protein-coding,ALPS4|CMNS|KRAS|N-ras|NCMS|NRAS1|NS6,GTPase NRas|N-ras protein part 4|neuroblastoma RAS viral (v-ras) oncogene homolog|neuroblastoma RAS viral oncogene homolog|proto-oncogene GTPase,ENSG00000213281,ENST00000369535|ENST00000899430|ENST00000931009|ENST00000931010,ENSP00000358548|ENSP00000569489|ENSP00000601068|ENSP00000601069,P01111,Q5U091,RASN_HUMAN,4893.0,NM_002524.5,NP_002515.1,NC_000001.11|NC_060925.1|NG_007572.1,7989.0,164790.0,PA31768,9606.ENSP00000358548,2N9C|3CON|5UHV|6E6H|6MPP|6ULI|6ULK|6ULN|6ULR|6UON|6WGH|6ZIO|6ZIR|6ZIZ|7F68|7OW3|7OW4|7OW5|7OW6|7PB2,3.6.5.2,IPR001806|IPR005225|IPR020849|IPR027417,PF00071,PS51419|PS51420|PS51421,1,114704469.0,114716771.0,-1.0,189.0,Cell membrane|Golgi apparatus membrane,9606.0,55661.0,Neuroblastoma RAS viral oncogene homolog,kegg:hsa04010|kegg:hsa04012|kegg:hsa04014|kegg:hsa04015|kegg:hsa04062|pid:cd8tcrdownstreampathway|pid:cd8tcrpathway|pid:cmyb_pathway|pid:cxcr3pathway|pid:ephbfwdpathway|reactome:R-HSA-109582|reactome:R-HSA-112314|reactome:R-HSA-112315|reactome:R-HSA-112316|reactome:R-HSA-112399|wikipathways:WP2261|wikipathways:WP2290|wikipathways:WP231|wikipathways:WP2586|wikipathways:WP2828,True,"NRAS proto-oncogene, GTPase",132,52,IRINOTECAN HYDROCHLORIDE|CISPLATIN|DABRAFENIB|CHELIDONINE|VEMURAFENIB|ERK1/2 INHIBITOR ERAS-007|P53-HDM2 INTERACTION INHIBITOR MI-773|BINIMETINIB|FORETINIB|MIRDAMETINIB|ERK INHIBITOR CC-90003|TAK-632|GEDATOLISIB|DACTOLISIB|LENVATINIB|INOSITOL|CHLOROQUINE|RAVOXERTINIB|TUNLAMETINIB|GILTERITINIB,IRINOTECAN HYDROCHLORIDE|CISPLATIN|DABRAFENIB|VEMURAFENIB|BINIMETINIB|LENVATINIB|INOSITOL|CHLOROQUINE|GILTERITINIB|CETUXIMAB,CHELIDONINE|TUNLAMETINIB|LIFIRAFENIB|GI-4000|TAPOTOCLAX,DRUG RESISTANCE|CLINICALLY ACTIONABLE|ENZYME,inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|PharmGKB - The Pharmacogenomics Knowledgebase|The Clinical Knowledgebase|Cancer Genome Interpreter|NCI Cancer Gene Index|The ChEMBL Bioactivity Database|Therapeutic Target Database|OncoKB: A Precision Oncology Knowledge Base",True,CHEMBL2079845,SINGLE PROTEIN,0,0,300,300,1000,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,GTPase NRas,Ras proteins bind GDP/GTP and possess intrinsic GTPase activity,3D-structure|Acetylation|Cell membrane|Disease variant|Glycoprotein|Golgi apparatus|GTP-binding|Hydrolase|Isopeptide bond|Lipoprotein|Membrane|Methylation|Nucleotide-binding|Palmitate|Phosphoprotein|Prenylation|Proteomics identification|Proto-oncogene|Reference proteome|Ubl conjugation,Belongs to the small GTPase superfamily. Ras family,PF00071:Ras,1,IPR027417:P-loop_NTPase|IPR005225:Small_GTP-bd|IPR001806:Small_GTPase|IPR020849:Small_GTPase_Ras-type,4,,domain|family|homologous_superfamily,True,GTPase|Motor Protein|Hydrolase,HIGH,Motor Protein: InterPro: IPR027417|GTPase: Keyword: gtpase|GTPase: Keyword: ras protein|GTPase: Keyword: small gtpase|GTPase: InterPro: IPR001806|GTPase: InterPro: IPR005225|GTPase: InterPro: IPR027417|GTPase: Pfam: PF00071|Hydrolase: Keyword: hydrolase,GTPase,True,27,2N9C|3CON|5UHV|6E6H|6MPP|6ULI|6ULK|6ULN|6ULR|6UON,2N9C,,SOLUTION NMR,protein_structures/pdb_experimental/2N9C.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/2N9C.pdb,,True,1,1.0,218.637,0.185,41.6,0.456,True,1,Moderate,Low,Adequate volume (219A3),Low druggability (0.18),219,0.18,P1:Vol=219:Drug=0.18
HRAS,HRAS,"HRas proto-oncogene, GTPase","This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, cognitive disability, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for this gene. [provided by RefSeq, Jul 2008].",protein-coding,C-BAS/HAS|C-H-RAS|C-HA-RAS1|CTLO|H-RASIDX|HAMSV|HRAS1|RASH1|p21ras,GTP- and GDP-binding peptide B|GTPase HRas|Ha-Ras1 proto-oncoprotein|Harvey rat sarcoma viral oncogene homolog|Harvey rat sarcoma viral oncoprotein,ENSG00000276536,ENST00000610977|ENST00000615062|ENST00000616241|ENST00000631404|ENST00000631627|ENST00000631967|ENST00000632658|ENST00000632849|ENST00000633137|ENST00000633700,ENSP00000480317|ENSP00000480686|ENSP00000482366|ENSP00000488225|ENSP00000488296|ENSP00000488397|ENSP00000488757,P01112,A0A804HKM6|X5D945|A0A804HJ06|A0A8C8MQR2|A0A0J9YXG8,RASH_HUMAN,3265.0,NM_001130442.3|NM_001318054.2|NM_005343.4|NM_176795.5|XM_054368610.1,NP_001123914.1|NP_001304983.1|NP_005334.1|NP_789765.1|XP_054224585.1,NC_000011.10|NC_060935.1|NG_007666.1|NT_187586.1,5173.0,190020.0,PA29444,9606.ENSP00000407586,121P|1AA9|1AGP|1BKD|1CLU|1CRP|1CRQ|1CRR|1CTQ|1GNP|1GNQ|1GNR|1HE8|1IAQ|1IOZ|1JAH|1JAI|1K8R|1LF0|1LF5,3.6.5.2,IPR001806|IPR005225|IPR020849|IPR027417,PF00071,PS51419|PS51420|PS51421,11,532242.0,537343.0,-1.0,189.0,Cell membrane|Golgi apparatus|Golgi apparatus membrane,9606.0,55890.0,HRAS,biocarta:at1rpathway|biocarta:barrestinsrcpathway|biocarta:bcrpathway|biocarta:biopeptidespathway|biocarta:cardiacegfpathway|kegg:hsa04010|kegg:hsa04012|kegg:hsa04014|kegg:hsa04015|kegg:hsa04062|netpath:Pathway_EGFR1|netpath:Pathway_IL3|netpath:Pathway_IL5|netpath:Pathway_IL6|netpath:Pathway_KitReceptor|pid:a6b1_a6b4_integrin_pathway|pid:ajdiss_2pathway|pid:ar_nongenomic_pathway|pid:bcr_5pathway|pid:cd8tcrdownstreampathway|reactome:R-HSA-109582|reactome:R-HSA-112314|reactome:R-HSA-112315|reactome:R-HSA-112316|reactome:R-HSA-112399|smpdb:SMP00320|smpdb:SMP00321|smpdb:SMP00358|smpdb:SMP00391|wikipathways:WP185|wikipathways:WP2032|wikipathways:WP2034|wikipathways:WP2037|wikipathways:WP2261,True,"HRas proto-oncogene, GTPase",83,35,"INSULIN, REGULAR, HUMAN|ANTISENSE OLIGONUCLEOTIDES|STREPTOZOCIN|FEXAGRATINIB|LY3009120|L-744,832|LORLATINIB|RIGOSERTIB|HYDROXYUREA|UPROSERTIB|NAPORAFENIB|ADENOVIRUS VECTOR|NST-628|TUCATINIB|ANTINEOPLASTIC AGENT|PELAREOREP|TIPIFARNIB|MRTX-1133|PANITUMUMAB|SIROLIMUS","INSULIN, REGULAR, HUMAN|STREPTOZOCIN|LORLATINIB|HYDROXYUREA|TUCATINIB|PANITUMUMAB|SIROLIMUS|VEMURAFENIB|DOCETAXEL ANHYDROUS|PACLITAXEL","TIPIFARNIB|L-744,832|MRTX-1133|ISIS-2503|OPNURASIB",DRUGGABLE GENOME|ENZYME|DRUG RESISTANCE|CLINICALLY ACTIONABLE|TUMOR SUPPRESSOR,antisense oligonucleotide|inhibitor,"The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication (Rask-Andersen, Masuram, Schioth 2014)|CIViC: Clinical Interpretation of Variants in Cancer|PharmGKB - The Pharmacogenomics Knowledgebase|The Clinical Knowledgebase|Targeted Agents in Lung Cancer (Commentary, 2014)|Cancer Genome Interpreter|NCI Cancer Gene Index|The ChEMBL Bioactivity Database|OncoKB: A Precision Oncology Knowledge Base",True,CHEMBL2167,SINGLE PROTEIN,0,0,111,111,142,False,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,GTPase HRas,"Involved in the activation of Ras protein signal transduction (PubMed:22821884). Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:12740440, PubMed:14500341, PubMed:9020151)",3D-structure|Acetylation|Alternative splicing|Cell membrane|Cytoplasm|Direct protein sequencing|Disease variant|Glycoprotein|Golgi apparatus|GTP-binding|Hydrolase|Isopeptide bond|Lipoprotein|Membrane|Methylation|Nucleotide-binding|Nucleus|Palmitate|Prenylation|Proteomics identification,Belongs to the small GTPase superfamily. Ras family,PF00071:Ras,1,IPR027417:P-loop_NTPase|IPR005225:Small_GTP-bd|IPR001806:Small_GTPase|IPR020849:Small_GTPase_Ras-type,4,,domain|family|homologous_superfamily,True,GTPase|Motor Protein|Hydrolase,HIGH,Motor Protein: InterPro: IPR027417|GTPase: Keyword: gtpase|GTPase: Keyword: ras protein|GTPase: Keyword: small gtpase|GTPase: InterPro: IPR001806|GTPase: InterPro: IPR005225|GTPase: InterPro: IPR027417|GTPase: Pfam: PF00071|Hydrolase: Keyword: hydrolase,GTPase,True,232,121P|1AA9|1AGP|1BKD|1CLU|1CRP|1CRQ|1CRR|1CTQ|1GNP,121P,1.54,X-RAY DIFFRACTION,protein_structures/pdb_experimental/121P.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/121P.pdb,Excellent (<2.0Å),True,6,1.0,1456.386,0.569,10.963,0.492,True,4,Good,Medium,Optimal volume (1456A3),,1456|396|323|465|418|285,0.57|0.00|0.00|0.04|0.00,P1:Vol=1456:Drug=0.57|P2:Vol=396:Drug=0.00|P3:Vol=323:Drug=0.00|P4:Vol=465:Drug=0.04|P5:Vol=418:Drug=0.00|P6:Vol=285:Drug=0.00
RAC1,RNASE1,"ribonuclease A family member 1, pancreatic","This gene encodes a member of the pancreatic-type of secretory ribonucleases, a subset of the ribonuclease A superfamily. The encoded endonuclease cleaves internal phosphodiester RNA bonds on the 3'-side of pyrimidine bases. It prefers poly(C) as a substrate and hydrolyzes 2',3'-cyclic nucleotides, with a pH optimum near 8.0. The encoded protein is monomeric and more commonly acts to degrade ds-RNA over ss-RNA. Alternative splicing occurs at this locus and four transcript variants encoding the same protein have been identified. [provided by RefSeq, Jul 2008].",protein-coding,RAC1|RIB1|RNS1,HP-RNase|RIB-1|RNase 1|RNase A|RNase upI-1,ENSG00000129538,ENST00000340900|ENST00000397967|ENST00000397970|ENST00000412779|ENST00000555698|ENST00000884083|ENST00000884084|ENST00000884085|ENST00000884086|ENST00000884087,ENSP00000344193|ENSP00000381057|ENSP00000381060|ENSP00000399493|ENSP00000451058|ENSP00000554142|ENSP00000554143|ENSP00000554144|ENSP00000554145|ENSP00000554146,P07998,G3V357|W0UV93,RAC1_HUMAN,6035.0,NM_002933.5|NM_198232.3|NM_198234.3|NM_198235.3,NP_002924.1|NP_937875.1|NP_937877.1|NP_937878.1,NC_000014.9|NC_060938.1,10044.0,180440.0,PA34412,9606.ENSP00000348461,1DZA|1E21|1H8X|1Z7X|2E0J|2E0L|2E0M|2E0O|2K11|2Q4G|3F8G|4KXH,4.6.1.18,IPR001427|IPR023411|IPR023412|IPR036816,PF00074,,14,20801228.0,20802884.0,-1.0,192.0,Cell membrane|Melanosome|Cytoplasm,9606.0,7919.0,RNASE1,reactome:R-HSA-1266738|reactome:R-HSA-9612973|reactome:R-HSA-9613829|reactome:R-HSA-9615710|reactome:R-HSA-9734767,True,Rac family small GTPase 1,9,3,CHEMBL:CHEMBL554475|AZATHIOPRINE|CHEMBL:CHEMBL563777|CHEMBL:CHEMBL562095|CHEMBL:CHEMBL579882|VEMURAFENIB|DABRAFENIB|PLX-4720|NSC 23766,AZATHIOPRINE|VEMURAFENIB|DABRAFENIB,NSC 23766|CHEMBL:CHEMBL554475|CHEMBL:CHEMBL563777|CHEMBL:CHEMBL562095|CHEMBL:CHEMBL579882,KINASE|CLINICALLY ACTIONABLE|DRUG RESISTANCE,,CIViC: Clinical Interpretation of Variants in Cancer|PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons,True,CHEMBL5628,SINGLE PROTEIN,0,0,13,13,30,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Ribonuclease pancreatic,Endonuclease that catalyzes the cleavage of RNA on the 3' side of pyrimidine nucleotides. Acts on single-stranded and double-stranded RNA,3D-structure|Direct protein sequencing|Disulfide bond|Endonuclease|Glycoprotein|Hydrolase|Lyase|Nuclease|Proteomics identification|Reference proteome|Secreted|Signal,Belongs to the pancreatic ribonuclease family,PF00074:RnaseA,1,IPR001427:RNaseA|IPR036816:RNaseA-like_dom_sf|IPR023411:RNaseA_AS|IPR023412:RNaseA_domain,4,,domain|family|active_site|homologous_superfamily,True,Histone Acetyltransferase|Hydrolase|Lyase,HIGH,Histone Acetyltransferase: Keyword: hat|Hydrolase: Keyword: hydrolase|Hydrolase: Keyword: nuclease|Lyase: Keyword: lyase,Histone Acetyltransferase,True,12,1DZA|1E21|1H8X|1Z7X|2E0J|2E0L|2E0M|2E0O|2K11|2Q4G,1DZA,1.65,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1DZA.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1DZA.pdb,Excellent (<2.0Å),True,17,1.0,694.525,0.897,5.72,0.409,True,16,Good,Medium,Optimal volume (695A3)|High druggability (0.90),,695|222|490|191|511|504|337|438|291|264|400|501|240|286|233|211|400,0.90|0.00|0.80|0.00|0.01|0.00|0.08|0.00|0.49,P1:Vol=695:Drug=0.90|P2:Vol=222:Drug=0.00|P3:Vol=490:Drug=0.80|P4:Vol=191:Drug=0.00|P5:Vol=511:Drug=0.01|P6:Vol=504:Drug=0.00|P7:Vol=337:Drug=0.00|P8:Vol=438:Drug=0.00|P9:Vol=291:Drug=0.08|P10:Vol=264:Drug=0.00
CDC42,CDC42,cell division cycle 42,"The protein encoded by this gene is a small GTPase of the Rho-subfamily, which regulates signaling pathways that control diverse cellular functions including cell morphology, migration, endocytosis and cell cycle progression. This protein is highly similar to Saccharomyces cerevisiae Cdc 42, and is able to complement the yeast cdc42-1 mutant. The product of oncogene Dbl was reported to specifically catalyze the dissociation of GDP from this protein. This protein could regulate actin polymerization through its direct binding to Neural Wiskott-Aldrich syndrome protein (N-WASP), which subsequently activates Arp2/3 complex. Alternative splicing of this gene results in multiple transcript variants. Pseudogenes of this gene have been identified on chromosomes 3, 4, 5, 7, 8 and 20. [provided by RefSeq, Apr 2013].",protein-coding,CDC42Hs|G25K|TKS,"G25K GTP-binding protein|GTP binding protein, 25kDa|cell division control protein 42 homolog|dJ224A6.1.1 (cell division cycle 42 (GTP-binding protein, 25kD))|dJ224A6.1.2 (cell division cycle 42 (GTP-binding protein, 25kD))",ENSG00000070831,ENST00000315554|ENST00000344548|ENST00000400259|ENST00000411827|ENST00000498236|ENST00000651171|ENST00000652582|ENST00000656825|ENST00000662562|ENST00000667384,ENSP00000314458|ENSP00000341072|ENSP00000383118|ENSP00000398327|ENSP00000496911|ENSP00000498275|ENSP00000499132|ENSP00000499457|ENSP00000499473|ENSP00000499612,P60953,A0A3B3IRV0|A0A590UJK8|A0A8Q3SI43|A0A8Q3WLC5|A0A494BZX6,CDC42_HUMAN,998.0,NM_001039802.2|NM_001791.4|NM_044472.3,NP_001034891.1|NP_001782.1|NP_426359.1,NC_000001.11|NC_060925.1|NG_047042.3,1736.0,116952.0,PA26266,9606.ENSP00000497733,1A4R|1AJE|1AM4|1AN0|1CEE|1CF4|1DOA|1E0A|1EES|1GRN|1GZS|1KI1|1KZ7|1KZG|1NF3|2ASE|2DFK|2KB0|2NGR|2ODB,3.6.5.2,IPR001806|IPR003578|IPR005225|IPR027417|IPR037874,PF00071,PS51419|PS51420|PS51421,1,22052627.0,22101360.0,1.0,191.0,"Cell membrane|Cytoplasm, cytoskeleton, microtubule organizing center, centrosome|Cytoplasm, cytoskeleton, spindle",9606.0,123986.0,CDC42,biocarta:actinypathway|biocarta:agrpathway|biocarta:cdc42racpathway|biocarta:malpathway|biocarta:p38mapkpathway|kegg:hsa04010|kegg:hsa04014|kegg:hsa04015|kegg:hsa04062|kegg:hsa04144|pid:ajdiss_2pathway|pid:ar_nongenomic_pathway|pid:avb3_opn_pathway|pid:cdc42_pathway|pid:cdc42_reg_pathway|smpdb:SMP00320|smpdb:SMP00321|wikipathways:WP138|wikipathways:WP1471|wikipathways:WP185|wikipathways:WP1984|wikipathways:WP2018,True,cell division cycle 42,6,0,CHEMBL:CHEMBL554475|SECRAMINE A|SECRAMINE B|GONADORELIN ACETATE|CHEMBL:CHEMBL563777|CHEMBL:CHEMBL562095,,SECRAMINE A|SECRAMINE B|CHEMBL:CHEMBL554475|CHEMBL:CHEMBL563777|CHEMBL:CHEMBL562095,DRUGGABLE GENOME,,NCI Cancer Gene Index|Drug Target Commons,True,CHEMBL3308925,SINGLE PROTEIN,0,0,3,3,3,True,0,0,0,0,0,,,,False,False,True,LOW - Bioactive compounds or interactions reported,Cell division control protein 42 homolog,"Plasma membrane-associated small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state. In active state binds to a variety of effector proteins to regulate cellular responses. Involved in epithelial cell polarization processes. Regulates the bipolar attachment of spindle microtubules to kinetochores before chromosome congression in metaphase (PubMed:15642749). Regulates cell migration (PubMed:17038317, PubMed:22843693). In neurons, plays a role in the extension and maintenance of the formation of filopodia, thin and actin-rich surface projections (PubMed:14978216). Required for DOCK10-mediated spine formation in Purkinje cells and hippocampal neurons. In podocytes, facilitates filopodia and podosomes formation upon DOCK11-activation (PubMed:33523862). Upon activation by CaMKII, modulates dendritic spine structural plasticity by relaying CaMKII transient activation to synapse-specific, long-term signaling (By similarity). Also plays a role in phagocytosis through organization of the F-actin cytoskeleton associated with forming phagocytic cups (PubMed:26465210). Upon activation by PLEKHG4B, involved in actin cytoskeletal remodeling during epithelial cell-cell junction formation (PubMed:33310911)",3D-structure|Alternative splicing|Cell membrane|Cell projection|Cytoplasm|Cytoskeleton|Differentiation|Direct protein sequencing|Disease variant|Glycoprotein|GTP-binding|Hydrolase|Intellectual disability|Lipoprotein|Membrane|Methylation|Neurogenesis|Nucleotide-binding|Phosphoprotein|Prenylation,Belongs to the small GTPase superfamily. Rho family. CDC42 subfamily,PF00071:Ras,1,IPR037874:Cdc42|IPR027417:P-loop_NTPase|IPR005225:Small_GTP-bd|IPR001806:Small_GTPase|IPR003578:Small_GTPase_Rho,5,,domain|family|homologous_superfamily,True,Actin|Motor Protein|Tubulin|GTPase|Hydrolase,HIGH,Tubulin: Keyword: microtubule|Actin: Keyword: actin|Motor Protein: InterPro: IPR027417|GTPase: Keyword: gtpase|GTPase: Keyword: small gtpase|GTPase: InterPro: IPR001806|GTPase: InterPro: IPR005225|GTPase: InterPro: IPR027417|GTPase: Pfam: PF00071|Hydrolase: Keyword: hydrolase,Actin,True,45,1A4R|1AJE|1AM4|1AN0|1CEE|1CF4|1DOA|1E0A|1EES|1GRN,1A4R,2.5,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1A4R.pdb,False,,,,,PDB,protein_structures/pdb_experimental/1A4R.pdb,Good (2.0-2.5Å),True,30,1.0,226.383,0.265,36.889,0.206,True,26,Moderate,Low,Adequate volume (226A3),Low druggability (0.27),226|226|729|232|311|274|439|188|227|259|455|348|222|229|289|231|246|447|198|240|233|366|421|348|255|288|346|386|1976|1209,0.27|0.02|0.00|0.00|0.01|0.00|0.04|0.00|0.00|0.01|0.00|0.00|0.00|0.00|0.00|0.06|0.00|0.01|0.00,P1:Vol=226:Drug=0.27|P2:Vol=226:Drug=0.00|P3:Vol=729:Drug=0.02|P4:Vol=232:Drug=0.00|P5:Vol=311:Drug=0.00|P6:Vol=274:Drug=0.00|P7:Vol=439:Drug=0.00|P8:Vol=188:Drug=0.01|P9:Vol=227:Drug=0.00|P10:Vol=259:Drug=0.04
RHOA,RHOA,ras homolog family member A,"This gene encodes a member of the Rho family of small GTPases, which cycle between inactive GDP-bound and active GTP-bound states and function as molecular switches in signal transduction cascades. Rho proteins promote reorganization of the actin cytoskeleton and regulate cell shape, attachment, and motility. Overexpression of this gene is associated with tumor cell proliferation and metastasis. Multiple alternatively spliced variants have been identified. [provided by RefSeq, Sep 2015].",protein-coding,ARH12|ARHA|EDFAOB|RHO12|RHOH12,Aplysia ras-related homolog 12|epididymis secretory sperm binding protein|oncogene RHO H12|small GTP binding protein RhoA|transforming protein RhoA,ENSG00000067560,ENST00000265538|ENST00000418115|ENST00000422781|ENST00000431929|ENST00000445425|ENST00000454011|ENST00000676712|ENST00000677684|ENST00000678200|ENST00000678921,ENSP00000394483|ENSP00000400175|ENSP00000408402|ENSP00000413587|ENSP00000503282|ENSP00000503490|ENSP00000504180|ENSP00000504494|ENSP00000504603|ENSP00000550139,P61586,C9JX21|A0A024R324|Q9BVT0|A0A7I2YQV1|B4DKN9,RHOA_HUMAN,387.0,NM_001313941.2|NM_001313943.2|NM_001313944.2|NM_001313945.2|NM_001313946.2|NM_001313947.2|NM_001664.4,NP_001300870.1|NP_001300872.1|NP_001300873.1|NP_001300874.1|NP_001300875.1|NP_001300876.1|NP_001655.1,NC_000003.12|NC_060927.1|NG_051308.1,667.0,165390.0,PA134865095,9606.ENSP00000400175,1A2B|1CC0|1CXZ|1DPF|1FTN|1KMQ|1LB1|1OW3|1S1C|1TX4|1X86|1XCG|2RGN|3KZ1|3LW8|3LWN|3LXR|3MSX|3T06|4D0N,3.6.5.2,IPR001806|IPR003578|IPR005225|IPR027417,PF00071,PS51419|PS51420|PS51421,3,49359136.0,49412998.0,-1.0,193.0,"Cell membrane|Cytoplasm, cytoskeleton|Cleavage furrow",9606.0,68986.0,RHOA,biocarta:akap13pathway|biocarta:akapcentrosomepathway|biocarta:cardiacegfpathway|biocarta:ccr3pathway|biocarta:cdc42racpathway|kegg:hsa04014|kegg:hsa04015|kegg:hsa04022|kegg:hsa04024|kegg:hsa04062|netpath:Pathway_Alpha6Beta4Integrin|netpath:Pathway_EGFR1|netpath:Pathway_RAGE|netpath:Pathway_TGF_beta_Receptor|netpath:Pathway_Wnt|pid:a4b7_pathway|pid:amb2_neutrophils_pathway|pid:arf6downstreampathway|pid:aurora_b_pathway|pid:avb3_integrin_pathway|reactome:R-HSA-109582|reactome:R-HSA-114604|reactome:R-HSA-1227986|reactome:R-HSA-1266738|reactome:R-HSA-1266738|wikipathways:WP138|wikipathways:WP1528|wikipathways:WP1544|wikipathways:WP2034|wikipathways:WP2272,True,ras homolog family member A,7,3,QUINIDINE|PRAVASTATIN SODIUM|NS004|ROTTLERIN|CLAUSINE E|SIMVASTATIN|NS1619,QUINIDINE|PRAVASTATIN SODIUM|SIMVASTATIN,CLAUSINE E|NS004|NS1619|ROTTLERIN|PRAVASTATIN SODIUM,CLINICALLY ACTIONABLE|KINASE,blocker|activator,Guide to Pharmacology|PharmGKB - The Pharmacogenomics Knowledgebase|Drug Target Commons,True,CHEMBL4523479,SINGLE PROTEIN,0,0,1,1,2,True,0,0,0,0,0,,,,True,False,True,HIGH - Approved drugs exist,Transforming protein RhoA,"(Microbial infection) Serves as a target for the yopT cysteine peptidase from Yersinia pestis, vector of the plague",3D-structure|ADP-ribosylation|Cell cycle|Cell division|Cell membrane|Cell projection|Cytoplasm|Cytoskeleton|Direct protein sequencing|Disease variant|Ectodermal dysplasia|Glycoprotein|GTP-binding|Host-virus interaction|Hydrolase|Isopeptide bond|Lipoprotein|Magnesium|Membrane|Methylation,Belongs to the small GTPase superfamily. Rho family,PF00071:Ras,1,IPR027417:P-loop_NTPase|IPR005225:Small_GTP-bd|IPR001806:Small_GTPase|IPR003578:Small_GTPase_Rho,4,,domain|family|homologous_superfamily,True,Hydrolase|GTPase|Protease|Motor Protein,HIGH,Protease: Keyword: peptidase|Motor Protein: InterPro: IPR027417|GTPase: Keyword: gtpase|GTPase: Keyword: small gtpase|GTPase: InterPro: IPR001806|GTPase: InterPro: IPR005225|GTPase: InterPro: IPR027417|GTPase: Pfam: PF00071|Hydrolase: Keyword: hydrolase,Hydrolase,True,125,1A2B|1CC0|1CXZ|1DPF|1FTN|1KMQ|1LB1|1OW3|1S1C|1TX4,1A2B,2.4,X-RAY DIFFRACTION,protein_structures/pdb_experimental/1A2B.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1A2B.pdb,Good (2.0-2.5Å),True,8,1.0,1115.811,0.973,23.276,0.767,True,7,Excellent,High,Optimal volume (1116A3)|High druggability (0.97),,1116|232|184|394|156|439|355|227,0.97|0.00|0.00|0.47|0.00,P1:Vol=1116:Drug=0.97|P2:Vol=232:Drug=0.00|P3:Vol=184:Drug=0.00|P4:Vol=394:Drug=0.00|P5:Vol=156:Drug=0.00|P6:Vol=439:Drug=0.47|P7:Vol=355:Drug=0.00|P8:Vol=227:Drug=0.00
RPS6,RPS6,ribosomal protein S6,"Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a cytoplasmic ribosomal protein that is a component of the 40S subunit. The protein belongs to the S6E family of ribosomal proteins. It is the major substrate of protein kinases in the ribosome, with subsets of five C-terminal serine residues phosphorylated by different protein kinases. Phosphorylation is induced by a wide range of stimuli, including growth factors, tumor-promoting agents, and mitogens. Dephosphorylation occurs at growth arrest. The protein may contribute to the control of cell growth and proliferation through the selective translation of particular classes of mRNA. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. [provided by RefSeq, Jul 2008].",protein-coding,S6|eS6,40S ribosomal protein S6|phosphoprotein NP33|small ribosomal subunit protein eS6,ENSG00000137154,ENST00000315377|ENST00000380381|ENST00000380384|ENST00000380394|ENST00000498815|ENST00000889072|ENST00000889073|ENST00000889074|ENST00000889075|ENST00000889076,ENSP00000369741|ENSP00000369743|ENSP00000369745|ENSP00000369757|ENSP00000559131|ENSP00000559132|ENSP00000559133|ENSP00000559134|ENSP00000559135|ENSP00000559136,P62753,A2A3R5|A2A3R6|A2A3R7,RS6_HUMAN,6194.0,NM_001010.3,NP_001001.2,NC_000009.12|NC_060933.1,10429.0,180460.0,PA34844,9606.ENSP00000369757,4UG0|4V6X|5A2Q|5AJ0|5FLX|5LKS|5OA3|5T2C|5VYC|6F4P|6F4Q|6FEC|6G18|6G4S|6G4W|6G51|6G53|6G5H|6G5I|6IP5,,IPR001377|IPR014401|IPR018282,PF01092,,9,19375715.0,19380282.0,-1.0,249.0,"Cytoplasm|Nucleus, nucleolus",9606.0,85949.0,,biocarta:igf1mtorpathway|biocarta:mtorpathway|kegg:hsa03010|kegg:hsa04066|kegg:hsa04150|kegg:hsa04151|kegg:hsa04371|netpath:Pathway_BCR|netpath:Pathway_Gastrin|netpath:Pathway_IL11|netpath:Pathway_IL2|netpath:Pathway_KitReceptor|pid:erbb1_downstream_pathway|pid:il2_pi3kpathway|reactome:R-HSA-1266738|reactome:R-HSA-1430728|reactome:R-HSA-156827|reactome:R-HSA-156842|reactome:R-HSA-156902|wikipathways:WP127|wikipathways:WP2032|wikipathways:WP2034|wikipathways:WP2035|wikipathways:WP2037,True,ribosomal protein S6,6,1,DORLIMOMAB ARITOX|EXALUREN|CYCLOHEXIMIDE|MT-3724|ATALUREN|SONOLISIB,ATALUREN,SONOLISIB|DORLIMOMAB ARITOX|EXALUREN|MT-3724|ATALUREN,KINASE,modulator|inhibitor,"The ChEMBL Bioactivity Database|Targeted Agents in Lung Cancer (Commentary, 2014)",True,CHEMBL3351215,SINGLE PROTEIN,0,0,53,53,101,True,31,1,7,16,1,ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|MT-3724|ATALUREN,Unknown|Small molecule,80S Ribosome modulator|80S Ribosome inhibitor,True,True,True,HIGH - Approved drugs exist,Small ribosomal subunit protein eS6,"Component of the 40S small ribosomal subunit (PubMed:23636399, PubMed:8706699). Plays an important role in controlling cell growth and proliferation through the selective translation of particular classes of mRNA (PubMed:17220279). Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome (PubMed:34516797)",3D-structure|Acetylation|ADP-ribosylation|Cytoplasm|Direct protein sequencing|Hydroxylation|Isopeptide bond|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|Ribonucleoprotein|Ribosomal protein|Ubl conjugation,Belongs to the eukaryotic ribosomal protein eS6 family,PF01092:Ribosomal_S6e,1,IPR001377:Ribosomal_eS6|IPR014401:Ribosomal_eS6-like|IPR018282:Ribosomal_eS6_CS,3,,conserved_site|family,True,Chaperone,LOW,Chaperone: Keyword: chaperone,Chaperone,True,149,4UG0|4V6X|5A2Q|5AJ0|5FLX|5LKS|5OA3|5T2C|5VYC|6F4P,4UG0,3.6,ELECTRON MICROSCOPY,,False,,,,,,,,False,0,,,,,,False,0,,,,,,,
RPL5,RPL5,ribosomal protein L5,"Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of four RNA species and approximately 80 structurally distinct proteins. This gene encodes a member of the L18P family of ribosomal proteins and component of the 60S subunit. The encoded protein binds 5S rRNA to form a stable complex called the 5S ribonucleoprotein particle (RNP), which is necessary for the transport of nonribosome-associated cytoplasmic 5S rRNA to the nucleolus for assembly into ribosomes. The encoded protein may also function to inhibit tumorigenesis through the activation of downstream tumor suppressors and the downregulation of oncoprotein expression. Mutations in this gene have been identified in patients with Diamond-Blackfan Anemia (DBA). This gene is co-transcribed with the small nucleolar RNA gene U21, which is located in its fifth intron. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed throughout the genome. [provided by RefSeq, Mar 2017].",protein-coding,L5|MSTP030|PPP1R135|uL18,"60S ribosomal protein L5|large ribosomal subunit protein uL18|protein phosphatase 1, regulatory subunit 135",ENSG00000122406,ENST00000315741|ENST00000370321|ENST00000461952|ENST00000470843|ENST00000497519|ENST00000643510|ENST00000644549|ENST00000645119|ENST00000645300|ENST00000645908,ENSP00000359338|ENSP00000359345|ENSP00000473675|ENSP00000493811|ENSP00000495589|ENSP00000550573|ENSP00000550574|ENSP00000550575|ENSP00000550576|ENSP00000550577,P46777,A0A2R8Y4A2|A2RUM7|Q5T7N0|A0A2R8Y6J3|R4GNJ2,RL5_HUMAN,6125.0,NM_000969.5|NR_146333.1,NP_000960.2,NC_000001.11|NC_060925.1|NG_011779.2|NG_033051.1,10360.0,603634.0,PA34755,9606.ENSP00000359345,4UG0|4V6X|5AJ0|5LKS|5T2C|6IP5|6IP6|6IP8|6LQM|6LSR|6LSS|6LU8|6OLE|6OLF|6OLG|6OLI|6OLZ|6OM0|6OM7|6QZP,3.6.5.3,IPR005485|IPR025607,PF14204|PF17144,,1,92831990.0,92841924.0,1.0,297.0,"Cytoplasm|Nucleus, nucleolus",9606.0,110649.0,Ribosomal protein L5,kegg:hsa03010|kegg:hsa05171|reactome:R-HSA-1266738|reactome:R-HSA-1430728|reactome:R-HSA-156827|reactome:R-HSA-156842|reactome:R-HSA-156902|wikipathways:WP3888|wikipathways:WP477,True,ribosomal protein L5,5,1,MT-3724|EXALUREN|DORLIMOMAB ARITOX|ATALUREN|CYCLOHEXIMIDE,ATALUREN,EXALUREN|DORLIMOMAB ARITOX|MT-3724|ATALUREN|CYCLOHEXIMIDE,CLINICALLY ACTIONABLE,modulator|inhibitor,The ChEMBL Bioactivity Database,True,CHEMBL6066896,SINGLE PROTEIN,0,0,2,2,4,True,31,1,7,16,1,ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|MT-3724|ATALUREN,Unknown|Small molecule,80S Ribosome modulator|80S Ribosome inhibitor,True,True,True,HIGH - Approved drugs exist,Large ribosomal subunit protein uL18,"Component of the ribosome, a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell. The small ribosomal subunit (SSU) binds messenger RNAs (mRNAs) and translates the encoded message by selecting cognate aminoacyl-transfer RNA (tRNA) molecules. The large subunit (LSU) contains the ribosomal catalytic site termed the peptidyl transferase center (PTC), which catalyzes the formation of peptide bonds, thereby polymerizing the amino acids delivered by tRNAs into a polypeptide chain. The nascent polypeptides leave the ribosome through a tunnel in the LSU and interact with protein factors that function in enzymatic processing, targeting, and the membrane insertion of nascent chains at the exit of the ribosomal tunnel. As part of the 5S RNP/5S ribonucleoprotein particle it is an essential component of the LSU, required for its formation and the maturation of rRNAs (PubMed:12962325, PubMed:19061985, PubMed:23636399, PubMed:24120868). It also couples ribosome biogenesis to p53/TP53 activation. As part of the 5S RNP it accumulates in the nucleoplasm and inhibits MDM2, when ribosome biogenesis is perturbed, mediating the stabilization and the activation of TP53 (PubMed:24120868)",3D-structure|Acetylation|Cytoplasm|Diamond-Blackfan anemia|Direct protein sequencing|Disease variant|Isopeptide bond|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|Ribonucleoprotein|Ribosomal protein|RNA-binding|rRNA-binding|Ubl conjugation,Belongs to the universal ribosomal protein uL18 family,PF14204:Ribosomal_L18_c|PF17144:Ribosomal_L5e,2,IPR005485:Rbsml_uL18_euk|IPR025607:Ribosomal_uL18_C_euk,2,,domain|family,True,Transferase|Histone Acetyltransferase,MEDIUM,Histone Acetyltransferase: Keyword: hat|Transferase: Keyword: transferase,Transferase,True,125,4UG0|4V6X|5AJ0|5LKS|5T2C|6IP5|6IP6|6IP8|6LQM|6LSR,4UG0,3.6,ELECTRON MICROSCOPY,,True,2025-08-01T00:00:00Z,,Unknown,,,,,False,0,,,,,,False,0,,,,,,,
RPS3,RPS3,ribosomal protein S3,"Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a ribosomal protein that is a component of the 40S subunit, where it forms part of the domain where translation is initiated. The protein belongs to the S3P family of ribosomal proteins. Studies of the mouse and rat proteins have demonstrated that the protein has an extraribosomal role as an endonuclease involved in the repair of UV-induced DNA damage. The protein appears to be located in both the cytoplasm and nucleus but not in the nucleolus. Higher levels of expression of this gene in colon adenocarcinomas and adenomatous polyps compared to adjacent normal colonic mucosa have been observed. This gene is co-transcribed with the small nucleolar RNA genes U15A and U15B, which are located in its first and fifth introns, respectively. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2012].",protein-coding,S3|uS3,40S ribosomal protein S3|IMR-90 ribosomal protein S3|small ribosomal subunit protein uS3,ENSG00000149273,ENST00000278572|ENST00000422465|ENST00000524851|ENST00000525690|ENST00000525933|ENST00000526248|ENST00000526608|ENST00000527273|ENST00000527446|ENST00000528439,ENSP00000278572|ENSP00000416745|ENSP00000431737|ENSP00000431834|ENSP00000432458|ENSP00000432542|ENSP00000433155|ENSP00000433421|ENSP00000433821|ENSP00000434643,P23396,H0YCJ7|E9PQ96|E9PL09|E9PPU1|E9PQX2,RS3_HUMAN,6188.0,NM_001005.5|NM_001256802.2|NM_001260506.2|NM_001260507.2,NP_000996.2|NP_001243731.1|NP_001247435.1|NP_001247436.1,NC_000011.10|NC_060935.1,10420.0,600454.0,PA34829,9606.ENSP00000278572,1WH9|4UG0|4V6X|5A2Q|5AJ0|5FLX|5LKS|5OA3|5T2C|5VYC|6FEC|6G51|6G53|6G5H|6G5I|6IP5|6IP6|6IP8|6OLE|6OLF,4.2.99.18,IPR001351|IPR004044|IPR005703|IPR009019|IPR015946|IPR018280|IPR036419,PF00189|PF07650,PS50823,11,75394327.0,75422280.0,1.0,243.0,"Cytoplasm|Nucleus|Nucleus, nucleolus",9606.0,779.0,RPS3,kegg:hsa03010|kegg:hsa05130|kegg:hsa05132|kegg:hsa05171|reactome:R-HSA-1266738|reactome:R-HSA-1430728|reactome:R-HSA-156827|reactome:R-HSA-156842|reactome:R-HSA-156902,True,ribosomal protein S3,5,1,EXALUREN|CYCLOHEXIMIDE|MT-3724|ATALUREN|DORLIMOMAB ARITOX,ATALUREN,EXALUREN|DORLIMOMAB ARITOX|MT-3724|ATALUREN|CYCLOHEXIMIDE,TRANSCRIPTION FACTOR|DNA REPAIR,modulator|inhibitor,The ChEMBL Bioactivity Database,True,CHEMBL6066939,SINGLE PROTEIN,0,0,3,3,10,True,31,1,7,16,1,ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|MT-3724|ATALUREN,Unknown|Small molecule,80S Ribosome modulator|80S Ribosome inhibitor,True,True,True,HIGH - Approved drugs exist,Small ribosomal subunit protein uS3,"Component of the small ribosomal subunit (PubMed:23636399, PubMed:8706699). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399, PubMed:8706699). Has endonuclease activity and plays a role in repair of damaged DNA (PubMed:7775413). Cleaves phosphodiester bonds of DNAs containing altered bases with broad specificity and cleaves supercoiled DNA more efficiently than relaxed DNA (PubMed:15707971). Displays high binding affinity for 7,8-dihydro-8-oxoguanine (8-oxoG), a common DNA lesion caused by reactive oxygen species (ROS) (PubMed:14706345). Has also been shown to bind with similar affinity to intact and damaged DNA (PubMed:18610840). Stimulates the N-glycosylase activity of the base excision protein OGG1 (PubMed:15518571). Enhances the uracil excision activity of UNG1 (PubMed:18973764). Also stimulates the cleavage of the phosphodiester backbone by APEX1 (PubMed:18973764). When located in the mitochondrion, reduces cellular ROS levels and mitochondrial DNA damage (PubMed:23911537). Has also been shown to negatively regulate DNA repair in cells exposed to hydrogen peroxide (PubMed:17049931). Plays a role in regulating transcription as part of the NF-kappa-B p65-p50 complex where it binds to the RELA/p65 subunit, enhances binding of the complex to DNA and promotes transcription of target genes (PubMed:18045535). Represses its own translation by binding to its cognate mRNA (PubMed:20217897). Binds to and protects TP53/p53 from MDM2-mediated ubiquitination (PubMed:19656744). Involved in spindle formation and chromosome movement during mitosis by regulating microtubule polymerization (PubMed:23131551). Involved in induction of apoptosis through its role in activation of CASP8 (PubMed:14988002). Induces neuronal apoptosis by interacting with the E2F1 transcription factor and acting synergistically with it to up-regulate pro-apoptotic proteins BCL2L11/BIM and HRK/Dp5 (PubMed:20605787). Interacts with TRADD following exposure to UV radiation and induces apoptosis by caspase-dependent JNK activation (PubMed:22510408)",3D-structure|Acetylation|Alternative splicing|Apoptosis|Cell cycle|Cell division|Cytoplasm|Cytoskeleton|Direct protein sequencing|DNA damage|DNA repair|DNA-binding|Isopeptide bond|Lyase|Membrane|Methylation|Mitochondrion|Mitochondrion inner membrane|Mitosis|Nucleus,Belongs to the universal ribosomal protein uS3 family,PF07650:KH_2|PF00189:Ribosomal_S3_C,2,IPR015946:KH_dom-like_a/b|IPR004044:KH_dom_type_2|IPR009019:KH_sf_prok-type|IPR036419:Ribosomal_S3_C_sf|IPR001351:Ribosomal_uS3_C|IPR018280:Ribosomal_uS3_CS|IPR005703:Ribosomal_uS3_euk/arc,7,,domain|family|conserved_site|homologous_superfamily,True,Actin|Tubulin|E3 Ubiquitin Ligase|Protease|Hydrolase|Lyase|Transcription Factor,HIGH,Protease: Keyword: caspase|E3 Ubiquitin Ligase: Keyword: ubiquitination|Tubulin: Keyword: microtubule|Actin: Keyword: actin|Transcription Factor: Keyword: transcription factor|Transcription Factor: Keyword: dna-binding|Hydrolase: Keyword: nuclease|Lyase: Keyword: lyase,Actin,True,133,1WH9|4UG0|4V6X|5A2Q|5AJ0|5FLX|5LKS|5OA3|5T2C|5VYC,1WH9,,SOLUTION NMR,protein_structures/pdb_experimental/1WH9.pdb,True,2025-08-01T00:00:00Z,,Unknown,,PDB,protein_structures/pdb_experimental/1WH9.pdb,,True,7,7.0,325.596,0.242,48.143,0.024,True,6,Moderate,Low,Adequate volume (326A3),Low druggability (0.24),302|529|341|347|249|236|326,0.07|0.01|0.00|0.05|0.24,P1:Vol=302:Drug=0.07|P2:Vol=529:Drug=0.01|P3:Vol=341:Drug=0.00|P4:Vol=347:Drug=0.00|P5:Vol=249:Drug=0.05|P6:Vol=236:Drug=0.00|P7:Vol=326:Drug=0.24
RPL10,RPL15,ribosomal protein L15,"Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of four RNA species and approximately 80 structurally distinct proteins. This gene encodes a member of the L15E family of ribosomal proteins and a component of the 60S subunit. This gene shares sequence similarity with the yeast ribosomal protein YL10 gene. Elevated expression of this gene has been observed in esophageal tumors and gastric cancer tissues, and deletion of this gene has been observed in a Diamond-Blackfan anemia (DBA) patient. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. [provided by RefSeq, Mar 2017].",protein-coding,DBA12|EC45|L15|RPL10|RPLY10|RPYL10|eL15,60S ribosomal protein L15|large ribosomal subunit protein eL15,ENSG00000174748,ENST00000307839|ENST00000354811|ENST00000412097|ENST00000413699|ENST00000415719|ENST00000422218|ENST00000434031|ENST00000436146|ENST00000456530|ENST00000465786,ENSP00000309334|ENSP00000346867|ENSP00000387925|ENSP00000388529|ENSP00000398788|ENSP00000405590|ENSP00000408243|ENSP00000411176|ENSP00000416692|ENSP00000483260,P61313,A0A2R8YEM3|E7ERA2|E7EX53|E7ENU7|A0A2R8Y738,RL10_HUMAN,6138.0,NM_001253379.2|NM_001253380.2|NM_001253382.2|NM_001253383.3|NM_001253384.2|NM_002948.5,NP_001240308.1|NP_001240309.1|NP_001240311.1|NP_001240312.1|NP_001240313.1|NP_002939.2,NC_000003.12|NC_060927.1|NG_033850.2,10306.0,604174.0,PA34674,9606.ENSP00000413436,4UG0|4V6X|5AJ0|5LKS|5T2C|6IP5|6IP6|6IP8|6LQM|6LSR|6LSS|6LU8|6OLE|6OLF|6OLG|6OLI|6OLZ|6OM0|6OM7|6QZP,,IPR000439|IPR012678|IPR020925|IPR024794,PF00827,,3,23916591.0,23924374.0,1.0,214.0,Cytoplasm,9606.0,37713.0,RPL15,kegg:hsa03010|kegg:hsa05171|reactome:R-HSA-1266738|reactome:R-HSA-1430728|reactome:R-HSA-156827|reactome:R-HSA-156842|reactome:R-HSA-156902,True,ribosomal protein L10,6,1,CYCLOHEXIMIDE|MT-3724|DORLIMOMAB ARITOX|EXALUREN|RECOMBINANT TRANSFORMING GROWTH FACTOR|ATALUREN,ATALUREN,RECOMBINANT TRANSFORMING GROWTH FACTOR|DORLIMOMAB ARITOX|EXALUREN|MT-3724|ATALUREN,CLINICALLY ACTIONABLE,modulator|inhibitor,The ChEMBL Bioactivity Database|NCI Cancer Gene Index,True,CHEMBL6066928,SINGLE PROTEIN,0,0,2,2,4,True,31,1,7,16,1,ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|MT-3724|ATALUREN,Unknown|Small molecule,80S Ribosome modulator|80S Ribosome inhibitor,True,True,True,HIGH - Approved drugs exist,Large ribosomal subunit protein eL15,Component of the large ribosomal subunit. The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell,3D-structure|Alternative splicing|Cytoplasm|Diamond-Blackfan anemia|Isopeptide bond|Lipoprotein|Myristate|Phosphoprotein|Proteomics identification|Reference proteome|Ribonucleoprotein|Ribosomal protein|Ubl conjugation,Belongs to the eukaryotic ribosomal protein eL15 family,PF00827:Ribosomal_L15e,1,IPR024794:Rbsml_eL15_core_dom_sf|IPR000439:Ribosomal_eL15|IPR020925:Ribosomal_eL15_CS|IPR012678:Ribosomal_uL23/eL15/eS24_sf,4,,homologous_superfamily|family|conserved_site,False,,NONE,,,True,133,4UG0|4V6X|5AJ0|5LKS|5T2C|6IP5|6IP6|6IP8|6LQM|6LSR,4UG0,3.6,ELECTRON MICROSCOPY,,True,2025-08-01T00:00:00Z,,Unknown,,,,,False,0,,,,,,False,0,,,,,,,
RPS19,RPS19,ribosomal protein S19,"Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a ribosomal protein that is a component of the 40S subunit. The protein belongs to the S19E family of ribosomal proteins. It is located in the cytoplasm. Mutations in this gene cause Diamond-Blackfan anemia (DBA), a constitutional erythroblastopenia characterized by absent or decreased erythroid precursors, in a subset of patients. This suggests a possible extra-ribosomal function for this gene in erythropoietic differentiation and proliferation, in addition to its ribosomal function. Higher expression levels of this gene in some primary colon carcinomas compared to matched normal colon tissues has been observed. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. [provided by RefSeq, Jul 2008].",protein-coding,DBA|DBA1|LOH19CR1|S19|eS19,"40S ribosomal protein S19|loss of heterozygosity on chromosome 19, region 1|loss of heterozygosity, 19, chromosomal region 1|small ribosomal subunit protein eS19",ENSG00000105372,ENST00000221975|ENST00000593863|ENST00000598261|ENST00000598399|ENST00000598466|ENST00000598742|ENST00000600467|ENST00000601492|ENST00000858696|ENST00000858697,ENSP00000221975|ENSP00000469228|ENSP00000469798|ENSP00000470004|ENSP00000470972|ENSP00000471621|ENSP00000472660|ENSP00000528755|ENSP00000528756|ENSP00000603974,P39019,M0R140|B0ZBD0|A0A075B6E2|M0R2L9|M0QYF7,RS19_HUMAN,6223.0,NM_001022.4|NM_001321483.2|NM_001321484.2|NM_001321485.2,NP_001013.1|NP_001308412.1|NP_001308413.1|NP_001308414.1,NC_000019.10|NC_060943.1|NG_007080.3,10402.0,603474.0,PA34803,9606.ENSP00000470972,4UG0|4V6X|5A2Q|5AJ0|5FLX|5LKS|5OA3|5T2C|5VYC|6G18|6G4S|6G4W|6G51|6G53|6G5H|6G5I|6IP5|6IP6|6IP8|6OLE,,IPR001266|IPR018277|IPR036388|IPR036390,PF01090,,19,41860255.0,41872925.0,1.0,145.0,"Cytoplasm|Nucleus, nucleolus",9606.0,37416.0,Ribosomal protein S19,kegg:hsa03010|kegg:hsa05171|reactome:R-HSA-1266738|reactome:R-HSA-1430728|reactome:R-HSA-156827|reactome:R-HSA-156842|reactome:R-HSA-156902|wikipathways:WP2806|wikipathways:WP477,True,ribosomal protein S19,13,7,PREDNISOLONE|ATALUREN|RECOMBINANT HUMAN STEM CELL FACTOR|VITAMIN A|CYCLOSPORINE|EXALUREN|DEXAMETHASONE|RITUXIMAB|MT-3724|THERAPEUTIC CORTICOSTEROID|METOCLOPRAMIDE HYDROCHLORIDE|CYCLOHEXIMIDE|DORLIMOMAB ARITOX,PREDNISOLONE|ATALUREN|VITAMIN A|CYCLOSPORINE|DEXAMETHASONE|RITUXIMAB|METOCLOPRAMIDE HYDROCHLORIDE,RECOMBINANT HUMAN STEM CELL FACTOR|METOCLOPRAMIDE HYDROCHLORIDE|RITUXIMAB|THERAPEUTIC CORTICOSTEROID|VITAMIN A,,modulator|inhibitor,The ChEMBL Bioactivity Database|NCI Cancer Gene Index,True,CHEMBL6066908,SINGLE PROTEIN,0,0,3,3,11,True,31,1,7,16,1,ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|MT-3724|ATALUREN,Unknown|Small molecule,80S Ribosome modulator|80S Ribosome inhibitor,True,True,True,HIGH - Approved drugs exist,Small ribosomal subunit protein eS19,"Component of the small ribosomal subunit (PubMed:23636399). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399). Required for pre-rRNA processing and maturation of 40S ribosomal subunits (PubMed:16990592). Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome (PubMed:34516797)",3D-structure|Acetylation|Cytoplasm|Diamond-Blackfan anemia|Direct protein sequencing|Disease variant|Host-virus interaction|Methylation|Nucleus|Proteomics identification|Reference proteome|Ribonucleoprotein|Ribosomal protein,Belongs to the eukaryotic ribosomal protein eS19 family,PF01090:Ribosomal_S19e,1,IPR001266:Ribosomal_eS19|IPR018277:Ribosomal_eS19_CS|IPR036388:WH-like_DNA-bd_sf|IPR036390:WH_DNA-bd_sf,4,,conserved_site|family|homologous_superfamily,True,Chaperone,LOW,Chaperone: Keyword: chaperone,Chaperone,True,141,4UG0|4V6X|5A2Q|5AJ0|5FLX|5LKS|5OA3|5T2C|5VYC|6G18,4UG0,3.6,ELECTRON MICROSCOPY,,False,,,,,,,,False,0,,,,,,False,0,,,,,,,
RPL11,RPL11,ribosomal protein L11,"Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a ribosomal protein that is a component of the 60S subunit. The protein belongs to the L5P family of ribosomal proteins. It is located in the cytoplasm. The protein probably associates with the 5S rRNA. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. [provided by RefSeq, Dec 2010].",protein-coding,DBA7|GIG34|L11|uL5,60S ribosomal protein L11|CLL-associated antigen KW-12|cell growth-inhibiting protein 34|large ribosomal subunit protein uL5,ENSG00000142676,ENST00000374550|ENST00000443624|ENST00000458455|ENST00000467075|ENST00000482370|ENST00000643754|ENST00000895876|ENST00000933788|ENST00000933789|ENST00000933790,ENSP00000363676|ENSP00000398888|ENSP00000493634|ENSP00000496250|ENSP00000565935|ENSP00000603847|ENSP00000603848|ENSP00000603849|ENSP00000603850|ENSP00000603851,P62913,A0A2R8Y447|Q5VVD0|Q5VVC8,RL11_HUMAN,6135.0,NM_000975.5|NM_001199802.1,NP_000966.2|NP_001186731.1,NC_000001.11|NC_060925.1|NG_011741.2,10301.0,604175.0,PA34664,9606.ENSP00000496250,4UG0|4V6X|4XXB|5AJ0|5LKS|5T2C|6IP5|6IP6|6IP8|6LQM|6LSR|6LSS|6LU8|6OLE|6OLF|6OLG|6OLI|6OLZ|6OM0|6OM7,,IPR002132|IPR020929|IPR022803|IPR031309|IPR031310,PF00281|PF00673,,1,23691685.0,23696835.0,1.0,178.0,"Nucleus, nucleolus|Cytoplasm",9606.0,37376.0,RPL11,kegg:hsa03010|kegg:hsa05171|pid:myc_activpathway|pid:p53regulationpathway,True,ribosomal protein L11,5,1,MT-3724|ATALUREN|CYCLOHEXIMIDE|DORLIMOMAB ARITOX|EXALUREN,ATALUREN,DORLIMOMAB ARITOX|EXALUREN|MT-3724|ATALUREN|CYCLOHEXIMIDE,,modulator|inhibitor,The ChEMBL Bioactivity Database,True,CHEMBL6067549,SINGLE PROTEIN,0,0,2,2,4,True,31,1,7,16,1,ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|ATALUREN|MT-3724|ATALUREN,Unknown|Small molecule,80S Ribosome modulator|80S Ribosome inhibitor,True,True,True,HIGH - Approved drugs exist,Large ribosomal subunit protein uL5,"Component of the ribosome, a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:19191325, PubMed:32669547). The small ribosomal subunit (SSU) binds messenger RNAs (mRNAs) and translates the encoded message by selecting cognate aminoacyl-transfer RNA (tRNA) molecules (PubMed:19191325, PubMed:32669547). The large subunit (LSU) contains the ribosomal catalytic site termed the peptidyl transferase center (PTC), which catalyzes the formation of peptide bonds, thereby polymerizing the amino acids delivered by tRNAs into a polypeptide chain (PubMed:19191325, PubMed:32669547). The nascent polypeptides leave the ribosome through a tunnel in the LSU and interact with protein factors that function in enzymatic processing, targeting, and the membrane insertion of nascent chains at the exit of the ribosomal tunnel (PubMed:19191325, PubMed:32669547). As part of the 5S RNP/5S ribonucleoprotein particle it is an essential component of the LSU, required for its formation and the maturation of rRNAs (PubMed:12962325, PubMed:19061985, PubMed:24120868). It also couples ribosome biogenesis to p53/TP53 activation. As part of the 5S RNP it accumulates in the nucleoplasm and inhibits MDM2, when ribosome biogenesis is perturbed, mediating the stabilization and the activation of TP53 (PubMed:24120868). Promotes nucleolar location of PML (By similarity)",3D-structure|Acetylation|Alternative splicing|Cytoplasm|Diamond-Blackfan anemia|Direct protein sequencing|Disease variant|Isopeptide bond|Nucleus|Phosphoprotein|Proteomics identification|Reference proteome|Ribonucleoprotein|Ribosomal protein|RNA-binding|rRNA-binding|Ubl conjugation,Belongs to the universal ribosomal protein uL5 family,PF00281:Ribosomal_L5|PF00673:Ribosomal_L5_C,2,IPR002132:Ribosomal_uL5|IPR031309:Ribosomal_uL5_C|IPR020929:Ribosomal_uL5_CS|IPR022803:Ribosomal_uL5_dom_sf|IPR031310:Ribosomal_uL5_N,5,,conserved_site|family|domain|homologous_superfamily,True,Transferase|Histone Acetyltransferase,MEDIUM,Histone Acetyltransferase: Keyword: hat|Transferase: Keyword: transferase,Transferase,True,126,4UG0|4V6X|4XXB|5AJ0|5LKS|5T2C|6IP5|6IP6|6IP8|6LQM,4UG0,3.6,ELECTRON MICROSCOPY,,True,2025-08-01T00:00:00Z,,Unknown,,,,,False,0,,,,,,False,0,,,,,,,
